andersjacobsen-mirmaid_mir2disease 0.0.0 → 0.1.0

data/MIT-LICENSE

@@ -0,0 +1,20 @@
+Copyright (c) 2009 [name of plugin creator]
+
+Permission is hereby granted, free of charge, to any person obtaining
+a copy of this software and associated documentation files (the
+"Software"), to deal in the Software without restriction, including
+without limitation the rights to use, copy, modify, merge, publish,
+distribute, sublicense, and/or sell copies of the Software, and to
+permit persons to whom the Software is furnished to do so, subject to
+the following conditions:
+
+The above copyright notice and this permission notice shall be
+included in all copies or substantial portions of the Software.
+
+THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND,
+EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF
+MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND
+NONINFRINGEMENT. IN NO EVENT SHALL THE AUTHORS OR COPYRIGHT HOLDERS BE
+LIABLE FOR ANY CLAIM, DAMAGES OR OTHER LIABILITY, WHETHER IN AN ACTION
+OF CONTRACT, TORT OR OTHERWISE, ARISING FROM, OUT OF OR IN CONNECTION
+WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE SOFTWARE.

data/Rakefile

@@ -0,0 +1,46 @@
+require 'rake'
+require 'rake/testtask'
+require 'rake/rdoctask'
+require 'sdoc'
+
+# rake version:bump:major/minor/patch
+# rake gemspec
+begin
+  require 'jeweler'
+  Jeweler::Tasks.new do |gem|
+    gem.name = "mirmaid_mir2disease"
+    gem.summary = %Q{miR2Disease (http://www.mir2disease.org) plugin for MirMaid}
+    gem.description = %Q{TODO}
+    gem.email = "andersmbj@gmail.com"
+    gem.homepage = "http://github.com/andersjacobsen/mirmaid_mir2disease"
+    gem.authors = ["Anders Jacobsen"]
+    # gem is a Gem::Specification... see
+    # http://www.rubygems.org/read/chapter/20 for additional settings
+  end
+
+rescue LoadError
+  puts "Jeweler (or a dependency) not available. Install it with: sudo gem install jeweler"
+end
+
+
+desc 'Default: run unit tests.'
+task :default => :test
+
+desc 'Test the mir2disease plugin.'
+Rake::TestTask.new(:test) do |t|
+  t.libs << 'lib'
+  t.libs << 'test'
+  t.pattern = 'test/**/*_test.rb'
+  t.verbose = true
+end
+
+desc 'Generate documentation for the mir2disease plugin.'
+Rake::RDocTask.new(:rdoc) do |rdoc|
+  rdoc.rdoc_dir = 'rdoc'
+  rdoc.title    = 'MirMaid miR2Disease plugin'
+  #  rdoc.options << '--line-numbers' << '--inline-source'
+  rdoc.options << '--fmt' << 'shtml' # explictly set shtml generator
+  rdoc.rdoc_files.include('README')
+  rdoc.rdoc_files.include('lib/**/*.rb')
+  rdoc.rdoc_files.include('app/**/*.rb')
+end

data/VERSION

@@ -0,0 +1 @@
+0.1.0

data/app/controllers/m2d_disease_links_controller.rb

@@ -0,0 +1,44 @@
+class M2dDiseaseLinksController < ApplicationController
+  layout "application"
+  protect_from_forgery :only => [:create, :update, :destroy]
+  
+  # GET /m2d_disease_links
+  # GET /m2d_disease_links.xml
+  def index
+    @m2d_disease_links = nil
+    
+    params[:page] ||= 1
+        
+    if params[:mature_id]
+      @m2d_disease_links = Mature.find_rest(params[:mature_id]).m2d_disease_links
+    elsif params[:m2d_disease_id]
+      @m2d_disease_links = M2dDisease.find_rest(params[:m2d_disease_id]).m2d_disease_links
+    end
+
+    respond_to do |format|
+      format.html do
+        if @m2d_disease_links # subselect
+          @m2d_disease_links = M2dDiseaseLink.paginate @m2d_disease_links.map{|x| x.id}, :page => params[:page], :per_page => 12, :order => "mirna, mature_id"
+        else #all
+          @m2d_disease_links = M2dDiseaseLink.paginate :page => params[:page], :per_page => 12, :order => "mirna, mature_id"
+        end        
+      end
+      format.xml do
+        @m2d_disease_links = M2dDiseaseLink.find(:all) if !@m2d_disease_links
+        render :xml => @m2d_disease_links
+      end
+    end
+  end
+
+  # GET /m2d_disease_links/1
+  # GET /m2d_disease_links/1.xml
+  def show
+    @m2d_disease_link = M2dDiseaseLink.find(params[:id])
+    
+    respond_to do |format|
+      format.html # show.html.erb
+      format.xml  { render :xml => @m2d_disease_link }
+    end
+  end
+  
+end

data/app/controllers/m2d_diseases_controller.rb

@@ -0,0 +1,44 @@
+class M2dDiseasesController < ApplicationController
+  layout "application"
+  protect_from_forgery :only => [:create, :update, :destroy]
+  
+  # GET /m2d_diseases
+  # GET /m2d_diseases.xml
+  def index
+    @m2d_diseases = nil
+    
+    params[:page] ||= 1
+        
+    respond_to do |format|
+      format.html do
+        if @m2d_diseases # subselect
+          @m2d_diseases = M2dDisease.paginate @m2d_diseases.map{|x| x.id}, :page => params[:page], :per_page => 12, :order => :name
+        else #all
+          @m2d_diseases = M2dDisease.paginate :page => params[:page], :per_page => 12, :order => :name
+        end        
+      end
+      format.xml do
+        @m2d_diseases = M2dDisease.find(:all) if !@m2d_diseases
+        render :xml => @m2d_diseases
+      end
+    end
+  end
+
+  # GET /m2d_diseases/1
+  # GET /m2d_diseases/1.xml
+  def show
+    @m2d_disease = nil
+    
+    if params[:m2d_disease_link_id]
+      @m2d_disease = M2dDiseaseLink.find(params[:m2d_disease_link_id]).m2d_disease
+    else
+      @m2d_disease = M2dDisease.find_rest(params[:id])
+    end
+    
+    respond_to do |format|
+      format.html # show.html.erb
+      format.xml  { render :xml => @m2d_disease }
+    end
+  end
+  
+end

data/app/models/m2d_disease.rb

@@ -0,0 +1,22 @@
+# == Schema Information
+#
+# Table name: m2d_diseases
+#
+#  id   :integer         not null, primary key
+#  doid :integer
+#  name :string(255)
+#
+
+
+class M2dDisease < ActiveRecord::Base
+  has_many :m2d_disease_links
+  
+  def self.find_rest(id)
+    self.find_by_doid(id)
+  end
+
+  def to_param
+    self.doid.to_s
+  end
+ 
+end

data/app/models/m2d_disease_link.rb

@@ -0,0 +1,27 @@
+# == Schema Information
+#
+# Table name: m2d_disease_links
+#
+#  id             :integer         not null, primary key
+#  mature_id      :integer
+#  m2d_disease_id :integer
+#  mirna          :string(255)
+#  expression     :string(255)
+#  method         :string(255)
+#  description    :text
+#  year           :integer
+#  pmid           :integer
+#  causal         :string(255)
+#  genes          :string(255)
+#
+
+
+class M2dDiseaseLink < ActiveRecord::Base
+  belongs_to :m2d_disease
+  belongs_to :mature
+  
+  def self.find_rest(id)
+    self.find(id)
+  end
+  
+end

data/app/views/m2d_disease_links/_list_for_mature.html.erb

@@ -0,0 +1,21 @@
+
+<p>Disease links registered in <a href="http://www.mir2disease.org">miR2Disease</a> for mature miRNA.</p>
+<% if !list_for_mature.empty? %>
+<table class="search">
+<tr><th>Disease link</th><th>Disease</th><th>Pubmed ID</th><th>Expression</th><th>Method</th><th>Genes</th><tr>
+
+<% list_for_mature.sort_by{|x| x.m2d_disease_id}.each do |m2d_disease_link| %>
+
+<tr class="<%= cycle("even","odd") %>">
+  <td><%= link_to "details ...", m2d_disease_link_path(m2d_disease_link) %></td>
+  <td><%= link_to m2d_disease_link.m2d_disease.name, m2d_disease_path(m2d_disease_link.m2d_disease) %></td>
+  <td><%= link_to m2d_disease_link.pmid, "http://www.ncbi.nlm.nih.gov/pubmed/#{m2d_disease_link.pmid}" %></td>
+  <td><%= m2d_disease_link.expression %></td>
+  <td><%= m2d_disease_link.method %></td>
+  <td><%= m2d_disease_link.genes %></td>
+</tr>
+
+<% end %>
+
+</table>
+<% end %>

data/app/views/m2d_disease_links/_m2d_disease_link.html.erb

@@ -0,0 +1,9 @@
+<tr class="<%= cycle("even","odd") %>">
+  <td><%= link_to "details ...", m2d_disease_link_path(m2d_disease_link) %></td>
+  <td><%= link_to m2d_disease_link.mature.name, mature_path(m2d_disease_link.mature) %></td>
+  <td><%= link_to m2d_disease_link.m2d_disease.name, m2d_disease_path(m2d_disease_link.m2d_disease) %></td>
+  <td><%= link_to m2d_disease_link.pmid, "http://www.ncbi.nlm.nih.gov/pubmed/#{m2d_disease_link.pmid}" %></td>
+  <td><%= m2d_disease_link.expression %></td>
+  <td><%= m2d_disease_link.method %></td>
+  <td><%= m2d_disease_link.genes %></td>
+</tr>

data/app/views/m2d_disease_links/index.html.erb

@@ -0,0 +1,18 @@
+<div id="col-top"></div>
+<div id="col">
+
+<h3>Listing Diseases</h3>
+
+<%= will_paginate @m2d_disease_links, :params => params %>
+
+<% if !@m2d_disease_links.empty? %>
+<table class="search">
+  <tr><th>Disease link</th><th>miRNA</th><th>Disease</th><th>Pubmed ID</th><th>Expression</th><th>Method</th><th>Genes</th><tr>
+  <%= render @m2d_disease_links %>
+</table>
+<% end %>
+
+Plugin based on data from <a href="http://www.mir2disease.org">miR2Disease</a>.
+
+</div> <!-- /col -->
+<div id="col-bottom"></div>

data/app/views/m2d_disease_links/show.html.erb

@@ -0,0 +1,21 @@
+<div id="col-top"></div>    
+<div id="col" class="box">
+
+Disease link between <%= link_to @m2d_disease_link.mature.name, mature_path(@m2d_disease_link.mature) %> and <%= link_to @m2d_disease_link.m2d_disease.name, m2d_disease_path(@m2d_disease_link.m2d_disease) %>.
+
+<table>
+  <tr><th align=left>miRNA ID (from miR2Disease)</th><td><%= @m2d_disease_link.mirna %></td></tr>
+  <tr><th align=left>Expression</th><td><%= @m2d_disease_link.expression %></td></tr>
+  <tr><th align=left>Method</th><td><%= @m2d_disease_link.method %></td></tr>
+  <tr><th align=left>Description</th><td><%= @m2d_disease_link.description %></td></tr>
+  <tr><th align=left>Reference (Pubmed ID)</th><td><%= link_to @m2d_disease_link.pmid, "http://www.ncbi.nlm.nih.gov/pubmed/#{@m2d_disease_link.pmid}" %></td></tr>
+  <tr><th align=left>Year</th><td><%= @m2d_disease_link.year %></td></tr>
+  <tr><th align=left>Genes</th><td><%= @m2d_disease_link.genes %></td></tr>
+  <tr><th align=left>Causal</th><td><%= @m2d_disease_link.causal %></td></tr>
+</table>
+
+Plugin based on data from <a href="http://www.mir2disease.org">miR2Disease</a>.
+
+</div> <!-- /col -->
+<div id="col-bottom"></div>
+

data/app/views/m2d_diseases/_m2d_disease.html.erb

@@ -0,0 +1,4 @@
+<tr class="<%= cycle("even","odd") %>">
+  <td><%= link_to m2d_disease.doid, m2d_disease_path(m2d_disease) %></td>
+  <td><%= m2d_disease.name %></td>
+</tr>

data/app/views/m2d_diseases/index.html.erb

@@ -0,0 +1,20 @@
+<div id="col-top"></div>
+<div id="col">
+
+<h3>Listing Diseases</h3>
+
+halllo <%= @m2d_diseases.size %>
+
+<%= will_paginate @m2d_diseases, :params => params %>
+
+<% if !@m2d_diseases.empty? %>
+<table class="search">
+  <tr><th>DOID</th><th>name</th><tr>
+  <%= render @m2d_diseases %>
+</table>
+<% end %>
+
+Plugin based on data from <a href="http://www.mir2disease.org">miR2Disease</a>.
+
+</div> <!-- /col -->
+<div id="col-bottom"></div>

data/app/views/m2d_diseases/show.html.erb

@@ -0,0 +1,25 @@
+<div id="col-top"></div>    
+<div id="col" class="box">
+
+<table>
+  <tr><th align=left>DOID</th><td><%= @m2d_disease.doid %></td></tr>
+  <tr><th align=left>Name</th><td><%= @m2d_disease.name %></td></tr>
+</table>
+
+
+<!-- render disease links here ... -->
+<div class="infobox">
+<h4><%= link_to_function "Disease links [#{@m2d_disease.m2d_disease_links.size}]", visual_effect(:toggle_blind,'disease_links',:duration=>0.2)  %></h4>
+<div id="disease_links" style="">
+<% if !@m2d_disease.m2d_disease_links.empty? %>
+<table class="search">
+  <tr><th>Disease link</th><th>miRNA</th><th>Disease</th><th>Pubmed ID</th><th>Expression</th><th>Method</th><th>Genes</th><tr>
+  <%= render @m2d_disease.m2d_disease_links.sort_by{|x| x.mirna} %>
+</table>
+<% end %>
+</div></div>
+
+Plugin based on data from <a href="http://www.mir2disease.org">miR2Disease</a>.
+
+</div> <!-- /col -->
+<div id="col-bottom"></div>

data/config/routes.rb

@@ -0,0 +1,12 @@
+ActionController::Routing::Routes.draw do |map|
+
+  map.resources :m2d_diseases, :only => [:index,:show] do |m2d|
+    m2d.resources :m2d_disease_links, :only => [:index]
+  end
+  
+  map.resources :m2d_disease_links, :only => [:index,:show] do |m2dl|
+    m2dl.resource :m2d_disease, :only => [:show]
+    m2dl.resource :mature, :only => [:show]
+  end
+  
+end

data/data/mir2dis.txt

@@ -0,0 +1,2568 @@
+miRNA	DOID	Disease	Expression	Method	Description	target	tarbase	Years	PMID	Causal
+hsa-miR-186	5520	head and neck squamous cell carcinoma (HNSCC)	down-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-222	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	KIT	2007	17942673	Unspecified
+hsa-miR-106a	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Expression patterns for these 5 microRNAs(miR-20a, miR-21, miR-106a, miR-181b, and miR-203) distinguish tumor vs paired nontumor status with 96% or 98% accuracy based on 3 nearest neighbors or nearest centroid algorithms, respectively (10-fold cross validation, repeated 100 times)."	unknown	RB1	2008	18230780	Unspecified
+hsa-miR-125b-2	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	survival-related and metastasis-related miRNA.	unknown	unknown	2008	18176954	Unspecified
+hsa-miR-147	9119	acute promyelocytic leukemia (APL)	up-regulated	"Northern blot, qRT-PCR etc"	differentially expressed during ATRA treatment of NB4 cells	unknown	unknown	2007	17260024	Unspecified
+hsa-miR-195	10286	prostate cancer	down-regulated	"Northern blot, qRT-PCR etc"	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	6			
+hsa-miR-433	14330	Parkinson's disease	normal	"Northern blot, qRT-PCR etc"	"The risk allele for rs12720208 disrupts a binding site for microRNA-433, increasing translation of FGF20 in vitro and in vivo. In a cell-based system and in Parkinson disease (PD) brains, this increase in translation of FGF20 is correlated with increased a-synuclein expression, which has previously been shown to cause PD through both overexpression and point mutations."	FGF20	unknown	2008	18252210	Causal
+hsa-miR-518b	9088	psoriasis	down-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	unknown	2007	17622355	Unspecified
+hsa-miR-9*	8524	follicular lymphoma (FL)	up-regulated	microarray	"Nine miRNAs (hsa-miR-9, hsa-miR-301, hsa-miR-213, hsa-miR-9*, hsa-miR-330, hsa-miR-106a, hsa-miR-338, hsa-miR-155, hsa-miR-210) were significantly up- and three miRNAs (hsa-miR-320, hsa-miR-149, hsa-miR-139) down-regulated in the lymphoma samples. Expression of hsa-miR-9 was most strongly increased (12-fold) and of hsa-miR-320 most strongly decreased (3-fold)."	unknown	unknown	2008	18537969	Unspecified
+hsa-miR-99a	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-122a	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-130a	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	unknown	2007	17616664	Unspecified
+hsa-miR-143	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-199a*	1909	uveal melanoma	up-regulated	microarray	"The top six miRNA discriminators ( let-7b, miR-199a,miR-199a*, miR-143, miR-193b, and miR-652) accurately distinguished class 1 (low metastatic risk) from class 2 (high metastatic risk) with 100% sensitivity and specificity."	unknown	unknown	2008	18477892	Unspecified
+hsa-miR-200c	5745	serous ovarian cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients. Higher expression of miR-200a, miR-200b, miR-200c, miR-141, miR-18a, miR-93, and miR-429, and lower expression of ambi-miR-7039, let-7b, and miR-199a were significantly correlated with decreased progression-free survival and overall survival."	unknown	unknown	2008	18451233	Unspecified
+hsa-miR-155	3969	papillary thyroid carcinoma (PTC)	up-regulated	microarray	Differentially expressed miRNA in PTC tumors	unknown	AGTR1	2005	16365291	Unspecified
+hsa-let-7f	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-let-7f	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	18			
+hsa-let-7f-1	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	miRNA precursors with significantly different expression.	unknown	unknown	2005	16192569	Unspecified
+hsa-let-7f-1	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	miRNA precursors with significantly different expression.	unknown	unknown	2005	16192569	Unspecified
+hsa-let-7f-1	3905	lung cancer	up-regulated	"Northern blot, qRT-PCR etc"	miRNA precursors with significantly different expression.	unknown	unknown	2005	16192569	Unspecified
+hsa-let-7f-1	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Aberrantly expressed miRNA precursors in pancreatic adenocarcinoma.PAM testing was conducted on 10 tumor samples and 15 adjacent benign samples. PAM has correctly classified 100% of the tested tumor samples and 11 of 15 of the tested benign samples. The 20 top ranked differentially expressed miRNAs in pancreatic adenocarcinoma as selected by PAM.	unknown	unknown	2006	17149698	Unspecified
+hsa-let-7f-1	3829	pituitary adenoma	down-regulated	microarray	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	unknown	2007	17111382	Unspecified
+hsa-let-7f-2	3459	breast cancer	down-regulated	microarray	Differentially expressed between breast carcinoma and normal breast tissue.	unknown	unknown	2005	16103053	Unspecified
+hsa-let-7f-2	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	unknown	2007	17616664	Unspecified
+hsa-let-7f-2	4451	kidney cancer	up-regulated	microarray	"A set of 4 human micro-RNAs (miR-28, miR-185, miR-27, and let-7f-2) were found significantly up-regulated in renal cell carcinoma (P<0.05) compared to normal kidney."	unknown	unknown	2007	17826655	Unspecified
+hsa-let-7g	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	metastasis-related miRNA	unknown	unknown	2008	18176954	Unspecified
+hsa-let-7g	3905	lung cancer	down-regulated	"Northern blot, qRT-PCR etc"	Overexpression of let-7 in lung cancer cell lines alters cell cycle progression and reduces cell division.multiple genes involved in cell cycle and cell division functions are also directly or indirectly repressed by let-7.	"CDK6, CDC25A"	unknown	2007	17699775	Causal
+hsa-let-7g	3908	non-small cell lung cancer (NSCLC)	down-regulated	"Northern blot, qRT-PCR etc"	"Ectopic expression of let-7g in K-Ras(G12D)-expressing murine lung cancer cells induced both cell cycle arrest and cell death. In tumor xenografts, the authors observed significant growth reduction of both murine and human non-small cell lung tumors when overexpression of let-7g was induced from lentiviral vectors. In let-7g expressing tumors, reductions in Ras family and HMGA2 protein levels were detected."	"Ras,HMGA2"	unknown	2008	18308936	Causal
+hsa-let-7g	2144	ovarian cancer (OC)	down-regulated	"Northern blot, qRT-PCR etc"	let-7 Regulates HMGA2 Expression in ovarian cancer (OC) and Predicts Disease Progression.	HMGA2	unknown	2007	17600087	Causal
+hsa-let-7g	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	unknown	2006	16609010	Unspecified
+hsa-let-7g	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-let-7g	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	unknown	2007	17616664	Unspecified
+hsa-let-7g	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-let-7g	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-let-7g	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	36			
+hsa-let-7g	10286	prostate cancer	up-regulated	microarray	One of the upregulated microRNAs in tumors with perineural invasion (FDR 10%).	unknown	unknown	2008	18459106	Unspecified
+hsa-let-7i	10652	Alzheimer's disease	down-regulated	microarray	Significantly changed miRNAs in cortex of sporadic AD cases.	unknown	unknown	2008	18434550	Unspecified
+hsa-let-7i	3459	breast cancer	up-regulated	microarray	Differentially expressed between breast carcinoma and normal breast tissue.	unknown	unknown	2005	16103053	Unspecified
+hsa-let-7i	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-1	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	"The muscle-specific miR-1 was singularly downregulated as early as day 1, persisting through day 7, after aortic constriction�Cinduced hypertrophy in a mouse model. Overexpression experiments showed that miR-1 inhibited its in silico�Cpredicted, growth-related targets, including Ras GTPase�Cactivating protein (RasGAP), cyclin-dependent kinase 9 (Cdk9), fibronectin, and Ras homolog enriched in brain (Rheb), in addition to protein synthesis and cell size."	"RasGAP,Cdk9, fibronectin,Rheb"	"GJA1,Hand2,HDAC4,TMSB4X"	2008	17234972	Causal
+hsa-miR-1	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Down-regulation of miR-1 and miR-133 expression contributes to re-expression of HCN2/HCN4 thereby the electrical remodeling process in hypertrophic hearts.	HCN4	"GJA1,Hand2,HDAC4,TMSB4X"	2008	18458081	Causal
+hsa-miR-203	3498	pancreatic ductal adenocarcinoma (PDAC)	up-regulated	microarray	differentially expressed between normal and PDAC or cell line samples.	unknown	unknown	2007	17237814	Unspecified
+hsa-miR-203	13223	uterine leiomyoma (ULM)	down-regulated	microarray	Twenty most differentially expressed microRNA species in leiomyoma versus myometrium microarray.	unknown	unknown	2008	17765232	Unspecified
+hsa-miR-204	9119	acute myeloid leukemia (AML)	down-regulated	"Northern blot, qRT-PCR etc"	"The authors confirmed that miR-204 targets HOXA10 and MEIS1, suggesting that the HOX upregulation observed inNPMc AMLmaybe due in part by loss ofHOX regulators-miRNAs."	"HOXA10, MEIS1"	unknown	2008	18308931	Causal
+hsa-miR-204	3459	breast cancer	down-regulated	microarray	Differentially expressed between breast carcinoma and normal breast tissue.	unknown	unknown	2005	16103053	Unspecified
+hsa-miR-204	3903	Insulinoma	up-regulated	"Northern blot, qRT-PCR etc"	Overexpression of miR-204 is Specific to Insulinomas and Correlates With Immunohistochemical Expression of Insulin.	unknown	unknown	2006	16966691	Unspecified
+hsa-miR-204	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-204	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-205	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"All five members of the microRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141 and miR-429) and miR-205 were markedly downregulated in cells that had undergone EMT in response to transforming growth factor (TGF)-beta or to ectopic expression of the protein tyrosine phosphatase Pez. Enforced expression of the miR-200 family alone was sufficient to prevent TGF-beta-induced EMT. Together, these microRNAs cooperatively regulate expression of the E-cadherin transcriptional repressors ZEB1 (also known as deltaEF1) and SIP1 (also known as ZEB2), factors previously implicated in EMT and tumour metastasis. Inhibition of the microRNAs was sufficient to induce EMT in a process requiring upregulation of ZEB1 and/or SIP1. Conversely, ectopic expression of these microRNAs in mesenchymal cells initiated mesenchymal to epithelial transition (MET). Consistent with their role in regulating EMT, expression of these microRNAs was found to be lost in invasive breast cancer cell lines with mesenchymal phenotype. Expression of the miR-200 family was also lost in regions of metaplastic breast cancer specimens lacking E-cadherin. These data suggest that downregulation of the microRNAs may be an important step in tumour progression."					
+	"ZEB1(deltaEF1), SIP1(ZEB2)"	unknown	2008	18376396	Causal	1	50			
+hsa-miR-205	4007	bladder cancer	up-regulated	microarray	"Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b,miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P<0.05) compared to normal bladder"					
+mucosa.	unknown	unknown	2007	17826655	Unspecified	0	51			
+hsa-miR-205	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"miR-205 expression change is statistically significant at the CIS(n = 31,P<0.001, Wilcoxon signed-ranks test) and ICa stages (n =51,P<0.001, Wilcoxon signed-ranks test) compared with normal."	unknown	unknown	2007	18089790	Unspecified
+hsa-miR-205	1107	esophageal cancer	down-regulated	microarray	Both hsa-miR-203 and hsa-miR-205 were expressed 2- to 10-fold lower in squamous cell carcinoma and adenocarcinomas than in normal epithelium. The hsa-miR-21 expression was 3- to 5-fold higher in both tumors than in normal epithelium.	unknown	unknown	2008	18242245	Unspecified
+hsa-miR-205	11934	Head and neck cancer	up-regulated	"Northern blot, qRT-PCR etc"	miRNA precursors with significantly different expression.	unknown	unknown	2005	16192569	Unspecified
+hsa-miR-205	3905	lung cancer	up-regulated	"Northern blot, qRT-PCR etc"	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-205	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-205	3498	pancreatic ductal adenocarcinoma (PDAC)	up-regulated	microarray	differentially expressed between normal and PDAC or cell line samples.	unknown	unknown	2007	17237814	Unspecified
+hsa-miR-205	10286	prostate cancer	down-regulated	"Northern blot, qRT-PCR etc"	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	58			
+hsa-miR-206	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Transfection of MCF-7 cells with pre-miR-206 or 2'-O-methyl antagomiR-206 specifically decreased or increased, respectively, ER��  mRNA levels.MiR-206 expression was strongly inhibited by ER�� agonists, but not by an ER�� agonist or progesterone, indicating a mutually inhibitory feedback loop."	ER-alpha	"Fstl1,GJA1,Utrn"	2007	17312270	Causal
+hsa-miR-155	10222	polymyositis (PM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	AGTR1	2007	17942673	Unspecified
+hsa-miR-15a	1040	chronic lymphocytic leukemia (CLL)	up-regulated	"Northern blot, qRT-PCR etc"	MicroRNA Signature Associated with Prognostic Factors (ZAP-70 Expression and IgVH Mutations) and Disease Progression in Patients with CLL.	unknown	unknown	2005	16251535	Unspecified
+hsa-miR-15a	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	survival-related and metastasis-related miRNA.	unknown	unknown	2008	18176954	Unspecified
+hsa-miR-15a	9119	acute promyelocytic leukemia (APL)	up-regulated	"Northern blot, qRT-PCR etc"	There is a negative correlation between miR-15a and miR-16-1 expression and BCL2 during ATRA-induced granulocytic differentiation of NB4 cells.	"BCL2, RAS"	unknown	2007	17260024	Causal
+hsa-miR-15a	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	"Both miR-15a and miR-16-1 recognize target sites on the 3'UTR of BCL2, an anti-apoptotic"					
+oncogene. These miRNAs control the level of BCL2 in normal cells but the expression of the										
+oncogene is increased when the miRNAs are deleted leading to CLL.	BCL2	unknown	2005	16166262	Causal	1	64			
+hsa-miR-15a	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	"miR-15a and miR-16-1, both microRNAs negatively regulate BCL2 at a post-transcriptional level and BCL2 repression induces apoptosis in MEG-01 chronic leukemia cell line and reduced in-vivo tumorigenicity."	BCL2	unknown	2007	17707831	Causal
+hsa-miR-15a	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	"Among the components of the miR-15a/16-1 signature,The authors observed a statistically significant enrichment in AU-rich elements (AREs). By examining the Gene Ontology (GO) database, a significant enrichment in cancer genes (such as MCL1, BCL2, ETS1, or JUN) that directly or indirectly affect apoptosis and cell cycle was found."					
+	unknown	unknown	2008	18362358	Causal	1	66			
+hsa-miR-15a	3829	pituitary adenoma	down-regulated	"Northern blot, qRT-PCR etc"	"miR-15a and miR-16-1 are expressed at lower levels in pituitary adenomas as compared to normal pituitary tissue. Moreover, their expression inversely correlates with tumor diameter and with RARS expression (P<0.05), but directly correlates with p43 secretion (P<0.02)."	RAS	unknown	2005	15648093	Causal
+hsa-miR-15a	10652	Alzheimer's disease	down-regulated	microarray	Significantly changed miRNAs in cortex of sporadic AD cases.	unknown	unknown	2008	18434550	Unspecified
+hsa-miR-15a	1208	autism spectrum disorder (ASD)	up-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	unknown	2008	18563458	Unspecified
+hsa-miR-15a	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-15a	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-15a-2	10286	prostate cancer	up-regulated	microarray	One of the upregulated microRNAs in tumors with perineural invasion (FDR 10%).	unknown	unknown	2008	18459106	Unspecified
+hsa-miR-15b	5517	gastric cancer (stomach cancer)	down-regulated	"Northern blot, qRT-PCR etc"	"In vitro drug sensitivity assay demonstrated that overexpression of miR-15b or miR-16 sensitized SGC7901/VCR cells to anticancer drugs whereas inhibition of them using antisense oligonucleotides conferred SGC7901 cells MDR. The downregulation of miR-15b and miR-16 in SGC7901/VCR cells was concurrent with the upregulation of Bcl-2 protein. Enforced mir-15b or miR-16 expression reduced Bcl-2 protein level and the luciferase activity of a BCL2 3' untranslated region-based reporter construct in SGC7901/VCR cells, suggesting that BCL2 is a direct target of miR-15b and miR-16. Moreover, overexpression of miR-15b or miR-16 could sensitize SGC7901/VCR cells to VCR-induced apoptosis."	BCL2	unknown	2008	18449891	Causal
+hsa-miR-15b	9119	acute myeloid leukemia (AML)	down-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-15b	9119	acute promyelocytic leukemia (APL)	up-regulated	microarray	"Upregulation of miR-15a,miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223,miR-342 and miR-107, whereas miR-181b was downregulated in in acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment."	unknown	unknown	2007	17260024	Unspecified
+hsa-miR-15b	1208	autism spectrum disorder (ASD)	up-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	unknown	2008	18563458	Unspecified
+hsa-miR-15b	1040	B-cell chronic lymphocytic leukemia	up-regulated	microarray	Differentially expressed in CLL cells versus CD15 cells.	unknown	unknown	2004	15284443	Unspecified
+hsa-miR-15b	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-15b	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	eIF-4A	unknown	2006	16609010	Unspecified
+hsa-miR-15b	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	"miR-15b (p = 0.0278), miR-181b (p = 0.0002), miR-191(p = 0.0264) and miR-200c (p = 0.0017) were significantly over-expressed in tumors compared to normal colorectal samples."	unknown	unknown	2006	18079988	Unspecified
+hsa-miR-15b	3908	non-small cell lung cancer (NSCLC)	up-regulated	microarray	differentially expressed miRNA in TRAIL-resistant NSCLC cells.	unknown	unknown	2008	18246122	Unspecified
+hsa-let-7c	9119	acute myeloid leukemia (AML)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	unknown	2007	18056805	Unspecified
+hsa-let-7c	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-let-7c	2893	cervical cancer	down-regulated	microarray	"let-7b, let-7c, miR-23b, miR-196b, and miR-143 showed significantly reduced abundance in cervical cancer cell lines. miR-21 displayed higher abundance in the cancer group."	unknown	unknown	2007	17616659	Unspecified
+hsa-let-7c	14250	Down syndrome (DS)	up-regulated	"Northern blot, qRT-PCR etc"	"Bioinformatic analyses demonstrate that human chromosome 21(Hsa21) harbors five miRNA genes; miR-99a, let-7c, miR-125b-2, miR-155, and miR-802. MiRNA expression profiling, miRNA RT-PCR, and miRNA in situ hybridization experiments demonstrate that these miRNAs are overexpressed in fetal brain and heart specimens from individuals with DS when compared with age- and sex-matched controls."	unknown	unknown	2008	18387358	Unspecified
+hsa-let-7c	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	Differentially expressed between tumors and normals.	unknown	unknown	2007	17875710	Unspecified
+hsa-let-7c	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	unknown	2007	17616664	Unspecified
+hsa-let-7c	3905	lung cancer	up-regulated	"Northern blot, qRT-PCR etc"	miRNA precursors with significantly different expression.	unknown	unknown	2005	16192569	Unspecified
+hsa-let-7c	3905	lung cancer	down-regulated	"Northern blot, qRT-PCR etc"	"let-7c,miR-99a, and miR-125b-2 were also mapped in a region with Homozygous Deletion at 21q11-q21."	unknown	unknown	2007	17674361	Unspecified
+hsa-let-7c	10286	prostate cancer	up-regulated	"Northern blot, qRT-PCR etc"	miRNA precursors with significantly different expression.	unknown	unknown	2005	16192569	Unspecified
+hsa-let-7c	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	91			
+hsa-let-7c	13223	uterine leiomyoma (ULM)	up-regulated	"Northern blot, qRT-PCR etc"	One of the top five up-regulated miRNAs in Uterine Leiomyomas (ULMs).Overexpression of the let-7					
+"miRNAs is significant in more than two-thirds of the ULMs examined. The cause of let-7 overexpression in ULMs is unclear. Let-7 miRNAs may affect the tumorigenesis of ULMs in several aspects. First, overexpression of let-7 miRNAs in ULMs may play a role in promoting terminal differentiation of these smooth muscle tumors as we see in embryonic development. Second, given that ULMs are benign and rarely progress to malignancy, a high level of let-7 miRNAs in ULMs may be the"										
+"protective factors preventing overexpression of their targeting oncogenes, such as RAS and MYC."	HMGA2	unknown	2007	17243163	Unspecified	0	92			
+hsa-let-7d	9119	acute promyelocytic leukemia (APL)	up-regulated	"Northern blot, qRT-PCR etc"	"Upregulation of miR-15a,miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223,miR-342 and miR-107, whereas miR-181b was downregulated in in acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment."	"BCL2, RAS"	unknown	2007	17260024	Causal
+hsa-let-7d	3905	lung cancer	down-regulated	"Northern blot, qRT-PCR etc"	Overexpression of let-7 in lung cancer cell lines alters cell cycle progression and reduces cell division.multiple genes involved in cell cycle and cell division functions are also directly or indirectly repressed by let-7.	"CDK6, CDC25A"	unknown	2007	17699775	Causal
+hsa-let-7d	2144	ovarian cancer (OC)	down-regulated	"Northern blot, qRT-PCR etc"	Ovarian cancer (OC) patients with high HMGA2 and low let-7 expression in their cancer cells had a lower survival than patients with a low HMGA2/high let-7 ratio. HMGA2 upregulation occurs early during OC progression before the tumors begin to metastasize both in human patients and in an OC mouse model.HMGA2 is a more sensitive target of let-7 than RAS.	HMGA2	unknown	2007	17957144	Causal
+hsa-let-7d	3459	breast cancer	down-regulated	microarray	Differentially expressed between breast carcinoma and normal breast tissue.	unknown	unknown	2005	16103053	Unspecified
+hsa-let-7d	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	Differentially expressed between tumors and normals.	unknown	unknown	2007	17875710	Unspecified
+hsa-let-7d	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	DNA copy number status of 17 genomic loci containing miRNAs differentially expressed between IOSE cells and EOC cell lines.	unknown	unknown	2008	18458333	Unspecified
+hsa-let-7d	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	unknown	2007	17616664	Unspecified
+hsa-let-7d	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-let-7d	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-let-7d	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Aberrantly expressed miRNA precursors in pancreatic adenocarcinoma.PAM testing was conducted on 10 tumor samples and 15 adjacent benign samples. PAM has correctly classified 100% of the tested tumor samples and 11 of 15 of the tested benign samples. The 20 top ranked differentially expressed miRNAs in pancreatic adenocarcinoma as selected by PAM.	unknown	unknown	2006	17149698	Unspecified
+hsa-let-7d	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	103			
+hsa-let-7d*	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-let-7e	3905	lung cancer	down-regulated	"Northern blot, qRT-PCR etc"	let-7 reduces the expression of HMGA2 and cell proliferation.	HMGA2	SMC1L1	2007	17437991	Causal
+hsa-let-7e	9952	acute lymphoblastic leukemia (ALL)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	SMC1L1	2007	18056805	Unspecified
+hsa-let-7e	9119	acute myeloid leukemia (AML)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	SMC1L1	2007	18056805	Unspecified
+hsa-let-7e	9119	acute myeloid leukemia (AML)	up-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	SMC1L1	2008	18478077	Unspecified
+hsa-let-7e	353	diffuse large B-cell lymphoma (DLBCL)	down-regulated	microarray	"Four hsa-miR-As (miR-210, hsa-miR-155, hsa-miR-106a, hsa-miR-17-5p) were expressed at a significantly higher level in DLBCL than in normal tissue. In contrast, the remaining 11 miRNAs (hsa-miR-150, hsa-miR-145, hsa-miR-328, hsa-miR-139, hsa-miR-99a, hsa-miR-10a, hsa-miR-95, hsa-miR-149, hsa-miR-320, hsa-miR-151,let-7e) were expressed at a significantly lower level in DLBCL."	unknown	SMC1L1	2008	18537969	Unspecified
+hsa-let-7e	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	SMC1L1	2007	17222355	Unspecified
+hsa-let-7e	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	SMC1L1	2007	17616664	Unspecified
+hsa-let-7e	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	SMC1L1	2008	18379589	Unspecified
+hsa-let-7e	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	SMC1L1	2008	18381414	Unspecified
+hsa-let-7e	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	SMC1L1	2008	18560586	Unspecified
+hsa-let-7e	3829	pituitary adenoma	down-regulated	microarray	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	SMC1L1	2007	17111382	Unspecified
+hsa-let-7e	9088	psoriasis	down-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	SMC1L1	2007	17622355	Unspecified
+hsa-let-7f	3905	lung cancer	down-regulated	"Northern blot, qRT-PCR etc"	reduced let-7 expression is significantly associated with shortened postoperative survival and that overexpression of let-7 results in the inhibition of lung cancer cell growth.	unknown	unknown	2004	15172979	Causal
+hsa-miR-206	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	miR-206 regulate migration and morphology.	unknown	"Fstl1,GJA1,Utrn"	2008	18185580	Causal
+hsa-let-7a	4947	cholangiocarcinoma	up-regulated	"Northern blot, qRT-PCR etc"	miRNA expression both in vitro and in vivo is altered by overexpression of IL-6; selective miRNAs including let-7a are up-regulated and contribute to the survival effects of enforced IL-6 activity; and let-7a contributes to the constitutively increased phosphorylation of Stat-3 by a mechanism involving the neurofibromatosis 2 (NF2) gene.	NF2	NF2	2007	17220301	Causal
+hsa-let-7a	657	adenoma	normal	"Northern blot, qRT-PCR etc"	"Translocations involving HMGA2 and numerous translocation partners.These translocations generate a truncated HMGA2 mRNA lacking the let-7 complementary sites of the wild-type mRNA and are associated with the indicated tumors. In its 3'UTR, human HMGA2 has seven let-7 complementary sites, all of which are conserved in the mouse, rat, dog, and chicken."	HMGA2	NF2	2007	17322030	Causal
+hsa-let-7a	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Increased let-7 paralleled reduced H-RAS and HMGA2, known let-7 targets. Silencing H-RAS in a breast tumor-initiating cells(BTIC)- enriched cell line reduced self renewal but had no effect on differentiation, while silencing HMGA2 enhanced differentiation but did not affect self renewal. Therefore let-7 regulates multiple BT-IC stem cell-like properties by silencing more than one target."	"RAS, HMGA2"	NF2	2007	18083101	Causal
+hsa-let-7a	8584	Burkitt lymphoma	down-regulated	"Northern blot, qRT-PCR etc"	Regulation of MYC mRNA by let-7a was confirmed by transfections with pre-let-7a. Overexpression of let-7a(190%) decreased Myc mRNA (70%) and protein (75%).	MYC	NF2	2007	17942906	Causal
+hsa-let-7a	5517	gastric cancer (stomach cancer)	down-regulated	"Northern blot, qRT-PCR etc"	"High expression of HMGA2 in gastric cancer correlates with tumor invasiveness and is an independent prognostic factor. Furthermore, our findings suggest that HMGA2 is negatively regulated by the let-7 miRNA family in human gastric cancer."	HMGA2	NF2	2008	18413822	Causal
+hsa-let-7a	3462	hamartoma	normal	"Northern blot, qRT-PCR etc"	"Translocations involving HMGA2 and numerous translocation partners.These translocations generate a truncated HMGA2 mRNA lacking the let-7 complementary sites of the wild-type mRNA and are associated with the indicated tumors. In its 3'UTR, human HMGA2 has seven let-7 complementary sites, all of which are conserved in the mouse, rat, dog, and chicken."	HMGA2	NF2	2007	17322030	Causal
+hsa-let-7a	8567	Hodgkin's lymphoma	up-regulated	"Northern blot, qRT-PCR etc"	"miR-9 and let-7a functionally targeted specific binding sites in the 3' untranslated region of PRDM1/blimp-1 mRNA and repressed luciferase reporter activities through repression of translation. Similar to their in vitro counterparts, the majority of HRS cells in primary Hodgkin lymphoma (HL) cases showed weak or no PRDM1/Blimp-1 expression. Over-expression of miR-9 or let-7a reduced PRDM1/Blimp-1 levels in U266 cells by 30% to 50%, whereas simultaneous inhibition of their activities in L428 cells resulted in an approximately 2.6-fold induction in PRDM1/Blimp-1. MiRNA-mediated down-regulation of PRDM1/Blimp-1 may contribute to the phenotype maintenance and pathogenesis of HRS cells by interfering with normal B-cell terminal differentiation, thus representing a novel molecular lesion, as well as a potential therapeutic target in HL."	PRDM1/Blimp-1	NF2	2008	18583325	Causal
+hsa-let-7a	9291	lipoma	normal	"Northern blot, qRT-PCR etc"	Translocations involving HMGA2 and numerous translocation partners.These translocations generate					
+"a truncated HMGA2 mRNA lacking the let-7 complementary sites of the wild-type mRNA and are associated with the indicated tumors. In its 3'UTR, human HMGA2 has seven let-7 complementary sites, all of which are conserved in the mouse, rat, dog, and chicken."	HMGA2	NF2	2007	17322030	Causal	1	126			
+hsa-let-7a	3905	lung cancer	down-regulated	"Northern blot, qRT-PCR etc"	reduced let-7 expression is significantly associated with shortened postoperative survival and that overexpression of let-7 results in the inhibition of lung cancer cell growth.	unknown	NF2	2004	15172979	Causal
+hsa-let-7a	3905	lung cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Overexpression of let-7 can inhibit lung tumor cell line growth.the expression of the RAS oncogene is regulated by let-7, and RAS is significantly overexpressed in lung tumor samples strongly implicate let-7 as a tumor suppressor in lung tissue and suggests a possible mechanism."	RAS	NF2	2005	15766527	Causal
+hsa-let-7a	3905	lung cancer	down-regulated	"Northern blot, qRT-PCR etc"	Overexpression of let-7 in lung cancer cell lines alters cell cycle progression and reduces cell division.multiple genes involved in cell cycle and cell division functions are also directly or indirectly repressed by let-7.	"CDK6, CDC25A"	NF2	2007	17699775	Causal
+hsa-let-7a	2691	myoma	normal	"Northern blot, qRT-PCR etc"	"Translocations involving HMGA2 and numerous translocation partners.These translocations generate a truncated HMGA2 mRNA lacking the let-7 complementary sites of the wild-type mRNA and are associated with the indicated tumors. In its 3'UTR, human HMGA2 has seven let-7 complementary sites, all of which are conserved in the mouse, rat, dog, and chicken."	HMGA2	NF2	2007	17322030	Causal
+hsa-let-7a	3908	non-small cell lung cancer (NSCLC)	down-regulated	"Northern blot, qRT-PCR etc"	"A five-microRNA signature (let-7a, miR-221, miR-137, miR-372, and miR-182*) that is associated with survival and cancer relapse in NSCLC patients. This microRNA signature was validated by the testing set and an independent cohort. Patients with high-risk scores in their microRNA signatures had poor overall and disease-free survivals compared to the low-risk-score patients. This microRNA signature is an independent predictor of the cancer relapse and survival of NSCLC patients.promoted invasiveness of lung cancer cell lines."	unknown	NF2	2008	18167339	Causal
+hsa-let-7a	2144	ovarian cancer (OC)	down-regulated	"Northern blot, qRT-PCR etc"	let-7 Regulates HMGA2 Expression in ovarian cancer (OC) and Predicts Disease Progression.	HMGA2	NF2	2007	17600087	Causal
+hsa-let-7a	1115	sarcoma	normal	"Northern blot, qRT-PCR etc"	"Translocations involving HMGA2 and numerous translocation partners.These translocations generate a truncated HMGA2 mRNA lacking the let-7 complementary sites of the wild-type mRNA and are associated with the indicated tumors. In its 3'UTR, human HMGA2 has seven let-7 complementary sites, all of which are conserved in the mouse, rat, dog, and chicken."	HMGA2	NF2	2007	17322030	Causal
+hsa-let-7a	9952	acute lymphoblastic leukemia (ALL)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	NF2	2007	18056805	Unspecified
+hsa-let-7a	9119	acute myeloid leukemia (AML)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	NF2	2007	18056805	Unspecified
+hsa-let-7a	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	let-7a is conserved broadly in many animal species with higher levels in differentiated normal cells and to be decreased in tumoral undifferentiated cells.	unknown	NF2	2007	17989717	Unspecified
+hsa-let-7a	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	The expression of let-7 miRNA in tumour tissues was considerably down-regulated by over 90% in two of					
+the eight patients compared with the expression in adjacent normal tissues from the same patient.	unknown	NF2	2007	17944059	Unspecified	0	137			
+hsa-let-7a	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	Differentially expressed between tumors and normals.	unknown	NF2	2007	17875710	Unspecified
+hsa-let-7a	5517	gastric cancer (stomach cancer)	down-regulated	"Northern blot, qRT-PCR etc"	"The expression level of let-7a miRNA in tumors was significantly lower (down-regulation rate over 2-fold) in 14 patients tested. However, in the other 18 patients, no significant difference in let-7a miRNA expression was observed between tumors and normal tissues, and the up- or down-regulation rates were within two-fold."	unknown	NF2	2007	17569129	Unspecified
+hsa-let-7a	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	NF2	2008	18379589	Unspecified
+hsa-let-7a	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	NF2	2007	17942673	Unspecified
+hsa-let-7a	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	NF2	2007	17616669	Unspecified	0	142			
+hsa-let-7a-1	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	"let-7 low-expressing DLD-1 human colon cancer cells were transfected with let-7a-1 precursor miRNA, the cells underwent significant growth suppression. At that time, the levels of RAS and c-myc proteins were lowered after the transfection, whereas the levels of both of their mRNAs remained almost unchanged."	"RAS,c-myc"	unknown	2006	16651716	Causal
+hsa-let-7a-1	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	"Three of the deregulated miRNAs (miR-221, let-7a-1, and miR-122a) were further assayed by Northern blot and quantitative realtime RT-PCR for validation purposes.Overall, Northern blot analysis revealed that miR-221 was up-regulated in 83% of HCCs when compared with matched cirrhotic tissue, let-7a-1 was down-regulated in 70% of HCCs, and miR-122a resulted down-regulated in 70%"					
+of HCCs.	unknown	unknown	2007	17616664	Unspecified	0	144			
+hsa-let-7a-1	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-let-7a-1	3829	pituitary adenoma	down-regulated	microarray	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	unknown	2007	17111382	Unspecified
+hsa-let-7a-2	3905	lung cancer	down-regulated	"Northern blot, qRT-PCR etc"	"miRNAs (miR-155, miR-17-3p, miR-106a, miR-93, let-7a-2, miR-145, let-7b, and miR-21) were related to the adenocarcinoma patient��s survival. Patients with high expression of either mir-155, miR-17-3p, miR-106a, miR-93, or miR-21 and low expression of either let-7a-2, let-7b, or miR-145 were found to have a significantly worse prognosis."	unknown	unknown	2006	16530703	Unspecified
+hsa-let-7a-2	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	unknown	2007	17616664	Unspecified
+hsa-let-7a-2	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-let-7a-3	9119	acute promyelocytic leukemia (APL)	up-regulated	"Northern blot, qRT-PCR etc"	"Upregulation of miR-15a,miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223,miR-342 and miR-107, whereas miR-181b was downregulated in in acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment."	"BCL2, RAS"	unknown	2007	17260024	Causal
+hsa-let-7a-3	4001	epithelial ovarian cancer (EOC)	down-regulated	"Northern blot, qRT-PCR etc"	"let-7a-3 methylation was detected in epithelial ovarian cancer, and the expression of let-7a was slightly affected by the methylation, but the effect was not substantial. The methylation of let-7a-3, however, was inversely correlated with IGF-II expression and positively with insulin-like growth factor binding protein-3 (IGFBP-3) expression. Patients with methylated let-7a-3 seemed to have reduced risk for death compared with those without, and the association was independent of patient age at surgery, tumor grade, disease stage, and IGF-II or IGFBP-3 expression. No association was found for let-7a-3 methylation and disease progression. These results suggest that the let-7a-3 gene is methylated and the methylation may affect IGF-II expression and the survival of ovarian cancer patients."	IGF-II	unknown	2007	17974952	Causal
+hsa-let-7a-3	3905	lung cancer	up-regulated	"Northern blot, qRT-PCR etc"	"The let-7a-3's putative promoter region is heavily methylated by DNMT1 and DNMT3B in normal human tissues, but hypomethylated in lung adenocarcinomas. Let-7a-3��s promoter demethylation induced reactivation of the gene and increased proliferation in a lung cancer cell lines."	unknown	unknown	2007	17308078	Causal
+hsa-let-7a-3	3459	breast cancer	down-regulated	microarray	Differentially expressed between breast carcinoma and normal breast tissue.	unknown	unknown	2005	16103053	Unspecified
+hsa-let-7a-3	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	unknown	2007	17616664	Unspecified
+hsa-let-7a-3	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-let-7b	5745	serous ovarian cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients. Higher expression of miR-200a, miR-200b, miR-200c, miR-141, miR-18a, miR-93, and miR-429, and lower expression of ambi-miR-7039, let-7b, and miR-199a were significantly correlated with decreased progression-free survival and overall survival."	unknown	"Lin28,Mtpn"	2008	18451233	Unspecified
+hsa-let-7b	3905	lung cancer	down-regulated	"Northern blot, qRT-PCR etc"	let-7 reduces the expression of HMGA2 and cell proliferation.	HMGA2	"Lin28,Mtpn"	2007	17437991	Causal
+hsa-let-7b	3905	lung cancer	down-regulated	"Northern blot, qRT-PCR etc"	Overexpression of let-7 in lung cancer cell lines alters cell cycle progression and reduces cell division.multiple genes involved in cell cycle and cell division functions are also directly or indirectly repressed by let-7.	"CDK6, CDC25A"	"Lin28,Mtpn"	2007	17699775	Causal
+hsa-let-7b	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Immunoblot and immunofluorescence analyses showed that overexpression of let-7b in melanoma cells resulted in significant downregulation of cyclins D1, D3, and Cdk4 protein expression. Downregulation of cyclin A protein expression was less prominent. Moreover, the negative regulatory effect of let-7b on cyclin D1 expression was indeed mediated through binding to 3��UTR of the"					
+"target, as shown by in vitro luciferase assays.let-7b might be an important negative regulator of melanoma cell growth and proliferation via inhibition of cell cycle progression."	CCND1	"Lin28,Mtpn"	2008	18379589	Causal	1	159			
+hsa-let-7b	9952	acute lymphoblastic leukemia (ALL)	down-regulated	"Northern blot, qRT-PCR etc"	"miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly downregulated in ALL compared with AML. They are the most discriminatory miRNAs between ALL and AML. Using the expression signatures of a minimum of two of these miRNAs resulted in an accuracy rate of >95% in the diagnosis of ALL and AML."	unknown	"Lin28,Mtpn"	2007	18056805	Unspecified
+hsa-let-7b	9119	acute myeloid leukemia (AML)	up-regulated	"Northern blot, qRT-PCR etc"	"miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly downregulated in ALL compared with AML. They are the most discriminatory miRNAs between ALL and AML. Using the expression signatures of a minimum of two of these miRNAs resulted in an accuracy rate of >95% in the diagnosis of ALL and AML."	unknown	"Lin28,Mtpn"	2007	18056805	Unspecified
+hsa-let-7b	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	"Lin28,Mtpn"	2008	17234972	Unspecified
+hsa-let-7b	2893	cervical cancer	down-regulated	microarray	"let-7b, let-7c, miR-23b, miR-196b, and miR-143 showed significantly reduced abundance in cervical cancer cell lines. miR-21 displayed higher abundance in the cancer group."	unknown	"Lin28,Mtpn"	2007	17616659	Unspecified
+hsa-let-7b	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	"Lin28,Mtpn"	2006	16609010	Unspecified
+hsa-let-7b	11727	facioscapulohumeral muscular dystrophy (FSHD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	"Lin28,Mtpn"	2007	17942673	Unspecified
+hsa-let-7b	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	"Lin28,Mtpn"	2007	17616664	Unspecified
+hsa-let-7b	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	"Lin28,Mtpn"	2007	17942673	Unspecified
+hsa-let-7b	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	"Lin28,Mtpn"	2007	17942673	Unspecified
+hsa-let-7b	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	"Lin28,Mtpn"	2007	17942673	Unspecified
+hsa-let-7b	769	neuroblastoma (NB)	up-regulated	"Northern blot, qRT-PCR etc"	Positively correlated with MYCN-amplification in tumors in vivo.	unknown	"Lin28,Mtpn"	2007	17943719	Unspecified
+hsa-let-7b	12236	primary biliary cirrhosis (PBC)	down-regulated	"Northern blot, qRT-PCR etc"	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	"Lin28,Mtpn"	2008	18631158	Unspecified
+hsa-let-7b	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	"Lin28,Mtpn"	2007	17616669	Unspecified	0	172			
+hsa-let-7b	1909	uveal melanoma	up-regulated	"Northern blot, qRT-PCR etc"	"The top six miRNA discriminators ( let-7b, miR-199a,miR-199a*, miR-143, miR-193b, and miR-652) accurately distinguished class 1 (low metastatic risk) from class 2 (high metastatic risk) with 100% sensitivity and specificity."	unknown	"Lin28,Mtpn"	2008	18477892	Unspecified
+hsa-let-7c	9119	acute promyelocytic leukemia (APL)	up-regulated	"Northern blot, qRT-PCR etc"	"Upregulation of miR-15a,miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223,miR-342 and miR-107, whereas miR-181b was downregulated in in acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment."	"BCL2, RAS"	unknown	2007	17260024	Causal
+hsa-let-7c	3905	lung cancer	down-regulated	"Northern blot, qRT-PCR etc"	Overexpression of let-7 in lung cancer cell lines alters cell cycle progression and reduces cell division.multiple genes involved in cell cycle and cell division functions are also directly or indirectly repressed by let-7.	"CDK6, CDC25A"	unknown	2007	17699775	Causal
+hsa-let-7c	2144	ovarian cancer (OC)	down-regulated	"Northern blot, qRT-PCR etc"	let-7 Regulates HMGA2 Expression in ovarian cancer (OC) and Predicts Disease Progression.	HMGA2	unknown	2007	17600087	Causal
+hsa-let-7c	10286	prostate cancer	down-regulated	"Northern blot, qRT-PCR etc"	"let-7c, miR-145 and miR-125b target mRNAs whose proteins have been shown to be increased in prostate cancer. "	RAS	unknown	2007	17891175	Causal
+hsa-let-7c	13223	uterine leiomyoma (ULM)	down-regulated	"Northern blot, qRT-PCR etc"	exogenous Let-7 microRNAs could directly repress					
+the dominant transcript of HMGA2.Let-7 repression of HMGA2 inhibited cellular proliferation.	HMGA2	unknown	2008	18403645	Causal	1	178			
+hsa-miR-132	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	RICS/p250GAP	2007	17942673	Unspecified
+hsa-miR-132	11727	facioscapulohumeral muscular dystrophy (FSHD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	RICS/p250GAP	2007	17942673	Unspecified
+hsa-miR-132	3073	glioblastoma multiforme (GBM)	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed microRNA in glioblastoma multiforme tumors relative to non-neoplastic brain tissue.	unknown	RICS/p250GAP	2008	18577219	Unspecified
+hsa-miR-132	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	RICS/p250GAP	2007	17616664	Unspecified
+hsa-miR-132	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	RICS/p250GAP	2007	17942673	Unspecified
+hsa-miR-132	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	RICS/p250GAP	2007	17942673	Unspecified
+hsa-miR-132	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	RICS/p250GAP	2007	17942673	Unspecified
+hsa-miR-132	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	RICS/p250GAP	2008	18381414	Unspecified
+hsa-miR-132	3829	pituitary adenoma	down-regulated	microarray	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	RICS/p250GAP	2007	17111382	Unspecified
+hsa-miR-132	10222	polymyositis (PM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	RICS/p250GAP	2007	17942673	Unspecified
+hsa-miR-133a	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	"In vivo inhibition of miR-133 by a single infusion of an antagomir caused marked and sustained cardiac hypertrophy. We identified specific targets of miR-133: RhoA, a GDP-GTP exchange protein regulating cardiac hypertrophy; Cdc42, a signal transduction kinase implicated in hypertrophy; and Nelf-A/WHSC2, a nuclear factor involved in cardiogenesis."	"RhoA, Cdc42, Nelf-A/WHSC2"	unknown	2007	17468766	Causal
+hsa-miR-133a	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Down-regulation of miR-1 and miR-133 expression contributes to re-expression of HCN2/HCN4 thereby the electrical remodeling process in hypertrophic hearts.	"HCN2, HCN4"	unknown	2008	18458081	Causal
+hsa-miR-133a	3978	cardiomyopathy	up-regulated	"Northern blot, qRT-PCR etc"	"Depression of key K+ channel(Ikr) via repression of ERG by miR-133 may contribute to the slowing of myocyte repolarization, and thereby QT prolongation and the associated arrhythmias in diabetic hearts"	ERG	unknown	2007	17344217	Causal
+hsa-miR-133a	3978	cardiomyopathy	down-regulated	"Northern blot, qRT-PCR etc"	miR-1 and miR-133 are involved in regulating cell fate with increased miR-1 and/or decreased miR-133					
+levels favoring apoptosis and decreased miR-1 and/or miR-133 levels favoring survival. Post-transcriptional repression of HSP60 and HSP70 by miR-1 and of caspase-9 by miR-133 contributes significantly to their opposing actions.										
+	Casp9	unknown	2007	17715156	Causal	1	192			
+hsa-miR-133a	10944	tongue squamous cell carcinoma	down-regulated	"Northern blot, qRT-PCR etc"	"Tongue SCC cell lines transfected with miR-133a and miR-133b precursors displayed reduction in proliferation rate. In addition, the number of apoptotic cells was increased in response to the introduction of precursors. Computational target gene prediction suggested that both miR-133a and miR-133b are targeting transcript of pyruvate kinase type M2 (PKM2), a potential oncogene in solid cancers. In tongue SCC cell lines, PKM2 expression was reduced in response to miR-133a and miR-133b precursors transfection. Our results suggested that aberrant reduction of miR-133a and miR-133b was associated with the dysregulation of PKM2 in SCC of tongue."	PKM2	unknown	2008	18464261	Causal
+hsa-miR-133a	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	Differentially expressed between tumors and normals.	unknown	unknown	2007	17875710	Unspecified
+hsa-miR-133a	3073	glioblastoma multiforme (GBM)	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed microRNA in glioblastoma multiforme tumors relative to non-neoplastic brain tissue.	unknown	unknown	2008	18577219	Unspecified
+hsa-miR-133a	12236	primary biliary cirrhosis (PBC)	down-regulated	microarray	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	unknown	2008	18631158	Unspecified
+hsa-miR-133a	10584	retinitis pigmentosa (RP)	down-regulated	"Northern blot, qRT-PCR etc"	"Expression of miR-1 and miR-133 decreased by more than 2.5-fold (P<0.001), whereas expression of miR-96 and miR-183 increased by more than 3-fold (P<0.001) in Pro347Ser retinas, as validated by qPCR."	unknown	unknown	2007	18034880	Unspecified
+hsa-miR-133a	178	vascular disease	down-regulated	"Northern blot, qRT-PCR etc"	Aberrant Expression of miRNA in Injured Arteries Is Confirmed by qRT-PCR or Northern Blot Analysis.	unknown	unknown	2007	17478730	Unspecified
+hsa-miR-133b	14330	Parkinson's disease	down-regulated	microarray	miR-133b regulates the maturation and function of midbrain DNs within a negative feedback circuit that includes the paired-like homeodomain transcription factor Pitx3	Pitx3	unknown	2007	17761882	Causal
+hsa-miR-133b	10944	tongue squamous cell carcinoma	down-regulated	"Northern blot, qRT-PCR etc"	"Tongue SCC cell lines transfected with miR-133a and miR-133b precursors displayed reduction in proliferation rate. In addition, the number of apoptotic cells was increased in response to the introduction of precursors. Computational target gene prediction suggested that both miR-133a and miR-133b are targeting transcript of pyruvate kinase type M2 (PKM2), a potential oncogene in solid cancers. In tongue SCC cell lines, PKM2 expression was reduced in response to miR-133a and miR-133b precursors transfection. Our results suggested that aberrant reduction of miR-133a and miR-133b was associated with the dysregulation of PKM2 in SCC of tongue."	PKM2	unknown	2008	18464261	Causal
+hsa-miR-133b	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed between neoplastic conditions (CRC cell lines and tumor samples) and non-tumoral colon tissues.	unknown	unknown	2006	16854228	Unspecified
+hsa-miR-133b	3073	glioblastoma multiforme (GBM)	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed microRNA in glioblastoma multiforme tumors relative to non-neoplastic brain tissue.	unknown	unknown	2008	18577219	Unspecified
+hsa-miR-133b	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-133b	12236	primary biliary cirrhosis (PBC)	down-regulated	microarray	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	unknown	2008	18631158	Unspecified
+hsa-miR-133b	9088	psoriasis	down-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	unknown	2007	17622355	Unspecified
+hsa-miR-133b	5556	testicular germ cell tumor	up-regulated	microarray	Differentially expressed miRNA in the various histological subtypes of  germ cell tumour (GCT) (TE = teratoma; SE = seminoma; EC = embryonal carcinoma).	unknown	unknown	2007	17893849	Unspecified
+hsa-miR-134	9119	acute promyelocytic leukemia (APL)	down-regulated	"Northern blot, qRT-PCR etc"	miRNA precursors with significantly different expression.	unknown	unknown	2005	16192569	Unspecified
+hsa-miR-134	1040	B-cell chronic lymphocytic leukemia	up-regulated	microarray	Differentially expressed in CLL cells versus CD9 cells.	unknown	unknown	2004	15284443	Unspecified
+hsa-miR-134	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-134	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	Differentially expressed between tumors and normals.	unknown	unknown	2007	17875710	Unspecified
+hsa-miR-134	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-134	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-134	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-135a	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-135b	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed between neoplastic conditions (CRC cell lines and tumor samples) and non-tumoral colon tissues.	unknown	unknown	2006	16854228	Unspecified
+hsa-miR-135b	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-136	3459	breast cancer	up-regulated	microarray	Differentially expressed between breast carcinoma and normal breast tissue.	unknown	Rtl1/Peg11	2005	16103053	Unspecified
+hsa-miR-136	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	Rtl1/Peg11	2007	17616664	Unspecified
+hsa-miR-136	3829	pituitary adenoma	down-regulated	microarray	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	Rtl1/Peg11	2007	17111382	Unspecified
+hsa-miR-137	3073	glioblastoma multiforme (GBM)	down-regulated	"Northern blot, qRT-PCR etc"	"microRNA-124 and microRNA-137 induce differentiation of adult mouse neural stem cells, mouse oligodendroglioma-derived stem cells and human glioblastoma multiformederived stem cells and induce glioblastoma multiforme cell cycle arrest. These results suggest that targeted delivery of microRNA-124 and/or microRNA-137 to glioblastoma multiforme tumor cells may be therapeutically efficacious for the treatment of this disease.miR-124 and miR-137 inhibit CDK6 expression and phosphorylated retinoblastoma levels in GBM cells."	CDK6	unknown	2008	18577219	Causal
+hsa-miR-137	3908	non-small cell lung cancer (NSCLC)	up-regulated	"Northern blot, qRT-PCR etc"	"A five-microRNA signature (let-7a, miR-221, miR-137, miR-372, and miR-182*) that is associated with survival and cancer relapse in NSCLC patients. This microRNA signature was validated by the testing set and an independent cohort. Patients with high-risk scores in their microRNA signatures had poor overall and disease-free survivals compared to the low-risk-score patients. This microRNA signature is an independent predictor of the cancer relapse and survival of NSCLC patients.promoted invasiveness of lung cancer cell lines."	unknown	unknown	2008	18167339	Causal
+hsa-miR-137	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	"Northern blot, qRT-PCR etc"	the ectopic transfection of miR-137 or miR-193a into OSCC lines lacking their expressions significantly					
+"reduced cell growth, with down-regulation of the translation of cyclin-dependent kinase 6 or E2F transcription factor"										
+"6, respectively. Taken together, our results clearly show that miR-137 and miR-193a are tumor suppressor miRNAs epigenetically"										
+silenced during oral carcinogenesis.	CDK6	unknown	2008	18381414	Causal	1	222			
+hsa-miR-137	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	One of the 22 significantly up- and down-regulated miRNAs obtained using significance analysis of microarrays with false discovery rate of 5%. Majority of the predicted targets of these 22 differentially regulated miRNAs reside in pathways reported to be dysregulated during carcinogenesis.	unknown	unknown	2008	18319255	Unspecified
+hsa-miR-137	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-138	7012	anaplastic thyroid carcinoma (ATC)	down-regulated	"Northern blot, qRT-PCR etc"	miR-138 was significantly downregulated in ATC cell lines in comparison with papillary thyroid carcinoma (PTC)(P<0.01).Overexpression of miR-138 induced a reduction in human telomerase reverse transcriptase (hTERT) protein expression.	hTERT	unknown	2008	18201269	Causal
+hsa-miR-138	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-138-1	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-138-1	3969	papillary thyroid carcinoma (PTC)	up-regulated	microarray	Differentially expressed miRNA in PTC tumors	unknown	unknown	2005	16365291	Unspecified
+hsa-miR-138-2	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-206	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"We show for the first time that miR-206 expression is markedly decreased in ERalpha-positive human breast cancer tissues assayed by quantitative reverse transcription-PCR analysis. Moreover, we observe that miR-206 expression is inversely correlated with ERalpha but not ERbeta mRNA expression in breast cancer tissues. Transfection experiments revealed that introduction of miR-206 into estrogen-dependent MCF-7 breast cancer cells inhibits cell growth in a dose- and time-dependent manner. Our results suggest that miR-206 could be a novel candidate for endocrine therapy that targets only ERalpha in breast cancer."					
+	ER-alpha	"Fstl1,GJA1,Utrn"	2008	18593897	Causal	1	230			
+hsa-miR-206	5419	schizophrenia	normal	"Northern blot, qRT-PCR etc"	" Eighteen known SNPs within or near brain-expressed miRNAs in three samples (Danish, Swedish and Norwegian: 420/163/257 schizophrenia patients and 1006/177/293 control subjects), were analyzed. Subsequently, joint analysis of the three samples was performed on SNPs showing marginal association. Two SNPs rs17578796 and rs1700 in hsa-mir-206 (mir-206) and hsa-mit-198 (mir-198) showed nominal significant allelic association to schizophrenia in the Danish and Norwegian sample respectively (P = 0.0021 & p = 0.038), of which only rs17578796 was significant in the joint sample. In-silico analysis revealed that 8 of the 15 genes predicted to be regulated by both mir-206 and mir-198, are transcriptional targets or interaction partners of the JUN, ATF2 and TAF1 connected in a tight network. JUN and two of the miRNA targets (CCND2 and PTPN1) in the network have previously been associated with schizophrenia."	unknown	"Fstl1,GJA1,Utrn"	2008	17849003	Causal
+hsa-miR-206	3459	breast cancer	up-regulated	microarray	Differentially expressed between breast carcinoma and normal breast tissue.	unknown	"Fstl1,GJA1,Utrn"	2005	16103053	Unspecified
+hsa-miR-206	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	"Fstl1,GJA1,Utrn"	2008	18560586	Unspecified
+hsa-miR-207	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	metastasis-related miRNA	unknown	unknown	2008	18176954	Unspecified
+hsa-miR-208	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	"A cardiac-specific microRNA (miR-208) encoded by an intron of the aMHC gene is required for cardiomyocyte hypertrophy, fibrosis, and expression of bMHC in response to stress and hypothyroidism."	THRAP1	unknown	2007	17379774	Causal
+hsa-miR-20a	8552	chronic myeloid leukemia (CML)	down-regulated	"Northern blot, qRT-PCR etc"	cotransfection of the miR-17-5p and miR-20a antisense oligonucleotides					
+"(antagomir-17-5p and antagomiR-20a),increases normalized luciferase activity. luciferase activity is enhanced in K562 cells with RNAi-reduced c-myc expression and can be further increased by antagomir-17-5p or antagomir-20a."	unknown	TGFBR2	2007	17284533	Causal	1	237			
+hsa-miR-20a	3905	lung cancer	up-regulated	"Northern blot, qRT-PCR etc"	"frequent and marked overexpression, with occasional gene amplification, of clustered miRNAs (miR-17-92) within intron 3 of the C13orf 25 gene at 13q31.3 in lung cancers, especially examples with small-cell lung cancer histology.The authors further showed the stimulatory activity of this miRNA cluster in lung cancer cell growth."	unknown	TGFBR2	2005	16266980	Causal
+hsa-miR-20a	3905	lung cancer	up-regulated	"Northern blot, qRT-PCR etc"	Inhibition of miR-17-5p and miR-20a with antisense oligonucleotides (ONs) can induce apoptosis selectively in lung cancer cells overexpressing miR-17-92.	unknown	TGFBR2	2007	17384677	Causal
+hsa-miR-20a	1985	colorectal cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	TGFBR2	2006	16461460	Unspecified
+hsa-miR-20a	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed between neoplastic conditions (CRC cell lines and tumor samples) and non-tumoral colon tissues.	unknown	TGFBR2	2006	16854228	Unspecified
+hsa-miR-20a	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Expression patterns for these 5 microRNAs(miR-20a, miR-21, miR-106a, miR-181b, and miR-203) distinguish tumor vs paired nontumor status with 96% or 98% accuracy based on 3 nearest neighbors or nearest centroid algorithms, respectively (10-fold cross validation, repeated 100 times)."	unknown	TGFBR2	2008	18230780	Unspecified
+hsa-miR-20a	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	The degree of tumor differentiation was inversely related to the expression levels of this miRNA.	unknown	TGFBR2	2006	16331254	Unspecified
+hsa-miR-20a	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	TGFBR2	2006	16924677	Unspecified
+hsa-miR-20a	353	malignant lymphoma	up-regulated	"Northern blot, qRT-PCR etc"	"six mature miRNAs (miR-17-5p, miR-17-3p, miR-19a, miR-19b, miR-20 and miR-92-1) in the cell lines with a 13q31 gain/amplification displays overexpression significantly higher than in those without."	unknown	TGFBR2	2005	16167061	Unspecified
+hsa-miR-20a	4905	pancreatic cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	TGFBR2	2006	16461460	Unspecified
+hsa-miR-20a	12236	primary biliary cirrhosis (PBC)	down-regulated	"Northern blot, qRT-PCR etc"	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	TGFBR2	2008	18631158	Unspecified
+hsa-miR-20a	10286	prostate cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	TGFBR2	2006	16461460	Unspecified
+hsa-miR-20a	9088	psoriasis	up-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	TGFBR2	2007	17622355	Unspecified
+hsa-miR-20a	5745	serous ovarian cancer	up-regulated	microarray	Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients.	unknown	TGFBR2	2008	18451233	Unspecified
+hsa-miR-20b	715	T-cell leukemia	up-regulated	"Northern blot, qRT-PCR etc"	"The authors conclude that, in addition to miR-106a, miR-20b, miR-19b-2, and miR-92-2 overexpression in tumors, their capacity to induce anchorage independence growth strongly supports an oncogenic"					
+"potential for those miRNAs. they also conclude that Mylip and Rbp1-like are true targets of the miR-106-363 cluster(miR-106a, miR-18b, miR-20b, miR-19b-2, miR-92-2, and miR-363). More specifically, Rbp1-like seemed only targeted by miR-106a/miR-20b, whereas Mylip could be targeted by the four miRNAs(miR-106a, miR-20b, miR-19b-2, and miR-92-2) with miR-106a/miR-20b being more efficient."	"Mylip, Rbp1-like"	unknown	2006	17575136	Causal	1	251			
+hsa-miR-20b	5419	schizophrenia	down-regulated	microarray	Differentially expressed miRNA from the prefrontal cortex of subjects with schizophrenia compared to psychiatrically healthy subjects.	unknown	unknown	2007	17326821	Unspecified
+hsa-miR-21	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Tumors with high expression of miR-21 was associated with poor survival outcome and poor response to adjuvant chemotherapy in 2 independent cohorts, independent of staging and other clinical covariates suggesting that miR-21 may be a useful diagnostic biomarker for colon adenocarcinomas"					
+and survival prognosis including response to therapy.	unknown	"PTEN,TPM1"	2008	18230780	Unspecified	2	253			
+hsa-miR-21	353	diffuse large B-cell lymphoma (DLBCL)	up-regulated	"Northern blot, qRT-PCR etc"	"Expression of miR-21 was an independent prognostic indicator in de novo DLBCL (p<0.05).Identified microRNAs(miR-155, miR-21 and miR-221) that were more highly expressed in ABC-type than GCB-type cell lines. These microRNAs were over-expressed in de novo DLBCL (n=35), transformed DLBCL"					
+(n=14) and follicular center lymphoma cases (n=27) compared to normal B cells.	unknown	"PTEN,TPM1"	2007	17487835	Unspecified	2	254			
+hsa-miR-21	353	diffuse large B-cell lymphoma (DLBCL)	up-regulated	"Northern blot, qRT-PCR etc"	"Whether microRNAs have diagnostic utility by comparing levels of tumour-associated miR-155, miR-210 and miR-21 in serum from diffuse large B-cell lymphoma (DLBCL) patients (n=60) with healthy controls (n=43). Levels were higher in patient than control sera (P=0.009, 0.02 and 0.04 respectively). Moreover, high miR-21 expression was associated with relapse-free survival (P=0.05)."	unknown	"PTEN,TPM1"	2008	18318758	Unspecified
+hsa-miR-21	3905	lung cancer	up-regulated	"Northern blot, qRT-PCR etc"	"miRNAs (miR-155, miR-17-3p, miR-106a, miR-93, let-7a-2, miR-145, let-7b, and miR-21) were related to the adenocarcinoma patient's survival. Patients with high expression of either miR-155, miR-17-3p, miR-106a, miR-93, or miR-21 and low expression of either let-7a-2, let-7b, or miR-145 were found to have a significantly worse prognosis."	unknown	"PTEN,TPM1"	2006	16530703	Unspecified
+hsa-miR-21	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Although miR-21 expression did not correlate with tumor size, differentiation, nodal status, or T stage, strong miR-21 expression was predictive of poorer outcome compared to absent or faint/focal miR-21 expression in patients with node-negative disease (median 27.7 months vs. 15.2, p=0.037). Nodal status was also predictive of survival (p=0.029). MicroRNA-21 is significantly overexpressed in pancreatic cancers as detected by in situ hybridization. Its strong expression predicts limited survival in patients with node-negative disease and may be an important biologic marker for outcome."	unknown	"PTEN,TPM1"	2008	18642050	Unspecified
+hsa-miR-21	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	Transfected breast cancer MCF-7 cells with anti-miR-21 oligonucleotides and found that anti-miR-21 suppressed both cell growth in vitro and tumor growth in the xenograft mouse model.	BCL2	"PTEN,TPM1"	2007	17072344	Causal
+hsa-miR-21	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Down-regulation of TPM1 by mir-21 may explain, at least in part, why suppression of mir-21 can inhibit tumor growth, further supporting the notion that mir-21 functions as an oncogene."	TPM1	"PTEN,TPM1"	2007	17363372	Causal
+hsa-miR-21	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	Inhibition of mir-21 in MCF-7 breast cancer cells causes reduced cell growth.the tumor suppressor					
+protein Programmed Cell Death 4 (PDCD4) is regulated by miR-21.	PDCD4	"PTEN,TPM1"	2007	17991735	Causal	1	260			
+hsa-miR-21	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	Suppression of mir-21 in metastatic breast cancer MDA-MB-231 cells significantly reduces					
+"invasion and lung metastasis. Consistent with this, ectopic expression of TPM1 remarkably reduced cell invasion. Furthermore, miR-21 targets direactly programmed cell death 4 (PDCD4) and maspin, both of which have been implicated in invasion and metastasis."	"PDCD4, TPM1, maspin"	"PTEN,TPM1"	2008	18270520	Causal	1	261			
+hsa-miR-21	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"The translation of the tumor suppressor gene PDCD4 is negatively regulated by the miRNA miR-21 in HEK-293T, MCF-7 and JB6 cell lines, and provides evidence that the mir-21 gene functions as an oncogene to promote cell transformation.Reduced PDCD4 expression"					
+"has been reported in at least six human tumor types or cancer cell lines (lung, brain, renal, breast, colon and pancreas),indicating that mir-21/PDCD4 is likely to be a clinically significant oncogene:tumor suppressor pair in the induction and progression of human carcinomas."	PDCD4	"PTEN,TPM1"	2008	18372920	Causal	1	262			
+hsa-miR-21	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	"2'OMe-miR-21 decreased miR-21 levels and inhibited myocyte hypertrophy stimulated by either Ang II or PE as shown by the decreased cell size and leucine incorporation. In contrast, control oligos (2'OMe-EGFP) had no effect on miR-21 expression and cell hypertrophy."	unknown	"PTEN,TPM1"	2007	17525252	Causal
+hsa-miR-21	4947	cholangiocarcinoma	up-regulated	"Northern blot, qRT-PCR etc"	miR-21 directly alters PTEN expression and modulates gemcitabine-induced apoptosis by activating PI 3 kinase-signaling pathways.					
+	PTEN	"PTEN,TPM1"	2006	16762633	Causal	1	264			
+hsa-miR-21	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	"A bioinformatics search revealed a conserved target-site for miR-21 within the Pdcd4-3'-UTR at 228-249 nt. In 10 colorectal cell lines, an inverse correlation of miR-21 and Pdcd4-protein was observed. Transfection of Colo206f-cells with miR-21 significantly suppressed a luciferase-reporter containing the Pdcd4-3'-UTR, whereas transfection of RKO with anti-miR-21 increased activity of this construct. This was abolished when a construct mutated at the miR-21/nt228-249 target site was used instead. Anti-miR-21-transfected RKO cells showed an increase of Pdcd4-protein and reduced invasion. Moreover, these cells showed reduced intra-vasation and lung metastasis in a chicken-embryo-metastasis assay. In contrast, overexpression of miR-21 in Colo206f significantly reduced Pdcd4-protein amounts and increased invasion, while Pdcd4-mRNA was unaltered. Resected normal/tumor tissues of 22 colorectal cancer patients demonstrated an inverse correlation between miR-21 and Pdcd4-protein. This is the first study to show that Pdcd4 is negatively regulated by miR-21. Furthermore, it is the first report to demonstrate that miR-21 induces invasion/intravasation/metastasis."	PDCD4	"PTEN,TPM1"	2008	17968323	Causal
+hsa-miR-21	3471	Cowden Syndrome	up-regulated	"Northern blot, qRT-PCR etc"	"Differential expression of PTEN-targeting miR-19a and miR-21 modulates the PTEN protein levels and the CS phenotype, irrespective of the patient��s mutation status, and support their roles"					
+as genetic modifiers in CS.	PTEN	"PTEN,TPM1"	2008	18460397	Causal	1	266			
+hsa-miR-21	3068	glioblastoma	up-regulated	"Northern blot, qRT-PCR etc"	Knockdown of miR-21 in cultured glioblastoma cells triggers activation of caspases and leads to increased apoptotic cell death.	unknown	"PTEN,TPM1"	2005	16024602	Causal
+hsa-miR-21	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	"Aberrant expression of miR-21 can contribute to HCC growth and spread by modulating PTEN expression and PTEN-dependent pathways involved in mediating phenotypic characteristics of cancer cells such as cell growth, migration, and invasion."	PTEN	"PTEN,TPM1"	2007	17681183	Causal
+hsa-miR-151	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	One of the 22 significantly up- and down-regulated miRNAs obtained using significance analysis of microarrays with false discovery rate of 5%. Majority of the predicted targets of these 22 differentially regulated miRNAs reside in pathways reported to be dysregulated during carcinogenesis.	unknown	unknown	2008	18319255	Unspecified
+hsa-miR-151	9261	nasopharyngeal carcinoma (NPC)	up-regulated	microarray	miRNAs differentially expressed between normal and NPC tumor tissues.	unknown	unknown	2008	18390668	Unspecified
+hsa-miR-151	10286	prostate cancer	up-regulated	microarray	One of the upregulated microRNAs in tumors with perineural invasion (FDR 10%).	unknown	unknown	2008	18459106	Unspecified
+hsa-miR-151*	9952	acute lymphoblastic leukemia (ALL)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-151*	9119	acute myeloid leukemia (AML)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-152	2841	asthma	normal	"Northern blot, qRT-PCR etc"	" +3142C/G influences miRNA targeting of HLA-G and is associated with risk of asthma.Interestingly,"					
+"the three miRNA genes are located at regions that have been linked to asthma or IgE: 7p15(miR-148a), 12q13(miR-148b), and 17q21(miR-152), raising the possibility that variation in the miRNA genes themselves might contribute to asthma risk, perhaps by interacting with HLA-G."	HLA-G	unknown	2007	17847008	Causal	1	1654			
+hsa-miR-152	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Aberrant hypermethylation leads to miRNA gene inactivation in human breast cancer. Aberrant hypermethylation was shown for mir-9-1, mir-124a-3, mir-148, mir-152, and mir-663 in 34-86% of cases in a series of 71 primary human breast cancer specimens.miRNA gene hypermethylation correlated strongly with methylation of known tumour suppressor genes (p = 0.003)."	unknown	unknown	2007	17948228	Unspecified
+hsa-miR-152	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Aberrant hypermethylation was shown for miR-9-1, miR-124a-3, miR-148, miR-152, and miR-663 in 34-86% of cases in a series of 71 primary human breast cancer specimens. miRNA gene hypermethylation correlated strongly with methylation of known tumour suppressor genes (p = 0.003). "	unknown	unknown	2007	18314617	Unspecified
+hsa-miR-152	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	DNA copy number status of 17 genomic loci containing miRNAs differentially expressed between IOSE cells and EOC cell lines.	unknown	unknown	2008	18458333	Unspecified
+hsa-miR-153	1040	B-cell chronic lymphocytic leukemia	up-regulated	microarray	Differentially expressed in CLL cells versus CD13 cells.	unknown	unknown	2004	15284443	Unspecified
+hsa-miR-153	3073	glioblastoma multiforme (GBM)	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed microRNA in glioblastoma multiforme tumors relative to non-neoplastic brain tissue.	unknown	unknown	2008	18577219	Unspecified
+hsa-miR-154	1040	B-cell chronic lymphocytic leukemia	up-regulated	microarray	Differentially expressed in CLL cells versus CD14 cells.	unknown	unknown	2004	15284443	Unspecified
+hsa-miR-154	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-154	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-154	11727	facioscapulohumeral muscular dystrophy (FSHD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-154	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-154	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-21	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	The overexpression of miR-21 is strongly associated with both a high Ki67 proliferation index and presence of liver metastasis.	PDCD4	"PTEN,TPM1"	2006	16966691	Causal
+hsa-miR-21	178	vascular disease	up-regulated	"Northern blot, qRT-PCR etc"	Aberrant Expression of miRNA in Injured Arteries Is Confirmed by qRT-PCR or Northern Blot Analysis.Downregulation of overexpressed miR-21 decreases neointima formation in rat carotid artery after angioplasty.Inhibition of miR-21 decreases proliferation of cultured VSMCs.Inhibition of miR-21 increases apoptosis of cultured VSMCs.	"PTEN, BCL2"	"PTEN,TPM1"	2007	17478730	Causal
+hsa-miR-21	9952	acute lymphoblastic leukemia (ALL)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	"PTEN,TPM1"	2007	18056805	Unspecified
+hsa-miR-21	9119	acute myeloid leukemia (AML)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	"PTEN,TPM1"	2007	18056805	Unspecified
+hsa-miR-21	1208	autism spectrum disorder (ASD)	up-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	"PTEN,TPM1"	2008	18563458	Unspecified
+hsa-miR-21	3459	breast cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	"PTEN,TPM1"	2006	16461460	Unspecified
+hsa-miR-21	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change correlative with the increase in heart/body weight(7-14 days post-TAC).	unknown	"PTEN,TPM1"	2008	17234972	Unspecified
+hsa-miR-21	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	miR-18b and miR-21 regulate cardiomyocyte hypertrophy.	unknown	"PTEN,TPM1"	2007	17498736	Unspecified
+hsa-miR-21	2893	cervical cancer	up-regulated	"Northern blot, qRT-PCR etc"	"let-7b, let-7c, miR-23b, miR-196b, and miR-143 showed significantly reduced abundance in cervical cancer cell lines. miR-21 displayed higher abundance in the cancer group."	unknown	"PTEN,TPM1"	2007	17616659	Unspecified
+hsa-miR-21	1040	chronic lymphocytic leukemia (CLL)	up-regulated	"Northern blot, qRT-PCR etc"	miR-21 in CLL is on average 3.8-fold with a maximum of 10-fold compared to normal CD19 cells.	unknown	"PTEN,TPM1"	2007	17327404	Unspecified
+hsa-miR-21	1985	colorectal cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	"PTEN,TPM1"	2006	16461460	Unspecified
+hsa-miR-21	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	"PTEN,TPM1"	2006	16609010	Unspecified
+hsa-miR-21	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed between neoplastic conditions (CRC cell lines and tumor samples) and non-tumoral colon tissues.	unknown	"PTEN,TPM1"	2006	16854228	Unspecified
+hsa-miR-21	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Expression levels of analyzed miRNAs significantly differed among tumors and adjacent non-tumor tissues: miR-21 (p = 0.0001) and miR-31 (p = 0.0006) were upregulated, and miR-143 (p = 0.011) and miR-145 (p = 0.003) were downregulated in tumors."	unknown	"PTEN,TPM1"	2007	18196926	Unspecified
+hsa-miR-21	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	"PTEN,TPM1"	2007	17942673	Unspecified
+hsa-miR-21	14691	Duchenne muscular dystrophy (DMD)	up-regulated	"Northern blot, qRT-PCR etc"	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	"PTEN,TPM1"	2007	17942673	Unspecified
+hsa-miR-21	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	DNA copy number status of 17 genomic loci containing miRNAs differentially expressed between IOSE cells and EOC cell lines.	unknown	"PTEN,TPM1"	2008	18458333	Unspecified
+hsa-miR-21	1107	esophageal cancer	up-regulated	microarray	Both hsa-miR-203 and hsa-miR-205 were expressed 2- to 10-fold lower in squamous cell carcinoma and adenocarcinomas than in normal epithelium. The hsa-miR-21 expression was 3- to 5-fold higher in both tumors than in normal epithelium.	unknown	"PTEN,TPM1"	2008	18242245	Unspecified
+hsa-miR-21	11727	facioscapulohumeral muscular dystrophy (FSHD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	"PTEN,TPM1"	2007	17942673	Unspecified
+hsa-miR-21	5517	gastric cancer (stomach cancer)	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	"PTEN,TPM1"	2006	16461460	Unspecified
+hsa-miR-21	5517	gastric cancer (stomach cancer)	up-regulated	"Northern blot, qRT-PCR etc"	"miR-21 was overexpressed in 92% (34/37) of the gastric cancer samples examined. However, the patients with higher miR-21 expression did not have a worse prognosis.  miR-21 could serve as an efficient diagnostic marker for gastric cancer, but does not affect the clinical prognosis of gastric cancer patients."					
+	unknown	"PTEN,TPM1"	2008	18507035	Unspecified	0	289			
+hsa-miR-21	3068	glioblastoma	up-regulated	microarray	Significantly differentially expressed between glioblastoma cell line samples and the control samples.	unknown	"PTEN,TPM1"	2005	16039986	Unspecified
+hsa-miR-21	3073	glioblastoma multiforme (GBM)	up-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed microRNA in glioblastoma multiforme tumors relative to non-neoplastic brain tissue.	unknown	"PTEN,TPM1"	2008	18577219	Unspecified
+hsa-miR-21	2627	glioma	up-regulated	"Northern blot, qRT-PCR etc"	Pretreatment of glioma cells with locked nucleic acid (LNA)-antimiR-21 molecules leads to synergistic antitumor efficacy both in vitro and in vivo.	unknown	"PTEN,TPM1"	2007	17908999	Causal
+hsa-miR-21	2627	glioma	up-regulated	"Northern blot, qRT-PCR etc"	"We demonstrate that miR-21 regulates multiple genes associated with glioma cell apoptosis, migration, and invasiveness, including RECK and TIMP3, suppressors of malignancy and inhibitors of matrix metalloproteinases (MMPs). Our data suggest that miR-21 contributes to the glioma malignancy by down-regulation of MMP inhibitors that leads to activation of MMPs thus promoting invasiveness of cancer cells. Our results also indicate that inhibition of a single oncomir like miR-21 with specific antisense molecules can provide a novel therapeutic approach for ""physiological"" modulation of multiple proteins whose expression is de-regulated in cancer."					
+	"RECK, TIMP3"	"PTEN,TPM1"	2008	18591254	Causal	1	293			
+hsa-miR-21	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	Differentially Regulated miR in HCCs.	unknown	"PTEN,TPM1"	2006	16924677	Unspecified
+hsa-miR-21	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	One of the 22 significantly up- and down-regulated miRNAs obtained using significance analysis of microarrays with false discovery rate of 5%. Majority of the predicted targets of these 22 differentially regulated miRNAs reside in pathways reported to be dysregulated during carcinogenesis.	unknown	"PTEN,TPM1"	2008	18319255	Unspecified
+hsa-miR-21	3429	Inclusion body myositis (IBM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	"PTEN,TPM1"	2007	17942673	Unspecified
+hsa-miR-21	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	"PTEN,TPM1"	2007	17942673	Unspecified
+hsa-miR-21	3905	lung cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	"PTEN,TPM1"	2006	16461460	Unspecified
+hsa-miR-21	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	"PTEN,TPM1"	2007	17942673	Unspecified
+hsa-miR-21	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	"PTEN,TPM1"	2008	18560586	Unspecified
+hsa-miR-21	4905	pancreatic cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	"PTEN,TPM1"	2006	16461460	Unspecified
+hsa-miR-21	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Aberrantly expressed miRNA precursors in pancreatic adenocarcinoma.PAM testing was conducted on 10 tumor samples and 15 adjacent benign samples. PAM has correctly classified 100% of the tested tumor samples and 11 of 15 of the tested benign samples. The 20 top ranked differentially expressed miRNAs in pancreatic adenocarcinoma as selected by PAM.	unknown	"PTEN,TPM1"	2006	17149698	Unspecified
+hsa-miR-21	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	"PTEN,TPM1"	2007	17473300	Unspecified
+hsa-miR-21	3969	papillary thyroid carcinoma (PTC)	up-regulated	microarray	Differentially expressed miRNA in PTC tumors	unknown	"PTEN,TPM1"	2005	16365291	Unspecified
+hsa-miR-21	10222	polymyositis (PM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	"PTEN,TPM1"	2007	17942673	Unspecified
+hsa-miR-21	10286	prostate cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	"PTEN,TPM1"	2006	16461460	Unspecified
+hsa-miR-21	10286	prostate cancer	up-regulated	microarray	One of the upregulated microRNAs in tumors with perineural invasion (FDR 10%).	unknown	"PTEN,TPM1"	2008	18459106	Unspecified
+hsa-miR-21	9088	psoriasis	up-regulated	"Northern blot, qRT-PCR etc"	miR-21 was significantly up-regulated both in psoriasis (p<0.001) and atopic eczema (p<0.001) as compared with healthy skin.	unknown	"PTEN,TPM1"	2007	17622355	Unspecified
+hsa-miR-21	5745	serous ovarian cancer	up-regulated	microarray	Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients.	unknown	"PTEN,TPM1"	2008	18451233	Unspecified
+hsa-miR-21	13223	uterine leiomyoma (ULM)	up-regulated	"Northern blot, qRT-PCR etc"	One of the top five up-regulated miRNAs in Uterine Leiomyomas (ULMs).	unknown	"PTEN,TPM1"	2007	17243163	Unspecified
+hsa-miR-21	13223	uterine leiomyoma (ULM)	up-regulated	"Northern blot, qRT-PCR etc"	Real-time reverse transcriptase polymerase chain reaction (RT-PCR) validation of microarray. Realtime					
+"semiquantitative RT-PCR of five different microRNA species (miR-21, miR-34a, miR-125b, miR-139, and miR-323) across ten subjects. miR-21, miR-34a, miR-125b, and miR-323 were overexpressed in leiomyoma in the ten pairs tested and miR-139 was underexpressed, consistent with the microarray results."	unknown	"PTEN,TPM1"	2008	17765232	Unspecified	0	311			
+hsa-miR-210	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	miR-210 overexpression is induced by hypoxia in a hypoxia-inducible factor (HIF) -1alpha- and von Hippel-Lindau (VHL)-dependent fashion and its expression levels in breast cancer samples are an independent prognostic factor	unknown	unknown	2008	18316553	Unspecified
+hsa-miR-210	353	diffuse large B-cell lymphoma (DLBCL)	up-regulated	"Northern blot, qRT-PCR etc"	"Whether microRNAs have diagnostic utility by comparing levels of tumour-associated miR-155, miR-210 and miR-21 in serum from diffuse large B-cell lymphoma (DLBCL) patients (n=60) with healthy controls (n=43). Levels were higher in patient than control sera (P=0.009, 0.02 and 0.04 respectively). Moreover, high miR-21 expression was associated with relapse-free survival (P=0.05)."	unknown	unknown	2008	18318758	Unspecified
+hsa-miR-210	9952	acute lymphoblastic leukemia (ALL)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-210	9119	acute myeloid leukemia (AML)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-210	10652	Alzheimer's disease	down-regulated	microarray	Significantly changed miRNAs in cortex of sporadic AD cases.	unknown	unknown	2008	18434550	Unspecified
+hsa-miR-210	3459	breast cancer	up-regulated	microarray	Differentially expressed between breast carcinoma and normal breast tissue.	unknown	unknown	2005	16103053	Unspecified
+hsa-miR-210	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-210	353	diffuse large B-cell lymphoma (DLBCL)	up-regulated	microarray	"Four hsa-miR-As (miR-210, hsa-miR-155, hsa-miR-106a, hsa-miR-17-5p) were expressed at a significantly higher level in DLBCL than in normal tissue. In contrast, the remaining 11 miRNAs (hsa-miR-150, hsa-miR-145, hsa-miR-328, hsa-miR-139, hsa-miR-99a, hsa-miR-10a, hsa-miR-95, hsa-miR-149, hsa-miR-320, hsa-miR-151,let-7e) were expressed at a significantly lower level in DLBCL.A classification tree was"					
+"computed using four miRNAs (miR-330, miR-17-5p, miR-106a and miR-210) to correctly identify 98% of all 111 cases that were analysed in this study."	unknown	unknown	2008	18537969	Unspecified	0	319			
+hsa-miR-210	14691	Duchenne muscular dystrophy (DMD)	up-regulated	"Northern blot, qRT-PCR etc"	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-210	8524	follicular lymphoma (FL)	up-regulated	microarray	"Nine miRNAs (hsa-miR-9, hsa-miR-301, hsa-miR-213, hsa-miR-9*, hsa-miR-330, hsa-miR-106a, hsa-miR-338, hsa-miR-155, hsa-miR-210) were significantly up- and three miRNAs (hsa-miR-320, hsa-miR-149, hsa-miR-139) down-regulated in the lymphoma samples. Expression of hsa-miR-9 was most strongly increased (12-fold) and of hsa-miR-320 most strongly decreased (3-fold).A classification tree was computed using four miRNAs (miR-330, miR-17-5p, miR-106a and miR-210) to correctly identify 98% of all 111 cases that were analysed in this study."	unknown	unknown	2008	18537969	Unspecified
+hsa-miR-210	3073	glioblastoma multiforme (GBM)	up-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed microRNA in glioblastoma multiforme tumors relative to non-neoplastic brain tissue.	unknown	unknown	2008	18577219	Unspecified
+hsa-miR-210	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-210	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-210	3905	lung cancer	up-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-210	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-210	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-210	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-210	3498	pancreatic ductal adenocarcinoma (PDAC)	up-regulated	microarray	differentially expressed between normal and PDAC or cell line samples.	unknown	unknown	2007	17237814	Unspecified
+hsa-miR-210	10222	polymyositis (PM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-210	10286	prostate cancer	up-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	331			
+hsa-miR-211	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	Differentially expressed between tumors and normals.	unknown	unknown	2007	17875710	Unspecified
+hsa-miR-211	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-212	9454	alcoholic liver disease (ALD)	up-regulated	"Northern blot, qRT-PCR etc"	EtOH induces miR-212 over-expression which causes gut leakiness by down-regulating ZO-1 translation. 	ZO-1	unknown	2008	18162065	Unspecified
+hsa-miR-212	1208	autism spectrum disorder (ASD)	up-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	unknown	2008	18563458	Unspecified
+hsa-miR-212	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	unknown	2006	16924677	Unspecified
+hsa-miR-212	3905	lung cancer	up-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-212	9261	nasopharyngeal carcinoma (NPC)	down-regulated	microarray	miRNAs differentially expressed between normal and NPC tumor tissues.	unknown	unknown	2008	18390668	Unspecified
+hsa-miR-212	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Aberrantly expressed miRNA precursors in pancreatic adenocarcinoma.PAM testing was conducted on 10 tumor samples and 15 adjacent benign samples. PAM has correctly classified 100% of the tested tumor samples and 11 of 15 of the tested benign samples. The 20 top ranked differentially expressed miRNAs in pancreatic adenocarcinoma as selected by PAM.	unknown	unknown	2006	17149698	Unspecified
+hsa-miR-212	3829	pituitary adenoma	down-regulated	microarray	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	unknown	2007	17111382	Unspecified
+hsa-miR-212	12236	primary biliary cirrhosis (PBC)	down-regulated	microarray	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	unknown	2008	18631158	Unspecified
+hsa-miR-212	5419	schizophrenia	down-regulated	microarray	Differentially expressed miRNA from the prefrontal cortex of subjects with schizophrenia compared to psychiatrically healthy subjects.	unknown	unknown	2007	17326821	Unspecified
+hsa-miR-212	13223	uterine leiomyoma (ULM)	down-regulated	"Northern blot, qRT-PCR etc"	One of the top five down-regulated miRNAs in Uterine Leiomyomas (ULMs).	unknown	unknown	2007	17243163	Unspecified
+hsa-miR-213	1040	B-cell chronic lymphocytic leukemia	down-regulated	microarray	Differentially expressed in CLL cells versus CD23 cells.	unknown	unknown	2004	15284443	Unspecified
+hsa-miR-213	3459	breast cancer	up-regulated	microarray	Differentially expressed between breast carcinoma and normal breast tissue.	unknown	unknown	2005	16103053	Unspecified
+hsa-miR-213	8524	follicular lymphoma (FL)	up-regulated	microarray	"Nine miRNAs (hsa-miR-9, hsa-miR-301, hsa-miR-213, hsa-miR-9*, hsa-miR-330, hsa-miR-106a, hsa-miR-338, hsa-miR-155, hsa-miR-210) were significantly up- and three miRNAs (hsa-miR-320, hsa-miR-149, hsa-miR-139) down-regulated in the lymphoma samples. Expression of hsa-miR-9 was most strongly increased (12-fold) and of hsa-miR-320 most strongly decreased (3-fold)."	unknown	unknown	2008	18537969	Unspecified
+hsa-miR-213	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-213	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-213	3969	papillary thyroid carcinoma (PTC)	up-regulated	microarray	Differentially expressed miRNA in PTC tumors	unknown	unknown	2005	16365291	Unspecified
+hsa-miR-214	2144	ovarian cancer (OC)	down-regulated	"Northern blot, qRT-PCR etc"	"miR-214 induces cell survival and cisplatin resistance through targeting the 3'-untranslated region (UTR) of the PTEN, which leads to down-regulation of PTEN protein and activation of Akt pathway. Inhibition of Akt using Akt inhibitor, API-2/triciribine, or introduction of PTEN cDNA lacking 3'-UTR largely abrogates miR-214-induced cell survival."	PTEN	unknown	2008	18199536	Causal
+hsa-miR-214	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change correlative with the increase in heart/body weight(7-14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-214	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Confirmation of the Aberrant miRNA Expression in Hypertrophic Hearts by Northern Blot Analysis and/or qRT-PCR.	unknown	unknown	2007	17525252	Unspecified
+hsa-miR-214	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-214	14691	Duchenne muscular dystrophy (DMD)	up-regulated	"Northern blot, qRT-PCR etc"	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-214	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	Differentially expressed between tumors and normals.	unknown	unknown	2007	17875710	Unspecified
+hsa-miR-214	11727	facioscapulohumeral muscular dystrophy (FSHD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-214	5517	gastric cancer (stomach cancer)	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-214	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-214	6000	heart failure	up-regulated	"Northern blot, qRT-PCR etc"	"Northern blot analysis of the hypertrophy-regulated miRNAs in idiopathic end-stage failing human hearts showed increased expression of miR-24, miR-125b, miR-195, miR-199a, and miR-214."	unknown	unknown	2006	17108080	Unspecified
+hsa-miR-214	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	unknown	2007	17616664	Unspecified
+hsa-miR-214	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	One of the 22 significantly up- and down-regulated miRNAs obtained using significance analysis of microarrays with false discovery rate of 5%. Majority of the predicted targets of these 22 differentially regulated miRNAs reside in pathways reported to be dysregulated during carcinogenesis.	unknown	unknown	2008	18319255	Unspecified
+hsa-miR-214	3429	Inclusion body myositis (IBM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-214	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-214	3905	lung cancer	up-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-214	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-214	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-214	4905	pancreatic cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-214	10222	polymyositis (PM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-214	10286	prostate cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-214	5745	serous ovarian cancer	down-regulated	microarray	Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients.	unknown	unknown	2008	18451233	Unspecified
+hsa-miR-214	178	vascular disease	up-regulated	"Northern blot, qRT-PCR etc"	Aberrant Expression of miRNA in Injured Arteries Is Confirmed by qRT-PCR or Northern Blot Analysis.	unknown	unknown	2007	17478730	Unspecified
+hsa-miR-215	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	unknown	2006	16924677	Unspecified
+hsa-miR-215	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-215	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-215	9088	psoriasis	down-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	unknown	2007	17622355	Unspecified
+hsa-miR-216	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	One of the 22 significantly up- and down-regulated miRNAs obtained using significance analysis of microarrays with false discovery rate of 5%. Majority of the predicted targets of these 22 differentially regulated miRNAs reside in pathways reported to be dysregulated during carcinogenesis.	unknown	unknown	2008	18319255	Unspecified
+hsa-miR-216	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-216	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-216	9261	nasopharyngeal carcinoma (NPC)	down-regulated	microarray	miRNAs differentially expressed between normal and NPC tumor tissues.	unknown	unknown	2008	18390668	Unspecified
+hsa-miR-216	3498	pancreatic ductal adenocarcinoma (PDAC)	down-regulated	microarray	differentially expressed between normal and PDAC or cell line samples. miR-216 and miR-217 were found to be essentially specific to pancreas.					
+	unknown	unknown	2007	17237814	Unspecified	0	380			
+hsa-miR-217	1040	B-cell chronic lymphocytic leukemia	up-regulated	microarray	Differentially expressed in CLL cells versus CD24 cells.	unknown	unknown	2004	15284443	Unspecified
+hsa-miR-217	9261	nasopharyngeal carcinoma (NPC)	down-regulated	microarray	miRNAs differentially expressed between normal and NPC tumor tissues.	unknown	unknown	2008	18390668	Unspecified
+hsa-miR-217	3498	pancreatic ductal adenocarcinoma (PDAC)	down-regulated	"Northern blot, qRT-PCR etc"	differentially expressed between normal and PDAC or cell line samples. miR-216 and miR-217 were found to be essentially specific to pancreas.	unknown	unknown	2007	17237814	Unspecified
+hsa-miR-218	2893	cervical cancer	down-regulated	"Northern blot, qRT-PCR etc"	"microRNA-218 (miR-218) was specifically underexpressed in HPV-positive cell lines, cervical lesions and cancer tissues containing HPV-16 DNA compared to both C-33A and the normal cervix.Expression of the E6 oncogene of high-risk HPV-16, but not that of low-risk HPV-6, reduced miR-218 expression, and conversely, RNA interference of E6/E7 oncogenes in an HPV-16-positive cell line increased miR-218 expression. We also demonstrate that the epithelial cell-specific marker LAMB3 is a target of miR-218. We also show that LAMB3 expression is increased in the presence of the HPV-16 E6 oncogene and this effect is mediated through miR-218. "	LAMB3	unknown	2008	17998940	Causal
+hsa-miR-218	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-218-2	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-219	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-219-1	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	survival-related and metastasis-related miRNA.	unknown	unknown	2008	18176954	Unspecified
+hsa-miR-219-1	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	unknown	2006	16924677	Unspecified
+hsa-miR-219-1	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-219-1	3969	papillary thyroid carcinoma (PTC)	up-regulated	microarray	Differentially expressed miRNA in PTC tumors	unknown	unknown	2005	16365291	Unspecified
+hsa-miR-22	9952	acute lymphoblastic leukemia (ALL)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-22	9119	acute myeloid leukemia (AML)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-22	10652	Alzheimer's disease	down-regulated	microarray	Significantly changed miRNAs in cortex of sporadic AD cases.	unknown	unknown	2008	18434550	Unspecified
+hsa-miR-22	14691	Duchenne muscular dystrophy (DMD)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-22	5520	head and neck squamous cell carcinoma (HNSCC)	down-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-124a	10652	Alzheimer's disease	down-regulated	"Northern blot, qRT-PCR etc"	"Significant change in micro-RNA abundance in the hippocampal region of fetal, adult and Alzheimer's disease brain."	unknown	unknown	2007	17314675	Unspecified
+hsa-miR-16	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	Levels of miR-16 was decreased in NZB lymphoid tissue. Exogenous miR-16 delivered to an NZB malignant B-1 cell line resulted in cellcycle alterations and increased apoptosis.	BCL2	"BCL2,CGI-38"	2007	17351108	Causal
+hsa-miR-16	5517	gastric cancer (stomach cancer)	down-regulated	"Northern blot, qRT-PCR etc"	"In vitro drug sensitivity assay demonstrated that overexpression of miR-15b or miR-16 sensitized SGC7901/VCR cells to anticancer drugs whereas inhibition of them using antisense oligonucleotides conferred SGC7901 cells MDR. The downregulation of miR-15b and miR-16 in SGC7901/VCR cells was concurrent with the upregulation of Bcl-2 protein. Enforced mir-15b or miR-16 expression reduced Bcl-2 protein level and the luciferase activity of a BCL2 3' untranslated region-based reporter construct in SGC7901/VCR cells, suggesting that BCL2 is a direct target of miR-15b and miR-16. Moreover, overexpression of miR-15b or miR-16 could sensitize SGC7901/VCR cells to VCR-induced apoptosis. "	BCL2	"BCL2,CGI-38"	2008	18449891	Causal
+hsa-miR-16	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	"BCL2,CGI-38"	2007	17616669	Unspecified	0	400			
+hsa-miR-16	5745	serous ovarian cancer	up-regulated	microarray	Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients.	unknown	"BCL2,CGI-38"	2008	18451233	Unspecified
+hsa-miR-16-1	1040	chronic lymphocytic leukemia (CLL)	up-regulated	"Northern blot, qRT-PCR etc"	MicroRNA Signature Associated with Prognostic Factors (ZAP-70 Expression and IgVH Mutations) and Disease Progression in Patients with CLL.	unknown	unknown	2005	16251535	Unspecified
+hsa-miR-16-1	9119	acute promyelocytic leukemia (APL)	up-regulated	"Northern blot, qRT-PCR etc"	"Upregulation of miR-15a,miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223,miR-342 and miR-107, whereas miR-181b was downregulated in in acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment."	"BCL2, RAS"	unknown	2007	17260024	Causal
+hsa-miR-16-1	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	"Both miR-15a and miR-16-1 recognize target sites on the 3'UTR of BCL2, an anti-apoptotic"					
+oncogene. These miRNAs control the level of BCL2 in normal cells but the expression of the										
+oncogene is increased when the miRNAs are deleted leading to CLL.	BCL2	unknown	2005	16166262	Causal	1	404			
+hsa-miR-16-1	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	"miR-15a and miR-16-1, both microRNAs negatively regulate BCL2 at a post-transcriptional level and BCL2 repression induces apoptosis in MEG-01 chronic leukemia cell line and reduced in-vivo tumorigenicity."	BCL2	unknown	2007	17707831	Causal
+hsa-miR-16-1	353	mantle cell lymphoma (MCL)	normal	"Northern blot, qRT-PCR etc"	"Truncated CCND1 mRNA expression leads to increased total CCND1 mRNA, increased CCND1 protein expression, and increased S phase fraction in MCL cell lines. This truncation deletes miR-16-1 binding sites within the CCND1 mRNA 3'UTR and alters miRNA regulation of MCL."	CCND1	unknown	2008	18483394	Causal
+hsa-miR-16-1	3829	pituitary adenoma	down-regulated	"Northern blot, qRT-PCR etc"	"miR-15a and miR-16-1 are expressed at lower levels in pituitary adenomas as compared to normal pituitary tissue. Moreover, their expression inversely correlates with tumor diameter and with RARS expression (P<0.05), but directly correlates with p43 secretion (P<0.02)."	RAS	unknown	2005	15648093	Causal
+hsa-miR-16-1	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Aberrantly expressed miRNA precursors in pancreatic adenocarcinoma.PAM testing was conducted on 10 tumor samples and 15 adjacent benign samples. PAM has correctly classified 100% of the tested tumor samples and 11 of 15 of the tested benign samples. The 20 top ranked differentially expressed miRNAs in pancreatic adenocarcinoma as selected by PAM.	unknown	unknown	2006	17149698	Unspecified
+hsa-miR-16-2	1040	chronic lymphocytic leukemia (CLL)	up-regulated	"Northern blot, qRT-PCR etc"	MicroRNA Signature Associated with Prognostic Factors (ZAP-70 Expression and IgVH Mutations) and Disease Progression in Patients with CLL.	unknown	unknown	2005	16251535	Unspecified
+hsa-miR-164	3829	pituitary adenoma	down-regulated	microarray	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	unknown	2007	17111382	Unspecified
+hsa-miR-170	3459	breast cancer	up-regulated	microarray	Differentially expressed between breast carcinoma and normal breast tissue.	unknown	unknown	2005	16103053	Unspecified
+hsa-miR-172a-2	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	unknown	2006	16924677	Unspecified
+hsa-miR-17-3p	3905	lung cancer	up-regulated	microarray	"miRNAs (miR-155, miR-17-3p, miR-106a, miR-93, let-7a-2, miR-145, let-7b, and miR-21) were related to the adenocarcinoma patient��s survival. Patients with high expression of either hsamir-155, miR-17-3p, miR-106a, miR-93, or miR-21 and low expression of either let-7a-2, let-7b, or miR-145 were found to have a significantly worse prognosis."	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-17-3p	7012	anaplastic thyroid carcinoma (ATC)	up-regulated	"Northern blot, qRT-PCR etc"	"MiRNAs in a miR-17-92 cluster were overexpressed in ARO cells. We confirmed the overexpression of those miRNAs by Northern blot analysis in ARO and FRO cells. In 3 of 6 clinical ATC samples, miR-17-3p and miR-17-5p were robustly overexpressed in cancer lesions compared to adjacent normal tissue. To investigate the functional role of these miRNAs in ATC cells, ARO and FRO cells were transfected with miRNA inhibitors, antisense oligonucleotides containing locked nucleic acids. Suppression of miR-17-3p caused complete growth arrest, presumably due to caspase activation resulting in apoptosis. MiR-17-5p or miR-19a inhibitor also induced strong growth reduction, but only miR-17-5p inhibitor led to cellular senescence. On the other hand, miR-18a inhibitor only moderately attenuated the cell growth. Thus, we have clarified functional differences among the members of the cluster in ATC cells. In conclusion, these findings suggest that the miR-17-92 cluster plays an important role in certain types of ATCs and could be a novel target for ATC treatment."	unknown	unknown	2008	18429962	Causal
+hsa-miR-17-3p	3905	lung cancer	up-regulated	"Northern blot, qRT-PCR etc"	"frequent and marked overexpression, with occasional gene amplification, of clustered miRNAs (miR-17-92) within intron 3 of the C13orf 25 gene at 13q31.3 in lung cancers, especially examples with small-cell lung cancer histology.The authors further showed the stimulatory activity of this miRNA cluster in lung cancer cell growth."	unknown	unknown	2005	16266980	Causal
+hsa-miR-17-3p	353	MYC-rearranged lymphoma	up-regulated	"Northern blot, qRT-PCR etc"	Myc can upregulate the miR-17 cluster by binding directly upstream of the miR-17 locus.Deregulation of the miR-17 polycistron can be assumed to contribute to aggressive cancer development by repressing tumor suppressor genes.T��RII is the direct downstream target of the miR-17 polycistron.	T��RII	unknown	2007	17608773	Causal
+hsa-miR-17-3p	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	unknown	2006	16924677	Unspecified
+hsa-miR-17-3p	353	malignant lymphoma	up-regulated	"Northern blot, qRT-PCR etc"	"six mature miRNAs (miR-17-5p, miR-17-3p, miR-19a, miR-19b, miR-20 and miR-92-1) in the cell lines with a 13q31 gain/amplification displayed overexpression significantly higher than in those without."	unknown	unknown	2005	16167061	Unspecified
+hsa-miR-409-3p	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-409-3p	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-409-3p	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-409-3p	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-419	4001	epithelial ovarian cancer (EOC)	down-regulated	"Northern blot, qRT-PCR etc"	"All eight miRNAs located in chromosome 14 cluster at Dlk1-Gtl2 Domain(mir-337, mir-432, mir-495,mir-368, mir-376a, mir-376b, mir-377, and mir-419) were expressed in all four IOSE, but in no EOC cell line, which were silenced by epigenetic alterations in EOC. Down-regulation of miRNAs located at Dlk1-Gtl2 domain is associated with higher tumor proliferation and shorter patient survival, suggesting that miRNAs in this cluster function as tumor suppressor genes. "	unknown	unknown	2008	18458333	Causal
+hsa-miR-422a	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-422b	5520	head and neck squamous cell carcinoma (HNSCC)	down-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-423	14691	Duchenne muscular dystrophy (DMD)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-423	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-423	12236	primary biliary cirrhosis (PBC)	down-regulated	microarray	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	unknown	2008	18631158	Unspecified
+hsa-miR-424	9952	acute lymphoblastic leukemia (ALL)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-424	9119	acute myeloid leukemia (AML)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-424	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Confirmation of the Aberrant miRNA Expression in Hypertrophic Hearts by Northern Blot Analysis and/or qRT-PCR.	unknown	unknown	2007	17525252	Unspecified
+hsa-miR-424	5520	head and neck squamous cell carcinoma (HNSCC)	down-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-424	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-424	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Aberrantly expressed miRNA precursors in pancreatic adenocarcinoma.PAM testing was conducted on 10 tumor samples and 15 adjacent benign samples. PAM has correctly classified 100% of the tested tumor samples and 11 of 15 of the tested benign samples. The 20 top ranked differentially expressed miRNAs in pancreatic adenocarcinoma as selected by PAM.	unknown	unknown	2006	17149698	Unspecified
+hsa-miR-429	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"All five members of the microRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141 and miR-429) and miR-205 were markedly downregulated in cells that had undergone EMT in response to transforming growth factor (TGF)-beta or to ectopic expression of the protein tyrosine phosphatase Pez. Enforced expression of the miR-200 family alone was sufficient to prevent TGF-beta-induced EMT. Together, these microRNAs cooperatively regulate expression of the E-cadherin transcriptional repressors ZEB1 (also known as deltaEF1) and SIP1 (also known as ZEB2), factors previously implicated in EMT and tumour metastasis. Inhibition of the microRNAs was sufficient to induce EMT in a process requiring upregulation of ZEB1 and/or SIP1. Conversely, ectopic expression of these microRNAs in mesenchymal cells initiated mesenchymal to epithelial transition (MET). Consistent with their role in regulating EMT, expression of these microRNAs was found to be lost in invasive breast cancer cell lines with mesenchymal phenotype. Expression of the miR-200 family was also lost in regions of metaplastic breast cancer specimens lacking E-cadherin. These data suggest that downregulation of the microRNAs may be an important step in tumour progression."					
+	"ZEB1(deltaEF1), SIP1(ZEB2)"	unknown	2008	18376396	Causal	1	435			
+hsa-miR-429	-1	cancer	down-regulated	"Northern blot, qRT-PCR etc"	"The miR-200 family is composed of five members arranged as two clusters, miR-200a/200b/429 and"					
+miR-200c/141.Ectopic expression of the miR-200 family in 4TO7 carcinoma cells caused a rapid and										
+significant decrease in ZEB1 and ZEB2 levels.Over-expressing the miR-200 family in 4TO7 cells										
+"induced a dramatic morphological change from a spindle-like, mesenchymal phenotype towards a"										
+"more pronounced epithelial phenotype with formation of adheren junctions. Furthermore, overexpression of miR-200 significantly inhibits growth factor-induced directional migration, a hallmark of metastatic cancer cells.This suggests that ectopic expression of the miR-200 family can"										
+promote the mesenchymal-epithelial transition and reduce tumor cell migration.	"ZEB1, ZEB2"	unknown	2008	18411277	Causal	1	436			
+hsa-miR-431	1208	autism spectrum disorder (ASD)	up-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	Rtl1/Peg11	2008	18563458	Unspecified
+hsa-miR-432	4001	epithelial ovarian cancer (EOC)	down-regulated	"Northern blot, qRT-PCR etc"	"All eight miRNAs located in chromosome 14 cluster at Dlk1-Gtl2 Domain(mir-337, mir-432, mir-495,mir-368, mir-376a, mir-376b, mir-377, and mir-419) were expressed in all four IOSE, but in no EOC cell line, which were silenced by epigenetic alterations in EOC. Down-regulation of miRNAs located at Dlk1-Gtl2 domain is associated with higher tumor proliferation and shorter patient survival, suggesting that miRNAs in this cluster function as tumor suppressor genes. "	unknown	unknown	2008	18458333	Causal
+hsa-miR-432	1208	autism spectrum disorder (ASD)	down-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	unknown	2008	18563458	Unspecified
+hsa-miR-432	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-432	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-432	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-432	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-432*	12236	primary biliary cirrhosis (PBC)	down-regulated	microarray	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	unknown	2008	18631158	Unspecified
+hsa-miR-451	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"We for the first time show that DOX-resistant MCF-7 cells (MCF-7/DOX) exhibit a considerable dysregulation of the miRNAome profile and altered expression of miRNA processing enzymes Dicer and Argonaute 2. Furthermore, we show that microRNA-451 regulates the expression of multidrug resistance 1 gene. More importantly, transfection of the MCF-7/DOX-resistant cells with microRNA-451 resulted in the increased sensitivity of cells to DOX, indicating that correction of altered expression of miRNA may have significant implications for therapeutic strategies aiming to overcome cancer cell resistance. "	unknown	unknown	2008	18645025	Causal
+hsa-miR-451	9952	acute lymphoblastic leukemia (ALL)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-451	9119	acute myeloid leukemia (AML)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-451	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Confirmation of the Aberrant miRNA Expression in Hypertrophic Hearts by Northern Blot Analysis and/or qRT-PCR.	unknown	unknown	2007	17525252	Unspecified
+hsa-miR-451	10923	homozygous sickle cell disease (HbSS)	up-regulated	microarray	"Several microRNAs (miR-320, let-7s, miR-181, miR-141) were over-represented in the HbAA erythrocytes, while other microRNAs (miR-29a, miR-144, miR-451, miR-140) were overrepresented in the HbSS erythrocytes."	unknown	unknown	2008	18523662	Unspecified
+hsa-miR-451	12236	primary biliary cirrhosis (PBC)	up-regulated	"Northern blot, qRT-PCR etc"	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	unknown	2008	18631158	Unspecified
+hsa-miR-451	13223	uterine leiomyoma (ULM)	down-regulated	microarray	Twenty most differentially expressed microRNA species in leiomyoma versus myometrium microarray.	unknown	unknown	2008	17765232	Unspecified
+hsa-miR-452	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-452	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-452	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-452	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-483	13315	chronic pancreatitis	up-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-483	12236	primary biliary cirrhosis (PBC)	down-regulated	microarray	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	unknown	2008	18631158	Unspecified
+hsa-miR-484	1208	autism spectrum disorder (ASD)	up-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	unknown	2008	18563458	Unspecified
+hsa-miR-485-5p	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-486	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Confirmation of the Aberrant miRNA Expression in Hypertrophic Hearts by Northern Blot Analysis and/or qRT-PCR.	unknown	unknown	2007	17525252	Unspecified
+hsa-miR-486	14691	Duchenne muscular dystrophy (DMD)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-486	13223	uterine leiomyoma (ULM)	down-regulated	microarray	Twenty most differentially expressed microRNA species in leiomyoma versus myometrium microarray.	unknown	unknown	2008	17765232	Unspecified
+hsa-miR-487b	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-487b	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-487b	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-487b	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-487b	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-487b	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-491	10286	prostate cancer	up-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	469			
+hsa-miR-493-3p	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-493-3p	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-493-3p	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-493-5p	13223	uterine leiomyoma (ULM)	up-regulated	microarray	Twenty most differentially expressed microRNA species in leiomyoma versus myometrium microarray.	unknown	unknown	2008	17765232	Unspecified
+hsa-miR-494	13315	chronic pancreatitis	up-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-494	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-494	12236	primary biliary cirrhosis (PBC)	down-regulated	microarray	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	unknown	2008	18631158	Unspecified
+hsa-miR-495	4001	epithelial ovarian cancer (EOC)	down-regulated	"Northern blot, qRT-PCR etc"	"All eight miRNAs located in chromosome 14 cluster at Dlk1-Gtl2 Domain(mir-337, mir-432, mir-495,mir-368, mir-376a, mir-376b, mir-377, and mir-419) were expressed in all four IOSE, but in no EOC cell line, which were silenced by epigenetic alterations in EOC. Down-regulation of miRNAs located at Dlk1-Gtl2 domain is associated with higher tumor proliferation and shorter patient survival, suggesting that miRNAs in this cluster function as tumor suppressor genes. "	unknown	unknown	2008	18458333	Causal
+hsa-miR-495	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-495	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-495	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-495	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-495	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-497	13315	chronic pancreatitis	down-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-497	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	484			
+hsa-miR-498	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-498	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-498	10286	prostate cancer	up-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	487			
+hsa-miR-498	13223	uterine leiomyoma (ULM)	down-regulated	microarray	Twenty most differentially expressed microRNA species in leiomyoma versus myometrium microarray.	unknown	unknown	2008	17765232	Unspecified
+hsa-miR-5	9952	acute lymphoblastic leukemia (ALL)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-5	9119	acute myeloid leukemia (AML)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-501	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-501	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-501	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-501	10222	polymyositis (PM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-503	10286	prostate cancer	up-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	495			
+hsa-miR-508	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-510	9778	diarrhea predominant irritable bowel syndrome (IBS-D)	normal	"Northern blot, qRT-PCR etc"	"The novel HTR3E 3'UTR variant c.*76G>A (rs62625044) was associated with female IBS-D (P=0.033, OR=8.53). This association was confirmed in a replication study including 119 IBS-D patients and 195 controls from Germany (P=0.0046, OR=4.92). Pooled analysis resulted in a highly significant association of c.*76G>A with female IBS-D (P=0.0002, OR=5.39). In a reporter assay, c.*76G>A affected binding of miR-510 to the HTR3E 3'UTR and caused elevated luciferase expression. HTR3E and miR-510 co-localize in enterocytes of the gut epithelium as shown by in situ hybridization and RT-PCR. This is the first example indicating microRNA related expression regulation of a serotonin receptor gene with a cis-regulatory variant affecting this regulation and appearing to be associated with female IBS-D."	HTR3E	unknown	2008	18614545	Causal
+hsa-miR-511	10652	Alzheimer's disease	up-regulated	microarray	Significantly changed miRNAs in cortex of sporadic AD cases.	unknown	unknown	2008	18434550	Unspecified
+hsa-miR-513	10286	prostate cancer	up-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	499			
+hsa-miR-515-3p	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-516-5p	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-518a-2*	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-518a-2*	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-518b	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-519a	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-519d	12236	primary biliary cirrhosis (PBC)	down-regulated	microarray	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	unknown	2008	18631158	Unspecified
+hsa-miR-520c	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"miR-373 and miR-520c stimulated cancer cell migration and invasion in vitro and in vivo. Mechanistically, the migration phenotype of miR-373 and miR-520c can be explained by suppression of CD44. We found significant upregulation of miR-373 in clinical breast cancer metastasis samples that correlated inversely with CD44 expression."	CD44	unknown	2008	18193036	Causal
+hsa-miR-524*	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-524*	9088	psoriasis	down-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	unknown	2007	17622355	Unspecified
+hsa-miR-525*	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-539	1208	autism spectrum disorder (ASD)	down-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	unknown	2008	18563458	Unspecified
+hsa-miR-542-3p	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-542-3p	13223	uterine leiomyoma (ULM)	up-regulated	microarray	Twenty most differentially expressed microRNA species in leiomyoma versus myometrium microarray.	unknown	unknown	2008	17765232	Unspecified
+hsa-miR-542-5p	13223	uterine leiomyoma (ULM)	down-regulated	microarray	Twenty most differentially expressed microRNA species in leiomyoma versus myometrium microarray.	unknown	unknown	2008	17765232	Unspecified
+hsa-miR-550	1208	autism spectrum disorder (ASD)	down-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	unknown	2008	18563458	Unspecified
+hsa-miR-551a	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-563	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-565	5520	head and neck squamous cell carcinoma (HNSCC)	down-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-572	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-572	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-582	13223	uterine leiomyoma (ULM)	up-regulated	microarray	Twenty most differentially expressed microRNA species in leiomyoma versus myometrium microarray.	unknown	unknown	2008	17765232	Unspecified
+hsa-miR-594	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	unknown	2007	17616664	Unspecified
+hsa-miR-594	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-598	1208	autism spectrum disorder (ASD)	up-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	unknown	2008	18563458	Unspecified
+hsa-miR-605	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-608	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-611	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-622	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-627	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-628	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-635	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-637	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-637	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-642	13223	uterine leiomyoma (ULM)	down-regulated	microarray	Twenty most differentially expressed microRNA species in leiomyoma versus myometrium microarray.	unknown	unknown	2008	17765232	Unspecified
+hsa-miR-648	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-652	1208	autism spectrum disorder (ASD)	down-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	unknown	2008	18563458	Unspecified
+hsa-miR-652	1909	uveal melanoma	up-regulated	microarray	"The top six miRNA discriminators ( let-7b, miR-199a,miR-199a*, miR-143, miR-193b, and miR-652) accurately distinguished class 1 (low metastatic risk) from class 2 (high metastatic risk) with 100% sensitivity and specificity."	unknown	unknown	2008	18477892	Unspecified
+hsa-miR-657	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-662	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-663	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Aberrant hypermethylation leads to miRNA gene inactivation in human breast cancer. Aberrant hypermethylation was shown for mir-9-1, mir-124a-3, mir-148, mir-152, and mir-663 in 34-86% of cases in a series of 71 primary human breast cancer specimens.miRNA gene hypermethylation correlated strongly with methylation of known tumour suppressor genes (p = 0.003)."	unknown	unknown	2007	17948228	Unspecified
+hsa-miR-663	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Aberrant hypermethylation was shown for miR-9-1, miR-124a-3, miR-148, miR-152, and miR-663 in 34-86% of cases in a series of 71 primary human breast cancer specimens. miRNA gene hypermethylation correlated strongly with methylation of known tumour suppressor genes (p = 0.003). "	unknown	unknown	2007	18314617	Unspecified
+hsa-miR-663	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-7	3068	glioblastoma	down-regulated	"Northern blot, qRT-PCR etc"	"miR-7 potently suppressed epidermal growth factor receptor expression, and furthermore it independently inhibited the Akt pathwayvia targeting upstream regulators. miR-7 expression was down-regulated in glioblastoma versus surrounding brain, with a mechanism involving impaired processing. Importantly, transfection with miR-7 decreased viabilityand invasiveness of primary glioblastoma lines.This studyestablishes miR-7 as a regulator of major cancer pathways and suggests that it has therapeutic potential for glioblastoma."	EGFR	unknown	2008	18483236	Causal
+hsa-miR-7	1208	autism spectrum disorder (ASD)	up-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	unknown	2008	18563458	Unspecified
+hsa-miR-7	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-7	5419	schizophrenia	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed miRNA from the prefrontal cortex of subjects with schizophrenia compared to psychiatrically healthy subjects.	unknown	unknown	2007	17326821	Unspecified
+hsa-miR-7-1	3829	pituitary adenoma	down-regulated	microarray	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	unknown	2007	17111382	Unspecified
+hsa-miR-7-2	4451	kidney cancer	up-regulated	microarray	"A set of 4 human micro-RNAs (miR-28, miR-185, miR-27, and let-7f-2) were found significantly up-regulated in renal cell carcinoma (P<0.05) compared to normal kidney."	unknown	unknown	2007	17826655	Unspecified
+hsa-miR-7-3	13315	chronic pancreatitis	up-regulated	microarray	Differentially Expressed MicroRNA in chronic pancreatitis compared to Normal Pancreas	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-7-3	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	miRNA precursors with significantly different expression.	unknown	unknown	2005	16192569	Unspecified
+hsa-miR-7-3	3829	pituitary adenoma	down-regulated	microarray	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	unknown	2007	17111382	Unspecified
+hsa-miR-802	14250	Down syndrome (DS)	up-regulated	"Northern blot, qRT-PCR etc"	"Bioinformatic analyses demonstrate that human chromosome 21(Hsa21) harbors five miRNA genes; miR-99a, let-7c, miR-125b-2, miR-155, and miR-802. MiRNA expression profiling, miRNA RT-PCR, and miRNA in situ hybridization experiments demonstrate that these miRNAs are overexpressed in fetal brain and heart specimens from individuals with DS when compared with age- and sex-matched controls."	unknown	unknown	2008	18387358	Unspecified
+hsa-miR-9	8567	Hodgkin's lymphoma	up-regulated	"Northern blot, qRT-PCR etc"	"miR-9 and let-7a functionally targeted specific binding sites in the 3' untranslated region of PRDM1/blimp-1 mRNA and repressed luciferase reporter activities through repression of translation. Similar to their in vitro counterparts, the majority of HRS cells in primary Hodgkin lymphoma (HL) cases showed weak or no PRDM1/Blimp-1 expression. Over-expression of miR-9 or let-7a reduced PRDM1/Blimp-1 levels in U266 cells by 30% to 50%, whereas simultaneous inhibition of their activities in L428 cells resulted in an approximately 2.6-fold induction in PRDM1/Blimp-1. MiRNA-mediated down-regulation of PRDM1/Blimp-1 may contribute to the phenotype maintenance and pathogenesis of HRS cells by interfering with normal B-cell terminal differentiation, thus representing a novel molecular lesion, as well as a potential therapeutic target in HL."	PRDM1/Blimp-1	unknown	2008	18583325	Causal
+hsa-miR-9	14667	metabolic disease	up-regulated	"Northern blot, qRT-PCR etc"	miR-9 affects insulin release by decreasing the expression of one cut domain family member 2 
+(transcription factor ONECUT-2) and causing a rise in levels of synaptotagmin-like protein 4 (SYTL4; also known as granuphilin), a major controller of cell secretion."	"ONECUT-2,SYTL4"	unknown	
+2006	16831872	Causal		
+hsa-miR-9	6708	recurrent ovarian cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Target prediction analysis for the above miRNA ""recurrent metastatic signature"" identified genes previously validated in our transcriptome study. Common biological pathways well characterised in ovarian cancer were shared by miR-9 and miR-223 lists of predicted target genes. We provide strong evidence that miR-9 acts as a putative tumour suppressor gene in recurrent ovarian cancer. Based on integrated transcriptome and miRNA analysis, miR-9 and miR-223 can be of potential importance as biomarkers in recurrent ovarian cancer."					
+	unknown	unknown	2008	18442408	Causal
+hsa-miR-9	10652	Alzheimer's disease	up-regulated	"Northern blot, qRT-PCR etc"	"Significant change in micro-RNA abundance in the hippocampal region of fetal, adult and Alzheimer's disease brain."	unknown	unknown	2007	17314675	Unspecified
+hsa-miR-9	10652	Alzheimer's disease	down-regulated	microarray	Significantly changed miRNAs in cortex of sporadic AD cases.	unknown	unknown	2008	18434550	Unspecified
+hsa-miR-9	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	Differentially expressed between tumors and normals.	unknown	unknown	2007	17875710	Unspecified
+hsa-miR-9	8524	follicular lymphoma (FL)	up-regulated	microarray	"Nine miRNAs (hsa-miR-9, hsa-miR-301, hsa-miR-213, hsa-miR-9*, hsa-miR-330, hsa-miR-106a, hsa-miR-338, hsa-miR-155, hsa-miR-210) were significantly up- and three miRNAs (hsa-miR-320, hsa-miR-149, hsa-miR-139) down-regulated in the lymphoma samples. Expression of hsa-miR-9 was most strongly increased (12-fold) and of hsa-miR-320 most strongly decreased (3-fold)."	unknown	unknown	2008	18537969	Unspecified
+hsa-miR-9	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	One of the 22 significantly up- and down-regulated miRNAs obtained using significance analysis of microarrays with false discovery rate of 5%. Majority of the predicted targets of these 22 differentially regulated miRNAs reside in pathways reported to be dysregulated during carcinogenesis.	unknown	unknown	2008	18319255	Unspecified
+hsa-miR-9	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-9	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-9	769	neuroblastoma (NB)	down-regulated	"Northern blot, qRT-PCR etc"	"Three neuronal miRNAs (9,125a,and 125b) act in an additive manner by repressing a common target, the truncated isoform of the neurotrophin receptor tropomyosin-related kinase C, to control human neuroblastoma cell proliferation."	unknown	unknown	2007	17483472	Unspecified
+hsa-miR-9	3908	non-small cell lung cancer (NSCLC)	down-regulated	microarray	differentially expressed miRNA in TRAIL-resistant NSCLC cells.	unknown	unknown	2008	18246122	Unspecified
+hsa-miR-9*	9119	acute myeloid leukemia (AML)	down-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-9*	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	One of the 22 significantly up- and down-regulated miRNAs obtained using significance analysis of microarrays with false discovery rate of 5%. Majority of the predicted targets of these 22 differentially regulated miRNAs reside in pathways reported to be dysregulated during carcinogenesis.	unknown	unknown	2008	18319255	Unspecified
+hsa-miR-9*	8894	Oral Squamous Cell Carcinoma (OSCC)	up-regulated	microarray	miRNAs frequently up-regulated in OSCC cell lines(>1.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-9-1	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Aberrant hypermethylation leads to miRNA gene inactivation in human breast cancer. mir-9-1 gene is already hypermethylated in pre-invasive intraductal lesions, a good correlation between quantitative methylation level and reduction of expression could be demonstrated in a subset of primary human breast cancer specimen (r = 0.8)."	unknown	unknown	2007	17948228	Unspecified
+hsa-miR-9-1	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Aberrant hypermethylation was shown for miR-9-1, miR-124a-3, miR-148, miR-152, and miR-663 in 34-86% of cases in a series of 71 primary human breast cancer specimens. miRNA gene hypermethylation correlated strongly with methylation of known tumour suppressor genes (p = 0.003). After treatment of various breast cancer cell lines with the demethylating agent 5-aza-2'deoxycytidine, reduction of mir-9-1 gene methylation and concomitant reactivation of expression could be observed. For the mir-9-1 gene, which is already hypermethylated in preinvasive intraductal lesions, a good correlation between quantitative methylation level and reduction of expression could be demonstrated in a subset of primary human breast cancer specimen (r = 0.8). "	unknown	unknown	2007	18314617	Unspecified
+hsa-miR-9-1	8894	Oral Squamous Cell Carcinoma (OSCC)	up-regulated	microarray	miRNAs frequently up-regulated in OSCC cell lines(>1.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-92	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	miR-150 and miR-92 are significantly deregulated in patients with CLL.	unknown	unknown	2007	17327404	Unspecified
+hsa-miR-92	14691	Duchenne muscular dystrophy (DMD)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-92	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-92	769	neuroblastoma (NB)	up-regulated	"Northern blot, qRT-PCR etc"	Positively correlated with MYCN-amplification in tumors in vivo.	unknown	unknown	2007	17943719	Unspecified
+hsa-miR-92	12236	primary biliary cirrhosis (PBC)	down-regulated	microarray	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	unknown	2008	18631158	Unspecified
+hsa-miR-92	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	576			
+hsa-miR-92	5419	schizophrenia	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed miRNA from the prefrontal cortex of subjects with schizophrenia compared to psychiatrically healthy subjects.	unknown	unknown	2007	17326821	Unspecified
+hsa-miR-9-2	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	survival-related and metastasis-related miRNA.	unknown	unknown	2008	18176954	Unspecified
+hsa-miR-9-2	3068	glioblastoma	up-regulated	microarray	Significantly differentially expressed between glioblastoma cell line samples and the control samples.	unknown	unknown	2005	16039986	Unspecified
+hsa-miR-9-2	8894	Oral Squamous Cell Carcinoma (OSCC)	up-regulated	microarray	miRNAs frequently up-regulated in OSCC cell lines(>1.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-92-1	1040	B-cell chronic lymphocytic leukemia	up-regulated	microarray	Differentially expressed in CLL cells versus CD28 cells.	unknown	unknown	2004	15284443	Unspecified
+hsa-miR-92-1	353	malignant lymphoma	up-regulated	"Northern blot, qRT-PCR etc"	"six mature miRNAs (miR-17-5p, miR-17-3p, miR-19a, miR-19b, miR-20 and miR-92-1) in the cell lines with a 13q31 gain/amplification displays overexpression significantly higher than in those without."	unknown	unknown	2005	16167061	Unspecified
+hsa-miR-92-1	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Aberrantly expressed miRNA precursors in pancreatic adenocarcinoma.PAM testing was conducted on 10 tumor samples and 15 adjacent benign samples. PAM has correctly classified 100% of the tested tumor samples and 11 of 15 of the tested benign samples. The 20 top ranked differentially expressed miRNAs in pancreatic adenocarcinoma as selected by PAM.	unknown	unknown	2006	17149698	Unspecified
+hsa-miR-92-2	715	T-cell leukemia	up-regulated	"Northern blot, qRT-PCR etc"	"The authors conclude that, in addition to miR-106a, miR-20b, miR-19b-2, and miR-92-2 overexpression in tumors, their capacity to induce anchorage independence growth strongly supports an oncogenic"					
+"potential for those miRNAs. they also conclude that Mylip and Rbp1-like are true targets of the miR-106-363 cluster(miR-106a, miR-18b, miR-20b, miR-19b-2, miR-92-2, and miR-363). More specifically, Rbp1-like seemed only targeted by miR-106a/miR-20b, whereas Mylip could be targeted by the four miRNAs(miR-106a, miR-20b, miR-19b-2, and miR-92-2) with miR-106a/miR-20b being more efficient."	Rbp1-like	unknown	2006	17575136	Causal	1	584			
+hsa-miR-92-2	5517	gastric cancer (stomach cancer)	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-92-2	4905	pancreatic cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-92-2	10286	prostate cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-93	5745	serous ovarian cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients. Higher expression of miR-200a, miR-200b, miR-200c, miR-141, miR-18a, miR-93, and miR-429, and lower expression of ambi-miR-7039, let-7b, and miR-199a were significantly correlated with decreased progression-free survival and overall survival."	unknown	unknown	2008	18451233	Unspecified
+hsa-miR-93	5517	gastric cancer (stomach cancer)	up-regulated	"Northern blot, qRT-PCR etc"	"miR-106b-25 cluster, upregulated in a subset of human gastric tumors, is activated by E2F1 in parallel with its host gene, Mcm7. In turn, miR-106b and miR-93 regulate E2F1 expression, establishing a miRNA-directed negative feedback loop. Furthermore, upregulation of these miRNAs impairs the TGFbeta tumor suppressor pathway, interfering with the expression of CDKN1A (p21(Waf1/Cip1)) and BCL2L11 (Bim). "	E2F1	unknown	2008	18328430	Causal
+hsa-miR-93	10881	vesicular stomatitis	down-regulated	"Northern blot, qRT-PCR etc"	"miR-24 and miR-93 could target viral large protein (L protein) and phosphoprotein (P protein) genes, and in variant Dicer1 cells, a lack of host miR-24 and miR-93 was responsible for increased VSV replication."	"L protein,P protein"	unknown	2007	17613256	Causal
+hsa-miR-93	10652	Alzheimer's disease	down-regulated	microarray	Significantly changed miRNAs in cortex of sporadic AD cases.	unknown	unknown	2008	18434550	Unspecified
+hsa-miR-93	1208	autism spectrum disorder (ASD)	down-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	unknown	2008	18563458	Unspecified
+hsa-miR-93	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	unknown	2006	16924677	Unspecified
+hsa-miR-93	769	neuroblastoma (NB)	up-regulated	"Northern blot, qRT-PCR etc"	Positively correlated with MYCN-amplification in tumors in vivo.	unknown	unknown	2007	17943719	Unspecified
+hsa-miR-93	3498	pancreatic ductal adenocarcinoma (PDAC)	up-regulated	microarray	differentially expressed between normal and PDAC or cell line samples.	unknown	unknown	2007	17237814	Unspecified
+hsa-miR-9-3	8894	Oral Squamous Cell Carcinoma (OSCC)	up-regulated	microarray	miRNAs frequently up-regulated in OSCC cell lines(>1.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-9-3	3969	papillary thyroid carcinoma (PTC)	up-regulated	microarray	Differentially expressed miRNA in PTC tumors	unknown	unknown	2005	16365291	Unspecified
+hsa-miR-9-3	3829	pituitary adenoma	down-regulated	microarray	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	unknown	2007	17111382	Unspecified
+hsa-miR-9-3p	5419	schizophrenia	down-regulated	microarray	Differentially expressed miRNA from the prefrontal cortex of subjects with schizophrenia compared to psychiatrically healthy subjects.	unknown	unknown	2007	17326821	Unspecified
+hsa-miR-95	1208	autism spectrum disorder (ASD)	up-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	unknown	2008	18563458	Unspecified
+hsa-miR-95	353	diffuse large B-cell lymphoma (DLBCL)	down-regulated	microarray	"Four hsa-miR-As (miR-210, hsa-miR-155, hsa-miR-106a, hsa-miR-17-5p) were expressed at a significantly higher level in DLBCL than in normal tissue. In contrast, the remaining 11 miRNAs (hsa-miR-150, hsa-miR-145, hsa-miR-328, hsa-miR-139, hsa-miR-99a, hsa-miR-10a, hsa-miR-95, hsa-miR-149, hsa-miR-320, hsa-miR-151,let-7e) were expressed at a significantly lower level in DLBCL."	unknown	unknown	2008	18537969	Unspecified
+hsa-miR-95	14691	Duchenne muscular dystrophy (DMD)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-95	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-95	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-95	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-96	13315	chronic pancreatitis	down-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-96	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed between neoplastic conditions (CRC cell lines and tumor samples) and non-tumoral colon tissues.	unknown	unknown	2006	16854228	Unspecified
+hsa-miR-96	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	One of the 22 significantly up- and down-regulated miRNAs obtained using significance analysis of microarrays with false discovery rate of 5%. Majority of the predicted targets of these 22 differentially regulated miRNAs reside in pathways reported to be dysregulated during carcinogenesis.	unknown	unknown	2008	18319255	Unspecified
+hsa-miR-96	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	"Our study identified and validated miR-224 overexpression.Moreover, miR-96 was overexpressed in HBV tumors, and miR-126* was down-regulated in alcohol-related hepatocellular carcinoma."	unknown	unknown	2008	18433021	Unspecified
+hsa-miR-96	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-96	3908	non-small cell lung cancer (NSCLC)	down-regulated	microarray	differentially expressed miRNA in TRAIL-resistant NSCLC cells.	unknown	unknown	2008	18246122	Unspecified
+hsa-miR-96	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-96	3498	pancreatic ductal adenocarcinoma (PDAC)	down-regulated	microarray	differentially expressed between normal and PDAC or cell line samples.	unknown	unknown	2007	17237814	Unspecified
+hsa-miR-96	10584	retinitis pigmentosa (RP)	up-regulated	"Northern blot, qRT-PCR etc"	"Expression of miR-1 and miR-133 decreased by more than 2.5-fold (P<0.001), whereas expression of miR-96 and miR-183 increased by more than 3-fold (P<0.001) in Pro347Ser retinas, as validated by qPCR."	unknown	unknown	2007	18034880	Unspecified
+hsa-miR-98	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	"Northern blot, qRT-PCR etc"	"Albeit HMGA2 is associated with enhanced selective chemosensitivity towards topoisomerase (topo) II inhibitor, doxorubicin in HNSCC, the expression of HMGA2 is thwarted by hypoxia. This is accompanied by enhanced expression of miRNA-98 and other miRNAs, which predictably target HMGA2. Moreover, transfection of pre-miR-98? during normoxia diminishes HMGA2 and potentiates resistance to doxorubicin and cisplatin."	HMGA2	unknown	2007	17222355	Causal
+hsa-miR-99a	13315	chronic pancreatitis	up-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-99a	353	diffuse large B-cell lymphoma (DLBCL)	down-regulated	microarray	"Four hsa-miR-As (miR-210, hsa-miR-155, hsa-miR-106a, hsa-miR-17-5p) were expressed at a significantly higher level in DLBCL than in normal tissue. In contrast, the remaining 11 miRNAs (hsa-miR-150, hsa-miR-145, hsa-miR-328, hsa-miR-139, hsa-miR-99a, hsa-miR-10a, hsa-miR-95, hsa-miR-149, hsa-miR-320, hsa-miR-151,let-7e) were expressed at a significantly lower level in DLBCL."	unknown	unknown	2008	18537969	Unspecified
+hsa-miR-99a	14250	Down syndrome (DS)	up-regulated	"Northern blot, qRT-PCR etc"	"Bioinformatic analyses demonstrate that human chromosome 21(Hsa21) harbors five miRNA genes; miR-99a, let-7c, miR-125b-2, miR-155, and miR-802. MiRNA expression profiling, miRNA RT-PCR, and miRNA in situ hybridization experiments demonstrate that these miRNAs are overexpressed in fetal brain and heart specimens from individuals with DS when compared with age- and sex-matched controls."	unknown	unknown	2008	18387358	Unspecified
+hsa-miR-99a	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	Differentially expressed between tumors and normals.	unknown	unknown	2007	17875710	Unspecified
+hsa-miR-99a	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	DNA copy number status of 17 genomic loci containing miRNAs differentially expressed between IOSE cells and EOC cell lines.	unknown	unknown	2008	18458333	Unspecified
+hsa-miR-99a	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	miR-99a expression exhibited a positive correlation between expression levels and the degree of tumor differentiation.	unknown	unknown	2006	16331254	Unspecified
+hsa-miR-99a	3905	lung cancer	down-regulated	"Northern blot, qRT-PCR etc"	"let-7c,miR-99a, and miR-125b-2 were also mapped in a region with Homozygous Deletion at 21q11-q22."	unknown	unknown	2007	17674361	Unspecified
+hsa-miR-99a	769	neuroblastoma (NB)	up-regulated	"Northern blot, qRT-PCR etc"	Positively correlated with MYCN-amplification in tumors in vivo.	unknown	unknown	2007	17943719	Unspecified
+hsa-miR-99a	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-99a	10286	prostate cancer	down-regulated	"Northern blot, qRT-PCR etc"	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	625			
+hsa-miR-99a	5745	serous ovarian cancer	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients.	unknown	unknown	2008	18451233	Unspecified
+hsa-miR-99b	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-99b	11727	facioscapulohumeral muscular dystrophy (FSHD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-99b	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-99b	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-99b	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-99b	10222	polymyositis (PM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-99b	10286	prostate cancer	up-regulated	microarray	One of the upregulated microRNAs in tumors with perineural invasion (FDR 10%).	unknown	unknown	2008	18459106	Unspecified
+hsa-miR-99b	9088	psoriasis	down-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	unknown	2007	17622355	Unspecified
+hsa-miR-106b	5517	gastric cancer (stomach cancer)	up-regulated	"Northern blot, qRT-PCR etc"	"miR-106b-25 cluster, upregulated in a subset of human gastric tumors, is activated by E2F1 in parallel with its host gene, Mcm7. In turn, miR-106b and miR-93 regulate E2F1 expression, establishing a miRNA-directed negative feedback loop. Furthermore, upregulation of these miRNAs impairs the TGFbeta tumor suppressor pathway, interfering with the expression of CDKN1A (p21(Waf1/Cip1)) and BCL2L11 (Bim). "	E2F1	unknown	2008	18328430	Causal
+hsa-miR-106b	10652	Alzheimer's disease	down-regulated	microarray	Significantly changed miRNAs in cortex of sporadic AD cases.	unknown	unknown	2008	18434550	Unspecified
+hsa-miR-106b	1208	autism spectrum disorder (ASD)	down-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	unknown	2008	18563458	Unspecified
+hsa-miR-106b	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-106b	5419	schizophrenia	up-regulated	microarray	Differentially expressed miRNA from the prefrontal cortex of subjects with schizophrenia compared to psychiatrically healthy subjects.	unknown	unknown	2007	17326821	Unspecified
+hsa-miR-106b-1	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	unknown	2006	16924677	Unspecified
+hsa-miR-107	1107	esophageal cancer	up-regulated	"Northern blot, qRT-PCR etc"	"miR-103/107 showed a strong correlation between low expression levels and a high overall and disease-free survival periods for esophageal cancer patients by univariate analysis, as well as by multivariate analysis."	unknown	unknown	2008	18172293	Unspecified
+hsa-miR-107	10652	Alzheimer's disease	down-regulated	"Northern blot, qRT-PCR etc"	"The coordinated application of miRNA profiling, Affymetrix microarrays, new bioinformatics predictions, in situ hybridization, and biochemical validation indicate that miR-107 may be involved in accelerated disease progression through regulation of BACE1."	BACE1	unknown	2008	18234899	Causal
+hsa-miR-107	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-107	1985	colorectal cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-107	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	unknown	2006	16609010	Unspecified
+hsa-miR-107	5517	gastric cancer (stomach cancer)	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-107	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-107	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-107	4905	pancreatic cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-107	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	"the expression of miR-103 and miR-107, associated with lack of expression of miR-155, discriminates tumors from normal."	unknown	unknown	2006	16966691	Unspecified
+hsa-miR-107	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Aberrantly expressed miRNA precursors in pancreatic adenocarcinoma.PAM testing was conducted on 10 tumor samples and 15 adjacent benign samples. PAM has correctly classified 100% of the tested tumor samples and 11 of 15 of the tested benign samples. The 20 top ranked differentially expressed miRNAs in pancreatic adenocarcinoma as selected by PAM.	unknown	unknown	2006	17149698	Unspecified
+hsa-miR-107	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-10a	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	HOXA1	2008	17234972	Unspecified
+hsa-miR-10a	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	miRNA precursors with significantly different expression.	unknown	HOXA1	2005	16192569	Unspecified
+hsa-miR-10a	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	HOXA1	2006	16609010	Unspecified
+hsa-miR-10a	353	diffuse large B-cell lymphoma (DLBCL)	down-regulated	microarray	"Four hsa-miR-As (miR-210, hsa-miR-155, hsa-miR-106a, hsa-miR-17-5p) were expressed at a significantly higher level in DLBCL than in normal tissue. In contrast, the remaining 11 miRNAs (hsa-miR-150, hsa-miR-145, hsa-miR-328, hsa-miR-139, hsa-miR-99a, hsa-miR-10a, hsa-miR-95, hsa-miR-149, hsa-miR-320, hsa-miR-151,let-7e) were expressed at a significantly lower level in DLBCL."	unknown	HOXA1	2008	18537969	Unspecified
+hsa-miR-10a	8894	Oral Squamous Cell Carcinoma (OSCC)	up-regulated	microarray	miRNAs frequently up-regulated in OSCC cell lines(>1.5-fold expression).	unknown	HOXA1	2008	18381414	Unspecified
+hsa-miR-10a	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	HOXA1	2007	17473300	Unspecified
+hsa-miR-10a	10286	prostate cancer	up-regulated	microarray	One of the upregulated microRNAs in tumors with perineural invasion (FDR 10%).	unknown	HOXA1	2008	18459106	Unspecified
+hsa-miR-10a	9088	psoriasis	down-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	HOXA1	2007	17622355	Unspecified
+hsa-miR-10a	13223	uterine leiomyoma (ULM)	down-regulated	microarray	Twenty most differentially expressed microRNA species in leiomyoma versus myometrium microarray.	unknown	HOXA1	2008	17765232	Unspecified
+hsa-miR-10b	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"miR-10b is highly expressed in metastatic breast cancer cells and positively regulates cell migration and invasion. The miR-10b induced by Twist proceeds to inhibit translation of the messenger RNA encoding homeobox D10, resulting in increased expression of a well-characterized pro-metastatic gene, RHOC."	HOXD10	unknown	2007	17898713	Causal
+hsa-miR-10b	1040	B-cell chronic lymphocytic leukemia	up-regulated	microarray	Differentially expressed in CLL cells versus CD6 cells.	unknown	unknown	2004	15284443	Unspecified
+hsa-miR-10b	3459	breast cancer	down-regulated	microarray	Differentially expressed between breast carcinoma and normal breast tissue.	unknown	unknown	2005	16103053	Unspecified
+hsa-miR-10b	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-10b	13315	chronic pancreatitis	up-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-10b	3068	glioblastoma	up-regulated	microarray	Significantly differentially expressed between glioblastoma cell line samples and the control samples.	unknown	unknown	2005	16039986	Unspecified
+hsa-miR-10b	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-10b	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-10b	10286	prostate cancer	up-regulated	"Northern blot, qRT-PCR etc"	One of the upregulated microRNAs in tumors with perineural invasion (FDR 10%).	unknown	unknown	2008	18459106	Unspecified
+hsa-miR-10b	5745	serous ovarian cancer	down-regulated	microarray	Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients.	unknown	unknown	2008	18451233	Unspecified
+hsa-miR-1-2	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	survival-related and metastasis-related miRNA.	unknown	unknown	2008	18176954	Unspecified
+hsa-miR-1-2	3978	cardiomyopathy	down-regulated	"Northern blot, qRT-PCR etc"	"miR-1-2 regulates cardiac morphogenesis, cardiac conduction, and the cardiac cell cycle."	"Irx5, Hand2, Kcnd2"	unknown	2007	17397913	Causal
+hsa-miR-122a	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	survival-related and metastasis-related miRNA.	unknown	unknown	2008	18176954	Unspecified
+hsa-miR-122a	7324	HCV infection	up-regulated	"Northern blot, qRT-PCR etc"	miR-122 is specifically expressed and highly abundant in the human liver. the sequestration of miR-122 in liver cells results in marked loss of autonomously replicating hepatitis C viral RNAs.	unknown	unknown	2005	16141076	Causal
+hsa-miR-122a	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	Hepato-specific miR-122a was found downregulated in 70% of HCCs and in all HCC-derived cell lines.miR-122a can modulate cyclin G1 expression in HCC-derived cell lines and an inverse correlation between miR-122a and cyclin G1 expression exists in primary liver carcinomas	CCNG1	unknown	2007	17616664	Causal
+hsa-miR-122a	14667	metabolic disease	down-regulated	"Northern blot, qRT-PCR etc"	"miR-122 inhibition in normal mice resulted in reduced plasma cholesterol levels, increased hepatic fatty-acid oxidation, and a decrease in hepatic fatty-acid and cholesterol synthesis rates. Activation of the central metabolic sensor AMPK was also increased. miR-122 inhibition in a diet-induced obesity mouse model resulted in decreased plasma cholesterol levels and a significant improvement in liver steatosis, accompanied by reductions in several lipogenic genes."	AMPK	unknown	2006	16459310	Causal
+hsa-miR-122a	3459	breast cancer	up-regulated	microarray	Differentially expressed between breast carcinoma and normal breast tissue.	unknown	unknown	2005	16103053	Unspecified
+hsa-miR-122a	5520	head and neck squamous cell carcinoma (HNSCC)	down-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-122a	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	miRNA precursors with significantly different expression.	unknown	unknown	2005	16192569	Unspecified
+hsa-miR-122a	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	miR-122 is an abundant liver-specific miR. miR-122 expressionwas significantly (P=0.013) reduced in 10 out of 20 tumors compared to the pair-matched control tissues.	unknown	unknown	2006	16924677	Unspecified
+hsa-miR-122a	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"Distinct up-regulations of miR-222, miR-221, and miR-31, and down-regulations of miR-223, miR-126, and miR-122a were identified. Further investigations suggested the highly deregulated miR-223 and miR-222 could unequivocally distinguish HCC from adjacent nontumoral liver, irrespective of viral associations (P<=.0002)."	unknown	unknown	2008	18555017	Unspecified
+hsa-miR-122a	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-122a	9088	psoriasis	down-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	unknown	2007	17622355	Unspecified
+hsa-miR-123	1040	B-cell chronic lymphocytic leukemia	up-regulated	microarray	Differentially expressed in CLL cells versus CD7 cells.	unknown	unknown	2004	15284443	Unspecified
+hsa-miR-123	3068	glioblastoma	up-regulated	microarray	Significantly differentially expressed between glioblastoma cell line samples and the control samples.	unknown	unknown	2005	16039986	Unspecified
+hsa-miR-123	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	unknown	2006	16924677	Unspecified
+hsa-miR-124a	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	miR-124a undergoes transcriptional inactivation by CpG island hypermethylation. miR-124a epigenetic silencing mediates cyclin D kinase 6(CDK6)activation and retinoblastoma (Rb) phosphorylation.	CDK6	unknown	2007	17308079	Causal
+hsa-miR-124a	-1	cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Be methylated in tumor cells.The epigenetic silencing of miR-124a leads to the activation of cyclin D kinase 6 (CDK6), a bona fide oncogenic factor, and the phosphorylation of the retinoblastoma (Rb) tumor suppressor gene."	CDK6	unknown	2007	17581274	Causal
+hsa-miR-124a	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	miR-124a undergoes transcriptional inactivation by CpG island hypermethylation. miR-124a epigenetic silencing mediates cyclin D kinase 6(CDK6)activation and retinoblastoma (Rb) phosphorylation.	CDK6	unknown	2007	17308079	Causal
+hsa-miR-124a	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	miR-124a undergoes transcriptional inactivation by CpG island hypermethylation. miR-124a epigenetic silencing mediates cyclin D kinase 6(CDK6)activation and retinoblastoma (Rb) phosphorylation.	CDK6	unknown	2007	17308079	Causal
+hsa-miR-124a	3073	glioblastoma multiforme (GBM)	down-regulated	"Northern blot, qRT-PCR etc"	"microRNA-124 and microRNA-137 induce differentiation of adult mouse neural stem cells, mouse oligodendroglioma-derived stem cells and human glioblastoma multiformederived stem cells and induce glioblastoma multiforme cell cycle arrest. These results suggest that targeted delivery of microRNA-124 and/or microRNA-137 to glioblastoma multiforme tumor cells may be therapeutically efficacious for the treatment of this disease.miR-124 and miR-137 inhibit CDK6 expression and phosphorylated retinoblastoma levels in GBM cells."	CDK6	unknown	2008	18577219	Causal
+hsa-miR-124a	3905	lung cancer	down-regulated	"Northern blot, qRT-PCR etc"	miR-124a undergoes transcriptional inactivation by CpG island hypermethylation. miR-124a epigenetic silencing mediates cyclin D kinase 6(CDK6)activation and retinoblastoma (Rb) phosphorylation.	CDK6	unknown	2007	17308079	Causal
+hsa-miR-124a	3858	medulloblastoma	down-regulated	"Northern blot, qRT-PCR etc"	"We identified putative miR sites in the CDK6 including microRNA 124a, a brain enriched microRNA. Expression of miR 124a was significantly decreased in medulloblastoma cells compared to normal adult cerebellum. Functional association between miR 124a and CDK6 in medulloblastoma was established using luciferase assays. Additionally, re-expression of miR 124a in medulloblastoma cells decreased expression of CDK6 protein. Transfection of miR 124 significantly decreases medulloblastoma cell growth but does not alter apoptosis. Furthermore, in patient samples expression of miR 124a is significantly decreased. Our data strongly indicate that CDK6 is regulated by microRNA 124 in medulloblastoma and that miR 124 modulates medulloblastoma cell growth."					
+	CDK6	unknown	2008	18607543	Causal	1	694			
+hsa-miR-126	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"Distinct up-regulations of miR-222, miR-221, and miR-31, and down-regulations of miR-223, miR-126, and miR-122a were identified. Further investigations suggested the highly deregulated miR-223 and miR-222 could unequivocally distinguish HCC from adjacent nontumoral liver, irrespective of viral associations (P<=.0002)."	unknown	unknown	2008	18555017	Unspecified
+hsa-miR-126	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-126	8894	Oral Squamous Cell Carcinoma (OSCC)	up-regulated	microarray	miRNAs frequently up-regulated in OSCC cell lines(>1.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-126	10286	prostate cancer	up-regulated	microarray	One of the upregulated microRNAs in tumors with perineural invasion (FDR 10%).	unknown	unknown	2008	18459106	Unspecified
+hsa-miR-126*	10286	prostate cancer	down-regulated	"Northern blot, qRT-PCR etc"	Prostein was a specific target of ectopic miR-126*.Transfection of synthetic miR-126* into prostate cancer LNCaP cells strongly reduced the translation of prostein. Loss of prostein correlated with reduction of LNCaP cell migration and invasion.	prostein	unknown	2007	18193184	Causal
+hsa-miR-126*	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"Our study identified and validated miR-224 overexpression.Moreover, miR-96 was overexpressed in HBV tumors, and miR-126* was down-regulated in alcohol-related hepatocellular carcinoma."	unknown	unknown	2008	18433021	Unspecified
+hsa-miR-126*	3905	lung cancer	down-regulated	"Northern blot, qRT-PCR etc"	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-126-5p	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Confirmation of the Aberrant miRNA Expression in Hypertrophic Hearts by Northern Blot Analysis and/or qRT-PCR.	unknown	unknown	2007	17525252	Unspecified
+hsa-miR-127	4007	bladder cancer	down-regulated	"Northern blot, qRT-PCR etc"	"miR-127 is usually expressed as part of a miRNA cluster in normal cells but not in cancer cells, suggesting that it is subject to epigenetic silencing. In addition, the proto-oncogene BCL6, a potential target of miR-127, was translationally downregulated. These results suggest that DNA demethylation and histone deacetylase inhibition can activate expression of miRNAs that may act as tumor suppressors."	BCL6	"BCL6,Rtl1/Peg11"	2006	16766263	Causal
+hsa-miR-127	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"miR-127 is usually expressed as part of a miRNA cluster in normal cells but not in cancer cells, suggesting that it is subject to epigenetic silencing. In addition, the proto-oncogene BCL6, a potential target of miR-127, was translationally downregulated. These results suggest that DNA demethylation and histone deacetylase inhibition can activate expression of miRNAs that may act as tumor suppressors."	BCL6	"BCL6,Rtl1/Peg11"	2006	16766263	Causal
+hsa-miR-127	-1	cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Be methylated in tumor cells. miR-127 is located on chromosome 14q32, a region that is involved in several types of translocations in hematological malignancies and deleted by LOH in solid tumors."	BCL6	"BCL6,Rtl1/Peg11"	2007	17581274	Causal
+hsa-miR-127	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	"miR-127 is usually expressed as part of a miRNA cluster in normal cells but not in cancer cells, suggesting that it is subject to epigenetic silencing. In addition, the proto-oncogene BCL6, a potential target of miR-127, was translationally downregulated. These results suggest that DNA demethylation and histone deacetylase inhibition can activate expression of miRNAs that may act as tumor suppressors."	BCL6	"BCL6,Rtl1/Peg11"	2006	16766263	Causal
+hsa-miR-127	10286	prostate cancer	down-regulated	"Northern blot, qRT-PCR etc"	"miR-127, is embedded in a CpG island and is highly induced from its own promoter after treatment. miR-127 is usually expressed as part of a miRNA cluster in normal cells but not in cancer cells, suggesting that it is subject to epigenetic silencing.In addition, the proto-oncogene BCL6, a potential target of miR-127, was translationally downregulated after treatment."	BCL6	"BCL6,Rtl1/Peg11"	2006	16766263	Causal
+hsa-miR-127	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change correlative with the increase in heart/body weight(7-14 days post-TAC).	unknown	"BCL6,Rtl1/Peg11"	2008	17234972	Unspecified
+hsa-miR-127	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	"BCL6,Rtl1/Peg11"	2007	17942673	Unspecified
+hsa-miR-127	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	Differentially expressed between tumors and normals.	unknown	"BCL6,Rtl1/Peg11"	2007	17875710	Unspecified
+hsa-miR-127	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	"BCL6,Rtl1/Peg11"	2008	18379589	Unspecified
+hsa-miR-127	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	"BCL6,Rtl1/Peg11"	2007	17942673	Unspecified
+hsa-miR-127	10222	polymyositis (PM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	"BCL6,Rtl1/Peg11"	2007	17942673	Unspecified
+hsa-miR-128a	9952	acute lymphoblastic leukemia (ALL)	up-regulated	"Northern blot, qRT-PCR etc"	"miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly downregulated in ALL compared with AML. They are the most discriminatory miRNAs between ALL and AML. Using the expression signatures of a minimum of two of these miRNAs resulted in an accuracy rate of >95% in the diagnosis of ALL and AML."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-128a	9119	acute myeloid leukemia (AML)	down-regulated	"Northern blot, qRT-PCR etc"	"miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly downregulated in ALL compared with AML. They are the most discriminatory miRNAs between ALL and AML. Using the expression signatures of a minimum of two of these miRNAs resulted in an accuracy rate of >95% in the diagnosis of ALL and AML."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-128a	10652	Alzheimer's disease	up-regulated	"Northern blot, qRT-PCR etc"	"Significant change in micro-RNA abundance in the hippocampal region of fetal, adult and Alzheimer's disease brain."	unknown	unknown	2007	17314675	Unspecified
+hsa-miR-128a	1208	autism spectrum disorder (ASD)	up-regulated	microarray	one oftwenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	unknown	2008	18563458	Unspecified
+hsa-miR-128a	3068	glioblastoma	down-regulated	"Northern blot, qRT-PCR etc"	"The strong down-regulation of miR-128 and miR-181 family might indicate some non-random correlation with the de-differentiated state of tumor cells, or even with their stem-like nature, in some way resembling early embryonic stages."	unknown	unknown	2005	16039986	Unspecified
+hsa-miR-128a	3073	glioblastoma multiforme (GBM)	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed microRNA in glioblastoma multiforme tumors relative to non-neoplastic brain tissue.	unknown	unknown	2008	18577219	Unspecified
+hsa-miR-128a	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-128a	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-128a	3829	pituitary adenoma	down-regulated	microarray	Differentially expressed between neoplastic conditions (CRC cell lines and tumor samples) and non-tumoral colon tissues.	unknown	unknown	2007	17111382	Unspecified
+hsa-miR-128b	3905	lung cancer	down-regulated	"Northern blot, qRT-PCR etc"	miR-128b directly regulates EGFR. miR-128b LOH was frequent in tumor samples and correlated significantly with clinical response and survival following gefitinib. EGFR expression and mutation status did not correlate with survival outcome.	EGFR	unknown	2008	18304967	Causal
+hsa-miR-128b	9952	acute lymphoblastic leukemia (ALL)	up-regulated	"Northern blot, qRT-PCR etc"	"miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly downregulated in ALL compared with AML. They are the most discriminatory miRNAs between ALL and AML. Using the expression signatures of a minimum of two of these miRNAs resulted in an accuracy rate of >95% in the diagnosis of ALL and AML."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-128b	9119	acute myeloid leukemia (AML)	down-regulated	"Northern blot, qRT-PCR etc"	"miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly downregulated in ALL compared with AML. They are the most discriminatory miRNAs between ALL and AML. Using the expression signatures of a minimum of two of these miRNAs resulted in an accuracy rate of >95% in the diagnosis of ALL and AML."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-128b	3459	breast cancer	up-regulated	microarray	miRNAs differentially expressed between breast carcinoma and normal breast tissue.	unknown	unknown	2005	16103053	Unspecified
+hsa-miR-128b	13315	chronic pancreatitis	up-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-128b	1985	colorectal cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-128b	3905	lung cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-128b	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-128b	4905	pancreatic cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-129	1208	autism spectrum disorder (ASD)	up-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	unknown	2008	18563458	Unspecified
+hsa-miR-129	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed between neoplastic conditions (CRC cell lines and tumor samples) and non-tumoral colon tissues.	unknown	unknown	2006	16854228	Unspecified
+hsa-miR-129	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-129	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-129	12236	primary biliary cirrhosis (PBC)	up-regulated	"Northern blot, qRT-PCR etc"	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	unknown	2008	18631158	Unspecified
+hsa-miR-130a	9952	acute lymphoblastic leukemia (ALL)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-130a	9119	acute myeloid leukemia (AML)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-130a	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-130a	14691	Duchenne muscular dystrophy (DMD)	up-regulated	"Northern blot, qRT-PCR etc"	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-130a	3068	glioblastoma	up-regulated	microarray	Significantly differentially expressed between glioblastoma cell line samples and the control samples.	unknown	unknown	2005	16039986	Unspecified
+hsa-let-7c	9952	acute lymphoblastic leukemia (ALL)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-1	3978	cardiomyopathy	up-regulated	"Northern blot, qRT-PCR etc"	miR-1 and miR-133 are involved in regulating cell fate with increased miR-1 and/or decreased miR-133					
+levels favoring apoptosis and decreased miR-1 and/or miR-133 levels favoring survival. Post-transcriptional repression of HSP60 and HSP70 by miR-1 and of caspase-9 by miR-133 contributes significantly to their opposing actions.										
+	"HSP60,HSP70"	"GJA1,Hand2,HDAC4,TMSB4X"	2007	17715156	Causal	1	743			
+hsa-miR-124a	2786	Cerebellar neurodegeneration	down-regulated	"Northern blot, qRT-PCR etc"	Essential for the survival of Purkinje cells and its absence leads to a slow degeneration of these cells.	unknown	unknown	2007	17606634	Unspecified
+hsa-miR-139	4905	pancreatic cancer	down-regulated	"Northern blot, qRT-PCR etc"	Aberrantly expressed miRNA precursors in pancreatic adenocarcinoma.PAM testing was conducted on 10 tumor samples and 15 adjacent benign samples. PAM has correctly classified 100% of the tested tumor samples and 11 of 15 of the tested benign samples. The 20 top ranked differentially expressed miRNAs in pancreatic adenocarcinoma as selected by PAM.	unknown	unknown	2006	17149698	Unspecified
+hsa-miR-145	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Aberrant expression was correlated with specific breast cancer biopathologic features, such as estrogen and progesterone receptor expression, tumor stage, vascular invasion, or proliferation index"	unknown	FLJ21308	2005	16103053	Unspecified
+hsa-miR-155	9119	acute myeloid leukemia (AML)	up-regulated	"Northern blot, qRT-PCR etc"	FLT3-ITD  samples were characterized by upregulation of miR-155. Further experiments demonstrated that the up-regulation of miR-155 was independent from FLT3 signaling.	unknown	AGTR1	2008	18308931	Unspecified
+hsa-miR-16	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	"miR-15 and miR-16 are located at chromosome 13q14, a region deleted in more than half of B cell chronic lymphocytic leukemia (CLL)s (B-CLL). Detailed deletion and expression analysis shows that miR-15 and miR-16 are located within a 30-kb region of loss in CLL, and that both genes are deleted or down-regulated in the majority (68%) of CLL cases."	RARS	"BCL2,CGI-38"	2002	12434020	Causal
+hsa-miR-181a-2	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	unknown	2007	17616664	Unspecified
+hsa-miR-181b	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	"miR-29b and miR-181b target oncogene TCL1, which leads to malignant cell proliferation."	Tcl1	unknown	2006	17178851	Causal
+hsa-miR-181b	9119	acute myeloid leukemia (AML)	up-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-181b	9119	acute promyelocytic leukemia (APL)	down-regulated	microarray	"upregulation of miR-15a,miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223,miR-342 and miR-107, whereas miR-181b was downregulated in in acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment."	unknown	unknown	2007	17260024	Unspecified
+hsa-miR-181b	1040	B-cell chronic lymphocytic leukemia	up-regulated	microarray	Differentially expressed in CLL cells versus CD16 cells.	unknown	unknown	2004	15284443	Unspecified
+hsa-miR-181b	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	unknown	2006	16609010	Unspecified
+hsa-miR-181b	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	"miR-15b (p = 0.0278), miR-181b (p = 0.0002), miR-191(p = 0.0264) and miR-200c (p = 0.0017) were significantly over-expressed in tumors compared to normal colorectal samples.Sequencing analysis revealed that hsamiR-181b (p = 0.0098)expression was strongly associated with the mutation status of the p53 tumor suppressor gene."	unknown	unknown	2006	18079988	Unspecified
+hsa-miR-181b	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Expression patterns for these 5 microRNAs(miR-20a, miR-21, miR-106a, miR-181b, and miR-203) distinguish tumor vs paired nontumor status with 96% or 98% accuracy based on 3 nearest neighbors or nearest centroid algorithms, respectively (10-fold cross validation, repeated 100 times)."	unknown	unknown	2008	18230780	Unspecified
+hsa-miR-181b	3068	glioblastoma	down-regulated	"Northern blot, qRT-PCR etc"	"The strong down-regulation of miR-128 and miR-181 family might indicate some non-random correlation with the de-differentiated state of tumor cells, or even with their stem-like nature, in some way resembling early embryonic stages."	unknown	unknown	2005	16039986	Unspecified
+hsa-miR-181b-1	3459	breast cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-181b-1	4905	pancreatic cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-181b-1	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-181b-1	10286	prostate cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-181b-2	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-181c	9119	acute myeloid leukemia (AML)	up-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-181c	10652	Alzheimer's disease	down-regulated	microarray	Significantly changed miRNAs in cortex of sporadic AD cases.	unknown	unknown	2008	18434550	Unspecified
+hsa-miR-181c	3068	glioblastoma	down-regulated	"Northern blot, qRT-PCR etc"	"The strong down-regulation of miR-128 and miR-181 family might indicate some non-random correlation with the de-differentiated state of tumor cells, or even with their stem-like nature, in some way resembling early embryonic stages."	unknown	unknown	2005	16039986	Unspecified
+hsa-miR-181c	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	unknown	2007	17616664	Unspecified
+hsa-miR-181c	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-181c	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Aberrantly expressed miRNA precursors in pancreatic adenocarcinoma.PAM testing was conducted on 10 tumor samples and 15 adjacent benign samples. PAM has correctly classified 100% of the tested tumor samples and 11 of 15 of the tested benign samples. The 20 top ranked differentially expressed miRNAs in pancreatic adenocarcinoma as selected by PAM.	unknown	unknown	2006	17149698	Unspecified
+hsa-miR-181c	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-181c	3969	papillary thyroid carcinoma (PTC)	up-regulated	microarray	Differentially expressed miRNA in PTC tumors	unknown	unknown	2005	16365291	Unspecified
+hsa-miR-181d	1208	autism spectrum disorder (ASD)	down-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	unknown	2008	18563458	Unspecified
+hsa-miR-181d	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-181d	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-181d	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-182	9119	acute myeloid leukemia (AML)	down-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-182	4001	epithelial ovarian cancer (EOC)	up-regulated	microarray	DNA copy number status of 17 genomic loci containing miRNAs differentially expressed between IOSE cells and EOC cell lines.	unknown	unknown	2008	18458333	Unspecified
+hsa-miR-182	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	One of the 22 significantly up- and down-regulated miRNAs obtained using significance analysis of microarrays with false discovery rate of 5%. Majority of the predicted targets of these 22 differentially regulated miRNAs reside in pathways reported to be dysregulated during carcinogenesis.	unknown	unknown	2008	18319255	Unspecified
+hsa-miR-182	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-182*	3908	non-small cell lung cancer (NSCLC)	up-regulated	"Northern blot, qRT-PCR etc"	"A five-microRNA signature (let-7a, miR-221, miR-137, miR-372, and miR-182*) that is associated with survival and cancer relapse in NSCLC patients. This microRNA signature was validated by the testing set and an independent cohort. Patients with high-risk scores in their microRNA signatures had poor overall and disease-free survivals compared to the low-risk-score patients. This microRNA signature is an independent predictor of the cancer relapse and survival of NSCLC patients.promoted invasiveness of lung cancer cell lines."	unknown	unknown	2008	18167339	Causal
+hsa-miR-182*	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	One of the 22 significantly up- and down-regulated miRNAs obtained using significance analysis of microarrays with false discovery rate of 5%. Majority of the predicted targets of these 22 differentially regulated miRNAs reside in pathways reported to be dysregulated during carcinogenesis.	unknown	unknown	2008	18319255	Unspecified
+hsa-miR-183	1040	B-cell chronic lymphocytic leukemia	up-regulated	microarray	Differentially expressed in CLL cells versus CD17 cells.	unknown	unknown	2004	15284443	Unspecified
+hsa-miR-183	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed between neoplastic conditions (CRC cell lines and tumor samples) and non-tumoral colon tissues.	unknown	unknown	2006	16854228	Unspecified
+hsa-miR-183	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	One of the 22 significantly up- and down-regulated miRNAs obtained using significance analysis of microarrays with false discovery rate of 5%. Majority of the predicted targets of these 22 differentially regulated miRNAs reside in pathways reported to be dysregulated during carcinogenesis.	unknown	unknown	2008	18319255	Unspecified
+hsa-miR-183	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-183	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-183	10584	retinitis pigmentosa (RP)	up-regulated	"Northern blot, qRT-PCR etc"	"Expression of miR-1 and miR-133 decreased by more than 2.5-fold (P<0.001), whereas expression of miR-96 and miR-183 increased by more than 3-fold (P<0.001) in Pro347Ser retinas, as validated by qPCR."	unknown	unknown	2007	18034880	Unspecified
+hsa-miR-184	769	neuroblastoma (NB)	down-regulated	"Northern blot, qRT-PCR etc"	miR-184 overexpression induces neuroblastoma cell cycle arrest and apoptosis.	unknown	unknown	2007	17283129	Causal
+hsa-miR-184	9119	acute myeloid leukemia (AML)	down-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-184	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	DNA copy number status of 17 genomic loci containing miRNAs differentially expressed between IOSE cells and EOC cell lines.	unknown	unknown	2008	18458333	Unspecified
+hsa-miR-184	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-184	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-184	10286	prostate cancer	up-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	792			
+hsa-miR-185	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	metastasis-related miRNA	unknown	unknown	2008	18176954	Unspecified
+hsa-miR-185	4007	bladder cancer	up-regulated	microarray	"Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b,miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P<0.05) compared to normal bladder"					
+mucosa.	unknown	unknown	2007	17826655	Unspecified	0	794			
+hsa-miR-185	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change correlative with the increase in heart/body weight(7-14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-185	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Confirmation of the Aberrant miRNA Expression in Hypertrophic Hearts by Northern Blot Analysis and/or qRT-PCR.	unknown	unknown	2007	17525252	Unspecified
+hsa-miR-185	3073	glioblastoma multiforme (GBM)	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed microRNA in glioblastoma multiforme tumors relative to non-neoplastic brain tissue.	unknown	unknown	2008	18577219	Unspecified
+hsa-miR-185	4451	kidney cancer	up-regulated	microarray	"A set of 4 human micro-RNAs (miR-28, miR-185, miR-27, and let-7f-2) were found significantly up-regulated in renal cell carcinoma (P<0.05) compared to normal kidney."	unknown	unknown	2007	17826655	Unspecified
+hsa-miR-185	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-130a	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-130a	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-130a	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-130a	10222	polymyositis (PM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-130a-1	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	unknown	2006	16924677	Unspecified
+hsa-miR-130b	9952	acute lymphoblastic leukemia (ALL)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-130b	9119	acute myeloid leukemia (AML)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-130b	3498	pancreatic ductal adenocarcinoma (PDAC)	down-regulated	microarray	differentially expressed between normal and PDAC or cell line samples.	unknown	unknown	2007	17237814	Unspecified
+hsa-miR-130b-1	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	unknown	2006	16924677	Unspecified
+hsa-miR-132	12858	Huntington's disease (HD)	down-regulated	"Northern blot, qRT-PCR etc"	"increased levels of nuclear REST in HD leads to both a direct repression of REST target genes such as BDNF and to an indirect activation of gene expression by increased repression of miRNAexpression The latter is exemplified by loss of miR-132, in turn leading to higher levels of p250GAP mRNA."	p250GAP	RICS/p250GAP	2007	18082412	Causal
+hsa-miR-132	1208	autism spectrum disorder (ASD)	up-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	RICS/p250GAP	2008	18563458	Unspecified
+hsa-miR-132	1040	B-cell chronic lymphocytic leukemia	up-regulated	microarray	Differentially expressed in CLL cells versus CD8 cells.	unknown	RICS/p250GAP	2004	15284443	Unspecified
+hsa-miR-132	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	RICS/p250GAP	2006	16609010	Unspecified
+hsa-miR-139	13223	uterine leiomyoma (ULM)	down-regulated	"Northern blot, qRT-PCR etc"	Real-time reverse transcriptase polymerase chain reaction (RT-PCR) validation of microarray. Realtime					
+"semiquantitative RT-PCR of five different microRNA species (miR-21, miR-34a, miR-125b, miR-139, and miR-323) across ten subjects. miR-21, miR-34a, miR-125b, and miR-323 were overexpressed in leiomyoma in the ten pairs tested and miR-139 was underexpressed, consistent with the microarray results."	unknown	unknown	2008	17765232	Unspecified	0	813			
+hsa-miR-140	1208	autism spectrum disorder (ASD)	down-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	HDAC4	2008	18563458	Unspecified
+hsa-miR-140	1040	B-cell chronic lymphocytic leukemia	up-regulated	microarray	Differentially expressed in CLL cells versus CD10 cells.	unknown	HDAC4	2004	15284443	Unspecified
+hsa-miR-140	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	HDAC4	2008	17234972	Unspecified
+hsa-miR-140	4001	epithelial ovarian cancer (EOC)	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed between tumors and normals.	unknown	HDAC4	2007	17875710	Unspecified
+hsa-miR-140	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	DNA copy number status of 17 genomic loci containing miRNAs differentially expressed between IOSE cells and EOC cell lines.	unknown	HDAC4	2008	18458333	Unspecified
+hsa-miR-140	10923	homozygous sickle cell disease (HbSS)	up-regulated	microarray	"Several microRNAs (miR-320, let-7s, miR-181, miR-141) were over-represented in the HbAA erythrocytes, while other microRNAs (miR-29a, miR-144, miR-451, miR-140) were overrepresented in the HbSS erythrocytes."	unknown	HDAC4	2008	18523662	Unspecified
+hsa-miR-140	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	HDAC4	2006	16530703	Unspecified
+hsa-miR-140	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	HDAC4	2008	18379589	Unspecified
+hsa-miR-140	8894	Oral Squamous Cell Carcinoma (OSCC)	up-regulated	microarray	miRNAs frequently up-regulated in OSCC cell lines(>1.5-fold expression).	unknown	HDAC4	2008	18381414	Unspecified
+hsa-miR-140	5556	testicular germ cell tumor	up-regulated	microarray	Differentially expressed miRNA in the various histological subtypes of  germ cell tumour (GCT) (TE = teratoma; SE = seminoma; EC = embryonal carcinoma).	unknown	HDAC4	2007	17893849	Unspecified
+hsa-miR-140*	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-141	5745	serous ovarian cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients. Higher expression of miR-200a, miR-200b, miR-200c, miR-141, miR-18a, miR-93, and miR-429, and lower expression of ambi-miR-7039, let-7b, and miR-199a were significantly correlated with decreased progression-free survival and overall survival."	unknown	Clock	2008	18451233	Unspecified
+hsa-miR-141	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"All five members of the microRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141 and miR-429) and miR-205 were markedly downregulated in cells that had undergone EMT in response to transforming growth factor (TGF)-beta or to ectopic expression of the protein tyrosine phosphatase Pez. Enforced expression of the miR-200 family alone was sufficient to prevent TGF-beta-induced EMT. Together, these microRNAs cooperatively regulate expression of the E-cadherin transcriptional repressors ZEB1 (also known as deltaEF1) and SIP1 (also known as ZEB2), factors previously implicated in EMT and tumour metastasis. Inhibition of the microRNAs was sufficient to induce EMT in a process requiring upregulation of ZEB1 and/or SIP1. Conversely, ectopic expression of these microRNAs in mesenchymal cells initiated mesenchymal to epithelial transition (MET). Consistent with their role in regulating EMT, expression of these microRNAs was found to be lost in invasive breast cancer cell lines with mesenchymal phenotype. Expression of the miR-200 family was also lost in regions of metaplastic breast cancer specimens lacking E-cadherin. These data suggest that downregulation of the microRNAs may be an important step in tumour progression."					
+	"ZEB1(deltaEF1), SIP1(ZEB2)"	Clock	2008	18376396	Causal	1	826			
+hsa-miR-141	-1	cancer	down-regulated	"Northern blot, qRT-PCR etc"	"The miR-200 family is composed of five members arranged as two clusters, miR-200a/200b/429 and"					
+miR-200c/141.Ectopic expression of the miR-200 family in 4TO7 carcinoma cells caused a rapid and										
+significant decrease in ZEB1 and ZEB2 levels.Over-expressing the miR-200 family in 4TO7 cells										
+"induced a dramatic morphological change from a spindle-like, mesenchymal phenotype towards a"										
+"more pronounced epithelial phenotype with formation of adheren junctions. Furthermore, overexpression of miR-200 significantly inhibits growth factor-induced directional migration, a hallmark of metastatic cancer cells.This suggests that ectopic expression of the miR-200 family can"										
+promote the mesenchymal-epithelial transition and reduce tumor cell migration.	"ZEB1, ZEB2"	Clock	2008	18411277	Causal	1	827			
+hsa-miR-141	-1	cancer	down-regulated	"Northern blot, qRT-PCR etc"	"The embryonic programme 'epithelial�Cmesenchymal transition'(EMT) is thought to promote malignant tumour progression. The transcriptional repressor zinc-finger E-box binding homeobox 1(ZEB1) is a crucial inducer of EMT in various human tumours, and was recently shown to promote invasion and metastasis of tumour cells. ZEB1 directly suppresses transcription of microRNA-200 family members miR-141 and miR-200c. Notably, the EMT activators transforming growth factor b2 and ZEB1 are the"					
+predominant targets downregulated by these microRNAs.	ZEB1	Clock	2008	18483486	Causal	1	828			
+hsa-miR-141	4947	cholangiocarcinoma	up-regulated	"Northern blot, qRT-PCR etc"	inhibition of miR-141 decreased cell growth.	CLOCK	Clock	2006	16762633	Causal
+hsa-miR-141	1040	B-cell chronic lymphocytic leukemia	up-regulated	microarray	Differentially expressed in CLL cells versus CD11 cells.	unknown	Clock	2004	15284443	Unspecified
+hsa-miR-141	4001	epithelial ovarian cancer (EOC)	up-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed between tumors and normals.	unknown	Clock	2007	17875710	Unspecified
+hsa-miR-141	5520	head and neck squamous cell carcinoma (HNSCC)	down-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	Clock	2007	17222355	Unspecified
+hsa-miR-141	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	Clock	2007	17616664	Unspecified
+hsa-miR-141	10923	homozygous sickle cell disease (HbSS)	down-regulated	microarray	"Several microRNAs (miR-320, let-7s, miR-181, miR-141) were over-represented in the HbAA erythrocytes, while other microRNAs (miR-29a, miR-144, miR-451, miR-140) were overrepresented in the HbSS erythrocytes."	unknown	Clock	2008	18523662	Unspecified
+hsa-miR-141	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	Clock	2008	18379589	Unspecified
+hsa-miR-141	3498	pancreatic ductal adenocarcinoma (PDAC)	down-regulated	microarray	"differentially expressed between normal and PDAC or cell line samples. several miRNAs(hsa-miR-141, -148a, -200a, -200b, -200c, -216, -217 and -375) with expression patterns distinctive for pancreas, suggesting a possible role of these miRNAs in pancreas differentiation."					
+	unknown	Clock	2007	17237814	Unspecified	0	836			
+hsa-miR-198	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-200c	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-208	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-210	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-223	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	NFIA	2008	18998140	Unspecified
+hsa-miR-23a	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	"CXCL12,FLJ13158"	2008	18998140	Unspecified
+hsa-miR-296	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-30a-5p	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-30d	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-320	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-324-3p	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-324-5p	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-325	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-345	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-346	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-365	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-381	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-423	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-433	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-484	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-486	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-494	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-500	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-513	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-516-5p	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-518b	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-518c*	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-557	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-575	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-583	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-596	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-600	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-601	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-602	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-608	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-611	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-612	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-615	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-622	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-629	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-637	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-638	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-642	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-654	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-657	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-658	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-662	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-663	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-769-3p	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-92b	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-99a	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-221	1909	melanoma	up-regulated	"northern blot, qRT-PCR etc"	"The inhibition of miRNA-221 and -222, which are abnormally expressed in melanoma and favor the induction of the malignant phenotype by downregulating c-KIT receptor and p27Kip, might in the future represent an efficient treatment for translation into the clinical setting."	"c-KIT, p27(Kip1)"	KIT	2008	18983236	Causal
+hsa-miR-222	1909	melanoma	up-regulated	"Northern blot, qRT-PCR etc"	"The inhibition of miRNA-221 and -222, which are abnormally expressed in melanoma and favor the induction of the malignant phenotype by downregulating c-KIT receptor and p27Kip, might in the future represent an efficient treatment for translation into the clinical setting."	"c-KIT, p27(Kip1)"	KIT	2008	18983236	Causal
+hsa-let-7b	2786	neurodegeneration	up-regulated	"Northern blot, qRT-PCR etc"	"miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated. Only one of these miRNAs, miR-128, has previously been shown to be de-regulated in neurodegenerative disease. De-regulation of a unique subset of miRNAs suggests a conserved, disease-specific pattern of differentially expressed miRNAs is associated with prion-induced neurodegeneration."	unknown	"Lin28,Mtpn"	2008	18987751	Unspecified
+hsa-miR-128	2786	neurodegeneration	up-regulated	"Northern blot, qRT-PCR etc"	"miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated. Only one of these miRNAs, miR-128, has previously been shown to be de-regulated in neurodegenerative disease. De-regulation of a unique subset of miRNAs suggests a conserved, disease-specific pattern of differentially expressed miRNAs is associated with prion-induced neurodegeneration."	unknown	unknown	2008	18987751	Unspecified
+hsa-miR-139-5p	2786	neurodegeneration	up-regulated	"Northern blot, qRT-PCR etc"	"miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated. Only one of these miRNAs, miR-128, has previously been shown to be de-regulated in neurodegenerative disease. De-regulation of a unique subset of miRNAs suggests a conserved, disease-specific pattern of differentially expressed miRNAs is associated with prion-induced neurodegeneration."	unknown	unknown	2008	18987751	Unspecified
+hsa-miR-146a	2786	neurodegeneration	up-regulated	"Northern blot, qRT-PCR etc"	"miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated. Only one of these miRNAs, miR-128, has previously been shown to be de-regulated in neurodegenerative disease. De-regulation of a unique subset of miRNAs suggests a conserved, disease-specific pattern of differentially expressed miRNAs is associated with prion-induced neurodegeneration."	unknown	unknown	2008	18987751	Unspecified
+hsa-miR-181a-1*	2786	neurodegeneration	up-regulated	"Northern blot, qRT-PCR etc"	MiRNAs identified as differentially expressed in CNS tissues of scrapie infected mice.	unknown	unknown	2008	18987751	Unspecified
+hsa-miR-203	2786	neurodegeneration	up-regulated	"Northern blot, qRT-PCR etc"	MiRNAs identified as differentially expressed in CNS tissues of scrapie infected mice.	unknown	unknown	2008	18987751	Unspecified
+hsa-miR-320	2786	neurodegeneration	up-regulated	"Northern blot, qRT-PCR etc"	"miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated. Only one of these miRNAs, miR-128, has previously been shown to be de-regulated in neurodegenerative disease. De-regulation of a unique subset of miRNAs suggests a conserved, disease-specific pattern of differentially expressed miRNAs is associated with prion-induced neurodegeneration."	unknown	unknown	2008	18987751	Unspecified
+hsa-miR-328	2786	neurodegeneration	up-regulated	"Northern blot, qRT-PCR etc"	"miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated. Only one of these miRNAs, miR-128, has previously been shown to be de-regulated in neurodegenerative disease. De-regulation of a unique subset of miRNAs suggests a conserved, disease-specific pattern of differentially expressed miRNAs is associated with prion-induced neurodegeneration."	unknown	unknown	2008	18987751	Unspecified
+hsa-miR-337-3p	2786	neurodegeneration	down-regulated	"Northern blot, qRT-PCR etc"	"miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated. Only one of these miRNAs, miR-128, has previously been shown to be de-regulated in neurodegenerative disease. De-regulation of a unique subset of miRNAs suggests a conserved, disease-specific pattern of differentially expressed miRNAs is associated with prion-induced neurodegeneration."	unknown	unknown	2008	18987751	Unspecified
+hsa-miR-338-3p	2786	neurodegeneration	down-regulated	"Northern blot, qRT-PCR etc"	"miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated. Only one of these miRNAs, miR-128, has previously been shown to be de-regulated in neurodegenerative disease. De-regulation of a unique subset of miRNAs suggests a conserved, disease-specific pattern of differentially expressed miRNAs is associated with prion-induced neurodegeneration."	unknown	unknown	2008	18987751	Unspecified
+hsa-miR-339-5p	2786	neurodegeneration	up-regulated	"Northern blot, qRT-PCR etc"	MiRNAs identified as differentially expressed in CNS tissues of scrapie infected mice.	unknown	unknown	2008	18987751	Unspecified
+hsa-miR-342-3p	2786	neurodegeneration	up-regulated	"Northern blot, qRT-PCR etc"	"miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated. Only one of these miRNAs, miR-128, has previously been shown to be de-regulated in neurodegenerative disease. De-regulation of a unique subset of miRNAs suggests a conserved, disease-specific pattern of differentially expressed miRNAs is associated with prion-induced neurodegeneration."	unknown	unknown	2008	18987751	Unspecified
+hsa-let-7a	3908	non-small cell lung cancer (NSCLC)	down-regulated	"Northern blot, qRT-PCR etc"	"We have identified the first miRNA binding-site SNPthat alone can predict a significant increase in NSCLC risk in people with a moderate smoking history.The mechanism may be due to altered regulation of the KRAS oncogene and possibly cellular let-7 levels as well. we found that the levels of let-7a, b, d, and g were lower in patients with the variant allele compared with patients without the variant alleleThese findings give insight into a new paradigm and support the pursuit of 3'UTR sequencing for similar SNPs in all tumor-related genes to better understand their role in genetic cancer risk."	KRAS	NF2	2008	18922928	Causal
+hsa-let-7b	3908	non-small cell lung cancer (NSCLC)	down-regulated	"Northern blot, qRT-PCR etc"	"We have identified the first miRNA binding-site SNPthat alone can predict a significant increase in NSCLC risk in people with a moderate smoking history.The mechanism may be due to altered regulation of the KRAS oncogene and possibly cellular let-7 levels as well. we found that the levels of let-7a, b, d, and g were lower in patients with the variant allele compared with patients without the variant alleleThese findings give insight into a new paradigm and support the pursuit of 3'UTR sequencing for similar SNPs in all tumor-related genes to better understand their role in genetic cancer risk."	KRAS	"Lin28,Mtpn"	2008	18922928	Causal
+hsa-let-7d	3908	non-small cell lung cancer (NSCLC)	down-regulated	"Northern blot, qRT-PCR etc"	"We have identified the first miRNA binding-site SNPthat alone can predict a significant increase in NSCLC risk in people with a moderate smoking history.The mechanism may be due to altered regulation of the KRAS oncogene and possibly cellular let-7 levels as well. we found that the levels of let-7a, b, d, and g were lower in patients with the variant allele compared with patients without the variant alleleThese findings give insight into a new paradigm and support the pursuit of 3'UTR sequencing for similar SNPs in all tumor-related genes to better understand their role in genetic cancer risk."	KRAS	unknown	2008	18922928	Causal
+hsa-let-7g	3908	non-small cell lung cancer (NSCLC)	down-regulated	"Northern blot, qRT-PCR etc"	"We have identified the first miRNA binding-site SNPthat alone can predict a significant increase in NSCLC risk in people with a moderate smoking history.The mechanism may be due to altered regulation of the KRAS oncogene and possibly cellular let-7 levels as well. we found that the levels of let-7a, b, d, and g were lower in patients with the variant allele compared with patients without the variant alleleThese findings give insight into a new paradigm and support the pursuit of 3'UTR sequencing for similar SNPs in all tumor-related genes to better understand their role in genetic cancer risk."	KRAS	unknown	2008	18922928	Causal
+hsa-miR-21	8894	Oral Squamous Cell Carcinoma (OSCC)	up-regulated	"Northern blot, qRT-PCR etc"	"This study investigated the pathogenetic implications of miR-211 in oral carcinogenesis. An association was found between higher miR-211 expression and the most advanced nodal metastasis, vascular invasion, and poor prognosis of oral carcinoma. The function of enforced miR-211 expression in oral carcinoma cells was confirmed by the repression of LacZ in a reporter plasmid via miR-211 targeting. Enforced miR-211 expression significantly increased the proliferation, migration, and anchorage-independent colony formation of oral carcinoma cells, while it enhanced the tumorigenicity of only SAS high-grade oral carcinoma cells, but not OECM-1 non-tumorigenic cells. The findings suggest that high miR-211 expression may be associated with the progression of oral carcinoma and poor patient outcomes."	unknown	"PTEN,TPM1"	2008	18946016	Causal
+hsa-miR-15a	5898	Polycystic Kidney Disease	down-regulated	"Northern blot, qRT-PCR etc"	" Lee and colleagues provide data to support a novel mechanism for cystogenesis involving microRNA. They demonstrate that levels of the miRNA miR15a are decreased in livers of patients with autosomal recessive and autosomal dominant polycystic kidney disease (ARPKD and ADPKD, respectively) and congenital hepatic fibrosis as well as in the PKC rat model of ARPKD. This results in increased expression of the cell-cycle regulator Cdc25A, which is a direct target of miR15a, and increased cellular proliferation and cystogenesis in vitro. These findings suggest that other miRNAs may also participate in the molecular pathogenesis of cystic liver and kidney diseases."	Cdc25A	unknown	2008	18949056	Causal
+hsa-miR-15a	1173	Polycystic liver disease	down-regulated	"Northern blot, qRT-PCR etc"	" Lee and colleagues provide data to support a novel mechanism for cystogenesis involving microRNA. They demonstrate that levels of the miRNA miR15a are decreased in livers of patients with autosomal recessive and autosomal dominant polycystic kidney disease (ARPKD and ADPKD, respectively) and congenital hepatic fibrosis as well as in the PKC rat model of ARPKD. This results in increased expression of the cell-cycle regulator Cdc25A, which is a direct target of miR15a, and increased cellular proliferation and cystogenesis in vitro. These findings suggest that other miRNAs may also participate in the molecular pathogenesis of cystic liver and kidney diseases."	Cdc25A	unknown	2008	18949056	Causal
+hsa-miR-145	10286	prostate cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Paired analysis was carried out with microdissected, malignant and non-involved areas of each specimen, using high-throughput liquid-phase hybridization (mirMASA) reactions and 114 miRNA probes. Five miRNAs (miR-23b, -100, -145, -221 and -222) were significantly downregulated in malignant tissues, according to significance analysis of microarrays and paired t-test with Bonferroni correction. Lowered expression of miR-23b, -145, -221 and -222 in malignant tissues was validated by quantitative reverse transcription (qRT)-PCR analyses. Ectopic expression of these miRNAs significantly reduced LNCaP cancer cell growth, suggesting growth modulatory roles for these miRNAs."	unknown	FLJ21308	2008	18949015	Causal
+hsa-miR-15a	10286	prostate cancer	down-regulated	"Northern blot, qRT-PCR etc"	"We report that the miR-15a and miR-16-1 cluster targets CCND1 (encoding cyclin D1) and WNT3A, which promotes several tumorigenic features such as survival, proliferation and invasion. In cancer cells of advanced prostate tumors, the miR-15a and miR-16 level is significantly decreased, whereas the expression of BCL2, CCND1 and WNT3A is inversely upregulated. Delivery of antagomirs specific for miR-15a and miR-16 to normal mouse prostate results in marked hyperplasia, and knockdown of miR-15a and miR-16 promotes survival, proliferation and invasiveness of untransformed prostate cells, which become tumorigenic in immunodeficient NOD-SCID mice. Conversely, reconstitution of miR-15a and miR-16-1 expression results in growth arrest, apoptosis and marked regression of prostate tumor xenografts. Altogether, we propose that miR-15a and miR-16 act as tumor suppressor genes in prostate cancer through the control of cell survival, proliferation and invasion. These findings have therapeutic implications and may be exploited for future treatment of prostate cancer."					
+	"CCND1, WNT3A"	unknown	2008	18931683	Causal	1	2163			
+hsa-miR-16-1	10286	prostate cancer	down-regulated	"Northern blot, qRT-PCR etc"	"We report that the miR-15a and miR-16-1 cluster targets CCND1 (encoding cyclin D1) and WNT3A, which promotes several tumorigenic features such as survival, proliferation and invasion. In cancer cells of advanced prostate tumors, the miR-15a and miR-16 level is significantly decreased, whereas the expression of BCL2, CCND1 and WNT3A is inversely upregulated. Delivery of antagomirs specific for miR-15a and miR-16 to normal mouse prostate results in marked hyperplasia, and knockdown of miR-15a and miR-16 promotes survival, proliferation and invasiveness of untransformed prostate cells, which become tumorigenic in immunodeficient NOD-SCID mice. Conversely, reconstitution of miR-15a and miR-16-1 expression results in growth arrest, apoptosis and marked regression of prostate tumor xenografts. Altogether, we propose that miR-15a and miR-16 act as tumor suppressor genes in prostate cancer through the control of cell survival, proliferation and invasion. These findings have therapeutic implications and may be exploited for future treatment of prostate cancer."					
+	"CCND1, WNT3A"	unknown	2008	18931683	Causal	1	2164			
+hsa-miR-221	10286	prostate cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Paired analysis was carried out with microdissected, malignant and non-involved areas of each specimen, using high-throughput liquid-phase hybridization (mirMASA) reactions and 114 miRNA probes. Five miRNAs (miR-23b, -100, -145, -221 and -222) were significantly downregulated in malignant tissues, according to significance analysis of microarrays and paired t-test with Bonferroni correction. Lowered expression of miR-23b, -145, -221 and -222 in malignant tissues was validated by quantitative reverse transcription (qRT)-PCR analyses. Ectopic expression of these miRNAs significantly reduced LNCaP cancer cell growth, suggesting growth modulatory roles for these miRNAs."	unknown	KIT	2008	18949015	Causal
+hsa-miR-222	10286	prostate cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Paired analysis was carried out with microdissected, malignant and non-involved areas of each specimen, using high-throughput liquid-phase hybridization (mirMASA) reactions and 114 miRNA probes. Five miRNAs (miR-23b, -100, -145, -221 and -222) were significantly downregulated in malignant tissues, according to significance analysis of microarrays and paired t-test with Bonferroni correction. Lowered expression of miR-23b, -145, -221 and -222 in malignant tissues was validated by quantitative reverse transcription (qRT)-PCR analyses. Ectopic expression of these miRNAs significantly reduced LNCaP cancer cell growth, suggesting growth modulatory roles for these miRNAs."	unknown	KIT	2008	18949015	Causal
+hsa-miR-23b	10286	prostate cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Paired analysis was carried out with microdissected, malignant and non-involved areas of each specimen, using high-throughput liquid-phase hybridization (mirMASA) reactions and 114 miRNA probes. Five miRNAs (miR-23b, -100, -145, -221 and -222) were significantly downregulated in malignant tissues, according to significance analysis of microarrays and paired t-test with Bonferroni correction. Lowered expression of miR-23b, -145, -221 and -222 in malignant tissues was validated by quantitative reverse transcription (qRT)-PCR analyses. Ectopic expression of these miRNAs significantly reduced LNCaP cancer cell growth, suggesting growth modulatory roles for these miRNAs."	unknown	Notch1	2008	18949015	Causal
+hsa-miR-29b-2	3247	rhabdomyosarcoma (RMS)	down-regulated	"Northern blot, qRT-PCR etc"	"We describe the regulation and function of miR-29 in myogenesis and rhabdomyosarcoma (RMS). Results demonstrate that in myoblasts, miR-29 is repressed by NF-kappaB acting through YY1 and the Polycomb group. During myogenesis, NF-kappaB and YY1 downregulation causes derepression of miR-29, which in turn accelerates differentiation by targeting its repressor YY1. However, in RMS cells and primary tumors that possess impaired differentiation, miR-29 is epigenetically silenced by an activated NF-kappaB-YY1 pathway. Reconstitution of miR-29 in RMS in mice inhibits tumor growth and stimulates differentiation, suggesting that miR-29 acts as a tumor suppressor through its promyogenic function. Together, these results identify a NF-kappaB-YY1-miR-29 regulatory circuit whose disruption may contribute to RMS."	YY1	unknown	2008	18977326	Causal
+hsa-miR-29c	3247	rhabdomyosarcoma (RMS)	down-regulated	"Northern blot, qRT-PCR etc"	"We describe the regulation and function of miR-29 in myogenesis and rhabdomyosarcoma (RMS). Results demonstrate that in myoblasts, miR-29 is repressed by NF-kappaB acting through YY1 and the Polycomb group. During myogenesis, NF-kappaB and YY1 downregulation causes derepression of miR-29, which in turn accelerates differentiation by targeting its repressor YY1. However, in RMS cells and primary tumors that possess impaired differentiation, miR-29 is epigenetically silenced by an activated NF-kappaB-YY1 pathway. Reconstitution of miR-29 in RMS in mice inhibits tumor growth and stimulates differentiation, suggesting that miR-29 acts as a tumor suppressor through its promyogenic function. Together, these results identify a NF-kappaB-YY1-miR-29 regulatory circuit whose disruption may contribute to RMS."	YY1	unknown	2008	18977326	Causal
+hsa-miR-101	1441	Spinocerebellar ataxia 1	down-regulated	"Northern blot, qRT-PCR etc"	"Spinocerebellar ataxia type 1 is caused by expansion of a translated CAG repeat in ataxin1 (ATXN1). The level of the polyglutamine-expanded protein is one of the factors that contributes to disease severity. Here we found that miR-19, miR-101 and miR-130 co-regulate ataxin1 levels and that their inhibition enhanced the cytotoxicity of polyglutamine-expanded ATXN1 in human cells. We provide a new candidate mechanism for modulating the pathogenesis of neurodegenerative diseases sensitive to protein dosage."	ATXN1	"Enx-1,MYCN"	2008	18758459	Causal
+hsa-miR-130	1441	Spinocerebellar ataxia 1	down-regulated	"Northern blot, qRT-PCR etc"	"Spinocerebellar ataxia type 1 is caused by expansion of a translated CAG repeat in ataxin1 (ATXN1). The level of the polyglutamine-expanded protein is one of the factors that contributes to disease severity. Here we found that miR-19, miR-101 and miR-130 co-regulate ataxin1 levels and that their inhibition enhanced the cytotoxicity of polyglutamine-expanded ATXN1 in human cells. We provide a new candidate mechanism for modulating the pathogenesis of neurodegenerative diseases sensitive to protein dosage."	ATXN1	"MAFB,MCSF"	2008	18758459	Causal
+hsa-miR-19	1441	Spinocerebellar ataxia 1	down-regulated	"Northern blot, qRT-PCR etc"	"Spinocerebellar ataxia type 1 is caused by expansion of a translated CAG repeat in ataxin1 (ATXN1). The level of the polyglutamine-expanded protein is one of the factors that contributes to disease severity. Here we found that miR-19, miR-101 and miR-130 co-regulate ataxin1 levels and that their inhibition enhanced the cytotoxicity of polyglutamine-expanded ATXN1 in human cells. We provide a new candidate mechanism for modulating the pathogenesis of neurodegenerative diseases sensitive to protein dosage."	ATXN1	unknown	2008	18758459	Causal
+hsa-miR-130b	715	T-cell leukemia	up-regulated	"Northern blot, qRT-PCR etc"	"the up-regulated miRNAs (miR-93 and miR-130b) target the 3' untranslated region (3'UTR) of the mRNA for a tumor suppressor protein, tumor protein 53-induced nuclear protein 1 (TP53INP1). A low expression level of TP53INP1 protein was found in HTLV-1-transformed cells. Additionally, when antagomirs were used to knock down miR-93 and miR-130b in these cells, the expression of TP53INP1 was increased, suggesting that the latter is regulated inside cells by the former. A role for TP53INP1 in regulating cell growth was established by experiments that showed that enhanced TP53INP1 expression increased apoptosis. Collectively, the findings implicate a miR-93/miR-130b-TP53INP1 axis that affects the proliferation and survival of HTLV-1-infected/transformed cells."	TP53INP1	unknown	2008	18974142	Causal
+hsa-miR-93 	715	T-cell leukemia	up-regulated	"Northern blot, qRT-PCR etc"	"the up-regulated miRNAs (miR-93 and miR-130b) target the 3' untranslated region (3'UTR) of the mRNA for a tumor suppressor protein, tumor protein 53-induced nuclear protein 1 (TP53INP1). A low expression level of TP53INP1 protein was found in HTLV-1-transformed cells. Additionally, when antagomirs were used to knock down miR-93 and miR-130b in these cells, the expression of TP53INP1 was increased, suggesting that the latter is regulated inside cells by the former. A role for TP53INP1 in regulating cell growth was established by experiments that showed that enhanced TP53INP1 expression increased apoptosis. Collectively, the findings implicate a miR-93/miR-130b-TP53INP1 axis that affects the proliferation and survival of HTLV-1-infected/transformed cells."	TP53INP1	unknown	2008	18974142	Causal
+hsa-miR-144	10241	thalassemia	down-regulated	"Northern blot, qRT-PCR etc"	"Precise transcriptional control of developmental stage-specific expression and switching of alpha- and beta-globin genes is significantly important to understand the general principles controlling gene expression and the pathogenesis of thalassemia. Although transcription factors regulating beta-globin genes have been identified, little is known about the microRNAs and trans-acting mechanism controlling alpha-globin genes transcription.Here, we show that an erythroid lineage-specific microRNA gene, miR-144, expressed at specific developmental stages during zebrafish embryogenesis, negatively regulates the embryonic alpha-globin, but not embryonic beta-globin genes expression, through physiologically targeting klfd, an erythroid-specific Kruppel-like transcription factor. Klfd selectively binds to the CACCC boxes in the promoters of both alpha-globin and miR-144 genes to activate their transcriptions, thus forming a negative feedback circuitry to fine-tune the expression of embryonic alpha-globin gene. The selective effect of miR-144-Klfd pathway on globin gene regulation may thereby constitute a novel therapeutic target for improving the clinical outcome of patients with thalassemia."	Klfd	unknown	2008	18941117	Causal
+hsa-let-7f	8577	ulcerative colitis (UC)	up-regulated	microarray	Active UC was associated with the differential expression of 11 miRNAs; 3 were significantly decreased and 8 were significantly increased in UC tissues.	unknown	unknown	2008	18835392	Unspecified
+hsa-miR-126 	8577	ulcerative colitis (UC)	up-regulated	microarray	Active UC was associated with the differential expression of 11 miRNAs; 3 were significantly decreased and 8 were significantly increased in UC tissues.	unknown	unknown	2008	18835392	Unspecified
+hsa-miR-16 	8577	ulcerative colitis (UC)	up-regulated	microarray	Active UC was associated with the differential expression of 11 miRNAs; 3 were significantly decreased and 8 were significantly increased in UC tissues.	unknown	"BCL2,CGI-38"	2008	18835392	Unspecified
+hsa-miR-192 	8577	ulcerative colitis (UC)	down-regulated	"Northern blot, qRT-PCR etc"	"Active UC was associated with the differential expression of 11 miRNAs; 3 were significantly decreased and 8 were significantly increased in UC tissues. In situ hybridization analysis indicated that miR-192, an miRNA with decreased expression in active UC, was predominantly localized to colonic epithelial cells. Macrophage inflammatory peptide (MIP)-2 alpha, a chemokine expressed by epithelial cells, was identified as a target of miR-192. In colon epithelial cells, induction of MIP-2 alpha expression by tumor necrosis factor-alpha was accompanied by a concomitant reduction in miR-192 expression and miR-192 was observed to regulate the expression of MIP-2 alpha. CONCLUSIONS: These findings expand the known roles of miRNAs, indicating that tissues from patients with UC, and possibly other chronic inflammatory diseases, have altered miRNA expression patterns. These findings also demonstrate that miRNAs regulate colonic epithelial cell-derived chemokine expression."					
+	MIP-2 alpha	SIP1	2008	18835392	Causal	1	2179			
+hsa-miR-195 	8577	ulcerative colitis (UC)	up-regulated	microarray	Active UC was associated with the differential expression of 11 miRNAs; 3 were significantly decreased and 8 were significantly increased in UC tissues.	unknown	unknown	2008	18835392	Unspecified
+hsa-miR-199a* 	8577	ulcerative colitis (UC)	up-regulated	microarray	Active UC was associated with the differential expression of 11 miRNAs; 3 were significantly decreased and 8 were significantly increased in UC tissues.	unknown	unknown	2008	18835392	Unspecified
+hsa-miR-203 	8577	ulcerative colitis (UC)	up-regulated	microarray	Active UC was associated with the differential expression of 11 miRNAs; 3 were significantly decreased and 8 were significantly increased in UC tissues.	unknown	unknown	2008	18835392	Unspecified
+hsa-miR-21 	8577	ulcerative colitis (UC)	up-regulated	microarray	Active UC was associated with the differential expression of 11 miRNAs; 3 were significantly decreased and 8 were significantly increased in UC tissues.	unknown	"PTEN,TPM1"	2008	18835392	Unspecified
+hsa-miR-23a 	8577	ulcerative colitis (UC)	up-regulated	microarray	Active UC was associated with the differential expression of 11 miRNAs; 3 were significantly decreased and 8 were significantly increased in UC tissues.	unknown	"CXCL12,FLJ13158"	2008	18835392	Unspecified
+hsa-miR-23b 	8577	ulcerative colitis (UC)	up-regulated	microarray	Active UC was associated with the differential expression of 11 miRNAs; 3 were significantly decreased and 8 were significantly increased in UC tissues.	unknown	Notch1	2008	18835392	Unspecified
+hsa-miR-24 	8577	ulcerative colitis (UC)	up-regulated	microarray	Active UC was associated with the differential expression of 11 miRNAs; 3 were significantly decreased and 8 were significantly increased in UC tissues.	unknown	"MAPK14,Notch1"	2008	18835392	Unspecified
+hsa-miR-26a 	8577	ulcerative colitis (UC)	up-regulated	microarray	Active UC was associated with the differential expression of 11 miRNAs; 3 were significantly decreased and 8 were significantly increased in UC tissues.	unknown	PLAG1	2008	18835392	Unspecified
+hsa-miR-29a 	8577	ulcerative colitis (UC)	up-regulated	microarray	Active UC was associated with the differential expression of 11 miRNAs; 3 were significantly decreased and 8 were significantly increased in UC tissues.	unknown	unknown	2008	18835392	Unspecified
+hsa-miR-422b 	8577	ulcerative colitis (UC)	down-regulated	microarray	Active UC was associated with the differential expression of 11 miRNAs; 3 were significantly decreased and 8 were significantly increased in UC tissues.	unknown	unknown	2008	18835392	Unspecified
+hsa-miR-629 	8577	ulcerative colitis (UC)	down-regulated	microarray	Active UC was associated with the differential expression of 11 miRNAs; 3 were significantly decreased and 8 were significantly increased in UC tissues.	unknown	unknown	2008	18835392	Unspecified
+hsa-miR-17-5p	769	neuroblastoma (NB)	up-regulated	"Northern blot, qRT-PCR etc"	"In MYCN-amplified neuroblastoma, MYCN transactivates the miRNA 17-5p-92 cluster, which inhibits p21 and BIM translation by interaction with their mRNA 3'UTRs. Overexpression of miRNA 17-5p-92 cluster in MYCN-not-amplified neuroblastoma cells strongly augments their in vitro and in vivo tumorigenesis. In vitro or in vivo treatment with antagomir-17-5p abolishes the growth of MYCN-amplified and therapy-resistant neuroblastoma through p21 and BIM upmodulation, leading to cell cycling blockade and activation of apoptosis, respectively. In primary neuroblastoma, the majority of cases show a rise of miR-17-5p level leading to p21 downmodulation, which is particularly severe in patients with MYCN amplification and poor prognosis."	"p21,BIM"	"AIB1,E2F1"	2008	18493594	Causal
+hsa-miR-21	684	Hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	"The majority of miRNAs exhibiting altered expression in primary human HNSCC tumors (including miR-1, miR-133a, miR-205, and let-7d) show lower expression levels relative to normal adjacent tissue. In contrast, hsa-miR-21 is frequently overexpressed in human HNSCC tumors. "	unknown	"PTEN,TPM1"	2009	19179615	Unspecified
+hsa-miR-21	3068	glioblastoma	up-regulated	"Northern blot, qRT-PCR etc"	" In this study, bioinformatics analysis was used to identify miR-21 target sites in various genes. Luciferase activity assay showed that a number of genes involved in apoptosis, PDCD4, MTAP, and SOX5, carry putative miR-21 binding sites. Expression of PDCD4 protein correlates inversely with expression of miR-21 in a number of human glioblastoma cell lines such as T98G, A172, U87, and U251. Inhibition of miR-21 increases endogenous levels of PDCD4 in cell line T98G and over-expression miR-21 inhibits PDCD4-dependent apoptosis. Together, these results indicate that miR-21 expression plays a key role in regulating cellular processes in glioblastomas and may serve as a target for effective therapies."	PDCD4	"PTEN,TPM1"	2009	19013014	Causal
+hsa-miR-21	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	"Northern blot, qRT-PCR etc"	"Nine microRNAs were found by SAM to be upregulated or downregulated in tumor tissue including mir-21, let-7, 18, 29c, 142-3p, 155, 146b (overexpressed) and 494 (underexpressed). Mir-21 was validated by qRT-PCR. Functional validation by growth assays was performed, further validating mir-21. Transfection of mir-21 into JHU-011 and JHU-012 cell lines showed a 39% increase in cell growth at 72 hr relative to controls (p < 0.05). Transfection of the inhibitor into JHU-O12 cell lines showed a 92% decrease in cell growth relative to controls at 72 hr (p < 0.05). In addition, flow cytometry analysis of JHU-012 cells 48 hr after mir-21 inhibitor transfection showed a statistically significant increase in cytochrome c release and increased apoptosis. These differentially expressed microRNAs may be of interest as potential novel oncogenes and tumor suppressor genes in HNSCC. Mir-21 is a putative oncogenic microRNA in head and neck cancer."	unknown	"PTEN,TPM1"	2008	18798260	Causal
+hsa-miR-1	289	endometriosis	up-regulated	microarray	" We assessed miRNA expression by microarray analysis in paired ectopic and eutopic endometrial tissues and identified 14 up-regulated (miR-145, miR-143, miR-99a, miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-125a, miR-223, miR-194, miR-365, miR-29c and miR-1) and eight down-regulated (miR-200a, miR-141, miR-200b, miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b) miRNAs. The differential expression of six miRNAs was confirmed by quantitative RT-PCR. An in silico analysis identified 3851 mRNA transcripts as putative targets of the 22 miRNAs. Of these predicted targets, 673 were also differentially expressed in ectopic vs. eutopic endometrial tissue, as determined by microarray. Functional analysis suggested that the 673 miRNA targets constitute molecular pathways previously associated with endometriosis, including c-Jun, CREB-binding protein, protein kinase B (Akt), and cyclin D1 (CCND1) signaling. These pathways appeared to be regulated both transcriptionally as well as by miRNAs at posttranscriptional level. These data are a rich and novel resource for endometriosis and miRNA research and suggest that the 22 miRNAs and their cognate mRNA target sequences constitute pathways that promote endometriosis. Accordingly, miRNAs are potential therapeutic targets for treating this disease."					
+	unknown	"GJA1,Hand2,HDAC4,TMSB4X"	2009	19074548	Unspecified	0	2195			
+hsa-miR-1	11984	cardiac hypertrophy	down-regulated	"northern blot, qRT-PCR etc"	"Calcium signaling is a central regulator of cardiomyocyte growth and function. Calmodulin is a critical mediator of calcium signals. Because the amount of calmodulin within cardiomyocytes is limiting, precise control of calmodulin expression is important for regulation of calcium signaling. In this study, we show for the first time that calmodulin levels are regulated post-transcriptionally in heart failure. The cardiomyocyte-restricted microRNA miR-1 inhibited translation of calmodulin-encoding mRNAs via highly conserved target sites within their 3'-untranslated regions. In keeping with its effect on calmodulin expression, miR-1 downregulated calcium-calmodulin signaling through calcineurin to NFAT. miR-1 also negatively regulated expression of Mef2a and Gata4, key transcription factors that mediate calcium-dependent changes in gene expression. Consistent with downregulation of these hypertrophy-associated genes, miR-1 attenuated cardiomyocyte hypertrophy in cultured neonatal rat cardiomyocytes and in the intact adult heart. Our data indicate that miR-1 regulates cardiomyocyte growth responses by negatively regulating the calcium-signaling components calmodulin, Mef2a, and Gata4."	"calmodulin, Mef2a, Gata4"	"GJA1,Hand2,HDAC4,TMSB4X"	2009	19188439	Causal
+hsa-let-7d	684	Hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	" Using univariate and multivariable statistical models we show that low levels of hsa-miR205 are significantly associated with loco-regional recurrence independent of disease severity at diagnosis and treatment. In addition, combined low levels of hsa-miR-205 and hsa-let-7d expression in HNSCC tumors are significantly associated with poor head and neck cancer survival Our results show that miRNA expression levels can be used as prognostic markers of head and neck cancer."	unknown	unknown	2009	19179615	Unspecified
+hsa-let-7i	2144	ovarian cancer (OC)	down-regulated	"Northern blot, qRT-PCR etc"	"let-7i expression was significantly reduced in chemotherapy-resistant patients (n = 69, P = 0.003). This result was further validated by stem-loop real-time reverse transcription-PCR (n = 62, P = 0.015). Both loss-of-function (by synthetic let-7i inhibitor) and gain-of-function (by retroviral overexpression of let-7i) studies showed that reduced let-7i expression significantly increased the resistance of ovarian and breast cancer cells to the chemotherapy drug, cis-platinum. Finally, using miRNA microarray, we found that decreased let-7i expression was significantly associated with the shorter progression-free survival of patients with late-stage ovarian cancer (n = 72, P = 0.042). This finding was further validated in the same sample set by stem-loop real-time reverse transcription-PCR (n = 62, P = 0.001) and in an independent sample set by in situ hybridization (n = 53, P = 0.049). Taken together, our results strongly suggest that let-7i might be used as a therapeutic target to modulate platinum-based chemotherapy and as a biomarker to predict chemotherapy response and survival in patients with ovarian cancer."	unknown	unknown	2009	19074899	Causal
+hsa-miR-1	684	Hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	"The majority of miRNAs exhibiting altered expression in primary human HNSCC tumors (including miR-1, miR-133a, miR-205, and let-7d) show lower expression levels relative to normal adjacent tissue. In contrast, hsa-miR-21 is frequently overexpressed in human HNSCC tumors. "	unknown	"GJA1,Hand2,HDAC4,TMSB4X"	2009	19179615	Unspecified
+hsa-miR-100	289	endometriosis	up-regulated	microarray	" We assessed miRNA expression by microarray analysis in paired ectopic and eutopic endometrial tissues and identified 14 up-regulated (miR-145, miR-143, miR-99a, miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-125a, miR-223, miR-194, miR-365, miR-29c and miR-1) and eight down-regulated (miR-200a, miR-141, miR-200b, miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b) miRNAs. The differential expression of six miRNAs was confirmed by quantitative RT-PCR. An in silico analysis identified 3851 mRNA transcripts as putative targets of the 22 miRNAs. Of these predicted targets, 673 were also differentially expressed in ectopic vs. eutopic endometrial tissue, as determined by microarray. Functional analysis suggested that the 673 miRNA targets constitute molecular pathways previously associated with endometriosis, including c-Jun, CREB-binding protein, protein kinase B (Akt), and cyclin D1 (CCND1) signaling. These pathways appeared to be regulated both transcriptionally as well as by miRNAs at posttranscriptional level. These data are a rich and novel resource for endometriosis and miRNA research and suggest that the 22 miRNAs and their cognate mRNA target sequences constitute pathways that promote endometriosis. Accordingly, miRNAs are potential therapeutic targets for treating this disease."					
+	unknown	unknown	2009	19074548	Unspecified	0	2200			
+hsa-miR-101	684	Hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	"Decreased expression of miR-101 was found in all six hepatoma cell lines examined and in as high as 94.1% of HCC tissues, compared with their nontumor counterparts. Furthermore, ectopic expression of miR-101 dramatically suppressed the ability of hepatoma cells to form colonies in vitro and to develop tumors in nude mice. We also found that miR-101 could sensitize hepatoma cell lines to both serum starvation- and chemotherapeutic drug-induced apoptosis. Further investigation revealed that miR-101 significantly repressed the expression of luciferase carrying the 3'-untranslated region of Mcl-1 and reduced the endogenous protein level of Mcl-1, whereas the miR-101 inhibitor obviously up-regulated Mcl-1 expression and inhibited cell apoptosis. Moreover, silencing of Mcl-1 phenocopied the effect of miR-101 and forced expression of Mcl-1 could reverse the proapoptotic effect of miR-101. These results indicate that miR-101 may exert its proapoptotic function via targeting Mcl-1. Taken together, our data suggest an important role of miR-101 in the molecular etiology of cancer and implicate the potential application of miR-101 in cancer therapy."	Mcl-1	"Enx-1,MYCN"	2009	19155302	Causal
+hsa-miR-101	684	Hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	"among the 20 HCC samples analyzed, microRNA-101 was significantly down-regulated twofold or more (twofold to 20-fold) in 16 samples compared with the matching nontumoral liver tissues. Using both a luciferase reporter assay and Western blot analysis, we showed that microRNA-101 repressed the expression of v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene, a key component of the activator protein-1 (AP-1) transcription factor. Moreover, using a luciferase expression vector (pAP-1-Luc) driven by seven copies of an AP-1 cis-element, we observed that microRNA-101 expression inhibited phorbol 12-myristate 13-acetate (PMA)-induced AP-1 activity. In in vitro Matrigel invasion and Transwell migration assays, enhanced microRNA-101 expression inhibited the invasion and migration of cultured HCC cells, respectively. These findings suggest that microRNA-101 may play an important role in HCC. Conclusion: MicroRNA-101, which is aberrantly expressed in HCC, could repress the expression of the FOS oncogene."	FOS	"Enx-1,MYCN"	2009	19133651	Causal
+hsa-miR-101	10286	prostate cancer	down-regulated	"northern blot, qRT-PCR etc"	"Enhancer of zeste homolog 2 (EZH2) is a mammalian histone methyltransferase that contributes to the epigenetic silencing of target genes and regulates the survival and metastasis of cancer cells. EZH2 is overexpressed in aggressive solid tumors by mechanisms that remain unclear. Here we show that the expression and function of EZH2 in cancer cell lines are inhibited by microRNA-101 (miR-101). Analysis of human prostate tumors revealed that miR-101 expression decreases during cancer progression, paralleling an increase in EZH2 expression. One or both of the two genomic loci encoding miR-101 were somatically lost in 37.5% of clinically localized prostate cancer cells (6 of 16) and 66.7% of metastatic disease cells (22 of 33). We propose that the genomic loss of miR-101 in cancer leads to overexpression of EZH2 and concomitant dysregulation of epigenetic pathways, resulting in cancer progression."	EZH2	"Enx-1,MYCN"	2009	19008416	Causal
+hsa-miR-106a	5517	gastric cancer (stomach cancer)	up-regulated	"Northern blot, qRT-PCR etc"	"The level of miR-106a in cancer tissues was significantly higher than that in non-tumor tissues, with an average 1.625-fold increase. miR-106a level was significantly associated with tumor stage, size and differentiation; lymphatic and distant metastasis; and invasion (P<0.01). The altered expression of miR-106a was confirmed in gastric cancer cell lines."	unknown	RB1	2009	18996365	Unspecified
+hsa-miR-106b	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	" Chronic lymphocytic leukemia (CLL) is characterized by cells that exhibit dysfunctional apoptosis. Here, we show, deacetylase inhibition led to the E2F1- and myc-mediated transcriptional activation of the microRNA, miR106b in primary CLL cells. Induction of miR106b was associated with a downregulation in the levels of the E3-ubiquitin ligase, Itch. Decreases in Itch protein levels were associated with a reciprocal accumulation of its proapoptotic substrate, TAp73 (p73), and induction of PUMA mRNA and protein. Ectopic expression of miR106b in CLL cells demonstrated that Itch was a direct target of miR106b such that miR106b-induced decreases in Itch resulted in an accumulation of p73. Thus, our results identify a novel regulatory mechanism wherein miRNA regulate cell survival by mediating the post-transcriptional downregulation of an ubiquitin ligase, leading to the induction of a proapoptotic regulator in malignant cells. Silencing of miRNA expression in CLL may selectively suppress proapoptotic pathways providing such tumors with a survival advantage. Consequently, chemotherapeutic drugs that activate miR106b could initiate a p53-independent mechanism that targets CLL cells."	Itch	unknown	2009	19096009	Causal
+hsa-miR-10a	4007	bladder cancer	up-regulated	microarray	"A score based on the expression levels of the 51 miRNAs, identified muscle invasive tumors with high precision and sensitivity. MiRNAs showing high expression in muscle invasive tumors included miR-222 and miR-125b and in Ta tumors miR-10a. A miRNA signature for FGFR3 mutated cases was also identified with miR-7 as an important member. MiR-31, located in 9p21, was found to be homozygously deleted in 3 cases and miR-452 and miR-452* were shown to be over expressed in node positive tumors. In addition, these latter miRNAs were shown to be excellent prognostic markers for death by disease as outcome. The presented data shows that pathological subtypes of urothelial carcinoma show distinct miRNA gene expression signatures."	unknown	HOXA1	2009	19127597	Unspecified
+hsa-miR-10a	8552	chronic myeloid leukemia (CML)	down-regulated	"northern blot, qRT-PCR etc"	" We detected an abnormal miRNA expression profile in mononuclear and CD34(+) cells from patients with CML compared with healthy controls. Of 157 miRNAs tested, hsa-miR-10a, hsa-miR-150, and hsa-miR-151 were down-regulated, whereas hsa-miR-96 was up-regulated in CML cells. Down-regulation of hsa-miR-10a was not dependent on BCR-ABL1 activity and contributed to the increased cell growth of CML cells. We identified the upstream stimulatory factor 2 (USF2) as a potential target of hsa-miR-10a and showed that overexpression of USF2 also increases cell growth. The clinical relevance of these findings was shown in a group of 85 newly diagnosed patients with CML in which expression of hsa-miR-10a was down-regulated in 71% of the patients, whereas expression of USF2 was up-regulated in 60% of the CML patients, with overexpression of USF2 being significantly associated with decreased expression of hsa-miR-10a (P = 0.004). Our results indicate that down-regulation of hsa-miR-10a may increase USF2 and contribute to the increase in cell proliferation of CML implicating a miRNA in the abnormal behavior of CML."	USF2 	HOXA1	2009	19074828	Causal
+hsa-miR-125a	3858	medulloblastoma	down-regulated	"northern blot, qRT-PCR etc"	"MicroRNAs expression profile clearly differentiates medulloblastoma from either adult or fetal normal cerebellar tissues. Only a few microRNAs displayed upregulated expression, while most of them were downregulated in tumor samples, suggesting a tumor growth-inhibitory function. This property has been addressed for miR-9 and miR-125a, whose rescued expression promoted medulloblastoma cell growth arrest and apoptosis while targeting the proproliferative truncated TrkC isoform. In conclusion, misregulated microRNA expression profiles characterize human medulloblastomas, and may provide potential targets for novel therapeutic strategies."	TrkC	"ERBB2,ERBB3,Lin28"	2009	18973228	Causal
+hsa-miR-125a	289	endometriosis	up-regulated	microarray	" We assessed miRNA expression by microarray analysis in paired ectopic and eutopic endometrial tissues and identified 14 up-regulated (miR-145, miR-143, miR-99a, miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-125a, miR-223, miR-194, miR-365, miR-29c and miR-1) and eight down-regulated (miR-200a, miR-141, miR-200b, miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b) miRNAs. The differential expression of six miRNAs was confirmed by quantitative RT-PCR. An in silico analysis identified 3851 mRNA transcripts as putative targets of the 22 miRNAs. Of these predicted targets, 673 were also differentially expressed in ectopic vs. eutopic endometrial tissue, as determined by microarray. Functional analysis suggested that the 673 miRNA targets constitute molecular pathways previously associated with endometriosis, including c-Jun, CREB-binding protein, protein kinase B (Akt), and cyclin D1 (CCND1) signaling. These pathways appeared to be regulated both transcriptionally as well as by miRNAs at posttranscriptional level. These data are a rich and novel resource for endometriosis and miRNA research and suggest that the 22 miRNAs and their cognate mRNA target sequences constitute pathways that promote endometriosis. Accordingly, miRNAs are potential therapeutic targets for treating this disease."					
+	unknown	"ERBB2,ERBB3,Lin28"	2009	19074548	Unspecified	0	2209			
+hsa-miR-125b	4007	bladder cancer	up-regulated	microarray	"A score based on the expression levels of the 51 miRNAs, identified muscle invasive tumors with high precision and sensitivity. MiRNAs showing high expression in muscle invasive tumors included miR-222 and miR-125b and in Ta tumors miR-10a. A miRNA signature for FGFR3 mutated cases was also identified with miR-7 as an important member. MiR-31, located in 9p21, was found to be homozygously deleted in 3 cases and miR-452 and miR-452* were shown to be over expressed in node positive tumors. In addition, these latter miRNAs were shown to be excellent prognostic markers for death by disease as outcome. The presented data shows that pathological subtypes of urothelial carcinoma show distinct miRNA gene expression signatures."	unknown	Lin28	2009	19127597	Unspecified
+hsa-miR-125b	289	endometriosis	up-regulated	microarray	" We assessed miRNA expression by microarray analysis in paired ectopic and eutopic endometrial tissues and identified 14 up-regulated (miR-145, miR-143, miR-99a, miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-125a, miR-223, miR-194, miR-365, miR-29c and miR-1) and eight down-regulated (miR-200a, miR-141, miR-200b, miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b) miRNAs. The differential expression of six miRNAs was confirmed by quantitative RT-PCR. An in silico analysis identified 3851 mRNA transcripts as putative targets of the 22 miRNAs. Of these predicted targets, 673 were also differentially expressed in ectopic vs. eutopic endometrial tissue, as determined by microarray. Functional analysis suggested that the 673 miRNA targets constitute molecular pathways previously associated with endometriosis, including c-Jun, CREB-binding protein, protein kinase B (Akt), and cyclin D1 (CCND1) signaling. These pathways appeared to be regulated both transcriptionally as well as by miRNAs at posttranscriptional level. These data are a rich and novel resource for endometriosis and miRNA research and suggest that the 22 miRNAs and their cognate mRNA target sequences constitute pathways that promote endometriosis. Accordingly, miRNAs are potential therapeutic targets for treating this disease."					
+	unknown	Lin28	2009	19074548	Unspecified	0	2211			
+hsa-miR-126	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"mir-126 is one of the miRNAs underexpressed in breast cancer cells. Flow cytometry analysis showed that mir-126 inhibited cell cycle progression from G1/G0 to S. Further studies revealed that mir-126 targeted IRS-1 at the translation level. Knocking down of IRS-1 suppresses cell growth in HEK293 and breast cancer cell MCF-7, which recapitulates the effects of mir-126. "	IRS-1	unknown	2009	18834857	Causal
+hsa-miR-126	289	endometriosis	up-regulated	microarray	" We assessed miRNA expression by microarray analysis in paired ectopic and eutopic endometrial tissues and identified 14 up-regulated (miR-145, miR-143, miR-99a, miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-125a, miR-223, miR-194, miR-365, miR-29c and miR-1) and eight down-regulated (miR-200a, miR-141, miR-200b, miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b) miRNAs. The differential expression of six miRNAs was confirmed by quantitative RT-PCR. An in silico analysis identified 3851 mRNA transcripts as putative targets of the 22 miRNAs. Of these predicted targets, 673 were also differentially expressed in ectopic vs. eutopic endometrial tissue, as determined by microarray. Functional analysis suggested that the 673 miRNA targets constitute molecular pathways previously associated with endometriosis, including c-Jun, CREB-binding protein, protein kinase B (Akt), and cyclin D1 (CCND1) signaling. These pathways appeared to be regulated both transcriptionally as well as by miRNAs at posttranscriptional level. These data are a rich and novel resource for endometriosis and miRNA research and suggest that the 22 miRNAs and their cognate mRNA target sequences constitute pathways that promote endometriosis. Accordingly, miRNAs are potential therapeutic targets for treating this disease."					
+	unknown	unknown	2009	19074548	Unspecified	0	2213			
+hsa-miR-133a	684	Hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	"The majority of miRNAs exhibiting altered expression in primary human HNSCC tumors (including miR-1, miR-133a, miR-205, and let-7d) show lower expression levels relative to normal adjacent tissue. In contrast, hsa-miR-21 is frequently overexpressed in human HNSCC tumors. "	unknown	unknown	2009	19179615	Unspecified
+hsa-miR-141	4451	kidney cancer	down-regulated	"northern blot, qRT-PCR etc"	"We observed that miR-141 and miR-200c were the most significantly down-regulated miRNAs in CCCs. Indeed, in all cases of CCC analysed, both miR-141 and miR-200c were down-regulated in comparison with normal kidney. Microarray data and quantitative RT-PCR showed that these two miRNAs were expressed concordantly. TargetScan algorithm revealed that ZFHX1B mRNA is a hypothetical target of both miR-141 and -200c. We established by quantitative RT-PCR that, in CCCs in which miR-141 and miR-200c were down-regulated, ZFHX1B, a transcriptional repressor for CDH1/E-cadherin, tended to be up-regulated. Furthermore, we found that overexpression of miR-141 and miR-200c caused down-regulation of ZFHX1B and up-regulation of E-cadherin in two renal carcinoma cell lines, ACHN and 786-O. On the basis of these findings, we suggest that down-regulation of miR-141 and miR-200c in CCCs might be involved in suppression of CDH1/E-cadherin transcription via up-regulation of ZFHX1B."					
+	unknown	Clock	2009	18925646	Unspecified	0	2216			
+hsa-miR-141	289	endometriosis	down-regulated	microarray	" We assessed miRNA expression by microarray analysis in paired ectopic and eutopic endometrial tissues and identified 14 up-regulated (miR-145, miR-143, miR-99a, miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-125a, miR-223, miR-194, miR-365, miR-29c and miR-1) and eight down-regulated (miR-200a, miR-141, miR-200b, miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b) miRNAs. The differential expression of six miRNAs was confirmed by quantitative RT-PCR. An in silico analysis identified 3851 mRNA transcripts as putative targets of the 22 miRNAs. Of these predicted targets, 673 were also differentially expressed in ectopic vs. eutopic endometrial tissue, as determined by microarray. Functional analysis suggested that the 673 miRNA targets constitute molecular pathways previously associated with endometriosis, including c-Jun, CREB-binding protein, protein kinase B (Akt), and cyclin D1 (CCND1) signaling. These pathways appeared to be regulated both transcriptionally as well as by miRNAs at posttranscriptional level. These data are a rich and novel resource for endometriosis and miRNA research and suggest that the 22 miRNAs and their cognate mRNA target sequences constitute pathways that promote endometriosis. Accordingly, miRNAs are potential therapeutic targets for treating this disease."					
+	unknown	Clock	2009	19074548	Unspecified	0	2217			
+hsa-miR-142-3p	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	"Nine microRNAs were found by SAM to be upregulated or downregulated in tumor tissue including mir-21, let-7, 18, 29c, 142-3p, 155, 146b (overexpressed) and 494 (underexpressed). Mir-21 was validated by qRT-PCR. Functional validation by growth assays was performed, further validating mir-21. Transfection of mir-21 into JHU-011 and JHU-012 cell lines showed a 39% increase in cell growth at 72 hr relative to controls (p < 0.05). Transfection of the inhibitor into JHU-O12 cell lines showed a 92% decrease in cell growth relative to controls at 72 hr (p < 0.05). In addition, flow cytometry analysis of JHU-012 cells 48 hr after mir-21 inhibitor transfection showed a statistically significant increase in cytochrome c release and increased apoptosis. These differentially expressed microRNAs may be of interest as potential novel oncogenes and tumor suppressor genes in HNSCC. Mir-21 is a putative oncogenic microRNA in head and neck cancer."	unknown	unknown	2008	18798260	Unspecified
+hsa-miR-142-3p	289	endometriosis	down-regulated	microarray	" We assessed miRNA expression by microarray analysis in paired ectopic and eutopic endometrial tissues and identified 14 up-regulated (miR-145, miR-143, miR-99a, miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-125a, miR-223, miR-194, miR-365, miR-29c and miR-1) and eight down-regulated (miR-200a, miR-141, miR-200b, miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b) miRNAs. The differential expression of six miRNAs was confirmed by quantitative RT-PCR. An in silico analysis identified 3851 mRNA transcripts as putative targets of the 22 miRNAs. Of these predicted targets, 673 were also differentially expressed in ectopic vs. eutopic endometrial tissue, as determined by microarray. Functional analysis suggested that the 673 miRNA targets constitute molecular pathways previously associated with endometriosis, including c-Jun, CREB-binding protein, protein kinase B (Akt), and cyclin D1 (CCND1) signaling. These pathways appeared to be regulated both transcriptionally as well as by miRNAs at posttranscriptional level. These data are a rich and novel resource for endometriosis and miRNA research and suggest that the 22 miRNAs and their cognate mRNA target sequences constitute pathways that promote endometriosis. Accordingly, miRNAs are potential therapeutic targets for treating this disease."					
+	unknown	unknown	2009	19074548	Unspecified	0	2219			
+hsa-miR-143	4007	bladder cancer	down-regulated	"northern blot, qRT-PCR etc"	"miRNA-143 was 13.7 times lower in tumor than in the matched control. Consistent with microarray data, Northern blot analysis and real-time polymerase chain reaction confirmed that miRNA-143 expression was significantly down-regulated in bladder tumor tissues compared with normal adjacent tissues. The expression of miRNA-143 was not detected in the 2 human bladder cancer cell lines EJ and T24. Interestingly miRNA-143 transfection into EJ and T24 cells significantly inhibited cell proliferation. RAS protein expression in cancer tissues was much higher than in adjacent controls. Consistently RAS protein expression was also significantly decreased in miRNA-143 transfected cells compared with nonspecific miRNA transfected cells. CONCLUSIONS: miRNAs are differentially expressed in bladder cancer tissues. miRNA-143 may function as a tumor suppressor in bladder transitional cell carcinoma."	unknown	unknown	2009	19157460	Causal
+hsa-miR-143	289	endometriosis	up-regulated	microarray	" We assessed miRNA expression by microarray analysis in paired ectopic and eutopic endometrial tissues and identified 14 up-regulated (miR-145, miR-143, miR-99a, miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-125a, miR-223, miR-194, miR-365, miR-29c and miR-1) and eight down-regulated (miR-200a, miR-141, miR-200b, miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b) miRNAs. The differential expression of six miRNAs was confirmed by quantitative RT-PCR. An in silico analysis identified 3851 mRNA transcripts as putative targets of the 22 miRNAs. Of these predicted targets, 673 were also differentially expressed in ectopic vs. eutopic endometrial tissue, as determined by microarray. Functional analysis suggested that the 673 miRNA targets constitute molecular pathways previously associated with endometriosis, including c-Jun, CREB-binding protein, protein kinase B (Akt), and cyclin D1 (CCND1) signaling. These pathways appeared to be regulated both transcriptionally as well as by miRNAs at posttranscriptional level. These data are a rich and novel resource for endometriosis and miRNA research and suggest that the 22 miRNAs and their cognate mRNA target sequences constitute pathways that promote endometriosis. Accordingly, miRNAs are potential therapeutic targets for treating this disease."					
+	unknown	unknown	2009	19074548	Unspecified	0	2221			
+hsa-miR-143	9256	colorectal cancer	down-regulated	"northern blot, qRT-PCR etc"	" KRAS oncogene has been further experimentally validated as the target of miR-143. First, an inverse correlation between KRAS protein and miR-143 in vivo was found. Second, KRAS expression in Lovo cells was significantly abolished by treatment with miR-143 mimic, whereas miR-143 inhibitor increased KRAS protein level. Third, luciferase reporter assay confirmed that miR-143 directly recognize the 3'-untranslated region of KRAS transcripts. Four, Lovo cells treated with miR-143 inhibitor showed a stimulated cell proliferation, whereas miR-143 overexpression had an opposite effect. Finally, inhibition of KRAS expression by miR-143 inhibits constitutive phosphorylation of ERK1/2. Taken together, the present study provides the first evidences that miR-143 is significant in suppressing colorectal cancer cell growth through inhibition of KRAS translation."	KRAS	unknown	2009	19137007	Causal
+hsa-miR-145	289	endometriosis	up-regulated	microarray	" We assessed miRNA expression by microarray analysis in paired ectopic and eutopic endometrial tissues and identified 14 up-regulated (miR-145, miR-143, miR-99a, miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-125a, miR-223, miR-194, miR-365, miR-29c and miR-1) and eight down-regulated (miR-200a, miR-141, miR-200b, miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b) miRNAs. The differential expression of six miRNAs was confirmed by quantitative RT-PCR. An in silico analysis identified 3851 mRNA transcripts as putative targets of the 22 miRNAs. Of these predicted targets, 673 were also differentially expressed in ectopic vs. eutopic endometrial tissue, as determined by microarray. Functional analysis suggested that the 673 miRNA targets constitute molecular pathways previously associated with endometriosis, including c-Jun, CREB-binding protein, protein kinase B (Akt), and cyclin D1 (CCND1) signaling. These pathways appeared to be regulated both transcriptionally as well as by miRNAs at posttranscriptional level. These data are a rich and novel resource for endometriosis and miRNA research and suggest that the 22 miRNAs and their cognate mRNA target sequences constitute pathways that promote endometriosis. Accordingly, miRNAs are potential therapeutic targets for treating this disease."					
+	unknown	FLJ21308	2009	19074548	Unspecified	0	2223			
+hsa-miR-146a*	3963	thyroid cancer	normal	"northern blot, qRT-PCR etc"	"Here, we show that GC heterozygotes differ from both GG and CC homozygotes by producing 3 mature microRNAs: 1 from the leading strand (miR-146a), and 2 from the passenger strand (miR-146a*G and miR-146a*C), each with its distinct set of target genes. TaqMan analysis of paired tumor/normal samples revealed 1.5- to 2.6-fold overexpression of polymorphic miR-146a* in 7 of 8 tumors compared with the unaffected part of the same gland. The microarray data showed that widely different transcriptomes occurred in the tumors and in unaffected parts of the thyroid from GC and GG patients. The modulated genes are mainly involved in regulation of apoptosis leading to exaggerated DNA-damage response in heterozygotes potentially explaining the predisposition to cancer. We propose that contrary to previously held views transcripts from the passenger strand of miRs can profoundly affect the downstream effects. Heterozygosity for polymorphisms within the premiR sequence can cause epistasis through the production of additional mature miRs. We propose that mature miRs from the passenger strand may regulate many genetic processes."	unknown	unknown	2009	19164563	Causal
+hsa-miR-146b	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	"Nine microRNAs were found by SAM to be upregulated or downregulated in tumor tissue including mir-21, let-7, 18, 29c, 142-3p, 155, 146b (overexpressed) and 494 (underexpressed). Mir-21 was validated by qRT-PCR. Functional validation by growth assays was performed, further validating mir-21. Transfection of mir-21 into JHU-011 and JHU-012 cell lines showed a 39% increase in cell growth at 72 hr relative to controls (p < 0.05). Transfection of the inhibitor into JHU-O12 cell lines showed a 92% decrease in cell growth relative to controls at 72 hr (p < 0.05). In addition, flow cytometry analysis of JHU-012 cells 48 hr after mir-21 inhibitor transfection showed a statistically significant increase in cytochrome c release and increased apoptosis. These differentially expressed microRNAs may be of interest as potential novel oncogenes and tumor suppressor genes in HNSCC. Mir-21 is a putative oncogenic microRNA in head and neck cancer."	unknown	unknown	2008	18798260	Unspecified
+hsa-miR-15	8552	chronic myeloid leukemia (CML)	down-regulated	"northern blot, qRT-PCR etc"	"Herein we show that c-Myb expression is subject to posttranscriptional regulation by microRNA (miRNA)-15a. Using a luciferase reporter assay, we found that miR-15a directly binds the 3'-UTR of c-myb mRNA. By transfecting K562 myeloid leukemia cells with a miR-15a mimic, functionality of binding was shown. The mimic decreased c-Myb expression, and blocked the cells in the G(1) phase of cell cycle. Exogenous expression of c-myb mRNA lacking the 3'-UTR partially rescued the miR-15a induced cell-cycle block. Of interest, the miR-15a promoter contained several potential c-Myb protein binding sites. Occupancy of one canonical c-Myb binding site was demonstrated by chromatin immunoprecipitation analysis and shown to be required for miR-15a expression in K562 cells. Finally, in studies using normal human CD34(+) cells, we showed that c-Myb and miR-15a expression were inversely correlated in cells undergoing erythroid differentiation, and that overexpression of miR-15a blocked both erythroid and myeloid colony formation in vitro. In aggregate, these findings suggest the presence of a c-Myb-miR-15a autoregulatory feedback loop of potential importance in human hematopoiesis."	c-myb	"BCL2,DMTF1"	2009	18818396	Causal
+hsa-miR-150	289	endometriosis	up-regulated	microarray	" We assessed miRNA expression by microarray analysis in paired ectopic and eutopic endometrial tissues and identified 14 up-regulated (miR-145, miR-143, miR-99a, miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-125a, miR-223, miR-194, miR-365, miR-29c and miR-1) and eight down-regulated (miR-200a, miR-141, miR-200b, miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b) miRNAs. The differential expression of six miRNAs was confirmed by quantitative RT-PCR. An in silico analysis identified 3851 mRNA transcripts as putative targets of the 22 miRNAs. Of these predicted targets, 673 were also differentially expressed in ectopic vs. eutopic endometrial tissue, as determined by microarray. Functional analysis suggested that the 673 miRNA targets constitute molecular pathways previously associated with endometriosis, including c-Jun, CREB-binding protein, protein kinase B (Akt), and cyclin D1 (CCND1) signaling. These pathways appeared to be regulated both transcriptionally as well as by miRNAs at posttranscriptional level. These data are a rich and novel resource for endometriosis and miRNA research and suggest that the 22 miRNAs and their cognate mRNA target sequences constitute pathways that promote endometriosis. Accordingly, miRNAs are potential therapeutic targets for treating this disease."					
+	unknown	unknown	2009	19074548	Unspecified	0	2227			
+hsa-miR-155	9080	Waldenstrom Macroglobulinemia (WM)	up-regulated	"Northern blot, qRT-PCR etc"	"Multi-level genetic characterization of Waldenstrom Macroglobulinemia (WM) is required to improve our understanding of the underlying molecular changes that lead to the initiation and progression of this disease. We performed microRNA-expression-profiling of bone marrow-derived CD19(+) WM cells, compared to their normal cellular counterparts and validated data by qRT-PCR. We identified a WM-specific microRNA signature characterized by increased expression of microRNA-363*/-206/-494/-155/-184/-542-3p; and decreased expression of microRNA-9* (ANOVA; P<0.01). We found that microRNA-155 regulates proliferation and growth of WM cells in vitro and in vivo, by inhibiting MAPK/ERK, PI3/AKT and NF-kB pathways. Potential microRNA-155 target genes were identified using gene-expression-profiling and included genes involved in cell cycle progression, adhesion, and migration. Importantly, increased expression of the 6 miRNAs significantly correlated with a poorer outcome predicted by the International-Prognostic-Staging-System for WM. We further demonstrated that therapeutic agents commonly used in WM (rituximab/perifosine/bortezomib) alter the levels of the major miRNAs identified, by inducing down-modulation of five increased miRNAs (all but miR-206) and up-modulation of patient-downexpressed miRNA-9*. These data indicate that microRNAs play a pivotal role in the biology of WM; represent important prognostic marker; and provide the basis for the development of new microRNA-based targeted therapies in WM."	unknown	AGTR1	2009	19074725	Unspecified
+hsa-miR-155	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	"Nine microRNAs were found by SAM to be upregulated or downregulated in tumor tissue including mir-21, let-7, 18, 29c, 142-3p, 155, 146b (overexpressed) and 494 (underexpressed). Mir-21 was validated by qRT-PCR. Functional validation by growth assays was performed, further validating mir-21. Transfection of mir-21 into JHU-011 and JHU-012 cell lines showed a 39% increase in cell growth at 72 hr relative to controls (p < 0.05). Transfection of the inhibitor into JHU-O12 cell lines showed a 92% decrease in cell growth relative to controls at 72 hr (p < 0.05). In addition, flow cytometry analysis of JHU-012 cells 48 hr after mir-21 inhibitor transfection showed a statistically significant increase in cytochrome c release and increased apoptosis. These differentially expressed microRNAs may be of interest as potential novel oncogenes and tumor suppressor genes in HNSCC. Mir-21 is a putative oncogenic microRNA in head and neck cancer."	unknown	AGTR1	2008	18798260	Unspecified
+hsa-miR-15b	2627	glioma	down-regulated	"Northern blot, qRT-PCR etc"	"Here, we studied the function of one miRNA, miR-15b, in glioma carcinogenesis and elucidated its downstream targets. Over-expression of miR-15b resulted in cell cycle arrest at G0/G1 phase while suppression of miR-15b expression resulted in a decrease of cell populations in G0/G1 and a corresponding increase of cell populations in S phase. We further showed that CCNE1 (encoding cyclin E1) is one of the downstream targets of miR-15b. Taken together, our findings indicate that miR-15b regulates cell cycle progression in glioma cells by targeting cell cycle-related molecules."	CCNE1	unknown	2009	19135980	Causal
+hsa-miR-18	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	"Nine microRNAs were found by SAM to be upregulated or downregulated in tumor tissue including mir-21, let-7, 18, 29c, 142-3p, 155, 146b (overexpressed) and 494 (underexpressed). Mir-21 was validated by qRT-PCR. Functional validation by growth assays was performed, further validating mir-21. Transfection of mir-21 into JHU-011 and JHU-012 cell lines showed a 39% increase in cell growth at 72 hr relative to controls (p < 0.05). Transfection of the inhibitor into JHU-O12 cell lines showed a 92% decrease in cell growth relative to controls at 72 hr (p < 0.05). In addition, flow cytometry analysis of JHU-012 cells 48 hr after mir-21 inhibitor transfection showed a statistically significant increase in cytochrome c release and increased apoptosis. These differentially expressed microRNAs may be of interest as potential novel oncogenes and tumor suppressor genes in HNSCC. Mir-21 is a putative oncogenic microRNA in head and neck cancer."	unknown	unknown	2008	18798260	Unspecified
+hsa-miR-184	9080	Waldenstrom Macroglobulinemia (WM)	up-regulated	"Northern blot, qRT-PCR etc"	"Multi-level genetic characterization of Waldenstrom Macroglobulinemia (WM) is required to improve our understanding of the underlying molecular changes that lead to the initiation and progression of this disease. We performed microRNA-expression-profiling of bone marrow-derived CD19(+) WM cells, compared to their normal cellular counterparts and validated data by qRT-PCR. We identified a WM-specific microRNA signature characterized by increased expression of microRNA-363*/-206/-494/-155/-184/-542-3p; and decreased expression of microRNA-9* (ANOVA; P<0.01). We found that microRNA-155 regulates proliferation and growth of WM cells in vitro and in vivo, by inhibiting MAPK/ERK, PI3/AKT and NF-kB pathways. Potential microRNA-155 target genes were identified using gene-expression-profiling and included genes involved in cell cycle progression, adhesion, and migration. Importantly, increased expression of the 6 miRNAs significantly correlated with a poorer outcome predicted by the International-Prognostic-Staging-System for WM. We further demonstrated that therapeutic agents commonly used in WM (rituximab/perifosine/bortezomib) alter the levels of the major miRNAs identified, by inducing down-modulation of five increased miRNAs (all but miR-206) and up-modulation of patient-downexpressed miRNA-9*. These data indicate that microRNAs play a pivotal role in the biology of WM; represent important prognostic marker; and provide the basis for the development of new microRNA-based targeted therapies in WM."	unknown	unknown	2009	19074725	Unspecified
+hsa-miR-192	9256	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Here, we used array hybridization to find that p53 induces two additional, mutually related clusters of microRNAs, leading to the up-regulation of miR-192, miR-194, and miR-215. The same microRNAs were detected at high levels in normal colon tissue but were severely reduced in many colon cancer samples. On the other hand, miR-192 and its cousin miR-215 can each contribute to enhanced CDKN1A/p21 levels, colony suppression, cell cycle arrest, and cell detachment from a solid support. These effects were partially dependent on the presence of wild-type p53. Antagonizing endogenous miR-192 attenuated 5-fluorouracil-induced accumulation of p21. Hence, miR-192 and miR-215 can act as effectors as well as regulators of p53; they seem to suppress cancerogenesis through p21 accumulation and cell cycle arrest."	CDKN1A/p21	SIP1	2009	19074875	Causal
+hsa-miR-194	9256	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Here, we used array hybridization to find that p53 induces two additional, mutually related clusters of microRNAs, leading to the up-regulation of miR-192, miR-194, and miR-215. The same microRNAs were detected at high levels in normal colon tissue but were severely reduced in many colon cancer samples. On the other hand, miR-192 and its cousin miR-215 can each contribute to enhanced CDKN1A/p21 levels, colony suppression, cell cycle arrest, and cell detachment from a solid support. These effects were partially dependent on the presence of wild-type p53. Antagonizing endogenous miR-192 attenuated 5-fluorouracil-induced accumulation of p21. Hence, miR-192 and miR-215 can act as effectors as well as regulators of p53; they seem to suppress cancerogenesis through p21 accumulation and cell cycle arrest."	unknown	unknown	2009	19074875	Causal
+hsa-miR-194	289	endometriosis	up-regulated	microarray	" We assessed miRNA expression by microarray analysis in paired ectopic and eutopic endometrial tissues and identified 14 up-regulated (miR-145, miR-143, miR-99a, miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-125a, miR-223, miR-194, miR-365, miR-29c and miR-1) and eight down-regulated (miR-200a, miR-141, miR-200b, miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b) miRNAs. The differential expression of six miRNAs was confirmed by quantitative RT-PCR. An in silico analysis identified 3851 mRNA transcripts as putative targets of the 22 miRNAs. Of these predicted targets, 673 were also differentially expressed in ectopic vs. eutopic endometrial tissue, as determined by microarray. Functional analysis suggested that the 673 miRNA targets constitute molecular pathways previously associated with endometriosis, including c-Jun, CREB-binding protein, protein kinase B (Akt), and cyclin D1 (CCND1) signaling. These pathways appeared to be regulated both transcriptionally as well as by miRNAs at posttranscriptional level. These data are a rich and novel resource for endometriosis and miRNA research and suggest that the 22 miRNAs and their cognate mRNA target sequences constitute pathways that promote endometriosis. Accordingly, miRNAs are potential therapeutic targets for treating this disease."					
+	unknown	unknown	2009	19074548	Unspecified	0	2235			
+hsa-miR-196b	289	endometriosis	down-regulated	microarray	" We assessed miRNA expression by microarray analysis in paired ectopic and eutopic endometrial tissues and identified 14 up-regulated (miR-145, miR-143, miR-99a, miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-125a, miR-223, miR-194, miR-365, miR-29c and miR-1) and eight down-regulated (miR-200a, miR-141, miR-200b, miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b) miRNAs. The differential expression of six miRNAs was confirmed by quantitative RT-PCR. An in silico analysis identified 3851 mRNA transcripts as putative targets of the 22 miRNAs. Of these predicted targets, 673 were also differentially expressed in ectopic vs. eutopic endometrial tissue, as determined by microarray. Functional analysis suggested that the 673 miRNA targets constitute molecular pathways previously associated with endometriosis, including c-Jun, CREB-binding protein, protein kinase B (Akt), and cyclin D1 (CCND1) signaling. These pathways appeared to be regulated both transcriptionally as well as by miRNAs at posttranscriptional level. These data are a rich and novel resource for endometriosis and miRNA research and suggest that the 22 miRNAs and their cognate mRNA target sequences constitute pathways that promote endometriosis. Accordingly, miRNAs are potential therapeutic targets for treating this disease."					
+	unknown	unknown	2009	19074548	Unspecified	0	2236			
+hsa-miR-19a	3858	medulloblastoma 	up-regulated	"northern blot, qRT-PCR etc"	"Analysis of human MBs demonstrated that 3 miR-17 approximately 92 cluster miRNAs (miR-92, miR-19a, and miR-20) were also overexpressed in human MBs with a constitutively activated Sonic Hedgehog (SHH) signaling pathway, but not in other forms of the disease. To test whether the miR-17 approximately 92 cluster could promote MB formation, we enforced expression of these miRNAs in GNPs isolated from cerebella of postnatal (P) day P6 Ink4c-/-; Ptch1+/- mice. These, but not similarly engineered cells from Ink4c-/-; p53-/- mice, formed MBs in orthotopic transplants with complete penetrance. Interestingly, orthotopic mouse tumors ectopically expressing miR-17 approximately 92 lost expression of the wild-type Ptch1 allele. Our findings suggest a functional collaboration between the miR-17 approximately 92 cluster and the SHH signaling pathway in the development of MBs in mouse and man."	unknown	PTEN	2009	19196975	Causal
+hsa-miR-20	3858	medulloblastoma 	up-regulated	"northern blot, qRT-PCR etc"	"Analysis of human MBs demonstrated that 3 miR-17 approximately 92 cluster miRNAs (miR-92, miR-19a, and miR-20) were also overexpressed in human MBs with a constitutively activated Sonic Hedgehog (SHH) signaling pathway, but not in other forms of the disease. To test whether the miR-17 approximately 92 cluster could promote MB formation, we enforced expression of these miRNAs in GNPs isolated from cerebella of postnatal (P) day P6 Ink4c-/-; Ptch1+/- mice. These, but not similarly engineered cells from Ink4c-/-; p53-/- mice, formed MBs in orthotopic transplants with complete penetrance. Interestingly, orthotopic mouse tumors ectopically expressing miR-17 approximately 92 lost expression of the wild-type Ptch1 allele. Our findings suggest a functional collaboration between the miR-17 approximately 92 cluster and the SHH signaling pathway in the development of MBs in mouse and man."	unknown	E2F1	2009	19196975	Causal
+hsa-miR-200a	289	endometriosis	down-regulated	microarray	" We assessed miRNA expression by microarray analysis in paired ectopic and eutopic endometrial tissues and identified 14 up-regulated (miR-145, miR-143, miR-99a, miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-125a, miR-223, miR-194, miR-365, miR-29c and miR-1) and eight down-regulated (miR-200a, miR-141, miR-200b, miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b) miRNAs. The differential expression of six miRNAs was confirmed by quantitative RT-PCR. An in silico analysis identified 3851 mRNA transcripts as putative targets of the 22 miRNAs. Of these predicted targets, 673 were also differentially expressed in ectopic vs. eutopic endometrial tissue, as determined by microarray. Functional analysis suggested that the 673 miRNA targets constitute molecular pathways previously associated with endometriosis, including c-Jun, CREB-binding protein, protein kinase B (Akt), and cyclin D1 (CCND1) signaling. These pathways appeared to be regulated both transcriptionally as well as by miRNAs at posttranscriptional level. These data are a rich and novel resource for endometriosis and miRNA research and suggest that the 22 miRNAs and their cognate mRNA target sequences constitute pathways that promote endometriosis. Accordingly, miRNAs are potential therapeutic targets for treating this disease."					
+	unknown	unknown	2009	19074548	Unspecified	0	2239			
+hsa-miR-200b	289	endometriosis	down-regulated	microarray	" We assessed miRNA expression by microarray analysis in paired ectopic and eutopic endometrial tissues and identified 14 up-regulated (miR-145, miR-143, miR-99a, miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-125a, miR-223, miR-194, miR-365, miR-29c and miR-1) and eight down-regulated (miR-200a, miR-141, miR-200b, miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b) miRNAs. The differential expression of six miRNAs was confirmed by quantitative RT-PCR. An in silico analysis identified 3851 mRNA transcripts as putative targets of the 22 miRNAs. Of these predicted targets, 673 were also differentially expressed in ectopic vs. eutopic endometrial tissue, as determined by microarray. Functional analysis suggested that the 673 miRNA targets constitute molecular pathways previously associated with endometriosis, including c-Jun, CREB-binding protein, protein kinase B (Akt), and cyclin D1 (CCND1) signaling. These pathways appeared to be regulated both transcriptionally as well as by miRNAs at posttranscriptional level. These data are a rich and novel resource for endometriosis and miRNA research and suggest that the 22 miRNAs and their cognate mRNA target sequences constitute pathways that promote endometriosis. Accordingly, miRNAs are potential therapeutic targets for treating this disease."					
+	unknown	unknown	2009	19074548	Unspecified	0	2240			
+hsa-miR-200c	4451	kidney cancer	down-regulated	"northern blot, qRT-PCR etc"	"We observed that miR-141 and miR-200c were the most significantly down-regulated miRNAs in CCCs. Indeed, in all cases of CCC analysed, both miR-141 and miR-200c were down-regulated in comparison with normal kidney. Microarray data and quantitative RT-PCR showed that these two miRNAs were expressed concordantly. TargetScan algorithm revealed that ZFHX1B mRNA is a hypothetical target of both miR-141 and -200c. We established by quantitative RT-PCR that, in CCCs in which miR-141 and miR-200c were down-regulated, ZFHX1B, a transcriptional repressor for CDH1/E-cadherin, tended to be up-regulated. Furthermore, we found that overexpression of miR-141 and miR-200c caused down-regulation of ZFHX1B and up-regulation of E-cadherin in two renal carcinoma cell lines, ACHN and 786-O. On the basis of these findings, we suggest that down-regulation of miR-141 and miR-200c in CCCs might be involved in suppression of CDH1/E-cadherin transcription via up-regulation of ZFHX1B."					
+	unknown	unknown	2009	18925646	Unspecified	0	2241			
+hsa-miR-204	4947	cholangiocarcinoma	down-regulated	"northern blot, qRT-PCR etc"	The exogenous expression of mir-320 or mir-204 could negatively regulate Mcl-1 or Bcl-2 expression and facilitate chemotherapeutic drug-triggered apoptosis. 	"Mcl-1, BCL2"	unknown	2009	19070389	Causal
+hsa-miR-205	684	Hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	" Using univariate and multivariable statistical models we show that low levels of hsa-miR205 are significantly associated with loco-regional recurrence independent of disease severity at diagnosis and treatment. In addition, combined low levels of hsa-miR-205 and hsa-let-7d expression in HNSCC tumors are significantly associated with poor head and neck cancer survival Our results show that miRNA expression levels can be used as prognostic markers of head and neck cancer."	unknown	unknown	2009	19179615	Unspecified
+hsa-miR-205	1749	squamous carcinoma	up-regulated	"northern blot, qRT-PCR etc"	" Here we demonstrate not only that the lipid phosphatase SHIP2 is a target of miRNA-205 (miR-205) in epithelial cells, but, more importantly, that the corneal epithelial-specific miR-184 can interfere with the ability of miR-205 to suppress SHIP2 levels. This is the first example of a miRNA negatively regulating another to maintain levels of a target protein. Interfering with miR-205 function by using a synthetic antagomir, or by the ectopic expression of miR-184, leads to a coordinated damping of the Akt signaling pathway via SHIP2 induction. This was associated with a marked increase in keratinocyte apoptosis and cell death. Aggressive squamous cell carcinoma (SCC) cells exhibited elevated levels of miR-205. This was associated with a concomitant reduction in SHIP2 levels. Partial knockdown of endogenous miR-205 in SCCs markedly decreased phosphorylated Akt and phosphorylated BAD levels and increased apoptosis. We were able to increase SHIP2 levels in SCC cells after inhibition of miR-205. Therefore, miR-205 might have diagnostic value in determining the aggressivity of SCCs. Blockage of miR-205 activity with an antagomir or via ectopic expression of miR-184 could be novel therapeutic approaches for treating aggressive SCCs."					
+	SHIP2	unknown	2009	19033458	Causal	1	2244			
+hsa-miR-205	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	"northern blot, qRT-PCR etc"	"Approximately one third of all miRNA will exhibit substantial tissue specificity. Using a quantitative reverse transcription-polymerase chain reaction-based assay, we examined the expression of microRNA-205 (mir-205) across tissues and demonstrated that its expression is highly specific for squamous epithelium. We applied this assay to tissue samples, and we could detect metastatic HNSCC in each positive lymph node specimen, whereas benign specimens did not express this marker. When compared to metastases from other primary tumors, HNSCC-positive lymph nodes were distinguishable by the high expression of this marker. Using an in vitro lymphoid tissue model, we were able to detect as little as one squamous cell in a background of 1 million lymphocytes. By combining the sensitivity of quantitative reverse transcription-polymerase chain reaction with the specificity of mir-205 for squamous epithelium, we demonstrate a novel molecular marker for the detection of metastatic HNSCC."	unknown	unknown	2009	19043531	Unspecified
+hsa-miR-206	9080	Waldenstrom Macroglobulinemia (WM)	up-regulated	"Northern blot, qRT-PCR etc"	"Multi-level genetic characterization of Waldenstrom Macroglobulinemia (WM) is required to improve our understanding of the underlying molecular changes that lead to the initiation and progression of this disease. We performed microRNA-expression-profiling of bone marrow-derived CD19(+) WM cells, compared to their normal cellular counterparts and validated data by qRT-PCR. We identified a WM-specific microRNA signature characterized by increased expression of microRNA-363*/-206/-494/-155/-184/-542-3p; and decreased expression of microRNA-9* (ANOVA; P<0.01). We found that microRNA-155 regulates proliferation and growth of WM cells in vitro and in vivo, by inhibiting MAPK/ERK, PI3/AKT and NF-kB pathways. Potential microRNA-155 target genes were identified using gene-expression-profiling and included genes involved in cell cycle progression, adhesion, and migration. Importantly, increased expression of the 6 miRNAs significantly correlated with a poorer outcome predicted by the International-Prognostic-Staging-System for WM. We further demonstrated that therapeutic agents commonly used in WM (rituximab/perifosine/bortezomib) alter the levels of the major miRNAs identified, by inducing down-modulation of five increased miRNAs (all but miR-206) and up-modulation of patient-downexpressed miRNA-9*. These data indicate that microRNAs play a pivotal role in the biology of WM; represent important prognostic marker; and provide the basis for the development of new microRNA-based targeted therapies in WM."	unknown	"Fstl1,GJA1,Utrn"	2009	19074725	Unspecified
+hsa-miR-20a	289	endometriosis	down-regulated	microarray	" We assessed miRNA expression by microarray analysis in paired ectopic and eutopic endometrial tissues and identified 14 up-regulated (miR-145, miR-143, miR-99a, miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-125a, miR-223, miR-194, miR-365, miR-29c and miR-1) and eight down-regulated (miR-200a, miR-141, miR-200b, miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b) miRNAs. The differential expression of six miRNAs was confirmed by quantitative RT-PCR. An in silico analysis identified 3851 mRNA transcripts as putative targets of the 22 miRNAs. Of these predicted targets, 673 were also differentially expressed in ectopic vs. eutopic endometrial tissue, as determined by microarray. Functional analysis suggested that the 673 miRNA targets constitute molecular pathways previously associated with endometriosis, including c-Jun, CREB-binding protein, protein kinase B (Akt), and cyclin D1 (CCND1) signaling. These pathways appeared to be regulated both transcriptionally as well as by miRNAs at posttranscriptional level. These data are a rich and novel resource for endometriosis and miRNA research and suggest that the 22 miRNAs and their cognate mRNA target sequences constitute pathways that promote endometriosis. Accordingly, miRNAs are potential therapeutic targets for treating this disease."					
+	unknown	TGFBR2	2009	19074548	Unspecified	0	2247			
+hsa-miR-21	5517	gastric cancer (stomach cancer)	up-regulated	"northern blot, qRT-PCR etc"	" Using TaqMan quantitative real-time PCR, we confirmed that miR-21 was significantly overexpressed in human gastric cancer tissues and cell lines. Remarkably, miR-21 was also significantly overexpressed in H. pylori-infected gastric mucosa, implying that overexpression of miR-21 in gastric cancer may be due in part to H. pylori infection. More importantly, we showed that forced expression of miR-21 significantly enhanced cell proliferation and invasion in AGS cells, a human gastric cancer cell line, whereas knockdown of miR-21 by inhibitor caused a significant reduction in cell proliferation and a significant increase in apoptosis. Furthermore, we demonstrated that knockdown of miR-21 significantly decreased cell invasion and migration of AGS cells. Finally, we showed that RECK, a known tumor suppressor in gastric cancer, is a bona fide target of miR-21. Taken together, miR-21 may be important in the initiation and progression of gastric cancers as an oncomiR, likely through regulating RECK. Our findings suggest a potential regulatory pathway in which H. pylori infection upregulates expression of miR-21, which in turn downregulates RECK, and then leads to the development of gastric cancer."	RECK	"PTEN,TPM1"	2009	18794849	Causal
+hsa-miR-21	6000	heart failure	up-regulated	"northern blot, qRT-PCR etc"	"Here we show that microRNA-21 (miR-21, also known as Mirn21) regulates the ERK-MAP kinase signalling pathway in cardiac fibroblasts, which has impacts on global cardiac structure and function. miR-21 levels are increased selectively in fibroblasts of the failing heart, augmenting ERK-MAP kinase activity through inhibition of sprouty homologue 1 (Spry1). This mechanism regulates fibroblast survival and growth factor secretion, apparently controlling the extent of interstitial fibrosis and cardiac hypertrophy. In vivo silencing of miR-21 by a specific antagomir in a mouse pressure-overload-induced disease model reduces cardiac ERK-MAP kinase activity, inhibits interstitial fibrosis and attenuates cardiac dysfunction. These findings reveal that microRNAs can contribute to myocardial disease by an effect in cardiac fibroblasts. Our results validate miR-21 as a disease target in heart failure and establish the therapeutic efficacy of microRNA therapeutic intervention in a cardiovascular disease setting."	Spry1	"PTEN,TPM1"	2009	19043405	Causal
+hsa-miR-215	9256	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Here, we used array hybridization to find that p53 induces two additional, mutually related clusters of microRNAs, leading to the up-regulation of miR-192, miR-194, and miR-215. The same microRNAs were detected at high levels in normal colon tissue but were severely reduced in many colon cancer samples. On the other hand, miR-192 and its cousin miR-215 can each contribute to enhanced CDKN1A/p21 levels, colony suppression, cell cycle arrest, and cell detachment from a solid support. These effects were partially dependent on the presence of wild-type p53. Antagonizing endogenous miR-192 attenuated 5-fluorouracil-induced accumulation of p21. Hence, miR-192 and miR-215 can act as effectors as well as regulators of p53; they seem to suppress cancerogenesis through p21 accumulation and cell cycle arrest."	CDKN1A/p21	unknown	2009	19074875	Causal
+hsa-miR-221	1909	melanoma	up-regulated	"Northern blot, qRT-PCR etc"	"mir-221 can directly interact with c-kit 3'UTR and inhibit cKit protein translation. Observed inverse correlation of the c-kit and mir-221 expression in various melanocytic cells pointed to its involvement in regulation of cKit in melanoma. Moreover, a series of functional assays demonstrated that mir-221 could directly inhibit cKit, p27(Kip1) and, possibly, other pivotal proteins in melanoma. Collectively, the studies presented here indicate that mir-221 could be a novel therapeutic target for the treatment of cutaneous melanoma. They also suggest that regulation of expression and functional activity of identified up-regulated miRNAs should be further studied in the context of malignant melanoma."	"c-KIT, p27(Kip1)"	KIT	2009	19126397	Causal
+hsa-miR-222	4007	bladder cancer	up-regulated	"northern blot, qRT-PCR etc"	"A score based on the expression levels of the 51 miRNAs, identified muscle invasive tumors with high precision and sensitivity. MiRNAs showing high expression in muscle invasive tumors included miR-222 and miR-125b and in Ta tumors miR-10a. A miRNA signature for FGFR3 mutated cases was also identified with miR-7 as an important member. MiR-31, located in 9p21, was found to be homozygously deleted in 3 cases and miR-452 and miR-452* were shown to be over expressed in node positive tumors. In addition, these latter miRNAs were shown to be excellent prognostic markers for death by disease as outcome. The presented data shows that pathological subtypes of urothelial carcinoma show distinct miRNA gene expression signatures."	unknown	KIT	2009	19127597	Unspecified
+hsa-miR-223	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"northern blot, qRT-PCR etc"	"Aberrant expression of microRNAs has been recently associated with chronic lymphocytic leukemia (CLL) outcome. Although disease evolution can be predicted by several prognostic factors, a better outcome individualization in a given patient is still of utmost interest. Here, we showed that miR-29c and miR-223 expression levels decreased significantly with progression from Binet Stage A to C, were significantly lower in poor prognostic subgroups (defined by several prognostic factors) and could significantly predict treatment-free survival (TFS) and overall survival (OS). Furthermore, we developed a quantitative real-time PCR score combining miR-29c, miR-223, ZAP70 and LPL (from 0 to 4 poor prognostic markers) to stratify treatment and death risk in a cohort of 110 patients with a median follow-up of 72 months (range, 2-312). Patients with a score of 0/4, 1/4, 2/4, 3/4, and 4/4 had a median TFS of >312, 129, 80, 36 and 19 months, respectively (hazard ratio, HR0/4<1/4<2/4<3/4<4/4=17.00, P<0.0001). Patients with a score of 0-1/4, 2-3/4 and 4/4 had a median OS of >312, 183 and 106 months, respectively (HR0/4<1/4<2/4<3/4<4/4=13.69, P=0.0001). This score will help to identify, among the good and poor prognosis subgroups, patients who will need early therapy and thus will require a closer follow-up."					
+	unknown	NFIA	2009	19144983	Unspecified	2	2255			
+hsa-miR-223	289	endometriosis	up-regulated	microarray	" We assessed miRNA expression by microarray analysis in paired ectopic and eutopic endometrial tissues and identified 14 up-regulated (miR-145, miR-143, miR-99a, miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-125a, miR-223, miR-194, miR-365, miR-29c and miR-1) and eight down-regulated (miR-200a, miR-141, miR-200b, miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b) miRNAs. The differential expression of six miRNAs was confirmed by quantitative RT-PCR. An in silico analysis identified 3851 mRNA transcripts as putative targets of the 22 miRNAs. Of these predicted targets, 673 were also differentially expressed in ectopic vs. eutopic endometrial tissue, as determined by microarray. Functional analysis suggested that the 673 miRNA targets constitute molecular pathways previously associated with endometriosis, including c-Jun, CREB-binding protein, protein kinase B (Akt), and cyclin D1 (CCND1) signaling. These pathways appeared to be regulated both transcriptionally as well as by miRNAs at posttranscriptional level. These data are a rich and novel resource for endometriosis and miRNA research and suggest that the 22 miRNAs and their cognate mRNA target sequences constitute pathways that promote endometriosis. Accordingly, miRNAs are potential therapeutic targets for treating this disease."					
+	unknown	NFIA	2009	19074548	Unspecified	0	2256			
+hsa-miR-23b	769	neuroblastoma (NB)	up-regulated	"northern blot, qRT-PCR etc"	"Expression of the mu opioid receptor (MOR1) protein is regulated temporally and spatially. Although transcription of its gene has been studied extensively, regulation of MOR1 protein production at the level of translation is poorly understood. Using reporter assays, we found that the MOR1 3'-untranslated region (UTR) represses reporter expression at the post-transcriptional level. Suppression by the 3'-UTR of MOR1 is mediated through decreased mRNA association with polysomes, which requires microRNA23b (miRNA23b), a specific miRNA that is expressed in mouse brain and NS20Y mouse neuroblastoma cells. miRNA23b interacts with the MOR1 3'-UTR via a K box motif. By knocking down endogenous miRNA23b in NS20Y cells, we confirmed that miRNA23b inhibits MOR1 protein expression in vivo. This is the first study reporting a translationally repressive role for the MOR1 3'-UTR. We propose a mechanism in which miRNA23b blocks the association of MOR1 mRNA with polysomes, thereby arresting its translation and suppressing the production of MOR1 protein."	MOR1	Notch1	2009	18716031	Unspecified
+hsa-miR-27a	5517	gastric cancer (stomach cancer)	up-regulated	"Northern blot, qRT-PCR etc"	"miR-27a is up-regulated in human gastric adenocarcinoma. Suppression of miR-27a inhibits gastric cancer cell growth. Subsequently, prohibitin is identified as a potential miR-27a target, combining bioinformatics and microarray analysis. EGFP report experiment also confirms that the 3' untranslated region (3'UTR) of prohibitin carries the directly binding site of miR-27a. After knockdown of miR-27a in gastric cancer cells, mRNA level and protein level of prohibitin are both elevated. Down-regulation of prohibitin by miR-27a may explain why suppression of miR-27a can inhibit gastric cancer cell growth, further supporting that miR-27a functions as an oncogene."	prohibitin	unknown	2009	18789835	Causal
+hsa-miR-298	10652	Alzheimer's disease	down-regulated	"northern blot, qRT-PCR etc"	"Intriguingly, previous post-mortem analyses showed higher beta-amyloid precursor protein-converting enzyme (BACE) protein, but not mRNA, levels in the brain of patients that suffered from Alzheimer disease (AD). Here we also observed a loss of correlation between BACE1 mRNA and protein levels in the hippocampus of a mouse model of AD. Consistent with an impairment of miRNA-mediated regulation of BACE1 expression, these findings prompted us to investigate the regulatory role of the BACE1 3'-UTR element and the possible involvement of specific miRNAs in cultured neuronal (N2a) and fibroblastic (NIH 3T3) cells. Through various experimental approaches, we validated computational predictions and demonstrated that miR-298 and miR-328 recognize specific binding sites in the 3'-UTR of BACE1 mRNA and exert regulatory effects on BACE1 protein expression in cultured neuronal cells. Our results may provide the molecular basis underlying BACE1 deregulation in AD and offer new perspectives on the etiology of this neurological disorder."					
+	BACE1	unknown	2009	18986979	Causal	1	2259			
+hsa-miR-29b	9119	acute myeloid leukemia (AML)	down-regulated	"Northern blot, qRT-PCR etc"	"Aberrant DNA hypermethylation contributes to myeloid leukemogenesis by silencing structurally normal genes involved in hematopoiesis. In the current study, we showed that enforced expression of miR-29b in acute myeloid leukemia (AML) cells resulted in marked reduction of the expression of DNA methyltransferases DNMT1, DNMT3A and 3B at both RNA and protein levels. This in turn led to decrease in global DNA methylation and re-expression of p15(INK4b) and ESR1 via promoter DNA hypomethylation. While down-regulation of DNMT3A and 3B was the result of a direct interaction of miR-29b with the 3' untranslated regions (UTR) of these genes, no predicted miR-29b interaction sites were found in the DNMT1 3'UTR. Further experiments revealed that miR-29b down-regulates DNMT1 indirectly by targeting Sp1, a transactivator of the DNMT1 gene. Altogether, these data provide novel functional links between miRNAs and aberrant DNA hypermethylation in AML and suggest a potentially therapeutic use of synthetic miR-29b oligonucleotides as effective hypomethylating compounds."	"DNMT3A, DNMT3B, Sp1"	unknown	2009	19211935	Causal
+hsa-miR-29c	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"northern blot, qRT-PCR etc"	"Aberrant expression of microRNAs has been recently associated with chronic lymphocytic leukemia (CLL) outcome. Although disease evolution can be predicted by several prognostic factors, a better outcome individualization in a given patient is still of utmost interest. Here, we showed that miR-29c and miR-223 expression levels decreased significantly with progression from Binet Stage A to C, were significantly lower in poor prognostic subgroups (defined by several prognostic factors) and could significantly predict treatment-free survival (TFS) and overall survival (OS). Furthermore, we developed a quantitative real-time PCR score combining miR-29c, miR-223, ZAP70 and LPL (from 0 to 4 poor prognostic markers) to stratify treatment and death risk in a cohort of 110 patients with a median follow-up of 72 months (range, 2-312). Patients with a score of 0/4, 1/4, 2/4, 3/4, and 4/4 had a median TFS of >312, 129, 80, 36 and 19 months, respectively (hazard ratio, HR0/4<1/4<2/4<3/4<4/4=17.00, P<0.0001). Patients with a score of 0-1/4, 2-3/4 and 4/4 had a median OS of >312, 183 and 106 months, respectively (HR0/4<1/4<2/4<3/4<4/4=13.69, P=0.0001). This score will help to identify, among the good and poor prognosis subgroups, patients who will need early therapy and thus will require a closer follow-up."					
+	unknown	unknown	2009	19144983	Unspecified	2	2261			
+hsa-miR-29c	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	"Nine microRNAs were found by SAM to be upregulated or downregulated in tumor tissue including mir-21, let-7, 18, 29c, 142-3p, 155, 146b (overexpressed) and 494 (underexpressed). Mir-21 was validated by qRT-PCR. Functional validation by growth assays was performed, further validating mir-21. Transfection of mir-21 into JHU-011 and JHU-012 cell lines showed a 39% increase in cell growth at 72 hr relative to controls (p < 0.05). Transfection of the inhibitor into JHU-O12 cell lines showed a 92% decrease in cell growth relative to controls at 72 hr (p < 0.05). In addition, flow cytometry analysis of JHU-012 cells 48 hr after mir-21 inhibitor transfection showed a statistically significant increase in cytochrome c release and increased apoptosis. These differentially expressed microRNAs may be of interest as potential novel oncogenes and tumor suppressor genes in HNSCC. Mir-21 is a putative oncogenic microRNA in head and neck cancer."	unknown	unknown	2008	18798260	Unspecified
+hsa-miR-29c	289	endometriosis	up-regulated	microarray	" We assessed miRNA expression by microarray analysis in paired ectopic and eutopic endometrial tissues and identified 14 up-regulated (miR-145, miR-143, miR-99a, miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-125a, miR-223, miR-194, miR-365, miR-29c and miR-1) and eight down-regulated (miR-200a, miR-141, miR-200b, miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b) miRNAs. The differential expression of six miRNAs was confirmed by quantitative RT-PCR. An in silico analysis identified 3851 mRNA transcripts as putative targets of the 22 miRNAs. Of these predicted targets, 673 were also differentially expressed in ectopic vs. eutopic endometrial tissue, as determined by microarray. Functional analysis suggested that the 673 miRNA targets constitute molecular pathways previously associated with endometriosis, including c-Jun, CREB-binding protein, protein kinase B (Akt), and cyclin D1 (CCND1) signaling. These pathways appeared to be regulated both transcriptionally as well as by miRNAs at posttranscriptional level. These data are a rich and novel resource for endometriosis and miRNA research and suggest that the 22 miRNAs and their cognate mRNA target sequences constitute pathways that promote endometriosis. Accordingly, miRNAs are potential therapeutic targets for treating this disease."					
+	unknown	unknown	2009	19074548	Unspecified	0	2263			
+hsa-miR-31	4007	bladder cancer	down-regulated	microarray	"A score based on the expression levels of the 51 miRNAs, identified muscle invasive tumors with high precision and sensitivity. MiRNAs showing high expression in muscle invasive tumors included miR-222 and miR-125b and in Ta tumors miR-10a. A miRNA signature for FGFR3 mutated cases was also identified with miR-7 as an important member. MiR-31, located in 9p21, was found to be homozygously deleted in 3 cases and miR-452 and miR-452* were shown to be over expressed in node positive tumors. In addition, these latter miRNAs were shown to be excellent prognostic markers for death by disease as outcome. The presented data shows that pathological subtypes of urothelial carcinoma show distinct miRNA gene expression signatures."	unknown	unknown	2009	19127597	Unspecified
+hsa-miR-320	4947	cholangiocarcinoma	down-regulated	"northern blot, qRT-PCR etc"	The exogenous expression of mir-320 or mir-204 could negatively regulate Mcl-1 or Bcl-2 expression and facilitate chemotherapeutic drug-triggered apoptosis. 	"Mcl-1, BCL2"	unknown	2009	19070389	Causal
+hsa-miR-320	9119	acute myeloid leukemia (AML)	down-regulated	"northern blot, qRT-PCR etc"	" we have identified a panel of TPA-induced miRNAs that are expressed coincident with HL-60 stereotypic morphological changes characteristic of monocytic differentiation. The transferrin receptor 1(TfR-1; CD71), whose surface expression is downregulated during TPA-mediated HL-60 cell differentiation, has been identified as a target of the TPA-induced miRNA miR-320. Cell culture experiments indicate that enforced miR-320 expression can suppress TfR-1 expression and cell proliferation. CONCLUSION: TPA induces the expression of several miRNAs in HL-60 cells, one such miRNA (miR-320) contributes to downregulation of TfR-1 surface expression characteristically seen during HL-60 monocytic differentiation. Moreover, TfR-1-targeting miRNAs, such as miR-320, may have potential as novel therapeutic agents for cancer due to their inhibitory effects on cell proliferation."	TfR-1	unknown	2009	19135902	Causal
+hsa-miR-328	10652	Alzheimer's disease	down-regulated	"northern blot, qRT-PCR etc"	"Intriguingly, previous post-mortem analyses showed higher beta-amyloid precursor protein-converting enzyme (BACE) protein, but not mRNA, levels in the brain of patients that suffered from Alzheimer disease (AD). Here we also observed a loss of correlation between BACE1 mRNA and protein levels in the hippocampus of a mouse model of AD. Consistent with an impairment of miRNA-mediated regulation of BACE1 expression, these findings prompted us to investigate the regulatory role of the BACE1 3'-UTR element and the possible involvement of specific miRNAs in cultured neuronal (N2a) and fibroblastic (NIH 3T3) cells. Through various experimental approaches, we validated computational predictions and demonstrated that miR-298 and miR-328 recognize specific binding sites in the 3'-UTR of BACE1 mRNA and exert regulatory effects on BACE1 protein expression in cultured neuronal cells. Our results may provide the molecular basis underlying BACE1 deregulation in AD and offer new perspectives on the etiology of this neurological disorder."					
+	BACE1	unknown	2009	18986979	Causal	1	2267			
+hsa-miR-34a	1909	melanoma	down-regulated	"northern blot, qRT-PCR etc"	"miR-34a is actively expressed in melanocytes but not in uveal melanoma cells based on Northern blot analysis. Transfection of miR-34a into uveal melanoma cells led to a significant decrease in cell growth and migration. Following identification of two putative miR-34a binding sites within the 3' UTR of the human c-Met mRNA, miR-34a was shown to suppress luciferase activity using HEK293 cells with a luciferase reporter construct containing the binding sites. miR-34a was confirmed to downregulate the expression of c-Met protein by Western blotting and immunofluorescence. Furthermore, introduction of miR-34a also downregulated phosphorylated Akt and cell cycle-related proteins. CONCLUSIONS. Our results demonstrate that miR-34a acts as a tumor suppressor in uveal melanoma cell proliferation and migration through downregulation of c-Met."	c-Met	E2F3	2008	19029026	Causal
+hsa-miR-34c	289	endometriosis	down-regulated	microarray	" We assessed miRNA expression by microarray analysis in paired ectopic and eutopic endometrial tissues and identified 14 up-regulated (miR-145, miR-143, miR-99a, miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-125a, miR-223, miR-194, miR-365, miR-29c and miR-1) and eight down-regulated (miR-200a, miR-141, miR-200b, miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b) miRNAs. The differential expression of six miRNAs was confirmed by quantitative RT-PCR. An in silico analysis identified 3851 mRNA transcripts as putative targets of the 22 miRNAs. Of these predicted targets, 673 were also differentially expressed in ectopic vs. eutopic endometrial tissue, as determined by microarray. Functional analysis suggested that the 673 miRNA targets constitute molecular pathways previously associated with endometriosis, including c-Jun, CREB-binding protein, protein kinase B (Akt), and cyclin D1 (CCND1) signaling. These pathways appeared to be regulated both transcriptionally as well as by miRNAs at posttranscriptional level. These data are a rich and novel resource for endometriosis and miRNA research and suggest that the 22 miRNAs and their cognate mRNA target sequences constitute pathways that promote endometriosis. Accordingly, miRNAs are potential therapeutic targets for treating this disease."					
+	unknown	unknown	2009	19074548	Unspecified	0	2270			
+hsa-miR-363*	9080	Waldenstrom Macroglobulinemia (WM)	up-regulated	"Northern blot, qRT-PCR etc"	"Multi-level genetic characterization of Waldenstrom Macroglobulinemia (WM) is required to improve our understanding of the underlying molecular changes that lead to the initiation and progression of this disease. We performed microRNA-expression-profiling of bone marrow-derived CD19(+) WM cells, compared to their normal cellular counterparts and validated data by qRT-PCR. We identified a WM-specific microRNA signature characterized by increased expression of microRNA-363*/-206/-494/-155/-184/-542-3p; and decreased expression of microRNA-9* (ANOVA; P<0.01). We found that microRNA-155 regulates proliferation and growth of WM cells in vitro and in vivo, by inhibiting MAPK/ERK, PI3/AKT and NF-kB pathways. Potential microRNA-155 target genes were identified using gene-expression-profiling and included genes involved in cell cycle progression, adhesion, and migration. Importantly, increased expression of the 6 miRNAs significantly correlated with a poorer outcome predicted by the International-Prognostic-Staging-System for WM. We further demonstrated that therapeutic agents commonly used in WM (rituximab/perifosine/bortezomib) alter the levels of the major miRNAs identified, by inducing down-modulation of five increased miRNAs (all but miR-206) and up-modulation of patient-downexpressed miRNA-9*. These data indicate that microRNAs play a pivotal role in the biology of WM; represent important prognostic marker; and provide the basis for the development of new microRNA-based targeted therapies in WM."	unknown	unknown	2009	19074725	Unspecified
+hsa-miR-365	289	endometriosis	up-regulated	microarray	" We assessed miRNA expression by microarray analysis in paired ectopic and eutopic endometrial tissues and identified 14 up-regulated (miR-145, miR-143, miR-99a, miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-125a, miR-223, miR-194, miR-365, miR-29c and miR-1) and eight down-regulated (miR-200a, miR-141, miR-200b, miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b) miRNAs. The differential expression of six miRNAs was confirmed by quantitative RT-PCR. An in silico analysis identified 3851 mRNA transcripts as putative targets of the 22 miRNAs. Of these predicted targets, 673 were also differentially expressed in ectopic vs. eutopic endometrial tissue, as determined by microarray. Functional analysis suggested that the 673 miRNA targets constitute molecular pathways previously associated with endometriosis, including c-Jun, CREB-binding protein, protein kinase B (Akt), and cyclin D1 (CCND1) signaling. These pathways appeared to be regulated both transcriptionally as well as by miRNAs at posttranscriptional level. These data are a rich and novel resource for endometriosis and miRNA research and suggest that the 22 miRNAs and their cognate mRNA target sequences constitute pathways that promote endometriosis. Accordingly, miRNAs are potential therapeutic targets for treating this disease."					
+	unknown	unknown	2009	19074548	Unspecified	0	2272			
+hsa-miR-377	2370	diabetic nephropathy	up-regulated	"Northern blot, qRT-PCR etc"	"Here, we exposed cultured human and mouse mesangial cells to high glucose and transforming growth factor-beta to simulate the diabetic milieu. In these conditions in vitro, as well as in mouse diabetic nephropathy models in vivo, microRNA-377 was consistently up-regulated relative to controls. Through a combination of computational and biological approaches, we identified relevant miR-377 target genes. Although fibronectin was induced by miR-377, it was not a direct target of miR-377. However, miR-377 led to reduced expressions of p21-activated kinase and superoxide dismutase, which enhanced fibronectin protein production. Thus, overexpression of miR-377 in diabetic nephropathy indirectly leads to increased fibronectin protein production; as such, miR-377 can have a critical role in the pathophysiology of this prevalent human disease."	unknown	unknown	2009	18716028	Causal
+hsa-miR-424	289	endometriosis	down-regulated	microarray	" We assessed miRNA expression by microarray analysis in paired ectopic and eutopic endometrial tissues and identified 14 up-regulated (miR-145, miR-143, miR-99a, miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-125a, miR-223, miR-194, miR-365, miR-29c and miR-1) and eight down-regulated (miR-200a, miR-141, miR-200b, miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b) miRNAs. The differential expression of six miRNAs was confirmed by quantitative RT-PCR. An in silico analysis identified 3851 mRNA transcripts as putative targets of the 22 miRNAs. Of these predicted targets, 673 were also differentially expressed in ectopic vs. eutopic endometrial tissue, as determined by microarray. Functional analysis suggested that the 673 miRNA targets constitute molecular pathways previously associated with endometriosis, including c-Jun, CREB-binding protein, protein kinase B (Akt), and cyclin D1 (CCND1) signaling. These pathways appeared to be regulated both transcriptionally as well as by miRNAs at posttranscriptional level. These data are a rich and novel resource for endometriosis and miRNA research and suggest that the 22 miRNAs and their cognate mRNA target sequences constitute pathways that promote endometriosis. Accordingly, miRNAs are potential therapeutic targets for treating this disease."					
+	unknown	unknown	2009	19074548	Unspecified	0	2274			
+hsa-miR-452	4007	bladder cancer	up-regulated	microarray	"A score based on the expression levels of the 51 miRNAs, identified muscle invasive tumors with high precision and sensitivity. MiRNAs showing high expression in muscle invasive tumors included miR-222 and miR-125b and in Ta tumors miR-10a. A miRNA signature for FGFR3 mutated cases was also identified with miR-7 as an important member. MiR-31, located in 9p21, was found to be homozygously deleted in 3 cases and miR-452 and miR-452* were shown to be over expressed in node positive tumors. In addition, these latter miRNAs were shown to be excellent prognostic markers for death by disease as outcome. The presented data shows that pathological subtypes of urothelial carcinoma show distinct miRNA gene expression signatures."	unknown	unknown	2009	19127597	Unspecified
+hsa-miR-452*	4007	bladder cancer	up-regulated	microarray	"A score based on the expression levels of the 51 miRNAs, identified muscle invasive tumors with high precision and sensitivity. MiRNAs showing high expression in muscle invasive tumors included miR-222 and miR-125b and in Ta tumors miR-10a. A miRNA signature for FGFR3 mutated cases was also identified with miR-7 as an important member. MiR-31, located in 9p21, was found to be homozygously deleted in 3 cases and miR-452 and miR-452* were shown to be over expressed in node positive tumors. In addition, these latter miRNAs were shown to be excellent prognostic markers for death by disease as outcome. The presented data shows that pathological subtypes of urothelial carcinoma show distinct miRNA gene expression signatures."	unknown	unknown	2009	19127597	Unspecified
+hsa-miR-494	9080	Waldenstrom Macroglobulinemia (WM)	up-regulated	"Northern blot, qRT-PCR etc"	"Multi-level genetic characterization of Waldenstrom Macroglobulinemia (WM) is required to improve our understanding of the underlying molecular changes that lead to the initiation and progression of this disease. We performed microRNA-expression-profiling of bone marrow-derived CD19(+) WM cells, compared to their normal cellular counterparts and validated data by qRT-PCR. We identified a WM-specific microRNA signature characterized by increased expression of microRNA-363*/-206/-494/-155/-184/-542-3p; and decreased expression of microRNA-9* (ANOVA; P<0.01). We found that microRNA-155 regulates proliferation and growth of WM cells in vitro and in vivo, by inhibiting MAPK/ERK, PI3/AKT and NF-kB pathways. Potential microRNA-155 target genes were identified using gene-expression-profiling and included genes involved in cell cycle progression, adhesion, and migration. Importantly, increased expression of the 6 miRNAs significantly correlated with a poorer outcome predicted by the International-Prognostic-Staging-System for WM. We further demonstrated that therapeutic agents commonly used in WM (rituximab/perifosine/bortezomib) alter the levels of the major miRNAs identified, by inducing down-modulation of five increased miRNAs (all but miR-206) and up-modulation of patient-downexpressed miRNA-9*. These data indicate that microRNAs play a pivotal role in the biology of WM; represent important prognostic marker; and provide the basis for the development of new microRNA-based targeted therapies in WM."	unknown	unknown	2009	19074725	Unspecified
+hsa-miR-494	5520	head and neck squamous cell carcinoma (HNSCC)	down-regulated	microarray	"Nine microRNAs were found by SAM to be upregulated or downregulated in tumor tissue including mir-21, let-7, 18, 29c, 142-3p, 155, 146b (overexpressed) and 494 (underexpressed). Mir-21 was validated by qRT-PCR. Functional validation by growth assays was performed, further validating mir-21. Transfection of mir-21 into JHU-011 and JHU-012 cell lines showed a 39% increase in cell growth at 72 hr relative to controls (p < 0.05). Transfection of the inhibitor into JHU-O12 cell lines showed a 92% decrease in cell growth relative to controls at 72 hr (p < 0.05). In addition, flow cytometry analysis of JHU-012 cells 48 hr after mir-21 inhibitor transfection showed a statistically significant increase in cytochrome c release and increased apoptosis. These differentially expressed microRNAs may be of interest as potential novel oncogenes and tumor suppressor genes in HNSCC. Mir-21 is a putative oncogenic microRNA in head and neck cancer."	unknown	unknown	2008	18798260	Unspecified
+hsa-miR-542-3p	9080	Waldenstrom Macroglobulinemia (WM)	up-regulated	"Northern blot, qRT-PCR etc"	"Multi-level genetic characterization of Waldenstrom Macroglobulinemia (WM) is required to improve our understanding of the underlying molecular changes that lead to the initiation and progression of this disease. We performed microRNA-expression-profiling of bone marrow-derived CD19(+) WM cells, compared to their normal cellular counterparts and validated data by qRT-PCR. We identified a WM-specific microRNA signature characterized by increased expression of microRNA-363*/-206/-494/-155/-184/-542-3p; and decreased expression of microRNA-9* (ANOVA; P<0.01). We found that microRNA-155 regulates proliferation and growth of WM cells in vitro and in vivo, by inhibiting MAPK/ERK, PI3/AKT and NF-kB pathways. Potential microRNA-155 target genes were identified using gene-expression-profiling and included genes involved in cell cycle progression, adhesion, and migration. Importantly, increased expression of the 6 miRNAs significantly correlated with a poorer outcome predicted by the International-Prognostic-Staging-System for WM. We further demonstrated that therapeutic agents commonly used in WM (rituximab/perifosine/bortezomib) alter the levels of the major miRNAs identified, by inducing down-modulation of five increased miRNAs (all but miR-206) and up-modulation of patient-downexpressed miRNA-9*. These data indicate that microRNAs play a pivotal role in the biology of WM; represent important prognostic marker; and provide the basis for the development of new microRNA-based targeted therapies in WM."	unknown	unknown	2009	19074725	Unspecified
+hsa-miR-7	4007	bladder cancer	up-regulated	microarray	"A score based on the expression levels of the 51 miRNAs, identified muscle invasive tumors with high precision and sensitivity. MiRNAs showing high expression in muscle invasive tumors included miR-222 and miR-125b and in Ta tumors miR-10a. A miRNA signature for FGFR3 mutated cases was also identified with miR-7 as an important member. MiR-31, located in 9p21, was found to be homozygously deleted in 3 cases and miR-452 and miR-452* were shown to be over expressed in node positive tumors. In addition, these latter miRNAs were shown to be excellent prognostic markers for death by disease as outcome. The presented data shows that pathological subtypes of urothelial carcinoma show distinct miRNA gene expression signatures."	unknown	unknown	2009	19127597	Unspecified
+hsa-miR-9	3858	medulloblastoma	down-regulated	"northern blot, qRT-PCR etc"	"MicroRNAs expression profile clearly differentiates medulloblastoma from either adult or fetal normal cerebellar tissues. Only a few microRNAs displayed upregulated expression, while most of them were downregulated in tumor samples, suggesting a tumor growth-inhibitory function. This property has been addressed for miR-9 and miR-125a, whose rescued expression promoted medulloblastoma cell growth arrest and apoptosis while targeting the proproliferative truncated TrkC isoform. In conclusion, misregulated microRNA expression profiles characterize human medulloblastomas, and may provide potential targets for novel therapeutic strategies."	TrkC	unknown	2009	18973228	Causal
+hsa-miR-9	12858	Huntington's disease (HD)	down-regulated	"northern blot, qRT-PCR etc"	"The transcription factor REST silences neuronal gene expression in non-neuronal cells. In neurons, the protein is sequestered in the cytoplasm in part through binding to huntingtin. Polyglutamine expansions in huntingtin, which causes Huntington's disease (HD), abrogates REST-huntingtin binding. Consequently, REST translocates to the nucleus, occupies RE1 repressor sequences and decreases neuronal gene expression. In this work, we found that levels of several microRNAs (miRNAs) with upstream RE1 sites are decreased in HD patient cortices relative to healthy controls. Interestingly, one of these, the bifunctional brain enriched miR-9/miR-9*, targets two components of the REST complex: miR-9 targets REST and miR-9* targets CoREST. These data provide evidence for a double negative feedback loop between the REST silencing complex and the miRNAs it regulates."	REST	unknown	2009	19118166	Causal
+hsa-miR-9*	9080	Waldenstrom Macroglobulinemia (WM)	down-regulated	"Northern blot, qRT-PCR etc"	"Multi-level genetic characterization of Waldenstrom Macroglobulinemia (WM) is required to improve our understanding of the underlying molecular changes that lead to the initiation and progression of this disease. We performed microRNA-expression-profiling of bone marrow-derived CD19(+) WM cells, compared to their normal cellular counterparts and validated data by qRT-PCR. We identified a WM-specific microRNA signature characterized by increased expression of microRNA-363*/-206/-494/-155/-184/-542-3p; and decreased expression of microRNA-9* (ANOVA; P<0.01). We found that microRNA-155 regulates proliferation and growth of WM cells in vitro and in vivo, by inhibiting MAPK/ERK, PI3/AKT and NF-kB pathways. Potential microRNA-155 target genes were identified using gene-expression-profiling and included genes involved in cell cycle progression, adhesion, and migration. Importantly, increased expression of the 6 miRNAs significantly correlated with a poorer outcome predicted by the International-Prognostic-Staging-System for WM. We further demonstrated that therapeutic agents commonly used in WM (rituximab/perifosine/bortezomib) alter the levels of the major miRNAs identified, by inducing down-modulation of five increased miRNAs (all but miR-206) and up-modulation of patient-downexpressed miRNA-9*. These data indicate that microRNAs play a pivotal role in the biology of WM; represent important prognostic marker; and provide the basis for the development of new microRNA-based targeted therapies in WM."	unknown	unknown	2009	19074725	Unspecified
+hsa-miR-9*	12858	Huntington's disease (HD)	down-regulated	"northern blot, qRT-PCR etc"	"The transcription factor REST silences neuronal gene expression in non-neuronal cells. In neurons, the protein is sequestered in the cytoplasm in part through binding to huntingtin. Polyglutamine expansions in huntingtin, which causes Huntington's disease (HD), abrogates REST-huntingtin binding. Consequently, REST translocates to the nucleus, occupies RE1 repressor sequences and decreases neuronal gene expression. In this work, we found that levels of several microRNAs (miRNAs) with upstream RE1 sites are decreased in HD patient cortices relative to healthy controls. Interestingly, one of these, the bifunctional brain enriched miR-9/miR-9*, targets two components of the REST complex: miR-9 targets REST and miR-9* targets CoREST. These data provide evidence for a double negative feedback loop between the REST silencing complex and the miRNAs it regulates."	CoREST	unknown	2009	19118166	Causal
+hsa-miR-92	3858	medulloblastoma 	up-regulated	"northern blot, qRT-PCR etc"	"Analysis of human MBs demonstrated that 3 miR-17 approximately 92 cluster miRNAs (miR-92, miR-19a, and miR-20) were also overexpressed in human MBs with a constitutively activated Sonic Hedgehog (SHH) signaling pathway, but not in other forms of the disease. To test whether the miR-17 approximately 92 cluster could promote MB formation, we enforced expression of these miRNAs in GNPs isolated from cerebella of postnatal (P) day P6 Ink4c-/-; Ptch1+/- mice. These, but not similarly engineered cells from Ink4c-/-; p53-/- mice, formed MBs in orthotopic transplants with complete penetrance. Interestingly, orthotopic mouse tumors ectopically expressing miR-17 approximately 92 lost expression of the wild-type Ptch1 allele. Our findings suggest a functional collaboration between the miR-17 approximately 92 cluster and the SHH signaling pathway in the development of MBs in mouse and man."	unknown	unknown	2009	19196975	Causal
+hsa-miR-99a	289	endometriosis	up-regulated	microarray	" We assessed miRNA expression by microarray analysis in paired ectopic and eutopic endometrial tissues and identified 14 up-regulated (miR-145, miR-143, miR-99a, miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-125a, miR-223, miR-194, miR-365, miR-29c and miR-1) and eight down-regulated (miR-200a, miR-141, miR-200b, miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b) miRNAs. The differential expression of six miRNAs was confirmed by quantitative RT-PCR. An in silico analysis identified 3851 mRNA transcripts as putative targets of the 22 miRNAs. Of these predicted targets, 673 were also differentially expressed in ectopic vs. eutopic endometrial tissue, as determined by microarray. Functional analysis suggested that the 673 miRNA targets constitute molecular pathways previously associated with endometriosis, including c-Jun, CREB-binding protein, protein kinase B (Akt), and cyclin D1 (CCND1) signaling. These pathways appeared to be regulated both transcriptionally as well as by miRNAs at posttranscriptional level. These data are a rich and novel resource for endometriosis and miRNA research and suggest that the 22 miRNAs and their cognate mRNA target sequences constitute pathways that promote endometriosis. Accordingly, miRNAs are potential therapeutic targets for treating this disease."					
+	unknown	unknown	2009	19074548	Unspecified	0	2289			
+hsa-miR-99b	289	endometriosis	up-regulated	microarray	" We assessed miRNA expression by microarray analysis in paired ectopic and eutopic endometrial tissues and identified 14 up-regulated (miR-145, miR-143, miR-99a, miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-125a, miR-223, miR-194, miR-365, miR-29c and miR-1) and eight down-regulated (miR-200a, miR-141, miR-200b, miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b) miRNAs. The differential expression of six miRNAs was confirmed by quantitative RT-PCR. An in silico analysis identified 3851 mRNA transcripts as putative targets of the 22 miRNAs. Of these predicted targets, 673 were also differentially expressed in ectopic vs. eutopic endometrial tissue, as determined by microarray. Functional analysis suggested that the 673 miRNA targets constitute molecular pathways previously associated with endometriosis, including c-Jun, CREB-binding protein, protein kinase B (Akt), and cyclin D1 (CCND1) signaling. These pathways appeared to be regulated both transcriptionally as well as by miRNAs at posttranscriptional level. These data are a rich and novel resource for endometriosis and miRNA research and suggest that the 22 miRNAs and their cognate mRNA target sequences constitute pathways that promote endometriosis. Accordingly, miRNAs are potential therapeutic targets for treating this disease."					
+	unknown	unknown	2009	19074548	Unspecified	0	2290			
+hsa-miR-328	12236	primary biliary cirrhosis (PBC)	up-regulated	"northern blot, qRT-PCR etc"	"We compared the expression of 377 miRNAs in explanted livers form subjects with PBC versus controls with normal liver histology. A total of 35 independent miRNAs were found to be differentially expressed in PBC (p<0.001). Quantitative PCR was employed to validate down-regulation of microRNA-122a (miR-122a) and miR-26a and the increased expression of miR-328 and miR-299-5p. The predicted targets of these miRNAs are known to affect cell proliferation, apoptosis, inflammation, oxidative stress, and metabolism. Our data are the first to demonstrate that PBC is characterized by altered expression of hepatic miRNA; however additional studies are required to demonstrate a causal link between those miRNA and the development of PBC."	unknown	unknown	2009	19345069	unspecified
+hsa-miR-532-5p	1909	malignant melanoma	up-regulated	"northern blot, qRT-PCR etc"	"RUNX3 is a known tumor suppressor gene in several carcinomas.  RUNX3 mRNA expression was down-regulated in 11 of 11 (100%) metastatic melanoma lines relative to normal melanocytes (P < 0.001). Among 123 primary and metastatic melanoma tumors and 12 normal skin samples, RUNX3 expression was significantly down-regulated in primary melanomas (n = 82; P = 0.02) and in melanoma metastasis (n = 41; P < 0.0001) versus normal skin (n = 12). This suggested that RUNX3 down-regulation may play a role in the development and progression of melanoma. RUNX3 promoter region hypermethylation was assessed as a possible regulator of RUNX3 expression using methylation-specific PCR. Assessment of RUNX3 promoter region methylation showed that only 5 of 17 (29%) melanoma lines, 2 of 52 (4%) primary melanomas, and 5 of 30 (17%) metastatic melanomas had hypermethylation of the promoter region. A microRNA (miR-532-5p) was identified as a target of RUNX3 mRNA sequences. miR-532-5p expression was shown to be significantly up-regulated in melanoma lines and metastatic melanoma tumors relative to normal melanocytes and primary melanomas, respectively. To investigate the relation between RUNX3 and miR-532-5p, anti-miR-532-5p was transfected into melanoma lines. Inhibition of miR-532-5p up-regulated both RUNX3 mRNA and protein expression.CONCLUSIONS: RUNX3 is down-regulated during melanoma progression and miR-532-5p is a regulatory factor of RUNX3 expression."	RUNX3	unknown	2009	19336521	causal
+hsa-let-7d	5520	head and neck squamous cell carcinoma (HNSCC)	down-regulated	"northern blot, qRT-PCR etc"	"Using univariate and multivariable statistical models we show that low levels of hsa-miR205 are significantly associated with loco-regional recurrence independent of disease severity at diagnosis and treatment. In addition, combined low levels of hsa-miR-205 and hsa-let-7d expression in HNSCC tumors are significantly associated with poor head and neck cancer survival Our results show that miRNA expression levels can be used as prognostic markers of head and neck cancer."	unknown	unknown	2009	19179615	unspecified
+hsa-miR-101	4007	bladder cancer	down-regulated	"northern blot, qRT-PCR etc"	"The Polycomb Repressive Complex 2 (PRC2) mediates epigenetic gene silencing by trimethylating histone H3 lysine 27 (H3K27me3) and is known to aberrantly silence tumor suppressor genes in cancer. EZH2, the catalytic subunit of PRC2, enhances tumorigenesis and is commonly overexpressed in several types of cancer. Our microRNA profiling of bladder transitional cell carcinoma (TCC) patient samples revealed that microRNA-101 (miR-101) is down-regulated in TCC, and we showed that miR-101 inhibits cell proliferation and colony formation in TCC cell lines. Furthermore, our results confirm that miR-101 directly represses EZH2 and stable EZH2 knockdowns in TCC cell lines create a similar growth suppressive phenotype. This suggests that abnormal down-regulation of miR-101 could lead to the overexpression of EZH2 frequently seen in cancer. We conclude that miR-101 may be a potent tumor suppressor by altering global chromatin structure through repression of EZH2."	EZH2	"Enx-1,MYCN"	2009	19258506	causal
+hsa-miR-101	10286	prostate cancer	down-regulated	"northern blot, qRT-PCR etc"	"Enhancer of zeste homolog 2 (EZH2) is a mammalian histone methyltransferase that contributes to the epigenetic silencing of target genes and that regulates the survival and metastasis of cancer cells. EZH2 is overexpressed in aggressive solid tumors by mechanisms that remain unclear. Here, we show that the expression and function of EZH2 in cancer cell lines is inhibited by microRNA-101 (miR-101). Analysis of human prostate tumors revealed that miR-101 expression decreases during cancer progression, paralleling an increase in EZH2 expression. One or both of the two genomic loci encoding miR-101 were somatically lost in 37.5% of clinically localized prostate cancers (6/16) and 66.7% of metastatic disease (22/33). We propose that genomic loss of miR-101 in cancer leads to overexpression of EZH2 and concomitant dysregulation of epigenetic pathways, resulting in cancer progression."	unknown	"Enx-1,MYCN"	2009	19285253	causal
+hsa-miR-106b	10652	Alzheimer's disease	down-regulated	"northern blot, qRT-PCR etc"	"Gene dosage effects of Amyloid precursor protein (APP) can cause familial AD. Recent evidence suggest that microRNA (miRNA) pathways, implicated in gene transcriptional control, could be involved in the development of sporadic Alzheimer's disease (AD). We therefore investigated whether miRNAs could participate in the regulation of APP gene expression. We show that miRNAs belonging to the miR-20a family (that is, miR-20a, miR-17-5p and miR-106b) could regulate APP expression in vitro and at the endogenous level in neuronal cell lines. A tight correlation between these miRNAs and APP was found during brain development and in differentiating neurons. We thus identify miRNAs as novel endogenous regulators of APP expression, suggesting that variations in miRNA expression could contribute to changes in APP expression in the brain during development and disease. This possibility is further corroborated by the observation that a statistically significant decrease in miR-106b expression was found in sporadic AD patients."	APP	unknown	2009	19110058	causal
+hsa-miR-106b	5517	gastric cancer (stomach cancer)	up-regulated	"northern blot, qRT-PCR etc"	"Although it has been speculated that the miRNAs in the same cluster may play related biological functions, this has not been experimentally addressed. Here we report that the miRNAs in two clusters (miR-106b approximately 93 approximately 25 and miR-222 approximately 221) suppress the Cip/Kip family members of Cdk inhibitors (p57(Kip2), p21(Cip1) and p27(Kip1)). We show that miR-25 targets p57 through the 3'-UTR. Furthermore, miR-106b and miR-93 control p21 while miR-222 and miR-221 regulate both p27 and p57. Ectopic expression of these miRNAs results in activation of Cdk2 and facilitation of G1/S phase transition. Consistent with these results, both clusters are abnormally upregulated in gastric cancer tissues compared to the corresponding normal tissues. Ectopic expression of miR-222 cluster enhanced tumor growth in the mouse xenograft model. Our study demonstrates the functional associations between clustered miRNAs and further implicates that effective cancer treatment may require a combinatorial approach to target multiple oncogenic miRNA clusters."	p21	unknown	2009	19153141	causal
+hsa-miR-122a	12236	primary biliary cirrhosis (PBC)	down-regulated	"northern blot, qRT-PCR etc"	"We compared the expression of 377 miRNAs in explanted livers form subjects with PBC versus controls with normal liver histology. A total of 35 independent miRNAs were found to be differentially expressed in PBC (p<0.001). Quantitative PCR was employed to validate down-regulation of microRNA-122a (miR-122a) and miR-26a and the increased expression of miR-328 and miR-299-5p. The predicted targets of these miRNAs are known to affect cell proliferation, apoptosis, inflammation, oxidative stress, and metabolism. Our data are the first to demonstrate that PBC is characterized by altered expression of hepatic miRNA; however additional studies are required to demonstrate a causal link between those miRNA and the development of PBC."	unknown	unknown	2009	19345069	unspecified
+hsa-miR-127	353	diffuse large B-cell lymphoma (DLBCL)	up-regulated	"northern blot, qRT-PCR etc"	MiR-17-5p showed a significant higher expression level in the central nervous system compared with testicular and nodal diffuse large B-cell lymphomas (P<0.05). MiR-127 levels were significantly higher in testicular than in central nervous system and in nodal diffuse large B-cell lymphomas (P<0.05). We conclude that the location of diffuse large B-cell lymphoma is an important factor in determining the differential expression of miRNAs.	unknown	"BCL6,Rtl1/Peg11"	2009	19287466	unspecified
+hsa-miR-133a	5520	head and neck squamous cell carcinoma (HNSCC)	down-regulated	"northern blot, qRT-PCR etc"	"The majority of miRNAs exhibiting altered expression in primary human HNSCC tumors (including miR-1, miR-133a, miR-205, and let-7d) show lower expression levels relative to normal adjacent tissue. In contrast, hsa-miR-21 is frequently overexpressed in human HNSCC tumors."	unknown	unknown	2009	19179615	unspecified
+hsa-miR-141	5517	gastric cancer (stomach cancer)	down-regulated	"northern blot, qRT-PCR etc"	"MiR-141 was significantly down-regulated in 80% (28/35) of primary gastric cancer tissues compared with pair-matched adjacent non-tumor tissues (P < 0.01). The expression of miR-141 was also found to be substantially reduced in several human gastric cancer cell lines such as MGC-803, HGC-27, SGC-7901 and BGC-823 cells. Overexpression of miR-141 with its precursors significantly inhibited the proliferation of gastric cancer cells. CONCLUSIONS: These results suggest that miR-141 may be involved in the development of gastric cancer through its inhibitory effect on cell proliferation."	unknown	Clock	2009	19363643	causal
+hsa-miR-143	9256	colorectal cancer	down-regulated	microarray	"The expression of miR-31, miR-183, miR-17-5p, miR-18a, miR-20a and miR-92 were confirmed to be significantly higher in cancer tissues than in normal tissues (P<0.05). In contrast, the expression of miR-143 and miR-145 in cancer tissues were significantly lower than in normal tissues (P<0.05). The miR-18a overexpression group tended to have a poorer clinical prognosis than the low expression group (P=0.07). We identified miRNAs that were overexpressed or under-expressed in colorectal cancers and which may be correlated with colorectal carcinogenesis."	unknown	unknown	2009	19287964	unspecified
+hsa-miR-145	9256	colorectal cancer	down-regulated	microarray	"The expression of miR-31, miR-183, miR-17-5p, miR-18a, miR-20a and miR-92 were confirmed to be significantly higher in cancer tissues than in normal tissues (P<0.05). In contrast, the expression of miR-143 and miR-145 in cancer tissues were significantly lower than in normal tissues (P<0.05). The miR-18a overexpression group tended to have a poorer clinical prognosis than the low expression group (P=0.07). We identified miRNAs that were overexpressed or under-expressed in colorectal cancers and which may be correlated with colorectal carcinogenesis."	unknown	FLJ21308	2009	19287964	unspecified
+hsa-miR-146b	2627	glioma	down-regulated	"northern blot, qRT-PCR etc"	"Using miRNA microarray, we identified miR-146b as one of the miRNAs that is significantly dysregulated in human glioblastoma tissue. We showed that miR-146b overexpression by transfection with the precursor miR-146b, or knock-down by Locked Nucleic Acid (LNA)-modified anti-miR-146b, has no effect on the growth of human glioblastoma U373 cells. However, precursor miR-146b transfection significantly reduced the migration and invasion of U373 cells, while LNA-anti-miR-146b transfection generated the opposite result. Furthermore, we discovered that a matrix metalloproteinase gene, MMP16, is one of the downstream targets of miR-146b. Taken together, our findings suggest that miR-146b is involved in glioma cell migration and invasion by targeting MMPs, and implicate miR-146b as a metastasis-inhibiting miRNA in glioma."	MMP16	unknown	2009	19265686	causal
+hsa-miR-16	684	hepatocellular carcinoma (HCC)	up-regulated	"northern blot, qRT-PCR etc"	"By miRNA microarray analysis, EGCG treatment was found to modify the expressions of some of the miRNAs in human hepatocellular carcinoma HepG2 cells, 13 were up-regulated and 48 were down-regulated. miR-16 is one of the miRNAs up-regulated by EGCG and one of its target genes is confirmed to be the anti-apoptotic protein Bcl-2. EGCG treatment induced apoptosis and down-regulated Bcl-2 in HepG2 cells. Transfection with anti-miR-16 inhibitor suppressed miR-16 expression and counteracted the EGCG effects on Bcl-2 down-regulation and also induction of apoptosis in cells. Results from the present study confirm the role of miR-16 in mediating the apoptotic effect of EGCG and also support the importance of miRNAs in the regulation of the biological activity of EGCG."	BCL2	"BCL2,CGI-38"	2009	19269153	causal
+hsa-miR-17-5p	9256	colorectal cancer	up-regulated	microarray	"The expression of miR-31, miR-183, miR-17-5p, miR-18a, miR-20a and miR-92 were confirmed to be significantly higher in cancer tissues than in normal tissues (P<0.05). In contrast, the expression of miR-143 and miR-145 in cancer tissues were significantly lower than in normal tissues (P<0.05). The miR-18a overexpression group tended to have a poorer clinical prognosis than the low expression group (P=0.07). We identified miRNAs that were overexpressed or under-expressed in colorectal cancers and which may be correlated with colorectal carcinogenesis."	unknown	"AIB1,E2F1"	2009	19287964	unspecified
+hsa-miR-17-5p	353	diffuse large B-cell lymphoma (DLBCL)	up-regulated	"northern blot, qRT-PCR etc"	MiR-17-5p showed a significant higher expression level in the central nervous system compared with testicular and nodal diffuse large B-cell lymphomas (P<0.05). MiR-127 levels were significantly higher in testicular than in central nervous system and in nodal diffuse large B-cell lymphomas (P<0.05). We conclude that the location of diffuse large B-cell lymphoma is an important factor in determining the differential expression of miRNAs.	unknown	"AIB1,E2F1"	2009	19287466	unspecified
+hsa-miR-183	9256	colorectal cancer	up-regulated	microarray	"The expression of miR-31, miR-183, miR-17-5p, miR-18a, miR-20a and miR-92 were confirmed to be significantly higher in cancer tissues than in normal tissues (P<0.05). In contrast, the expression of miR-143 and miR-145 in cancer tissues were significantly lower than in normal tissues (P<0.05). The miR-18a overexpression group tended to have a poorer clinical prognosis than the low expression group (P=0.07). We identified miRNAs that were overexpressed or under-expressed in colorectal cancers and which may be correlated with colorectal carcinogenesis."	unknown	unknown	2009	19287964	unspecified
+hsa-miR-18a	9256	colorectal cancer	up-regulated	microarray	"The expression of miR-31, miR-183, miR-17-5p, miR-18a, miR-20a and miR-92 were confirmed to be significantly higher in cancer tissues than in normal tissues (P<0.05). In contrast, the expression of miR-143 and miR-145 in cancer tissues were significantly lower than in normal tissues (P<0.05). The miR-18a overexpression group tended to have a poorer clinical prognosis than the low expression group (P=0.07). We identified miRNAs that were overexpressed or under-expressed in colorectal cancers and which may be correlated with colorectal carcinogenesis."	unknown	unknown	2009	19287964	unspecified
+hsa-miR-196a	1107	esophageal cancer	up-regulated	"northern blot, qRT-PCR etc"	" Here, we evaluated miR-196a as a marker of BE progression to low-grade dysplasia, high-grade dysplasia, and EA using microdissected paraffin-embedded tissues from 11 patients. Higher levels of miR-196a were observed in EA, BE, and dysplastic lesions compared with normal squamous mucosa, and in high-grade dysplasia compared with BE and low-grade dysplasia. Using frozen tumor tissues from 10 additional patients who had advanced EA, we evaluated the correlation of miR-196a with its in silico-predicted targets, keratin 5 (KRT5), small proline-rich protein 2C (SPRR2C), and S100 calcium-binding protein A9 (S100A9), which are down-regulated during BE progression. MiR-196a levels inversely correlated with the predicted target mRNA levels in EA. We confirmed that miR-196a specifically targets KRT5, SPRR2C, and S100A9 3' UTRs using miR-196a-mimic and luciferase reporter-based assays. In conclusion, this study identified miR-196a as a potential marker of progression of BE and KRT5, SPRR2C, and S100A9 as its targets."	"KRT5, SPRR2C, S100A9"	unknown	2009	19342367	causal
+hsa-miR-199b-5p	3858	medulloblastoma	down-regulated	"northern blot, qRT-PCR etc"	" In a screening of MB cell lines, the miRNA miR-199b-5p was seen to be a regulator of the Notch pathway through its targeting of the transcription factor HES1. Down-regulation of HES1 expression by miR-199b-5p negatively regulates the proliferation rate and anchorage-independent growth of MB cells. MiR-199b-5p over-expression blocks expression of several cancer stem-cell genes, impairs the engrafting potential of MB cells in the cerebellum of athymic/nude mice, and of particular interest, decreases the MB stem-cell-like (CD133+) subpopulation of cells. In our analysis of 61 patients with MB, the expression of miR-199b-5p in the non-metastatic cases was significantly higher than in the metastatic cases (P = 0.001). Correlation with survival for these patients with high levels of miR-199b expression showed a positive trend to better overall survival than for the low-expressing patients. These data showing the down-regulation of miR-199b-5p in metastatic MBs suggest a potential silencing mechanism through epigenetic or genetic alterations. Upon induction of de-methylation using 5-aza-deoxycytidine, lower miR-199b-5p expression was seen in a panel of MB cell lines, supported an epigenetic mechanism of regulation. Furthermore, two cell lines (Med8a and UW228) showed significant up-regulation of miR-199b-5p upon treatment. Infection with MB cells in an induced xenograft model in the mouse cerebellum and the use of an adenovirus carrying miR-199b-5p indicate a clinical benefit through this negative influence of miR-199b-5p on tumor growth and on the subset of MB stem-cell-like cells, providing further proof of concept."	HES1	unknown	2009	19308264	causal
+hsa-miR-205	3459	breast cancer	down-regulated	"northern blot, qRT-PCR etc"	"HER2 overexpression is a hallmark of a particularly aggressive subset of breast tumors, and its activation is strictly dependent on the trans-interaction with other members of HER family; in particular, the activation of the PI3K/Akt survival pathway, so critically important in tumorigenesis, is predominantly driven through phosphorylation of the kinase-inactive member HER3. Here, we show that miR-205, down-modulated in breast tumors compared with normal breast tissue, directly targets HER3 receptor, and inhibits the activation of the downstream mediator Akt. The reintroduction of miR-205 in SKBr3 cells inhibits their clonogenic potential and increases the responsiveness to tyrosine-kinase inhibitors Gefitinib and Lapatinib, abrogating the HER3-mediated resistance and restoring a potent proapoptotic activity. Our data describe miR-205 as a new oncosuppressor gene in breast cancer, able to interfere with the proliferative pathway mediated by HER receptor family. Our study also provides experimental evidence suggesting that miR-205 can improve the responsiveness to specific anticancer therapies."	HER3	unknown	2009	19276373	causal
+hsa-miR-205	5520	head and neck squamous cell carcinoma (HNSCC)	down-regulated	"northern blot, qRT-PCR etc"	"Using univariate and multivariable statistical models we show that low levels of hsa-miR205 are significantly associated with loco-regional recurrence independent of disease severity at diagnosis and treatment. In addition, combined low levels of hsa-miR-205 and hsa-let-7d expression in HNSCC tumors are significantly associated with poor head and neck cancer survival Our results show that miRNA expression levels can be used as prognostic markers of head and neck cancer."	unknown	unknown	2009	19179615	unspecified
+hsa-miR-20a	9256	colorectal cancer	up-regulated	microarray	"The expression of miR-31, miR-183, miR-17-5p, miR-18a, miR-20a and miR-92 were confirmed to be significantly higher in cancer tissues than in normal tissues (P<0.05). In contrast, the expression of miR-143 and miR-145 in cancer tissues were significantly lower than in normal tissues (P<0.05). The miR-18a overexpression group tended to have a poorer clinical prognosis than the low expression group (P=0.07). We identified miRNAs that were overexpressed or under-expressed in colorectal cancers and which may be correlated with colorectal carcinogenesis."	unknown	TGFBR2	2009	19287964	unspecified
+hsa-miR-21	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	"northern blot, qRT-PCR etc"	"The majority of miRNAs exhibiting altered expression in primary human HNSCC tumors (including miR-1, miR-133a, miR-205, and let-7d) show lower expression levels relative to normal adjacent tissue. In contrast, hsa-miR-21 is frequently overexpressed in human HNSCC tumors."	unknown	"PTEN,TPM1"	2009	19179615	unspecified
+hsa-miR-21	10286	prostate cancer	up-regulated	"northern blot, qRT-PCR etc"	"In this study, the effects of miR-21 on prostate cancer cell proliferation, apoptosis, and invasion were examined. In addition, the targets of miR-21 were identified by a reported RISC-coimmunoprecipitation-based biochemical method. Inactivation of miR-21 by antisense oligonucleotides in androgen-independent prostate cancer cell lines DU145 and PC-3 resulted in sensitivity to apoptosis and inhibition of cell motility and invasion, whereas cell proliferation were not affected. We identified myristoylated alanine-rich protein kinase c substrate (MARCKS), which plays key roles in cell motility, as a new target in prostate cancer cells. Our data suggested that miR-21 could promote apoptosis resistance, motility, and invasion in prostate cancer cells and these effects of miR-21 may be partly due to its regulation of PDCD4, TPM1, and MARCKS. Gene therapy using miR-21 inhibition strategy may therefore be useful as a prostate cancer therapy."	MARCKS	"PTEN,TPM1"	2009	19302977	causal
+hsa-miR-21	1107	esophageal cancer	up-regulated	"northern blot, qRT-PCR etc"	"To evaluate the role of microRNA-21, cell proliferation and invasion were analyzed with anti-microRNA-21-transfected cells. In addition, the regulation of PDCD4 by microRNA-21 was elucidated to identify the mechanisms of this regulation. RESULTS: Of 20 paired samples, 18 cancer tissues overexpressed microRNA-21 in comparison with matched normal epitheliums. Specifically, patients with lymph node metastasis or venous invasion showed significantly high expression of microRNA-21. In situ hybridization for microRNA-21 showed strong positive staining in paraffin-embedded esophageal squamous cell carcinoma tissues. All seven esophageal squamous cell carcinoma cell lines also overexpressed microRNA-21, and anti-microRNA-21-transfected cells showed significant reduction in cellular proliferation and invasion. The PDCD4 protein levels in esophageal squamous cell carcinoma cells have an inverse correlation with microRNA-21 expression. Anti-microRNA-21-transfected cells increased PDCD4 protein expression without changing the PDCD4 mRNA level and increased a luciferase-reporter activity containing the PDCD4-3' untranslated region construct. CONCLUSIONS: MicroRNA-21 targets PDCD4 at the posttranscriptional level and regulates cell proliferation and invasion in esophageal squamous cell carcinoma. It may serve as a novel therapeutic target in esophageal squamous cell carcinoma."	PDCD4	"PTEN,TPM1"	2009	19276261	causal
+hsa-miR-221	10286	prostate cancer	up-regulated	"northern blot, qRT-PCR etc"	"miR-221 and miR-222, were significantly increased in CRPC cells (the LNCaP-derived cell line LNCaP-Abl), compared with those in the androgen-dependent prostate cancer cell line (LNCaP). Overexpression of miR-221 or miR-222 in LNCaP or another androgen-dependent cell line, LAPC-4, significantly reduced the level of the dihydrotestosterone (DHT) induced up-regulation of prostate-specific antigen (PSA) expression and increased androgen-independent growth of LNCaP cells. Knocking down the expression level of miR-221 and miR-222 with antagonist miRs in the LNCaP-Abl cell line restored the response to the DHT induction of PSA transcription and also increased the growth response of the LNCaP-Abl cells to the androgen treatment. Changing the expression level of p27/kip1, a known target of miR-221 and miR-222, alone in LNCaP cells affected the DHT-independent cell growth but did not significantly influence the response of PSA transcription to the DHT treatment. In conclusion, our data suggest the involvement of miR-221 and miR-222 in the development or maintenance of the CRPC phenotype."	unknown	KIT	2009	19351832	causal
+hsa-miR-221	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	"an expression ratio of miR-221:miR-375 showed a high sensitivity (0.92) and specificity (0.93) for disease prediction.CONCLUSIONS: These data suggest that cultured tumor cell lines are inappropriate for microRNA biomarker identification and that the pattern of microRNA expression in primary head and neck tissues is reflective of disease status, with certain microRNAs exhibiting strong predictive potential. These results indicate that miR-221 and miR-375 should be evaluated further as diagnostic biomarkers because they may hold utility in defining broadly responsive prevention and treatment strategies for HNSCC."	unknown	KIT	2009	19351747	unspecified
+hsa-miR-221	5517	gastric cancer (stomach cancer)	up-regulated	"northern blot, qRT-PCR etc"	"Although it has been speculated that the miRNAs in the same cluster may play related biological functions, this has not been experimentally addressed. Here we report that the miRNAs in two clusters (miR-106b approximately 93 approximately 25 and miR-222 approximately 221) suppress the Cip/Kip family members of Cdk inhibitors (p57(Kip2), p21(Cip1) and p27(Kip1)). We show that miR-25 targets p57 through the 3'-UTR. Furthermore, miR-106b and miR-93 control p21 while miR-222 and miR-221 regulate both p27 and p57. Ectopic expression of these miRNAs results in activation of Cdk2 and facilitation of G1/S phase transition. Consistent with these results, both clusters are abnormally upregulated in gastric cancer tissues compared to the corresponding normal tissues. Ectopic expression of miR-222 cluster enhanced tumor growth in the mouse xenograft model. Our study demonstrates the functional associations between clustered miRNAs and further implicates that effective cancer treatment may require a combinatorial approach to target multiple oncogenic miRNA clusters."	"p27, p57"	KIT	2009	19153141	causal
+hsa-miR-222	10286	prostate cancer	up-regulated	"northern blot, qRT-PCR etc"	"miR-221 and miR-222, were significantly increased in CRPC cells (the LNCaP-derived cell line LNCaP-Abl), compared with those in the androgen-dependent prostate cancer cell line (LNCaP). Overexpression of miR-221 or miR-222 in LNCaP or another androgen-dependent cell line, LAPC-4, significantly reduced the level of the dihydrotestosterone (DHT) induced up-regulation of prostate-specific antigen (PSA) expression and increased androgen-independent growth of LNCaP cells. Knocking down the expression level of miR-221 and miR-222 with antagonist miRs in the LNCaP-Abl cell line restored the response to the DHT induction of PSA transcription and also increased the growth response of the LNCaP-Abl cells to the androgen treatment. Changing the expression level of p27/kip1, a known target of miR-221 and miR-222, alone in LNCaP cells affected the DHT-independent cell growth but did not significantly influence the response of PSA transcription to the DHT treatment. In conclusion, our data suggest the involvement of miR-221 and miR-222 in the development or maintenance of the CRPC phenotype."	unknown	KIT	2009	19351832	causal
+hsa-miR-222	5517	gastric cancer (stomach cancer)	up-regulated	"northern blot, qRT-PCR etc"	"Although it has been speculated that the miRNAs in the same cluster may play related biological functions, this has not been experimentally addressed. Here we report that the miRNAs in two clusters (miR-106b approximately 93 approximately 25 and miR-222 approximately 221) suppress the Cip/Kip family members of Cdk inhibitors (p57(Kip2), p21(Cip1) and p27(Kip1)). We show that miR-25 targets p57 through the 3'-UTR. Furthermore, miR-106b and miR-93 control p21 while miR-222 and miR-221 regulate both p27 and p57. Ectopic expression of these miRNAs results in activation of Cdk2 and facilitation of G1/S phase transition. Consistent with these results, both clusters are abnormally upregulated in gastric cancer tissues compared to the corresponding normal tissues. Ectopic expression of miR-222 cluster enhanced tumor growth in the mouse xenograft model. Our study demonstrates the functional associations between clustered miRNAs and further implicates that effective cancer treatment may require a combinatorial approach to target multiple oncogenic miRNA clusters."	"p27, p57"	KIT	2009	19153141	causal
+hsa-miR-25	5517	gastric cancer (stomach cancer)	up-regulated	"northern blot, qRT-PCR etc"	"Although it has been speculated that the miRNAs in the same cluster may play related biological functions, this has not been experimentally addressed. Here we report that the miRNAs in two clusters (miR-106b approximately 93 approximately 25 and miR-222 approximately 221) suppress the Cip/Kip family members of Cdk inhibitors (p57(Kip2), p21(Cip1) and p27(Kip1)). We show that miR-25 targets p57 through the 3'-UTR. Furthermore, miR-106b and miR-93 control p21 while miR-222 and miR-221 regulate both p27 and p57. Ectopic expression of these miRNAs results in activation of Cdk2 and facilitation of G1/S phase transition. Consistent with these results, both clusters are abnormally upregulated in gastric cancer tissues compared to the corresponding normal tissues. Ectopic expression of miR-222 cluster enhanced tumor growth in the mouse xenograft model. Our study demonstrates the functional associations between clustered miRNAs and further implicates that effective cancer treatment may require a combinatorial approach to target multiple oncogenic miRNA clusters."	p57	unknown	2009	19153141	causal
+hsa-miR-26a	12236	primary biliary cirrhosis (PBC)	down-regulated	"northern blot, qRT-PCR etc"	"We compared the expression of 377 miRNAs in explanted livers form subjects with PBC versus controls with normal liver histology. A total of 35 independent miRNAs were found to be differentially expressed in PBC (p<0.001). Quantitative PCR was employed to validate down-regulation of microRNA-122a (miR-122a) and miR-26a and the increased expression of miR-328 and miR-299-5p. The predicted targets of these miRNAs are known to affect cell proliferation, apoptosis, inflammation, oxidative stress, and metabolism. Our data are the first to demonstrate that PBC is characterized by altered expression of hepatic miRNA; however additional studies are required to demonstrate a causal link between those miRNA and the development of PBC."	unknown	PLAG1	2009	19345069	unspecified
+hsa-miR-299-5p	12236	primary biliary cirrhosis (PBC)	up-regulated	"northern blot, qRT-PCR etc"	"We compared the expression of 377 miRNAs in explanted livers form subjects with PBC versus controls with normal liver histology. A total of 35 independent miRNAs were found to be differentially expressed in PBC (p<0.001). Quantitative PCR was employed to validate down-regulation of microRNA-122a (miR-122a) and miR-26a and the increased expression of miR-328 and miR-299-5p. The predicted targets of these miRNAs are known to affect cell proliferation, apoptosis, inflammation, oxidative stress, and metabolism. Our data are the first to demonstrate that PBC is characterized by altered expression of hepatic miRNA; however additional studies are required to demonstrate a causal link between those miRNA and the development of PBC."	unknown	unknown	2009	19345069	unspecified
+hsa-miR-31	9256	colorectal cancer	up-regulated	microarray	"The expression of miR-31, miR-183, miR-17-5p, miR-18a, miR-20a and miR-92 were confirmed to be significantly higher in cancer tissues than in normal tissues (P<0.05). In contrast, the expression of miR-143 and miR-145 in cancer tissues were significantly lower than in normal tissues (P<0.05). The miR-18a overexpression group tended to have a poorer clinical prognosis than the low expression group (P=0.07). We identified miRNAs that were overexpressed or under-expressed in colorectal cancers and which may be correlated with colorectal carcinogenesis."	unknown	unknown	2009	19287964	unspecified
+hsa-miR-328	3459	breast cancer	up-regulated	"northern blot, qRT-PCR etc"	"Breast cancer resistance protein (BCRP/ABCG2) is a molecular determinant of pharmacokinetic properties of many drugs in humans. To understand posttranscriptional regulation of ABCG2 and role of microRNAs (miRNAs) in drug disposition, we found that microRNA-328 (miR-328) might readily target the 3'-untranslated region (3'-UTR) of ABCG2 when considering target-site accessibility. We then noted an inverse relation between the levels of miR-328 and ABCG2 in MCF-7 and MCF-7/MX100 breast cancer cells, and the fact that miR-328 levels could be rescued in MCF-7/MX100 cells transfected with miR-328 plasmid. Luciferase reporter assays showed that ABCG2 3'-UTR-luciferase activity was decreased over 50% in MCF-7/MX100 cells after transfected with miR-328 plasmid, the activity was increased over 100% in MCF-7 cells transfected with a miR-328 antagomir, and disruption of miR-328 response element within ABCG2 3'-UTR led to a 3-fold increase in luciferase activity. Furthermore, the level of ABCG2 protein was down-regulated when miR-328 was over-expressed, and the level was up-regulated when miR-328 was inhibited by selective antagomir. Altered ABCG2 protein expression was associated with significantly declined or elevated levels of ABCG2 3'-UTR and coding sequence mRNAs, suggesting possible involvement of the mechanism of mRNA cleavage. Lastly, miR-328-directed down-regulation of ABCG2 expression in MCF-7/MX100 cells resulted in an increased mitoxantrone sensitivity, as manifested by a significantly lower IC50 value (2.46 +/- 1.64 microM) when compared to the control (151 +/- 32 microM). Together, these findings suggest that miR-328 targets ABCG2 3'-UTR and consequently, controls ABCG2 protein expression and influences drug disposition in human breast cancer cells."	ABCG2	unknown	2009	19270061	unspecified
+hsa-miR-346	5419	schizophrenia	down-regulated	"northern blot, qRT-PCR etc"	"Schizophrenia (SZ) is a neuropsychiatric disorder that affects about 1% of the adult population. Numerous genes have been implicated in SZ susceptibility. MicroRNAs (miRNA) are small RNA molecules that regulate the translation of mRNAs via interactions with their 3' untranslated regions. Identification of known miRNA targets on all human genes indicated that miRNA-346 targets SZ susceptibility genes listed in the SchizophreniaGene database twice as frequently as expected relative to other genes in the genome. The gene encoding this miRNA, miR-346, is located in intron 2 of the glutamate receptor ionotropic delta 1 (GRID1) gene, which has been previously implicated in SZ susceptibility. We used quantitative real-time PCR to determine the expression levels of miR-346 and GRID1 using brain RNA samples from the Stanley Array Collection, Stanley Medical Research Institute. Expression of both miR-346 and GRID1 is lower in SZ patients than that in normal controls (P=0.017 and 0.086, respectively). However, the expression of miR-346 and GRID1 is less correlated in SZ patients than in bipolar patients or in normal controls. This study implicates the importance of a miRNA in SZ."	unknown	unknown	2009	19264453	unspecified
+hsa-miR-34a	684	hepatocellular carcinoma (HCC)	down-regulated	"northern blot, qRT-PCR etc"	"In the present study, we identified the role of miR-34a in the regulation of tumor cell scattering, migration, and invasion. Down-regulation of miR-34a expression was highly significant in 19 of 25 (76%) human hepatocellular carcinoma (HCC) tissues compared with adjacent normal tissues and associated with the metastasis and invasion of tumors. Furthermore, resected normal/tumor tissues of 25 HCC patients demonstrated an inverse correlation between miR-34a and c-Met-protein. In HepG2 cells, ectopic expression of miR-34a potently inhibited tumor cell migration and invasion in a c-Met-dependent manner. miR-34a directly targeted c-Met and reduced both mRNA and protein levels of c-Met; thus, decreased c-Met-induced phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2). Taken together, these results provide evidence to show the suppression role of miR-34a in tumor migration and invasion through modulation of the c-Met signaling pathway."	c-Met	E2F3	2009	19006648	causal
+hsa-miR-34a	1909	malignant melanoma	down-regulated	"northern blot, qRT-PCR etc"	"miR-34a is actively expressed in melanocytes but not in uveal melanoma cells based on Northern blot analysis. Transfection of miR-34a into uveal melanoma cells led to a significant decrease in cell growth and migration. After identification of two putative miR-34a binding sites within the 3' UTR of the human c-Met mRNA, miR-34a was shown to suppress luciferase activity using HEK293 cells with a luciferase reporter construct containing the binding sites. miR-34a was confirmed to downregulate the expression of c-Met protein by Western blotting and immunofluorescence. Furthermore, the introduction of miR-34a downregulated phosphorylated Akt and cell cycle-related proteins. CONCLUSIONS: These results demonstrate that miR-34a acts as a tumor suppressor in uveal melanoma cell proliferation and migration through the downregulation of c-Met."	c-Met	E2F3	2009	19029026	causal
+hsa-miR-34b	9119	acute myeloid leukemia (AML)	down-regulated	"northern blot, qRT-PCR etc"	"Here, microRNAs (miRNA), which act as negative regulators of gene expression principally through translational repression, are investigated for the mediation of high CREB protein levels. A series of miRNAs that target CREB were identified. Real-time quantitative PCR revealed that miR-34b was expressed significantly less in myeloid cell lines, previously known for high CREB protein levels. Exogenous miR-34b expression was induced, and results revealed a direct interaction with the CREB 3'-untranslated region, with the consequent reduction of the CREB protein levels in vitro. miR-34b restored expression caused cell cycle abnormalities, reduced anchorage-independent growth, and altered CREB target gene expression, suggesting its suppressor potential. Using reverse-phase protein array, CREB target proteins (BCL-2, cyclin A1, cyclin B1, cyclin D, nuclear factor-kappaB, Janus-activated kinase 1, and signal transducer and activator of transcription 3), as well as many downstream protein kinases and cell survival signaling pathways (AKT/mammalian target of rapamycin and extracellular signal-regulated kinase) usually elicited by CREB, were observed to have decreased. The miR-34b/miR-34c promoter was shown to be methylated in the leukemia cell lines used. This epigenetic regulation should control the observed miR-34b expression levels to maintain the CREB protein overexpressed. In addition, the inverse correlation between miR-34b and CREB expression was found in a cohort of 78 pediatric patients at diagnosis of acute myeloid leukemia, supporting this relationship in vivo. Our results identify a direct miR-34b target gene, provide a possible mechanism for CREB overexpression, and provide new information about myeloid transformation and therapeutic strategies."	CREB	unknown	2009	19258499	causal
+hsa-miR-375	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	"an expression ratio of miR-221:miR-375 showed a high sensitivity (0.92) and specificity (0.93) for disease prediction.CONCLUSIONS: These data suggest that cultured tumor cell lines are inappropriate for microRNA biomarker identification and that the pattern of microRNA expression in primary head and neck tissues is reflective of disease status, with certain microRNAs exhibiting strong predictive potential. These results indicate that miR-221 and miR-375 should be evaluated further as diagnostic biomarkers because they may hold utility in defining broadly responsive prevention and treatment strategies for HNSCC."	unknown	"Adipor2,C1qbp,Jak2,Mtpn,Usp1"	2009	19351747	unspecified
+hsa-miR-449a	10286	prostate cancer	down-regulated	"northern blot, qRT-PCR etc"	"Histone deacetylases (HDACs) are frequently overexpressed in broad range of cancer types, where they alter cellular epigenetic programming to promote cell proliferation and survival. However, the mechanism by which HDACs become overexpressed in human cancers remains somewhat of a mystery. In this study, we investigated the expression and functional significance of miR-449a in prostate cancer cells. Using real-time PCR, we found that miR-449a is downregulated in prostate cancer tissues relative to patient-matched control tissue. Introduction of miR-449a into PC-3 prostate cancer cells resulted in cell-cycle arrest, apoptosis and a senescent-like phenotype. In silico analysis of 3'-UTR regions identified a number of genes involved in cell-cycle regulation as putative targets of miR-449a. Using a luciferase 3'-UTR reporter system, we established that HDAC-1 (histone deacetylase 1), a gene that is frequently overexpressed in many types of cancer, is a direct target of miR-449a. Further, our data indicate that miR-449a regulates cell growth and viability in part by repressing the expression of HDAC-1 in prostate cancer cells. Our findings provide new insight into the function of miRNA in regulating HDAC expression in normal versus cancerous tissue."	HDAC-1	unknown	2009	19252524	causal
+hsa-miR-451	5517	gastric cancer (stomach cancer)	down-regulated	"northern blot, qRT-PCR etc"	" Down-regulation of miR-451 was associated with worse prognosis. miR-451 was detected by in situ hybridization in epithelial cells and showed decreased expression in gastric and colorectal cancer versus nontumoral tissues. Overexpression of miR-451 in gastric and colorectal cancer cells reduced cell proliferation and increased sensitivity to radiotherapy. Microarray and bioinformatic analysis identified the novel oncogene macrophage migration inhibitory factor (MIF) as a potential target of miR-451. In fact, overexpression of miR-451 down-regulated mRNA and protein levels of MIF and decreased expression of reporter genes with MIF target sequences. Moreover, we found a significant inverse correlation between miR-451 and MIF expression in tumoral gastric biopsies. CONCLUSIONS: These findings support the role of miR-451 as a regulator of cancer proliferation and open new perspectives for the development of effective therapies for chemoradioresistant cancers."	MIF	unknown	2009	19318487	causal
+hsa-miR-451	9256	colorectal cancer	down-regulated	"northern blot, qRT-PCR etc"	" Down-regulation of miR-451 was associated with worse prognosis. miR-451 was detected by in situ hybridization in epithelial cells and showed decreased expression in gastric and colorectal cancer versus nontumoral tissues. Overexpression of miR-451 in gastric and colorectal cancer cells reduced cell proliferation and increased sensitivity to radiotherapy. Microarray and bioinformatic analysis identified the novel oncogene macrophage migration inhibitory factor (MIF) as a potential target of miR-451. In fact, overexpression of miR-451 down-regulated mRNA and protein levels of MIF and decreased expression of reporter genes with MIF target sequences. Moreover, we found a significant inverse correlation between miR-451 and MIF expression in tumoral gastric biopsies. CONCLUSIONS: These findings support the role of miR-451 as a regulator of cancer proliferation and open new perspectives for the development of effective therapies for chemoradioresistant cancers."	MIF	unknown	2009	19318487	causal
+hsa-miR-7	3905	lung cancer	down-regulated	"northern blot, qRT-PCR etc"	"The epidermal growth factor receptor (EGFR) is frequently overexpressed in cancer and is an important therapeutic target. Aberrant expression and function of microRNAs have been associated with tumorigenesis. Bioinformatic predictions suggest that the human EGFR mRNA 3'-untranslated region contains three microRNA-7 (miR-7) target sites, which are not conserved across mammals. We found that miR-7 down-regulates EGFR mRNA and protein expression in cancer cell lines (lung, breast, and glioblastoma) via two of the three sites, inducing cell cycle arrest and cell death. Because miR-7 was shown to decrease EGFR mRNA expression, we used microarray analysis to identify additional mRNA targets of miR-7. These included Raf1 and multiple other genes involved in EGFR signaling and tumorigenesis. Furthermore, miR-7 attenuated activation of protein kinase B (Akt) and extracellular signal-regulated kinase 1/2, two critical effectors of EGFR signaling, in different cancer cell lines. These data establish an important role for miR-7 in controlling mRNA expression and indicate that miR-7 has the ability to coordinately regulate EGFR signaling in multiple human cancer cell types."	EGFR	unknown	2009	19073608	causal
+hsa-miR-1 	5520	head and neck squamous cell carcinoma (HNSCC)	down-regulated	"northern blot, qRT-PCR etc"	"The majority of miRNAs exhibiting altered expression in primary human HNSCC tumors (including miR-1, miR-133a, miR-205, and let-7d) show lower expression levels relative to normal adjacent tissue. In contrast, hsa-miR-21 is frequently overexpressed in human HNSCC tumors."	unknown	"GJA1,Hand2,HDAC4,TMSB4X"	2009	19179615	unspecified
+hsa-miR-7	3459	breast cancer	down-regulated	"northern blot, qRT-PCR etc"	"The epidermal growth factor receptor (EGFR) is frequently overexpressed in cancer and is an important therapeutic target. Aberrant expression and function of microRNAs have been associated with tumorigenesis. Bioinformatic predictions suggest that the human EGFR mRNA 3'-untranslated region contains three microRNA-7 (miR-7) target sites, which are not conserved across mammals. We found that miR-7 down-regulates EGFR mRNA and protein expression in cancer cell lines (lung, breast, and glioblastoma) via two of the three sites, inducing cell cycle arrest and cell death. Because miR-7 was shown to decrease EGFR mRNA expression, we used microarray analysis to identify additional mRNA targets of miR-7. These included Raf1 and multiple other genes involved in EGFR signaling and tumorigenesis. Furthermore, miR-7 attenuated activation of protein kinase B (Akt) and extracellular signal-regulated kinase 1/2, two critical effectors of EGFR signaling, in different cancer cell lines. These data establish an important role for miR-7 in controlling mRNA expression and indicate that miR-7 has the ability to coordinately regulate EGFR signaling in multiple human cancer cell types."	EGFR	unknown	2009	19073608	causal
+hsa-miR-7	3068	glioblastoma	down-regulated	"northern blot, qRT-PCR etc"	"The epidermal growth factor receptor (EGFR) is frequently overexpressed in cancer and is an important therapeutic target. Aberrant expression and function of microRNAs have been associated with tumorigenesis. Bioinformatic predictions suggest that the human EGFR mRNA 3'-untranslated region contains three microRNA-7 (miR-7) target sites, which are not conserved across mammals. We found that miR-7 down-regulates EGFR mRNA and protein expression in cancer cell lines (lung, breast, and glioblastoma) via two of the three sites, inducing cell cycle arrest and cell death. Because miR-7 was shown to decrease EGFR mRNA expression, we used microarray analysis to identify additional mRNA targets of miR-7. These included Raf1 and multiple other genes involved in EGFR signaling and tumorigenesis. Furthermore, miR-7 attenuated activation of protein kinase B (Akt) and extracellular signal-regulated kinase 1/2, two critical effectors of EGFR signaling, in different cancer cell lines. These data establish an important role for miR-7 in controlling mRNA expression and indicate that miR-7 has the ability to coordinately regulate EGFR signaling in multiple human cancer cell types."	EGFR	unknown	2009	19073608	causal
+hsa-miR-92	9256	colorectal cancer	up-regulated	microarray	"The expression of miR-31, miR-183, miR-17-5p, miR-18a, miR-20a and miR-92 were confirmed to be significantly higher in cancer tissues than in normal tissues (P<0.05). In contrast, the expression of miR-143 and miR-145 in cancer tissues were significantly lower than in normal tissues (P<0.05). The miR-18a overexpression group tended to have a poorer clinical prognosis than the low expression group (P=0.07). We identified miRNAs that were overexpressed or under-expressed in colorectal cancers and which may be correlated with colorectal carcinogenesis."	unknown	unknown	2009	19287964	unspecified
+hsa-miR-93	5517	gastric cancer (stomach cancer)	up-regulated	"northern blot, qRT-PCR etc"	"Although it has been speculated that the miRNAs in the same cluster may play related biological functions, this has not been experimentally addressed. Here we report that the miRNAs in two clusters (miR-106b approximately 93 approximately 25 and miR-222 approximately 221) suppress the Cip/Kip family members of Cdk inhibitors (p57(Kip2), p21(Cip1) and p27(Kip1)). We show that miR-25 targets p57 through the 3'-UTR. Furthermore, miR-106b and miR-93 control p21 while miR-222 and miR-221 regulate both p27 and p57. Ectopic expression of these miRNAs results in activation of Cdk2 and facilitation of G1/S phase transition. Consistent with these results, both clusters are abnormally upregulated in gastric cancer tissues compared to the corresponding normal tissues. Ectopic expression of miR-222 cluster enhanced tumor growth in the mouse xenograft model. Our study demonstrates the functional associations between clustered miRNAs and further implicates that effective cancer treatment may require a combinatorial approach to target multiple oncogenic miRNA clusters."	p21	unknown	2009	19153141	causal
+hsa-miR-96	10004	hearing loss	normal	"northern blot, qRT-PCR etc"	"Impaired miRNA target binding resulting from SNPs within mRNA target sites has been shown to lead to pathologies associated with dysregulated gene expression. However, no pathogenic mutations within the mature sequence of a miRNA have been reported so far. Here we show that point mutations in the seed region of miR-96, a miRNA expressed in hair cells of the inner ear, result in autosomal dominant, progressive hearing loss. This is the first study implicating a miRNA in a mendelian disorder. The identified mutations have a strong impact on miR-96 biogenesis and result in a significant reduction of mRNA targeting. We propose that these mutations alter the regulatory role of miR-96 in maintaining gene expression profiles in hair cells required for their normal function."	unknown	unknown	2009	19363479	causal
+hsa-miR-17	3858	medulloblastoma	up-regulated	"northern blot, qRT-PCR etc"	"Profiling the expression of 427 mature microRNAs (miRNA) in a series of 90 primary human medulloblastomas revealed that components of the miR-17/92 polycistron are the most highly up-regulated miRNAs in medulloblastoma. Expression of miR-17/92 was highest in the subgroup of medulloblastomas associated with activation of the sonic hedgehog (Shh) signaling pathway compared with other subgroups of medulloblastoma. Medulloblastomas in which miR-17/92 was up-regulated also had elevated levels of MYC/MYCN expression. Consistent with its regulation by Shh, we observed that Shh treatment of primary cerebellar granule neuron precursors (CGNP), proposed cells of origin for the Shh-associated medulloblastomas, resulted in increased miR-17/92 expression. In CGNPs, the Shh effector N-myc, but not Gli1, induced miR-17/92 expression. Ectopic miR-17/92 expression in CGNPs synergized with exogenous Shh to increase proliferation and also enabled them to proliferate in the absence of Shh. We conclude that miR-17/92 is a positive effector of Shh-mediated proliferation and that aberrant expression/amplification of this miR confers a growth advantage to medulloblastomas"	unknown	unknown	2009	19351822	causal
+hsa-miR-18a	3858	medulloblastoma	up-regulated	"northern blot, qRT-PCR etc"	"Profiling the expression of 427 mature microRNAs (miRNA) in a series of 90 primary human medulloblastomas revealed that components of the miR-17/92 polycistron are the most highly up-regulated miRNAs in medulloblastoma. Expression of miR-17/92 was highest in the subgroup of medulloblastomas associated with activation of the sonic hedgehog (Shh) signaling pathway compared with other subgroups of medulloblastoma. Medulloblastomas in which miR-17/92 was up-regulated also had elevated levels of MYC/MYCN expression. Consistent with its regulation by Shh, we observed that Shh treatment of primary cerebellar granule neuron precursors (CGNP), proposed cells of origin for the Shh-associated medulloblastomas, resulted in increased miR-17/92 expression. In CGNPs, the Shh effector N-myc, but not Gli1, induced miR-17/92 expression. Ectopic miR-17/92 expression in CGNPs synergized with exogenous Shh to increase proliferation and also enabled them to proliferate in the absence of Shh. We conclude that miR-17/92 is a positive effector of Shh-mediated proliferation and that aberrant expression/amplification of this miR confers a growth advantage to medulloblastomas"	unknown	unknown	2009	19351822	causal
+hsa-miR-19a	3858	medulloblastoma	up-regulated	"northern blot, qRT-PCR etc"	"Profiling the expression of 427 mature microRNAs (miRNA) in a series of 90 primary human medulloblastomas revealed that components of the miR-17/92 polycistron are the most highly up-regulated miRNAs in medulloblastoma. Expression of miR-17/92 was highest in the subgroup of medulloblastomas associated with activation of the sonic hedgehog (Shh) signaling pathway compared with other subgroups of medulloblastoma. Medulloblastomas in which miR-17/92 was up-regulated also had elevated levels of MYC/MYCN expression. Consistent with its regulation by Shh, we observed that Shh treatment of primary cerebellar granule neuron precursors (CGNP), proposed cells of origin for the Shh-associated medulloblastomas, resulted in increased miR-17/92 expression. In CGNPs, the Shh effector N-myc, but not Gli1, induced miR-17/92 expression. Ectopic miR-17/92 expression in CGNPs synergized with exogenous Shh to increase proliferation and also enabled them to proliferate in the absence of Shh. We conclude that miR-17/92 is a positive effector of Shh-mediated proliferation and that aberrant expression/amplification of this miR confers a growth advantage to medulloblastomas"	unknown	PTEN	2009	19351822	causal
+hsa-miR-19b	3858	medulloblastoma	up-regulated	"northern blot, qRT-PCR etc"	"Profiling the expression of 427 mature microRNAs (miRNA) in a series of 90 primary human medulloblastomas revealed that components of the miR-17/92 polycistron are the most highly up-regulated miRNAs in medulloblastoma. Expression of miR-17/92 was highest in the subgroup of medulloblastomas associated with activation of the sonic hedgehog (Shh) signaling pathway compared with other subgroups of medulloblastoma. Medulloblastomas in which miR-17/92 was up-regulated also had elevated levels of MYC/MYCN expression. Consistent with its regulation by Shh, we observed that Shh treatment of primary cerebellar granule neuron precursors (CGNP), proposed cells of origin for the Shh-associated medulloblastomas, resulted in increased miR-17/92 expression. In CGNPs, the Shh effector N-myc, but not Gli1, induced miR-17/92 expression. Ectopic miR-17/92 expression in CGNPs synergized with exogenous Shh to increase proliferation and also enabled them to proliferate in the absence of Shh. We conclude that miR-17/92 is a positive effector of Shh-mediated proliferation and that aberrant expression/amplification of this miR confers a growth advantage to medulloblastomas"	unknown	unknown	2009	19351822	causal
+hsa-miR-20a	3858	medulloblastoma	up-regulated	"northern blot, qRT-PCR etc"	"Profiling the expression of 427 mature microRNAs (miRNA) in a series of 90 primary human medulloblastomas revealed that components of the miR-17/92 polycistron are the most highly up-regulated miRNAs in medulloblastoma. Expression of miR-17/92 was highest in the subgroup of medulloblastomas associated with activation of the sonic hedgehog (Shh) signaling pathway compared with other subgroups of medulloblastoma. Medulloblastomas in which miR-17/92 was up-regulated also had elevated levels of MYC/MYCN expression. Consistent with its regulation by Shh, we observed that Shh treatment of primary cerebellar granule neuron precursors (CGNP), proposed cells of origin for the Shh-associated medulloblastomas, resulted in increased miR-17/92 expression. In CGNPs, the Shh effector N-myc, but not Gli1, induced miR-17/92 expression. Ectopic miR-17/92 expression in CGNPs synergized with exogenous Shh to increase proliferation and also enabled them to proliferate in the absence of Shh. We conclude that miR-17/92 is a positive effector of Shh-mediated proliferation and that aberrant expression/amplification of this miR confers a growth advantage to medulloblastomas"	unknown	TGFBR2	2009	19351822	causal
+hsa-miR-92a	3858	medulloblastoma	up-regulated	"northern blot, qRT-PCR etc"	"Profiling the expression of 427 mature microRNAs (miRNA) in a series of 90 primary human medulloblastomas revealed that components of the miR-17/92 polycistron are the most highly up-regulated miRNAs in medulloblastoma. Expression of miR-17/92 was highest in the subgroup of medulloblastomas associated with activation of the sonic hedgehog (Shh) signaling pathway compared with other subgroups of medulloblastoma. Medulloblastomas in which miR-17/92 was up-regulated also had elevated levels of MYC/MYCN expression. Consistent with its regulation by Shh, we observed that Shh treatment of primary cerebellar granule neuron precursors (CGNP), proposed cells of origin for the Shh-associated medulloblastomas, resulted in increased miR-17/92 expression. In CGNPs, the Shh effector N-myc, but not Gli1, induced miR-17/92 expression. Ectopic miR-17/92 expression in CGNPs synergized with exogenous Shh to increase proliferation and also enabled them to proliferate in the absence of Shh. We conclude that miR-17/92 is a positive effector of Shh-mediated proliferation and that aberrant expression/amplification of this miR confers a growth advantage to medulloblastomas"	unknown	unknown	2009	19351822	causal
+hsa-miR-141	10286	prostate cancer	down-regulated	"Northern blot, qRT-PCR etc"	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	Clock	2007	17616669	Unspecified	0	837			
+hsa-miR-141	9088	psoriasis	up-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	Clock	2007	17622355	Unspecified
+hsa-miR-142-3p	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	unknown	2007	17616664	Unspecified
+hsa-miR-142-3p	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-142-3p	9088	psoriasis	up-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	unknown	2007	17622355	Unspecified
+hsa-miR-142-5p	9119	acute myeloid leukemia (AML)	up-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-142-5p	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	unknown	2007	17616664	Unspecified
+hsa-miR-142-5p	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-143	8584	Burkitt lymphoma	down-regulated	"Northern blot, qRT-PCR etc"	"Expression levels of miR-143 and -145 were significantly decreased in B-cell malignancies.Transfection of RAJI cells with precursor or mature miR-143 or -145, respectively, causes growth inhibition. "	ERK5	unknown	2007	17892514	Causal
+hsa-miR-143	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	"Expression levels of miR-143 and -145 were significantly decreased in B-cell malignancies.Transfection of RAJI cells with precursor or mature miR-143 or -145, respectively, causes growth inhibition. "	ERK5	unknown	2007	17892514	Causal
+hsa-miR-143	1985	colorectal cancer	down-regulated	"northern blot, qRT-PCR etc"	miR-143 and miR-145 expression levels were extremely reduced in the colon cancer cells. The transfection of each precursor miRNA into the cells demonstrated a significant growth inhibition in human colon cancer DLD-1 and SW480 cells.	ERK5	unknown	2006	16969504	Causal
+hsa-miR-143	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	Expression levels of miR-143 and -145 were inversely correlated with cell proliferation of DLD-1 cells.Persistent decreased levels of miR-143 in cancer cells may be directly involved in carcinogenesis through activation of the mitogenactivated protein kinase (MAPK) cascade via ERK5. 					
+	ERK5	unknown	2007	17504027	Causal	1	848			
+hsa-miR-143	353	diffuse large B-cell lymphoma (DLBCL)	down-regulated	"Northern blot, qRT-PCR etc"	"Expression levels of miR-143 and -145 were significantly decreased in B-cell malignancies.Transfection of RAJI cells with precursor or mature miR-143 or -145, respectively, causes growth inhibition. "	ERK5	unknown	2007	17892514	Causal
+hsa-miR-143	9970	Obesity	up-regulated	"Northern blot, qRT-PCR etc"	"miR-143 was involved in adipocyte differentiation, regulating fat metabolism. Inhibition of miR-143 effectively inhibited adipocyte differentiation. In addition, protein levels of the proposed miR-143 target ERK5 were higher in ASO-treated adipocytes."	ERK5	unknown	2004	15504739	Causal
+hsa-miR-143	3459	breast cancer	down-regulated	microarray	Differentially expressed between breast carcinoma and normal breast tissue.	unknown	unknown	2005	16103053	Unspecified
+hsa-miR-143	2893	cervical cancer	down-regulated	"Northern blot, qRT-PCR etc"	"let-7b, let-7c, miR-23b, miR-196b, and miR-143 showed significantly reduced abundance in cervical cancer cell lines. miR-21 displayed higher abundance in the cancer group."	unknown	unknown	2007	17616659	Unspecified
+hsa-miR-143	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	"miR-143 and miR-145, consistently display reduced steady-state levels of the mature miRNA at the adenomatous and cancer stages of colorectal neoplasia."	unknown	unknown	2003	14573789	Unspecified
+hsa-miR-143	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Expression levels of analyzed miRNAs significantly differed among tumors and adjacent non-tumor tissues: miR-21 (p = 0.0001) and miR-31 (p = 0.0006) were upregulated, and miR-143 (p = 0.011) and miR-145 (p = 0.005) were downregulated in tumors."	unknown	unknown	2007	18196926	Unspecified
+hsa-miR-143	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	Differentially expressed between tumors and normals.	unknown	unknown	2007	17875710	Unspecified
+hsa-miR-143	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	unknown	2007	17616664	Unspecified
+hsa-miR-143	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-143	3498	pancreatic ductal adenocarcinoma (PDAC)	up-regulated	"Northern blot, qRT-PCR etc"	differentially expressed between normal and PDAC or cell line samples.	unknown	unknown	2007	17237814	Unspecified
+hsa-miR-143	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	859			
+hsa-miR-143	5745	serous ovarian cancer	down-regulated	microarray	Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients.	unknown	unknown	2008	18451233	Unspecified
+hsa-miR-143	1909	uveal melanoma	up-regulated	microarray	"The top six miRNA discriminators ( let-7b, miR-199a,miR-199a*, miR-143, miR-193b, and miR-652) accurately distinguished class 1 (low metastatic risk) from class 2 (high metastatic risk) with 100% sensitivity and specificity."	unknown	unknown	2008	18477892	Unspecified
+hsa-miR-143	178	vascular disease	down-regulated	"Northern blot, qRT-PCR etc"	Aberrant Expression of miRNA in Injured Arteries Is Confirmed by qRT-PCR or Northern Blot Analysis.	unknown	unknown	2007	17478730	Unspecified
+hsa-miR-144	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-144	13223	uterine leiomyoma (ULM)	down-regulated	"Northern blot, qRT-PCR etc"	One of the top five down-regulated miRNAs in Uterine Leiomyomas (ULMs).	unknown	unknown	2007	17243163	Unspecified
+hsa-miR-145	3905	lung cancer	down-regulated	microarray	"miRNAs (miR-155, miR-17-3p, miR-106a, miR-93, let-7a-2, miR-145, let-7b, and miR-21) were related to the adenocarcinoma patient��s survival. Patients with high expression of either hsamir-155, miR-17-3p, miR-106a, miR-93, or miR-21 and low expression of either let-7a-2, let-7b, or miR-145 were found to have a significantly worse prognosis."	unknown	FLJ21308	2006	16530703	Unspecified
+hsa-miR-145	8584	Burkitt lymphoma	down-regulated	"Northern blot, qRT-PCR etc"	"Expression levels of miRs-143 and -145 were significantly decreased in B-cell malignancies.Transfection of RAJI cells with precursor or mature miR-143 or -145, respectively, causes growth inhibition. "	unknown	FLJ21308	2007	17892514	Causal
+hsa-miR-145	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	"Expression levels of miR-143 and -145 were significantly decreased in B-cell malignancies.Transfection of RAJI cells with precursor or mature miR-143 or -145, respectively, causes growth inhibition. "	unknown	FLJ21308	2007	17892514	Causal
+hsa-miR-145	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	 miR-143 and miR-145 expression levels were extremely reduced in the colon cancer cells. The transfection of each precursor miRNA into the cells demonstrated a significant growth inhibition in human colon cancer DLD-1 and SW480 cells.	unknown	FLJ21308	2006	16969504	Causal
+hsa-miR-145	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	Expression levels of miR-143 and -145 were inversely correlated with cell proliferation of					
+DLD-2 cells.										
+	unknown	FLJ21308	2007	17504027	Causal	1	869			
+hsa-miR-145	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	"miR-145 targets the 3 -UTR of IRS-1 mRNA, and that the targeting has a profound effect on the growth of human colon cancer cells. This is the first demonstration of a specific miR targeting a transduction molecule of the IGF-IR/insulin receptor signaling pathway. Its inhibition of growth in human cancer cells in culture is compatible with the well known ability of IRS-1 to stimulate"					
+cell proliferation and transformation.	IRS-1	FLJ21308	2007	17827156	Causal	1	870			
+hsa-miR-145	353	diffuse large B-cell lymphoma (DLBCL)	down-regulated	"Northern blot, qRT-PCR etc"	"Expression levels of miRs-143 and -145 were significantly decreased in B-cell malignancies.Transfection of RAJI cells with precursor or mature miR-143 or -145, respectively, causes growth inhibition. "	unknown	FLJ21308	2007	17892514	Causal
+hsa-miR-148a	3498	pancreatic ductal adenocarcinoma (PDAC)	down-regulated	microarray	differentially expressed between normal and PDAC or cell line samples.	unknown	unknown	2007	17237814	Unspecified
+hsa-miR-15b	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Aberrantly expressed miRNA precursors in pancreatic adenocarcinoma.PAM testing was conducted on 10 tumor samples and 15 adjacent benign samples. PAM has correctly classified 100% of the tested tumor samples and 11 of 15 of the tested benign samples. The 20 top ranked differentially expressed miRNAs in pancreatic adenocarcinoma as selected by PAM.	unknown	unknown	2006	17149698	Unspecified
+hsa-miR-197	3429	Inclusion body myositis (IBM)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-197	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-197	3905	lung cancer	up-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-197	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-197	3829	pituitary adenoma	up-regulated	microarray	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	unknown	2007	17111382	Unspecified
+hsa-miR-197	12236	primary biliary cirrhosis (PBC)	down-regulated	microarray	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	unknown	2008	18631158	Unspecified
+hsa-miR-197	9088	psoriasis	down-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	unknown	2007	17622355	Unspecified
+hsa-miR-197	13223	uterine leiomyoma (ULM)	down-regulated	"Northern blot, qRT-PCR etc"	One of the top five down-regulated miRNAs in Uterine Leiomyomas (ULMs).	unknown	unknown	2007	17243163	Unspecified
+hsa-miR-198	5419	schizophrenia	normal	"Northern blot, qRT-PCR etc"	" Eighteen known SNPs within or near brain-expressed miRNAs in three samples (Danish, Swedish and Norwegian: 420/163/257 schizophrenia patients and 1006/177/293 control subjects), were analyzed. Subsequently, joint analysis of the three samples was performed on SNPs showing marginal association. Two SNPs rs17578796 and rs1700 in hsa-mir-206 (mir-206) and hsa-mit-198 (mir-198) showed nominal significant allelic association to schizophrenia in the Danish and Norwegian sample respectively (P = 0.0021 & p = 0.038), of which only rs17578796 was significant in the joint sample. In-silico analysis revealed that 8 of the 15 genes predicted to be regulated by both mir-206 and mir-198, are transcriptional targets or interaction partners of the JUN, ATF2 and TAF1 connected in a tight network. JUN and two of the miRNA targets (CCND2 and PTPN1) in the network have previously been associated with schizophrenia."	unknown	unknown	2008	17849003	Causal
+hsa-miR-198	13315	chronic pancreatitis	up-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-198	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-198	10286	prostate cancer	up-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	885			
+hsa-miR-199a	-1	cancer	down-regulated	"Northern blot, qRT-PCR etc"	The expression of miR-199a/a* is silenced in all proliferating cell lines tested except fibroblasts. Introduction of miR-199a/a* caused apoptosis in cancer cells.	unknown	unknown	2008	18456660	Causal
+hsa-miR-199a	4001	epithelial ovarian cancer (EOC)	down-regulated	"Northern blot, qRT-PCR etc"	"Using EOC cellsisolated from malignant ovarian cancer ascites and solid tumors,The authors identified IKK-beta as a major factor promoting a functional TLR�CMyD88�CNF-k-beta pathway that confers to EOC cell the capacity to constitutively secrete proinflammatory/ protumor cytokines and therefore promoting tumor progression and chemoresistance.Furthermore, they describe for the first time the identification of the microRNA hsa-miR-199a as a regulator of IKK-beta expression."	IKK-beta	unknown	2008	18408758	Causal
+hsa-miR-199a	9119	acute myeloid leukemia (AML)	down-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-199a	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change correlative with the increase in heart/body weight(7-14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-199a	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-199a	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-199a	4001	epithelial ovarian cancer (EOC)	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed between tumors and normals.	unknown	unknown	2007	17875710	Unspecified
+hsa-miR-199a	11727	facioscapulohumeral muscular dystrophy (FSHD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-199a	6000	heart failure	up-regulated	"Northern blot, qRT-PCR etc"	"Northern blot analysis of the hypertrophy-regulated miRNAs in idiopathic end-stage failing human hearts showed increased expression of miR-24, miR-125b, miR-195, miR-199a, and miR-214."	unknown	unknown	2006	17108080	Unspecified
+hsa-miR-199a	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	Significantly differentially expressed between hepatocellular carcinoma and adjacent non-tumor tissue.	unknown	unknown	2006	16331254	Unspecified
+hsa-miR-199a	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-199a	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-199a	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-199a	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-199a	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-199a	10222	polymyositis (PM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-199a	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	902			
+hsa-miR-199a	1909	uveal melanoma	up-regulated	"Northern blot, qRT-PCR etc"	"The top six miRNA discriminators ( let-7b, miR-199a,miR-199a*, miR-143, miR-193b, and miR-652) accurately distinguished class 1 (low metastatic risk) from class 2 (high metastatic risk) with 100% sensitivity and specificity."	unknown	unknown	2008	18477892	Unspecified
+hsa-miR-199a*	-1	cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Met proto-oncogene is a target of miR-199a*. Several lines of evidence indicate that miR-199a* is a putative tumor suppressor: 1. The expression of miR-199a/a* is silenced in all proliferating cell lines tested except fibroblasts. 2. Introduction of miR-199a/a* caused apoptosis in cancer cells. 3. miR-199a* downregulates Met proto-oncogene and also downregulates ERK2, an effector downstream of Met."	"MET, ERK2"	unknown	2008	18456660	Causal
+hsa-miR-199a*	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change correlative with the increase in heart/body weight(7-14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-199a*	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-199a*	14691	Duchenne muscular dystrophy (DMD)	up-regulated	"Northern blot, qRT-PCR etc"	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-199a*	11727	facioscapulohumeral muscular dystrophy (FSHD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-199a*	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	Significantly differentially expressed between hepatocellular carcinoma and adjacent non-tumor tissue.	unknown	unknown	2006	16331254	Unspecified
+hsa-miR-199a*	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-199a*	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-199a*	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-199a*	2144	ovarian cancer (OC)	down-regulated	microarray	"Frequent deregulation of miR-199a*, miR-214, miR-200a, and miR-100 in human ovarian cancer."	unknown	unknown	2008	18199536	Unspecified
+hsa-miR-199a*	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	914			
+hsa-miR-199a-1	13315	chronic pancreatitis	up-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-199a-1	3905	lung cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-199a-1	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-199a-1	4905	pancreatic cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-199a-1	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-199a-1	10286	prostate cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-199a-1-5p	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	unknown	2007	17616664	Unspecified
+hsa-miR-199a-2	13315	chronic pancreatitis	up-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-199a-2	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-199a-2	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-199a-2-5p	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	unknown	2007	17616664	Unspecified
+hsa-miR-199a-3p	5745	serous ovarian cancer	down-regulated	microarray	Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients.	unknown	unknown	2008	18451233	Unspecified
+hsa-miR-199b	9952	acute lymphoblastic leukemia (ALL)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	LAMC2	2007	18056805	Unspecified
+hsa-miR-199b	9119	acute myeloid leukemia (AML)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	LAMC2	2007	18056805	Unspecified
+hsa-miR-199b	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change correlative with the increase in heart/body weight(7-14 days post-TAC).	unknown	LAMC2	2008	17234972	Unspecified
+hsa-miR-199b	13315	chronic pancreatitis	up-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	LAMC2	2007	17473300	Unspecified
+hsa-miR-199b	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	LAMC2	2007	17942673	Unspecified
+hsa-miR-199b	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	LAMC2	2007	17942673	Unspecified
+hsa-miR-199b	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	Differentially expressed between tumors and normals.	unknown	LAMC2	2007	17875710	Unspecified
+hsa-miR-199b	11727	facioscapulohumeral muscular dystrophy (FSHD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	LAMC2	2007	17942673	Unspecified
+hsa-miR-199b	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	LAMC2	2007	17616664	Unspecified
+hsa-miR-199b	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	LAMC2	2007	17942673	Unspecified
+hsa-miR-199b	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	LAMC2	2006	16530703	Unspecified
+hsa-miR-199b	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	LAMC2	2008	18379589	Unspecified
+hsa-miR-199b	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	LAMC2	2007	17942673	Unspecified
+hsa-miR-199b	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	LAMC2	2008	18381414	Unspecified
+hsa-miR-199b	10222	polymyositis (PM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	LAMC2	2007	17942673	Unspecified
+hsa-miR-199b	10286	prostate cancer	up-regulated	microarray	One of the upregulated microRNAs in tumors with perineural invasion (FDR 10%).	unknown	LAMC2	2008	18459106	Unspecified
+hsa-miR-19a	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	survival-related and metastasis-related miRNA.	unknown	PTEN	2008	18176954	Unspecified
+hsa-miR-19a	7012	anaplastic thyroid carcinoma (ATC)	up-regulated	"Northern blot, qRT-PCR etc"	"MiRNAs in a miR-17-92 cluster were overexpressed in ARO cells. We confirmed the overexpression of those miRNAs by Northern blot analysis in ARO and FRO cells. In 3 of 6 clinical ATC samples, miR-17-3p and miR-17-5p were robustly overexpressed in cancer lesions compared to adjacent normal tissue. To investigate the functional role of these miRNAs in ATC cells, ARO and FRO cells were transfected with miRNA inhibitors, antisense oligonucleotides containing locked nucleic acids. Suppression of miR-17-3p caused complete growth arrest, presumably due to caspase activation resulting in apoptosis. MiR-17-5p or miR-19a inhibitor also induced strong growth reduction, but only miR-17-5p inhibitor led to cellular senescence. On the other hand, miR-18a inhibitor only moderately attenuated the cell growth. Thus, we have clarified functional differences among the members of the cluster in ATC cells. In conclusion, these findings suggest that the miR-17-92 cluster plays an important role in certain types of ATCs and could be a novel target for ATC treatment."	unknown	PTEN	2008	18429962	Causal
+hsa-miR-19a	3471	Cowden Syndrome	up-regulated	"Northern blot, qRT-PCR etc"	"Differential expression of PTEN-targeting miR-19a and miR-21 modulates the PTEN protein levels and the CS phenotype, irrespective of the patient��s mutation status, and support their roles"					
+as genetic modifiers in CS.	PTEN	PTEN	2008	18460397	Causal	1	945			
+hsa-miR-19a	3905	lung cancer	up-regulated	"Northern blot, qRT-PCR etc"	"frequent and marked overexpression, with occasional gene amplification, of clustered miRNAs (miR-17-92) within intron 3 of the C13orf 25 gene at 13q31.3 in lung cancers, especially examples with small-cell lung cancer histology.The authors further showed the stimulatory activity of this miRNA cluster in lung cancer cell growth."	unknown	PTEN	2005	16266980	Causal
+hsa-miR-19a	1040	B-cell chronic lymphocytic leukemia	up-regulated	microarray	Differentially expressed in CLL cells versus CD22 cells.	unknown	PTEN	2004	15284443	Unspecified
+hsa-miR-19a	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed between neoplastic conditions (CRC cell lines and tumor samples) and non-tumoral colon tissues.	unknown	PTEN	2006	16854228	Unspecified
+hsa-miR-19a	5520	head and neck squamous cell carcinoma (HNSCC)	down-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	PTEN	2007	17222355	Unspecified
+hsa-miR-19a	353	malignant lymphoma	up-regulated	"Northern blot, qRT-PCR etc"	"six mature miRNAs (miR-17-5p, miR-17-3p, miR-19a, miR-19b, miR-20 and miR-92-1) in the cell lines with a 13q31 gain/amplification displays overexpression significantly higher than in those without."	unknown	PTEN	2005	16167061	Unspecified
+hsa-miR-19a	1909	malignant melanoma	up-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	PTEN	2008	18379589	Unspecified
+hsa-miR-19b	353	malignant lymphoma	up-regulated	"Northern blot, qRT-PCR etc"	"six mature miRNAs (miR-17-5p, miR-17-3p, miR-19a, miR-19b, miR-20 and miR-92-1) in the cell lines with a 13q31 gain/amplification displays overexpression significantly higher than in those without."	unknown	unknown	2005	16167061	Unspecified
+hsa-miR-19b	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	953			
+hsa-miR-19b-2	715	T-cell leukemia	up-regulated	"Northern blot, qRT-PCR etc"	"The authors conclude that, in addition to miR-106a, miR-20b, miR-19b-2, and miR-92-2 overexpression in tumors, their capacity to induce anchorage independence growth strongly supports an oncogenic"					
+"potential for those miRNAs. they also conclude that Mylip and Rbp1-like are true targets of the miR-106-363 cluster(miR-106a, miR-18b, miR-20b, miR-19b-2, miR-92-2, and miR-363). More specifically, Rbp1-like seemed only targeted by miR-106a/miR-20b, whereas Mylip could be targeted by the four miRNAs(miR-106a, miR-20b, miR-19b-2, and miR-92-2) with miR-106a/miR-20b being more efficient."	Rbp1-like	unknown	2006	17575136	Causal	1	954			
+hsa-miR-200a	5745	serous ovarian cancer	up-regulated	microarray	"Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients. Higher expression of miR-200a, miR-200b, miR-200c, miR-141, miR-18a, miR-93, and miR-429, and lower expression of ambi-miR-7039, let-7b, and miR-199a were significantly correlated with decreased progression-free survival and overall survival."	unknown	unknown	2008	18451233	Unspecified
+hsa-miR-200a	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"All five members of the microRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141 and miR-429) and miR-205 were markedly downregulated in cells that had undergone EMT in response to transforming growth factor (TGF)-beta or to ectopic expression of the protein tyrosine phosphatase Pez. Enforced expression of the miR-200 family alone was sufficient to prevent TGF-beta-induced EMT. Together, these microRNAs cooperatively regulate expression of the E-cadherin transcriptional repressors ZEB1 (also known as deltaEF1) and SIP1 (also known as ZEB2), factors previously implicated in EMT and tumour metastasis. Inhibition of the microRNAs was sufficient to induce EMT in a process requiring upregulation of ZEB1 and/or SIP1. Conversely, ectopic expression of these microRNAs in mesenchymal cells initiated mesenchymal to epithelial transition (MET). Consistent with their role in regulating EMT, expression of these microRNAs was found to be lost in invasive breast cancer cell lines with mesenchymal phenotype. Expression of the miR-200 family was also lost in regions of metaplastic breast cancer specimens lacking E-cadherin. These data suggest that downregulation of the microRNAs may be an important step in tumour progression."					
+	"ZEB1(deltaEF1), SIP1(ZEB2)"	unknown	2008	18376396	Causal	1	956			
+hsa-miR-200a	-1	cancer	down-regulated	"Northern blot, qRT-PCR etc"	"The miR-200 family is composed of five members arranged as two clusters, miR-200a/200b/429 and"					
+miR-200c/141.Ectopic expression of the miR-200 family in 4TO7 carcinoma cells caused a rapid and										
+significant decrease in ZEB1 and ZEB2 levels.Over-expressing the miR-200 family in 4TO7 cells										
+"induced a dramatic morphological change from a spindle-like, mesenchymal phenotype towards a"										
+"more pronounced epithelial phenotype with formation of adheren junctions. Furthermore, overexpression of miR-200 significantly inhibits growth factor-induced directional migration, a hallmark of metastatic cancer cells.This suggests that ectopic expression of the miR-200 family can"										
+promote the mesenchymal-epithelial transition and reduce tumor cell migration.	"ZEB1, ZEB2"	unknown	2008	18411277	Causal	1	957			
+hsa-miR-200a	4001	epithelial ovarian cancer (EOC)	up-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed between tumors and normals.	unknown	unknown	2007	17875710	Unspecified
+hsa-miR-200a	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-200a	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	Significantly differentially expressed between hepatocellular carcinoma and adjacent non-tumor tissue.	unknown	unknown	2006	16331254	Unspecified
+hsa-miR-200a	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-200a	2144	ovarian cancer (OC)	down-regulated	microarray	"Frequent deregulation of miR-199a*, miR-214, miR-200a, and miR-100 in human ovarian cancer."	unknown	unknown	2008	18199536	Unspecified
+hsa-miR-200a	9088	psoriasis	up-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	unknown	2007	17622355	Unspecified
+hsa-miR-200b	5745	serous ovarian cancer	up-regulated	microarray	"Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients. Higher expression of miR-200a, miR-200b, miR-200c, miR-141, miR-18a, miR-93, and miR-429, and lower expression of ambi-miR-7039, let-7b, and miR-199a were significantly correlated with decreased progression-free survival and overall survival."	unknown	unknown	2008	18451233	Unspecified
+hsa-miR-200b	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"All five members of the microRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141 and miR-429) and miR-205 were markedly downregulated in cells that had undergone EMT in response to transforming growth factor (TGF)-beta or to ectopic expression of the protein tyrosine phosphatase Pez. Enforced expression of the miR-200 family alone was sufficient to prevent TGF-beta-induced EMT. Together, these microRNAs cooperatively regulate expression of the E-cadherin transcriptional repressors ZEB1 (also known as deltaEF1) and SIP1 (also known as ZEB2), factors previously implicated in EMT and tumour metastasis. Inhibition of the microRNAs was sufficient to induce EMT in a process requiring upregulation of ZEB1 and/or SIP1. Conversely, ectopic expression of these microRNAs in mesenchymal cells initiated mesenchymal to epithelial transition (MET). Consistent with their role in regulating EMT, expression of these microRNAs was found to be lost in invasive breast cancer cell lines with mesenchymal phenotype. Expression of the miR-200 family was also lost in regions of metaplastic breast cancer specimens lacking E-cadherin. These data suggest that downregulation of the microRNAs may be an important step in tumour progression."					
+	"ZEB1(deltaEF1), SIP1(ZEB2)"	unknown	2008	18376396	Causal	1	965			
+hsa-miR-200b	-1	cancer	down-regulated	"Northern blot, qRT-PCR etc"	"The miR-200 family is composed of five members arranged as two clusters, miR-200a/200b/429 and"					
+miR-200c/141.Ectopic expression of the miR-200 family in 4TO7 carcinoma cells caused a rapid and										
+significant decrease in ZEB1 and ZEB2 levels.Over-expressing the miR-200 family in 4TO7 cells										
+"induced a dramatic morphological change from a spindle-like, mesenchymal phenotype towards a"										
+"more pronounced epithelial phenotype with formation of adheren junctions. Furthermore, overexpression of miR-200 significantly inhibits growth factor-induced directional migration, a hallmark of metastatic cancer cells.This suggests that ectopic expression of the miR-200 family can"										
+promote the mesenchymal-epithelial transition and reduce tumor cell migration.	"ZEB1, ZEB2"	unknown	2008	18411277	Causal	1	966			
+hsa-miR-200b	4947	cholangiocarcinoma	up-regulated	"Northern blot, qRT-PCR etc"	inhibition of miR-21 or miR-200b decreased gemcitabine-induced apoptosis.	PTPN12	unknown	2006	16762633	Causal
+hsa-miR-200b	4001	epithelial ovarian cancer (EOC)	up-regulated	microarray	Differentially expressed between tumors and normals.	unknown	unknown	2007	17875710	Unspecified
+hsa-miR-200b	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	unknown	2007	17616664	Unspecified
+hsa-miR-200b	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-200b	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-200c	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	miR-200c was significantly associated with patient survival (p = 0.0122). The patients (n = 15) with higher hsamiR-200c expression had a shorter survival time (median survival = 26 months) compared to patients(n = 9) with lower expression (median survival = 38 months).miR-200c (p = 0.0322) expression was strongly associated with the mutation status of the p53 tumor suppressor gene.	unknown	unknown	2006	18079988	Unspecified
+hsa-miR-200c	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"All five members of the microRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141 and miR-429) and miR-205 were markedly downregulated in cells that had undergone EMT in response to transforming growth factor (TGF)-beta or to ectopic expression of the protein tyrosine phosphatase Pez. Enforced expression of the miR-200 family alone was sufficient to prevent TGF-beta-induced EMT. Together, these microRNAs cooperatively regulate expression of the E-cadherin transcriptional repressors ZEB1 (also known as deltaEF1) and SIP1 (also known as ZEB2), factors previously implicated in EMT and tumour metastasis. Inhibition of the microRNAs was sufficient to induce EMT in a process requiring upregulation of ZEB1 and/or SIP1. Conversely, ectopic expression of these microRNAs in mesenchymal cells initiated mesenchymal to epithelial transition (MET). Consistent with their role in regulating EMT, expression of these microRNAs was found to be lost in invasive breast cancer cell lines with mesenchymal phenotype. Expression of the miR-200 family was also lost in regions of metaplastic breast cancer specimens lacking E-cadherin. These data suggest that downregulation of the microRNAs may be an important step in tumour progression."					
+	"ZEB1(deltaEF1), SIP1(ZEB2)"	unknown	2008	18376396	Causal	1	973			
+hsa-miR-200c	-1	cancer	down-regulated	"Northern blot, qRT-PCR etc"	"The miR-200 family is composed of five members arranged as two clusters, miR-200a/200b/429 and"					
+miR-200c/141.Ectopic expression of the miR-200 family in 4TO7 carcinoma cells caused a rapid and										
+significant decrease in ZEB1 and ZEB2 levels.Over-expressing the miR-200 family in 4TO7 cells										
+"induced a dramatic morphological change from a spindle-like, mesenchymal phenotype towards a"										
+"more pronounced epithelial phenotype with formation of adheren junctions. Furthermore, overexpression of miR-200 significantly inhibits growth factor-induced directional migration, a hallmark of metastatic cancer cells.This suggests that ectopic expression of the miR-200 family can"										
+promote the mesenchymal-epithelial transition and reduce tumor cell migration.	"ZEB1, ZEB2"	unknown	2008	18411277	Causal	1	974			
+hsa-miR-200c	-1	cancer	down-regulated	"Northern blot, qRT-PCR etc"	"The embryonic programme 'epithelial�Cmesenchymal transition'(EMT) is thought to promote malignant tumour progression. The transcriptional repressor zinc-finger E-box binding homeobox 1(ZEB1) is a crucial inducer of EMT in various human tumours, and was recently shown to promote invasion and metastasis of tumour cells. ZEB1 directly suppresses transcription of microRNA-200 family members miR-141 and miR-200c. Notably, the EMT activators transforming growth factor b2 and ZEB1 are the"					
+predominant targets downregulated by these microRNAs.	ZEB1	unknown	2008	18483486	Causal	1	975			
+hsa-miR-200c	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	unknown	2006	16609010	Unspecified
+hsa-miR-200c	4001	epithelial ovarian cancer (EOC)	up-regulated	microarray	Differentially expressed between tumors and normals.	unknown	unknown	2007	17875710	Unspecified
+hsa-miR-200c	1909	malignant melanoma	up-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-200c	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-200c	5556	testicular germ cell tumor	up-regulated	microarray	Differentially expressed miRNA in the various histological subtypes of  germ cell tumour (GCT) (TE = teratoma; SE = seminoma; EC = embryonal carcinoma).	unknown	unknown	2007	17893849	Unspecified
+hsa-miR-202	3459	breast cancer	up-regulated	microarray	Differentially expressed between breast carcinoma and normal breast tissue.	unknown	unknown	2005	16103053	Unspecified
+hsa-miR-202	10286	prostate cancer	up-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	983			
+hsa-miR-203	9952	acute lymphoblastic leukemia (ALL)	down-regulated	"Northern blot, qRT-PCR etc"	"We report a fragile chromosomal region lost in specific hematopoietic malignancies. This 7 Mb region encodes about 12% of all genomic microRNAs, including miR-203. This microRNA is additionally hypermethylated in several hematopoietic tumors, including chronic myelogenous leukemias and some acute lymphoblastic leukemias. A putative miR-203 target, ABL1, is specifically activated in these hematopoietic malignancies in some cases as a BCR-ABL1 fusion protein (Philadelphia chromosome). Re-expression of miR-203 reduces ABL1 and BCR-ABL1 fusion protein levels and inhibits tumor cell proliferation in an ABL1-dependent manner. Thus, miR-203 functions as a tumor suppressor, and re-expression of this microRNA might have therapeutic benefits in specific hematopoietic malignancies."	"ABL1, BCR-ABL1"	unknown	2008	18538733	Causal
+hsa-miR-203	8552	chronic myeloid leukemia (CML)	down-regulated	"Northern blot, qRT-PCR etc"	"We report a fragile chromosomal region lost in specific hematopoietic malignancies. This 7 Mb region encodes about 12% of all genomic microRNAs, including miR-203. This microRNA is additionally hypermethylated in several hematopoietic tumors, including chronic myelogenous leukemias and some acute lymphoblastic leukemias. A putative miR-203 target, ABL1, is specifically activated in these hematopoietic malignancies in some cases as a BCR-ABL1 fusion protein (Philadelphia chromosome). Re-expression of miR-203 reduces ABL1 and BCR-ABL1 fusion protein levels and inhibits tumor cell proliferation in an ABL1-dependent manner. Thus, miR-203 functions as a tumor suppressor, and re-expression of this microRNA might have therapeutic benefits in specific hematopoietic malignancies."	"ABL1, BCR-ABL1"	unknown	2008	18538733	Causal
+hsa-miR-203	9088	psoriasis	up-regulated	"Northern blot, qRT-PCR etc"	"The up-regulation of miR-203 in psoriatic plaques was concurrent with the down-regulation of an evolutionary conserved target of miR-203, suppressor of cytokine signaling 3 (SOCS-3), which is involved in inflammatory responses and keratinocyte functions."	SOCS-3	unknown	2007	17622355	Causal
+hsa-miR-203	37	skin disease	up-regulated	"Northern blot, qRT-PCR etc"	"miR-203 is induced in the skin concomitantly with stratification and differentiation. By altering miR-203's spatiotemporal expression in vivo, the authors show that miR-203 promotes epidermal differentiation by restricting proliferative potential and inducing cell-cycle exit. P63 is one of the conserved targets of miR-203 across vertebrates. Notably, p63 is an essential regulator of stem-cell maintenance in stratified epithelial tissues. The authors show that miR-203 directly represses the expression of p63: it fails to switch off suprabasally when either Dicer1 or miR-203 is absent and it becomes repressed basally when miR-203 is prematurely expressed."	p63	unknown	2008	18311128	Causal
+hsa-miR-203	4007	bladder cancer	up-regulated	microarray	"Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b,miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P<0.05) compared to normal bladder"					
+mucosa.	unknown	unknown	2007	17826655	Unspecified	0	988			
+hsa-miR-203	3459	breast cancer	up-regulated	microarray	Differentially expressed between breast carcinoma and normal breast tissue.	unknown	unknown	2005	16103053	Unspecified
+hsa-miR-203	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Expression patterns for these 5 microRNAs(miR-20a, miR-21, miR-106a, miR-181b, and miR-203) distinguish tumor vs paired nontumor status with 96% or 98% accuracy based on 3 nearest neighbors or nearest centroid algorithms, respectively (10-fold cross validation, repeated 100 times)."	unknown	unknown	2008	18230780	Unspecified
+hsa-miR-203	1107	esophageal cancer	down-regulated	microarray	Both hsa-miR-203 and hsa-miR-205 were expressed 2- to 10-fold lower in squamous cell carcinoma and adenocarcinomas than in normal epithelium. The hsa-miR-21 expression was 3- to 5-fold higher in both tumors than in normal epithelium.	unknown	unknown	2008	18242245	Unspecified
+hsa-miR-203	3905	lung cancer	up-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-203	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	"Northern blot, qRT-PCR etc"	"Four of miRNAs (i.e., miR-34b, miR-137, miR-193a, and miR-203) located around CpG islands.The expression of those four genes was restored by treatment with 5-aza-2'-deoxycytidine in OSCC cells lacking their expression. In addition, expression levels of the four miRNAs were inversely correlated with their DNA methylation status in the OSCC lines. In primary tumors of OSCC with paired"					
+"normal oral mucosa, down-regulation of miRNA expression through tumor-specific hypermethylation was more frequently"										
+observed for miR-137 and miR-193a than for miR-34b and miR-203.	unknown	unknown	2008	18381414	Unspecified	0	993			
+hsa-miR-155	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	"The expression of TP53INP1, which presents anti-tumoral activity, is repressed by the oncogenic miR-155."	TP53INP1	AGTR1	2007	17911264	Causal
+hsa-miR-155	9119	acute myeloid leukemia (AML)	up-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	AGTR1	2008	18478077	Unspecified
+hsa-miR-155	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Aberrant expression was correlated with specific breast cancer biopathologic features, such as estrogen and progesterone receptor expression, tumor stage, vascular invasion, or proliferation index"	unknown	AGTR1	2005	16103053	Unspecified
+hsa-miR-155	3459	breast cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	AGTR1	2006	16461460	Unspecified
+hsa-miR-155	8584	Burkitt lymphoma	up-regulated	"Northern blot, qRT-PCR etc"	"High expression of precursor miR-155/BIC in pediatric BL, but lack of BIC and miR-155"					
+expression in adult BL.	unknown	AGTR1	2004	14695998	Unspecified	0	998			
+hsa-miR-155	8584	Burkitt lymphoma	down-regulated	"Northern blot, qRT-PCR etc"	"Compared to Hodgkin's lymphoma and normal lymphoid tissues, adult Burkitt lymphoma patients have a low miR-155/BIC expression."	unknown	AGTR1	2005	16235244	Unspecified
+hsa-miR-155	8584	Burkitt lymphoma	down-regulated	"Northern blot, qRT-PCR etc"	"Expression of BIC is regulated by the BcR signaling pathway in a PKC and NF-kB-dependent manner. Classical Burkitt lymphoma cell lines, in contrast to normal B cells, Hodgkin's lymphoma cell lines and HEK293 cells,are not able to process BIC to mature miR-155.This indicates two levels of regulation of mature miR-155 expression, one at the transcriptional and one at the processing level."	unknown	AGTR1	2007	17173072	Unspecified
+hsa-miR-155	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	AGTR1	2008	17234972	Unspecified
+hsa-miR-155	1040	chronic lymphocytic leukemia (CLL)	up-regulated	"Northern blot, qRT-PCR etc"	2-fold overexpressed in CLL.	unknown	AGTR1	2007	17327404	Unspecified
+hsa-miR-155	1040	chronic lymphocytic leukemia (CLL)	up-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed between patients with different clinical outcomes.	unknown	AGTR1	2007	17989717	Unspecified
+hsa-miR-155	1985	colorectal cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	AGTR1	2006	16461460	Unspecified
+hsa-miR-155	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	AGTR1	2007	17942673	Unspecified
+hsa-miR-155	353	diffuse large B-cell lymphoma (DLBCL)	up-regulated	"Northern blot, qRT-PCR etc"	"Elevation in the amount of miR-155 occurs in a wide range of lymphomas derived from B cells of different developmental stages. Increased miR-155 levels (2,000-10,000 copies per cell vs 150 in normal circulating B cells) were observed in aggressive(DLBCL) and more indolent (CLL and MZ) lymphomas,and in non-HLs and HLs."	unknown	AGTR1	2005	15738415	Unspecified
+hsa-miR-155	353	diffuse large B-cell lymphoma (DLBCL)	up-regulated	"Northern blot, qRT-PCR etc"	"BIC and miR-155 are highly expressed in Hodgkin,primary mediastinal and diffuse large B cell lymphomas"	unknown	AGTR1	2005	16041695	Unspecified
+hsa-miR-155	353	diffuse large B-cell lymphoma (DLBCL)	up-regulated	"Northern blot, qRT-PCR etc"	"Identified microRNAs(miR-155, miR-21 and miR-221) that were more highly expressed in ABC-type than GCB-type cell lines. These microRNAs were over-expressed in de novo DLBCL (n=35), transformed DLBCL"					
+(n=14) and follicular center lymphoma cases (n=27) compared to normal B cells.	unknown	AGTR1	2007	17487835	Unspecified	0	1008			
+hsa-miR-155	353	diffuse large B-cell lymphoma (DLBCL)	up-regulated	microarray	"Four hsa-miR-As (miR-210, hsa-miR-155, hsa-miR-106a, hsa-miR-17-5p) were expressed at a significantly higher level in DLBCL than in normal tissue. In contrast, the remaining 11 miRNAs (hsa-miR-150, hsa-miR-145, hsa-miR-328, hsa-miR-139, hsa-miR-99a, hsa-miR-10a, hsa-miR-95, hsa-miR-149, hsa-miR-320, hsa-miR-151,let-7e) were expressed at a significantly lower level in DLBCL."	unknown	AGTR1	2008	18537969	Unspecified
+hsa-miR-155	14250	Down syndrome (DS)	up-regulated	"Northern blot, qRT-PCR etc"	"Bioinformatic analyses demonstrate that human chromosome 21(Hsa21) harbors five miRNA genes; miR-99a, let-7c, miR-125b-2, miR-155, and miR-802. MiRNA expression profiling, miRNA RT-PCR, and miRNA in situ hybridization experiments demonstrate that these miRNAs are overexpressed in fetal brain and heart specimens from individuals with DS when compared with age- and sex-matched controls."	unknown	AGTR1	2008	18387358	Unspecified
+hsa-miR-155	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	AGTR1	2007	17942673	Unspecified
+hsa-miR-155	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	DNA copy number status of 17 genomic loci containing miRNAs differentially expressed between IOSE cells and EOC cell lines.	unknown	AGTR1	2008	18458333	Unspecified
+hsa-miR-155	11727	facioscapulohumeral muscular dystrophy (FSHD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	AGTR1	2007	17942673	Unspecified
+hsa-miR-155	8524	follicular lymphoma (FL)	up-regulated	microarray	"Nine miRNAs (hsa-miR-9, hsa-miR-301, hsa-miR-213, hsa-miR-9*, hsa-miR-330, hsa-miR-106a, hsa-miR-338, hsa-miR-155, hsa-miR-210) were significantly up- and three miRNAs (hsa-miR-320, hsa-miR-149, hsa-miR-139) down-regulated in the lymphoma samples. Expression of hsa-miR-9 was most strongly increased (12-fold) and of hsa-miR-320 most strongly decreased (3-fold)."	unknown	AGTR1	2008	18537969	Unspecified
+hsa-miR-155	3073	glioblastoma multiforme (GBM)	up-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed microRNA in glioblastoma multiforme tumors relative to non-neoplastic brain tissue.	unknown	AGTR1	2008	18577219	Unspecified
+hsa-miR-155	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	AGTR1	2007	17616664	Unspecified
+hsa-miR-155	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	One of the 22 significantly up- and down-regulated miRNAs obtained using significance analysis of microarrays with false discovery rate of 5%. Majority of the predicted targets of these 22 differentially regulated miRNAs reside in pathways reported to be dysregulated during carcinogenesis.	unknown	AGTR1	2008	18319255	Unspecified
+hsa-miR-155	8567	Hodgkin's lymphoma	up-regulated	"Northern blot, qRT-PCR etc"	"BIC and miR-155 are highly expressed in Hodgkin,primary mediastinal and diffuse large B cell lymphomas"	unknown	AGTR1	2005	16041695	Unspecified
+hsa-miR-155	3429	Inclusion body myositis (IBM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	AGTR1	2007	17942673	Unspecified
+hsa-miR-155	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	AGTR1	2007	17942673	Unspecified
+hsa-miR-155	3905	lung cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	AGTR1	2006	16461460	Unspecified
+hsa-miR-155	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	AGTR1	2007	17942673	Unspecified
+hsa-miR-155	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	AGTR1	2007	17942673	Unspecified
+hsa-miR-155	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	AGTR1	2008	18381414	Unspecified
+hsa-miR-155	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	AGTR1	2008	18560586	Unspecified
+hsa-miR-155	4905	pancreatic cancer	down-regulated	"Northern blot, qRT-PCR etc"	"the expression of miR-103 and miR-107, associated with lack of expression of miR-155, discriminates tumors from normal."	unknown	AGTR1	2006	16966691	Unspecified
+hsa-miR-155	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Aberrantly expressed miRNA precursors in pancreatic adenocarcinoma.PAM testing was conducted on 10 tumor samples and 15 adjacent benign samples. PAM has correctly classified 100% of the tested tumor samples and 11 of 15 of the tested benign samples. The 20 top ranked differentially expressed miRNAs in pancreatic adenocarcinoma as selected by PAM.	unknown	AGTR1	2006	17149698	Unspecified
+hsa-miR-155	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	AGTR1	2007	17473300	Unspecified
+hsa-miR-155	3498	pancreatic ductal adenocarcinoma (PDAC)	up-regulated	"Northern blot, qRT-PCR etc"	differentially expressed between normal and PDAC or cell line samples.	unknown	AGTR1	2007	17237814	Unspecified
+hsa-miR-138-2	3969	papillary thyroid carcinoma (PTC)	up-regulated	microarray	Differentially expressed miRNA in PTC tumors	unknown	unknown	2005	16365291	Unspecified
+hsa-miR-138-2	3829	pituitary adenoma	down-regulated	microarray	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	unknown	2007	17111382	Unspecified
+hsa-miR-139	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-139	353	diffuse large B-cell lymphoma (DLBCL)	down-regulated	microarray	"Four hsa-miR-As (miR-210, hsa-miR-155, hsa-miR-106a, hsa-miR-17-5p) were expressed at a significantly higher level in DLBCL than in normal tissue. In contrast, the remaining 11 miRNAs (hsa-miR-150, hsa-miR-145, hsa-miR-328, hsa-miR-139, hsa-miR-99a, hsa-miR-10a, hsa-miR-95, hsa-miR-149, hsa-miR-320, hsa-miR-151,let-7e) were expressed at a significantly lower level in DLBCL."	unknown	unknown	2008	18537969	Unspecified
+hsa-miR-139	8524	follicular lymphoma (FL)	down-regulated	microarray	"Nine miRNAs (hsa-miR-9, hsa-miR-301, hsa-miR-213, hsa-miR-9*, hsa-miR-330, hsa-miR-106a, hsa-miR-338, hsa-miR-155, hsa-miR-210) were significantly up- and three miRNAs (hsa-miR-320, hsa-miR-149, hsa-miR-139) down-regulated in the lymphoma samples. Expression of hsa-miR-9 was most strongly increased (12-fold) and of hsa-miR-320 most strongly decreased (3-fold)."	unknown	unknown	2008	18537969	Unspecified
+hsa-miR-139	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	One of the 22 significantly up- and down-regulated miRNAs obtained using significance analysis of microarrays with false discovery rate of 5%. Majority of the predicted targets of these 22 differentially regulated miRNAs reside in pathways reported to be dysregulated during carcinogenesis.	unknown	unknown	2008	18319255	Unspecified
+hsa-miR-139	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-139	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-145	10286	prostate cancer	down-regulated	"Northern blot, qRT-PCR etc"	"let-7c, miR-145 and miR-125b target mRNAs whose proteins have been shown to be increased in prostate cancer."	unknown	FLJ21308	2007	17891175	Causal
+hsa-miR-222	3429	Inclusion body myositis (IBM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	KIT	2007	17942673	Unspecified
+hsa-miR-222	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	KIT	2007	17942673	Unspecified
+hsa-miR-222	1909	malignant melanoma	up-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	KIT	2008	18379589	Unspecified
+hsa-miR-222	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	KIT	2007	17942673	Unspecified
+hsa-miR-222	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	KIT	2007	17942673	Unspecified
+hsa-miR-222	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	KIT	2007	17473300	Unspecified
+hsa-miR-222	3498	pancreatic ductal adenocarcinoma (PDAC)	up-regulated	microarray	differentially expressed between normal and PDAC or cell line samples.	unknown	KIT	2007	17237814	Unspecified
+hsa-miR-222	3969	papillary thyroid carcinoma (PTC)	up-regulated	"Northern blot, qRT-PCR etc"	"Preliminary analysis of 6 miRNAs in 10 papillary thyroid carcinoma and 10 follicular adenoma identified significant overexpression of miR-146b, -221, and -222 in papillary thyroid carcinoma (P<0.02), but not miR-146a, -155, or -187 (P>0.08). particularly miR-146b, might potentially be adjunct markers for diagnosing papillary thyroid carcinoma in both FNA and surgical pathology specimens."	unknown	KIT	2008	18587330	Unspecified
+hsa-miR-222	10222	polymyositis (PM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	KIT	2007	17942673	Unspecified
+hsa-miR-222	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	KIT	2007	17616669	Unspecified	0	1048			
+hsa-miR-223	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	MicroRNA Signature Associated with Prognostic Factors (ZAP-70 Expression and IgVH Mutations) and Disease Progression in Patients with CLL.	unknown	NFIA	2005	16251535	Unspecified
+hsa-miR-223	9119	acute promyelocytic leukemia (APL)	up-regulated	"Northern blot, qRT-PCR etc"	"The expression levels of a specific miR-223 correlate with the differentiation fate of myeloid precursors. The activation of both pathways of transcriptional regulation by the myeloid lineage-specific transcription factor C/EBPalpha (CCAAT/enhancer-binding protein-alpha), and posttranscriptional regulation by miR-223 appears essential for granulocytic differentiation and clinical response of acute promyelocytic leukemia (APL) blasts to all-trans retinoic acid (ATRA). "	unknown	NFIA	2007	17217039	Causal
+hsa-miR-223	9119	acute promyelocytic leukemia (APL)	up-regulated	"Northern blot, qRT-PCR etc"	"Upregulation of miR-15a,miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223,miR-342 and miR-107, whereas miR-181b was downregulated in in acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment."	unknown	NFIA	2007	17260024	Causal
+hsa-miR-223	8552	chronic myeloid leukemia (CML)	down-regulated	"Northern blot, qRT-PCR etc"	miR-223 is a direct transcriptional target of AML1/ETO which induces heterochromatic silencing of miR-223.The relevance of the miR-223 silencing is also highlighted by the consequences of its ectopic expression that alone is sufficient to reprogram the myeloid differentiation program in distinct myeloid leukemia subtypes.	NFI-A	NFIA	2007	17996649	Causal
+hsa-miR-223	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	"The highly deregulated miR-223 and miR-222 could unequivocally distinguish HCC from adjacent nontumoral liver, irrespective of viral associations (P</=.0002). Re-expression of miR-223 in HBV, HCV, and non-HBV non-HCV-related HCC cell lines revealed a consistent inhibitory effect on cell viability (P<.01). Integrative analysis further implicated Stathmin 1 (STMN1) as a downstream target of miR-223. A strong inverse relationship between STMN1 mRNA and miR-223 expressions was shown (P =.006). At the protein level, restoration of miR-223 expressions in HCC cell lines led to a substantial reduction in STMN1 protein expression. We further showed that miR-223 readily could suppress the luciferase activity in reporter construct containing the STMN1 3' untranslated region (P =.02)."	STMN1	NFIA	2008	18555017	Causal
+hsa-miR-223	-1	neutrophilia	down-regulated	"Northern blot, qRT-PCR etc"	"myeloid-specific miR-223 negatively regulates progenitor proliferation and granulocyte differentiation and activation. miR-223 mutant mice have an expanded granulocytic compartment resulting from a cell-autonomous increase in the number of granulocyte progenitors. Mef2c, a transcription factor that promotes myeloid progenitor proliferation, is a target of miR-223, and that genetic ablation of Mef2c suppresses progenitor expansion and corrects the neutrophilic phenotype in miR-223 null mice. In addition, granulocytes lacking miR-223 are hypermature, hypersensitive to activating stimuli and display increased fungicidal activity."	Mef2c	NFIA	2008	18278031	Causal
+hsa-miR-223	6708	recurrent ovarian cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Target prediction analysis for the above miRNA ""recurrent metastatic signature"" identified genes previously validated in our transcriptome study. Common biological pathways well characterised in ovarian cancer were shared by miR-9 and miR-223 lists of predicted target genes. We provide strong evidence that miR-9 acts as a putative tumour suppressor gene in recurrent ovarian cancer. Based on integrated transcriptome and miRNA analysis, miR-9 and miR-223 can be of potential importance as biomarkers in recurrent ovarian cancer."					
+	unknown	NFIA	2008	18442408	Causal	1	1055			
+hsa-miR-223	9952	acute lymphoblastic leukemia (ALL)	down-regulated	"Northern blot, qRT-PCR etc"	"miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly downregulated in ALL compared with AML. They are the most discriminatory miRNAs between ALL and AML. Using the expression signatures of a minimum of two of these miRNAs resulted in an accuracy rate of >95% in the diagnosis of ALL and AML."	unknown	NFIA	2007	18056805	Unspecified
+hsa-miR-223	9119	acute myeloid leukemia (AML)	up-regulated	"Northern blot, qRT-PCR etc"	"miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly downregulated in ALL compared with AML. They are the most discriminatory miRNAs between ALL and AML. Using the expression signatures of a minimum of two of these miRNAs resulted in an accuracy rate of >95% in the diagnosis of ALL and AML."	unknown	NFIA	2007	18056805	Unspecified
+hsa-miR-223	4007	bladder cancer	up-regulated	microarray	"Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b,miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P<0.05) compared to normal bladder"					
+mucosa.	unknown	NFIA	2007	17826655	Unspecified	0	1058			
+hsa-miR-223	1985	colorectal cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	NFIA	2006	16461460	Unspecified
+hsa-miR-223	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	NFIA	2007	17942673	Unspecified
+hsa-miR-223	5517	gastric cancer (stomach cancer)	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	NFIA	2006	16461460	Unspecified
+hsa-miR-223	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	NFIA	2007	17616664	Unspecified
+hsa-miR-223	3429	Inclusion body myositis (IBM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	NFIA	2007	17942673	Unspecified
+hsa-miR-223	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	NFIA	2007	17942673	Unspecified
+hsa-miR-223	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	NFIA	2007	17942673	Unspecified
+hsa-miR-223	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	NFIA	2007	17942673	Unspecified
+hsa-miR-223	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	NFIA	2008	18381414	Unspecified
+hsa-miR-223	4905	pancreatic cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	NFIA	2006	16461460	Unspecified
+hsa-miR-223	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	NFIA	2007	17473300	Unspecified
+hsa-miR-223	3498	pancreatic ductal adenocarcinoma (PDAC)	up-regulated	"Northern blot, qRT-PCR etc"	differentially expressed between normal and PDAC or cell line samples.	unknown	NFIA	2007	17237814	Unspecified
+hsa-miR-223	3829	pituitary adenoma	down-regulated	microarray	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	NFIA	2007	17111382	Unspecified
+hsa-miR-223	12236	primary biliary cirrhosis (PBC)	down-regulated	microarray	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	NFIA	2008	18631158	Unspecified
+hsa-miR-223	10286	prostate cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	NFIA	2006	16461460	Unspecified
+hsa-miR-224	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	"miR-224, which is up-regulated in the tumors of HCC patients, sensitizes cells to apoptosis through"					
+"the inhibition of API-5 at the mRNA levels and increases cell proliferation. Significantly, miR-224 expression was found to be inversely correlated with API-5 expression in HCC patients."	API-5	unknown	2008	18319255	Causal	1	1074			
+hsa-miR-224	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	Differentially expressed between tumors and normals.	unknown	unknown	2007	17875710	Unspecified
+hsa-miR-224	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	Significantly differentially expressed between hepatocellular carcinoma and adjacent non-tumor tissue.	unknown	unknown	2006	16331254	Unspecified
+hsa-miR-224	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	"Our study identified and validated miR-224 overexpression.Moreover, miR-96 was overexpressed in HBV tumors, and miR-126* was down-regulated in alcohol-related hepatocellular carcinoma."	unknown	unknown	2008	18433021	Unspecified
+hsa-miR-224	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-224	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-224	8894	Oral Squamous Cell Carcinoma (OSCC)	up-regulated	microarray	miRNAs frequently up-regulated in OSCC cell lines(>1.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-224	3498	pancreatic ductal adenocarcinoma (PDAC)	up-regulated	microarray	differentially expressed between normal and PDAC or cell line samples.	unknown	unknown	2007	17237814	Unspecified
+hsa-miR-224	10286	prostate cancer	up-regulated	"Northern blot, qRT-PCR etc"	One of the upregulated microRNAs in tumors with perineural invasion (FDR 10%).	unknown	unknown	2008	18459106	Unspecified
+hsa-miR-23a	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	"miR-23a approximately 27a approximately 24, is induced in an early stage by TGF-beta in Huh-7 cells. Knockdown of Smad4, Smad2 or Smad3 expression by RNA interference can attenuate the response of miR-23a approximately 27a approximately 24 to TGF-beta addition, indicating that this induction is dependent on Smad pathway. We also explore that miR-23a approximately 27a approximately 24 can function as an antiapoptotic and proliferation-promoting factor in liver cancer cells. In addition, expression of this miRNA cluster is found to be remarkably upregulated in HCC tissues versus normal liver tissues. These findings suggest a novel, alternative mechanism through which TGF-beta could induce specific miRNA expression to escape from tumor-suppressive response in HCC cells."	unknown	"CXCL12,FLJ13158"	2008	18508316	Causal
+hsa-miR-23a	9952	acute lymphoblastic leukemia (ALL)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	"CXCL12,FLJ13158"	2007	18056805	Unspecified
+hsa-miR-23a	9119	acute myeloid leukemia (AML)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	"CXCL12,FLJ13158"	2007	18056805	Unspecified
+hsa-miR-23a	1208	autism spectrum disorder (ASD)	up-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	"CXCL12,FLJ13158"	2008	18563458	Unspecified
+hsa-miR-23a	4007	bladder cancer	up-regulated	microarray	"Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b,miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P<0.05) compared to normal bladder"					
+mucosa.	unknown	"CXCL12,FLJ13158"	2007	17826655	Unspecified	0	1087			
+hsa-miR-23a	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	"CXCL12,FLJ13158"	2008	17234972	Unspecified
+hsa-miR-23a	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	"CXCL12,FLJ13158"	2006	16609010	Unspecified
+hsa-miR-23a	3068	glioblastoma	up-regulated	microarray	Significantly differentially expressed between glioblastoma cell line samples and the control samples.	unknown	"CXCL12,FLJ13158"	2005	16039986	Unspecified
+hsa-miR-23a	6000	heart failure	up-regulated	"Northern blot, qRT-PCR etc"	"Northern blot analysis of the hypertrophy-regulated miRNAs in idiopathic end-stage failing human hearts showed increased expression of miR-24, miR-125b, miR-195, miR-199a, and miR-214."	unknown	"CXCL12,FLJ13158"	2006	17108080	Unspecified
+hsa-miR-23a	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	Differentially Regulated miR in HCCs.	unknown	"CXCL12,FLJ13158"	2006	16924677	Unspecified
+hsa-miR-23a	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	"CXCL12,FLJ13158"	2008	18381414	Unspecified
+hsa-miR-23a	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	"CXCL12,FLJ13158"	2007	17473300	Unspecified
+hsa-miR-23a	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	"CXCL12,FLJ13158"	2007	17616669	Unspecified	0	1095			
+hsa-miR-23a	5745	serous ovarian cancer	up-regulated	microarray	Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients.	unknown	"CXCL12,FLJ13158"	2008	18451233	Unspecified
+hsa-miR-23b	1040	chronic lymphocytic leukemia (CLL)	up-regulated	"Northern blot, qRT-PCR etc"	MicroRNA Signature Associated with Prognostic Factors (ZAP-70 Expression and IgVH Mutations) and Disease Progression in Patients with CLL.	unknown	Notch1	2005	16251535	Unspecified
+hsa-miR-23b	9952	acute lymphoblastic leukemia (ALL)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	Notch1	2007	18056805	Unspecified
+hsa-miR-23b	9119	acute myeloid leukemia (AML)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	Notch1	2007	18056805	Unspecified
+hsa-miR-23b	4007	bladder cancer	up-regulated	microarray	"Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b,miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P<0.05) compared to normal bladder"					
+mucosa.	unknown	Notch1	2007	17826655	Unspecified	0	1100			
+hsa-miR-23b	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change correlative with the increase in heart/body weight(7-14 days post-TAC).	unknown	Notch1	2008	17234972	Unspecified
+hsa-miR-23b	2893	cervical cancer	down-regulated	microarray	"let-7b, let-7c, miR-23b, miR-196b, and miR-143 showed significantly reduced abundance in cervical cancer cell lines. miR-21 displayed higher abundance in the cancer group."	unknown	Notch1	2007	17616659	Unspecified
+hsa-miR-23b	3068	glioblastoma	up-regulated	microarray	Significantly differentially expressed between glioblastoma cell line samples and the control samples.	unknown	Notch1	2005	16039986	Unspecified
+hsa-miR-23b	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	Differentially Regulated miR in HCCs.	unknown	Notch1	2006	16924677	Unspecified
+hsa-miR-23b	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	Notch1	2008	18379589	Unspecified
+hsa-miR-23b	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	Notch1	2008	18381414	Unspecified
+hsa-miR-23b	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	Notch1	2007	17473300	Unspecified
+hsa-miR-23b	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	Notch1	2007	17616669	Unspecified	0	1108			
+hsa-miR-23b	5745	serous ovarian cancer	up-regulated	microarray	Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients.	unknown	Notch1	2008	18451233	Unspecified
+hsa-miR-23b	13223	uterine leiomyoma (ULM)	up-regulated	"Northern blot, qRT-PCR etc"	One of the top five up-regulated miRNAs in Uterine Leiomyomas (ULMs).	unknown	Notch1	2007	17243163	Unspecified
+hsa-miR-24	10881	vesicular stomatitis	down-regulated	"Northern blot, qRT-PCR etc"	"miR-24 and miR-93 could target viral large protein (L protein) and phosphoprotein (P protein) genes, and in variant Dicer1 cells, a lack of host miR-24 and miR-93 was responsible for increased VSV replication."	"L protein,P protein"	"MAPK14,Notch1"	2007	17613256	Causal
+hsa-miR-24	9952	acute lymphoblastic leukemia (ALL)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	"MAPK14,Notch1"	2007	18056805	Unspecified
+hsa-miR-24	9119	acute myeloid leukemia (AML)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	"MAPK14,Notch1"	2007	18056805	Unspecified
+hsa-miR-24	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	"MAPK14,Notch1"	2008	17234972	Unspecified
+hsa-miR-24	6000	heart failure	up-regulated	"Northern blot, qRT-PCR etc"	"Northern blot analysis of the hypertrophy-regulated miRNAs in idiopathic end-stage failing human hearts showed increased expression of miR-24, miR-125b, miR-195, miR-199a, and miR-214."	unknown	"MAPK14,Notch1"	2006	17108080	Unspecified
+hsa-miR-24	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	"MAPK14,Notch1"	2006	16924677	Unspecified
+hsa-miR-24	10286	prostate cancer	up-regulated	microarray	One of the upregulated microRNAs in tumors with perineural invasion (FDR 10%).	unknown	"MAPK14,Notch1"	2008	18459106	Unspecified
+hsa-miR-24	5419	schizophrenia	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed miRNA from the prefrontal cortex of subjects with schizophrenia compared to psychiatrically healthy subjects.	unknown	"MAPK14,Notch1"	2007	17326821	Unspecified
+hsa-miR-24-1	1040	chronic lymphocytic leukemia (CLL)	up-regulated	"Northern blot, qRT-PCR etc"	MicroRNA Signature Associated with Prognostic Factors (ZAP-70 Expression and IgVH Mutations) and Disease Progression in Patients with CLL.	unknown	unknown	2005	16251535	Unspecified
+hsa-miR-24-1	1040	B-cell chronic lymphocytic leukemia	up-regulated	microarray	Differentially expressed in CLL cells versus CD26 cells.	unknown	unknown	2004	15284443	Unspecified
+hsa-miR-24-1	1985	colorectal cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-24-1	5517	gastric cancer (stomach cancer)	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-24-1	3068	glioblastoma	up-regulated	microarray	Significantly differentially expressed between glioblastoma cell line samples and the control samples.	unknown	unknown	2005	16039986	Unspecified
+hsa-miR-24-1	4905	pancreatic cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-24-1	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Aberrantly expressed miRNA precursors in pancreatic adenocarcinoma.PAM testing was conducted on 10 tumor samples and 15 adjacent benign samples. PAM has correctly classified 100% of the tested tumor samples and 11 of 15 of the tested benign samples. The 20 top ranked differentially expressed miRNAs in pancreatic adenocarcinoma as selected by PAM.	unknown	unknown	2006	17149698	Unspecified
+hsa-miR-24-1	3969	papillary thyroid carcinoma (PTC)	up-regulated	microarray	Differentially expressed miRNA in PTC tumors	unknown	unknown	2005	16365291	Unspecified
+hsa-miR-24-1	3829	pituitary adenoma	down-regulated	microarray	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	unknown	2007	17111382	Unspecified
+hsa-miR-24-2	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	"miR-23a approximately 27a approximately 24, is induced in an early stage by TGF-beta in Huh-7 cells. Knockdown of Smad4, Smad2 or Smad3 expression by RNA interference can attenuate the response of miR-23a approximately 27a approximately 24 to TGF-beta addition, indicating that this induction is dependent on Smad pathway. We also explore that miR-23a approximately 27a approximately 24 can function as an antiapoptotic and proliferation-promoting factor in liver cancer cells. In addition, expression of this miRNA cluster is found to be remarkably upregulated in HCC tissues versus normal liver tissues. These findings suggest a novel, alternative mechanism through which TGF-beta could induce specific miRNA expression to escape from tumor-suppressive response in HCC cells."	unknown	unknown	2008	18508316	Causal
+hsa-miR-24-2	1985	colorectal cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-24-2	5517	gastric cancer (stomach cancer)	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-24-2	3068	glioblastoma	up-regulated	microarray	Significantly differentially expressed between glioblastoma cell line samples and the control samples.	unknown	unknown	2005	16039986	Unspecified
+hsa-miR-24-2	3905	lung cancer	up-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-24-2	4905	pancreatic cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-24-2	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Aberrantly expressed miRNA precursors in pancreatic adenocarcinoma.PAM testing was conducted on 10 tumor samples and 15 adjacent benign samples. PAM has correctly classified 100% of the tested tumor samples and 11 of 15 of the tested benign samples. The 20 top ranked differentially expressed miRNAs in pancreatic adenocarcinoma as selected by PAM.	unknown	unknown	2006	17149698	Unspecified
+hsa-miR-24-2	3969	papillary thyroid carcinoma (PTC)	up-regulated	microarray	Differentially expressed miRNA in PTC tumors	unknown	unknown	2005	16365291	Unspecified
+hsa-miR-25	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	unknown	2006	16609010	Unspecified
+hsa-miR-25	5517	gastric cancer (stomach cancer)	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-25	3068	glioblastoma	up-regulated	microarray	Significantly differentially expressed between glioblastoma cell line samples and the control samples.	unknown	unknown	2005	16039986	Unspecified
+hsa-miR-25	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	One of the 22 significantly up- and down-regulated miRNAs obtained using significance analysis of microarrays with false discovery rate of 5%. Majority of the predicted targets of these 22 differentially regulated miRNAs reside in pathways reported to be dysregulated during carcinogenesis.	unknown	unknown	2008	18319255	Unspecified
+hsa-miR-25	4905	pancreatic cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-25	10286	prostate cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-26a	7012	anaplastic thyroid carcinoma (ATC)	down-regulated	"Northern blot, qRT-PCR etc"	miR-26a plays a role in slowing the cell proliferation.	HMGA(HMGA1 and HMGA2)	PLAG1	2007	17563749	Causal
+hsa-miR-26a	9952	acute lymphoblastic leukemia (ALL)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	PLAG1	2007	18056805	Unspecified
+hsa-miR-26a	9119	acute myeloid leukemia (AML)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	PLAG1	2007	18056805	Unspecified
+hsa-miR-26a	9119	acute myeloid leukemia (AML)	down-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	PLAG1	2008	18478077	Unspecified
+hsa-miR-26a	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	PLAG1	2008	17234972	Unspecified
+hsa-miR-26a	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	PLAG1	2006	16609010	Unspecified
+hsa-miR-26a	14691	Duchenne muscular dystrophy (DMD)	down-regulated	Northern blot or qRT-PCR etc	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	PLAG1	2007	17942673	Unspecified
+hsa-miR-26a	4001	epithelial ovarian cancer (EOC)	up-regulated	microarray	DNA copy number status of 17 genomic loci containing miRNAs differentially expressed between IOSE cells and EOC cell lines.	unknown	PLAG1	2008	18458333	Unspecified
+hsa-miR-26a	3829	pituitary adenoma	up-regulated	microarray	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	PLAG1	2007	17111382	Unspecified
+hsa-miR-26a	12236	primary biliary cirrhosis (PBC)	down-regulated	microarray	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	PLAG1	2008	18631158	Unspecified
+hsa-miR-26a	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	PLAG1	2007	17616669	Unspecified	0	1152			
+hsa-miR-26a	10286	prostate cancer	up-regulated	microarray	One of the upregulated microRNAs in tumors with perineural invasion (FDR 10%).	unknown	PLAG1	2008	18459106	Unspecified
+hsa-miR-26a	5745	serous ovarian cancer	down-regulated	microarray	Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients.	unknown	PLAG1	2008	18451233	Unspecified
+hsa-miR-26a-1	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	unknown	2006	16924677	Unspecified
+hsa-miR-26a-1	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-26a-1	3969	papillary thyroid carcinoma (PTC)	up-regulated	microarray	Differentially expressed miRNA in PTC tumors	unknown	unknown	2005	16365291	Unspecified
+hsa-miR-26a-2	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	unknown	2006	16924677	Unspecified
+hsa-miR-26b	10652	Alzheimer's disease	down-regulated	microarray	Significantly changed miRNAs in cortex of sporadic AD cases.	unknown	unknown	2008	18434550	Unspecified
+hsa-miR-26b	4007	bladder cancer	up-regulated	microarray	"Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b,miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P<0.05) compared to normal bladder"					
+"mucosa. with increasing tumor-nodes-metastasis staging in bladder cancer, miR-26b showed a moderate decreasing trend (P<0.082)."	unknown	unknown	2007	17826655	Unspecified	0	1160			
+hsa-miR-26b	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-26b	4001	epithelial ovarian cancer (EOC)	up-regulated	microarray	DNA copy number status of 17 genomic loci containing miRNAs differentially expressed between IOSE cells and EOC cell lines.	unknown	unknown	2008	18458333	Unspecified
+hsa-miR-26b	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-26b	3829	pituitary adenoma	up-regulated	microarray	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	unknown	2007	17111382	Unspecified
+hsa-miR-26b	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	1165			
+hsa-miR-26b	5419	schizophrenia	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed miRNA from the prefrontal cortex of subjects with schizophrenia compared to psychiatrically healthy subjects.	unknown	unknown	2007	17326821	Unspecified
+hsa-miR-27a	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"The oncogenic activity of miR-27a in MDA-MB-231 cells is due, in part, to suppression of ZBTB10 and Myt-1, which regulate specificity protein transcription factors and the G2-M chechpoint in MDA-MB-231 breast cancer Cells."	"ZBTB10, Myt-1"	unknown	2007	18006846	Causal
+hsa-miR-27a	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	"miR-23a approximately 27a approximately 24, is induced in an early stage by TGF-beta in Huh-7 cells. Knockdown of Smad4, Smad2 or Smad3 expression by RNA interference can attenuate the response of miR-23a approximately 27a approximately 24 to TGF-beta addition, indicating that this induction is dependent on Smad pathway. We also explore that miR-23a approximately 27a approximately 24 can function as an antiapoptotic and proliferation-promoting factor in liver cancer cells. In addition, expression of this miRNA cluster is found to be remarkably upregulated in HCC tissues versus normal liver tissues. These findings suggest a novel, alternative mechanism through which TGF-beta could induce specific miRNA expression to escape from tumor-suppressive response in HCC cells."	unknown	unknown	2008	18508316	Causal
+hsa-miR-27a	9952	acute lymphoblastic leukemia (ALL)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-27a	9119	acute myeloid leukemia (AML)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-27a	9119	acute myeloid leukemia (AML)	up-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-27a	1208	autism spectrum disorder (ASD)	up-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	unknown	2008	18563458	Unspecified
+hsa-miR-27a	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change correlative with the increase in heart/body weight(7-14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-27a	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Confirmation of the Aberrant miRNA Expression in Hypertrophic Hearts by Northern Blot Analysis and/or qRT-PCR.	unknown	unknown	2007	17525252	Unspecified
+hsa-miR-27a	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	unknown	2006	16609010	Unspecified
+hsa-miR-27a	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-27a	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-27a	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	1178			
+hsa-miR-27a	10286	prostate cancer	up-regulated	microarray	One of the upregulated microRNAs in tumors with perineural invasion (FDR 10%).	unknown	unknown	2008	18459106	Unspecified
+hsa-miR-27a	5745	serous ovarian cancer	up-regulated	microarray	Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients.	unknown	unknown	2008	18451233	Unspecified
+hsa-miR-27a	13223	uterine leiomyoma (ULM)	up-regulated	"Northern blot, qRT-PCR etc"	One of the top five up-regulated miRNAs in Uterine Leiomyomas (ULMs).	unknown	unknown	2007	17243163	Unspecified
+hsa-miR-27b	9952	acute lymphoblastic leukemia (ALL)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	"CYP1B1,Notch1"	2007	18056805	Unspecified
+hsa-miR-27b	9119	acute myeloid leukemia (AML)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	"CYP1B1,Notch1"	2007	18056805	Unspecified
+hsa-miR-27b	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change correlative with the increase in heart/body weight(7-14 days post-TAC).	unknown	"CYP1B1,Notch1"	2008	17234972	Unspecified
+hsa-miR-27b	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Confirmation of the Aberrant miRNA Expression in Hypertrophic Hearts by Northern Blot Analysis and/or qRT-PCR.	unknown	"CYP1B1,Notch1"	2007	17525252	Unspecified
+hsa-miR-27b	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	"CYP1B1,Notch1"	2006	16609010	Unspecified
+hsa-miR-27b	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	"CYP1B1,Notch1"	2006	16530703	Unspecified
+hsa-miR-27b	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	"CYP1B1,Notch1"	2008	18381414	Unspecified
+hsa-miR-27b	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	"CYP1B1,Notch1"	2007	17616669	Unspecified	0	1189			
+hsa-miR-27b	10286	prostate cancer	up-regulated	microarray	One of the upregulated microRNAs in tumors with perineural invasion (FDR 10%).	unknown	"CYP1B1,Notch1"	2008	18459106	Unspecified
+hsa-miR-28	4451	kidney cancer	up-regulated	microarray	"A set of 4 human micro-RNAs (miR-28, miR-185, miR-27, and let-7f-2) were found significantly up-regulated in renal cell carcinoma (P<0.05) compared to normal kidney."	unknown	unknown	2007	17826655	Unspecified
+hsa-miR-28	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-296	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	unknown	2006	16609010	Unspecified
+hsa-miR-296	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-296	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-296	12236	primary biliary cirrhosis (PBC)	down-regulated	microarray	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	unknown	2008	18631158	Unspecified
+hsa-miR-296	10286	prostate cancer	up-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	1197			
+hsa-miR-299-3p	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-299-3p	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-299-5p	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-299-5p	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-299-5p	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-299-5p	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-299-5p	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-29a	10652	Alzheimer's disease	down-regulated	"Northern blot, qRT-PCR etc"	"that miR-29a, -29b-1, and -9 can regulate BACE1 expression in vitro. The miR-29a/b-1 cluster was significantly (and AD-dementia-specific) decreased in AD patients displaying abnormally high BACE1 protein."	BACE1	unknown	2008	18434550	Causal
+hsa-miR-29a	3905	lung cancer	down-regulated	"Northern blot, qRT-PCR etc"	" Expression of miR-29s is inversely correlated to DNA methyltransferase(DNMT)3A and -3B in lung cancer tissues, and that miR-29s directly target both DNMT3A and -3B.The enforced expression of miR-29s in lung cancer cell lines restores normal patterns of DNA methylation, induces reexpression of methylation-silenced tumor suppressor genes."	"DNMT3A, DNMT3B"	unknown	2007	17890317	Causal
+hsa-miR-29a	9351	type 2 diabetes	up-regulated	"Northern blot, qRT-PCR etc"	"Adenovirus-mediated overexpression of miR-29a, miR-29b and miR-29c in rat adipocytes largely repressed insulin-stimulated glucose uptake, revealing a crucial role of miR-29 in type 2 diabetes."	unknown	unknown	2007	17652184	Causal
+hsa-miR-29a	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-29a	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Confirmation of the Aberrant miRNA Expression in Hypertrophic Hearts by Northern Blot Analysis and/or qRT-PCR.	unknown	unknown	2007	17525252	Unspecified
+hsa-miR-29a	2786	Cerebellar neurodegeneration	down-regulated	"Northern blot, qRT-PCR etc"	Essential for the survival of Purkinje cells and its absence leads to a slow degeneration of these cells.	unknown	unknown	2007	17606634	Unspecified
+hsa-miR-29a	14691	Duchenne muscular dystrophy (DMD)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-29a	11727	facioscapulohumeral muscular dystrophy (FSHD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-29a	10923	homozygous sickle cell disease (HbSS)	up-regulated	microarray	"Several microRNAs (miR-320, let-7s, miR-181, miR-141) were over-represented in the HbAA erythrocytes, while other microRNAs (miR-29a, miR-144, miR-451, miR-140) were overrepresented in the HbSS erythrocytes."	unknown	unknown	2008	18523662	Unspecified
+hsa-miR-29a	12858	Huntington's disease (HD)	up-regulated	"Northern blot, qRT-PCR etc"	mir-29a and mir-330 are significantly higher in HD samples.	unknown	unknown	2007	18082412	Unspecified
+hsa-miR-29a	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-29a	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	1216			
+hsa-miR-29a	5419	schizophrenia	down-regulated	microarray	Differentially expressed miRNA from the prefrontal cortex of subjects with schizophrenia compared to psychiatrically healthy subjects.	unknown	unknown	2007	17326821	Unspecified
+hsa-miR-29a	5745	serous ovarian cancer	down-regulated	microarray	Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients.	unknown	unknown	2008	18451233	Unspecified
+hsa-miR-29a-2	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	MicroRNA Signature Associated with Prognostic Factors (ZAP-70 Expression and IgVH Mutations) and Disease Progression in Patients with CLL.	unknown	unknown	2005	16251535	Unspecified
+hsa-miR-29a-2	3969	papillary thyroid carcinoma (PTC)	up-regulated	microarray	Differentially expressed miRNA in PTC tumors	unknown	unknown	2005	16365291	Unspecified
+hsa-miR-29b	4947	cholangiocarcinoma	down-regulated	"Northern blot, qRT-PCR etc"	Mcl-1 protein expression can be regulated by mir-29b. Enforced mir-29b expression reduced Mcl-1 cellular protein levels and sensitized the cancer cells to tumor necrosis factor-related apoptosisinducing ligand (TRAIL) cytotoxicity. Transfection of non-malignant cells (that express high levels ofmir -29) with a locked-nucleic acid antagonist ofmir-29b increased					
+"Mcl-1 levels and reduced TRAIL-mediated apoptosis. Thus mir-29 is an endogenous regulator ofM cl-1 protein expression, and thereby, apoptosis."	Mcl-1	unknown	2007	17404574	Causal	1	1221			
+hsa-miR-29b	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	miR-29 regulates Tcl1 expression	Tcl1	unknown	2006	17178851	Causal
+hsa-miR-29b	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	"miR-29b and miR-181b target oncogene TCL1, which leads to malignant cell proliferation."	Tcl1	unknown	2007	17707831	Causal
+hsa-miR-29b	3905	lung cancer	down-regulated	"Northern blot, qRT-PCR etc"	" Expression of miR-29s is inversely correlated to DNA methyltransferase(DNMT)3A and -3B in lung cancer tissues, and that miR-29s directly target both DNMT3A and -3B.The enforced expression of miR-29s in lung cancer cell lines restores normal patterns of DNA methylation, induces reexpression of methylation-silenced tumor suppressor genes."	"DNMT3A, DNMT3B"	unknown	2007	17890317	Causal
+hsa-miR-29b	9351	type 2 diabetes	up-regulated	"Northern blot, qRT-PCR etc"	"Adenovirus-mediated overexpression of miR-29a, miR-29b and miR-29c in rat adipocytes largely repressed insulin-stimulated glucose uptake, revealing a crucial role of miR-29 in type 2 diabetes."	unknown	unknown	2007	17652184	Causal
+hsa-miR-29b	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Confirmation of the Aberrant miRNA Expression in Hypertrophic Hearts by Northern Blot Analysis and/or qRT-PCR.	unknown	unknown	2007	17525252	Unspecified
+hsa-miR-29b	14691	Duchenne muscular dystrophy (DMD)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-29b	11727	facioscapulohumeral muscular dystrophy (FSHD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-29b	3073	glioblastoma multiforme (GBM)	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed microRNA in glioblastoma multiforme tumors relative to non-neoplastic brain tissue.	unknown	unknown	2008	18577219	Unspecified
+hsa-miR-29b	5520	head and neck squamous cell carcinoma (HNSCC)	down-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-29b	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-29b	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-29b	3191	nemaline myopathy (NM)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-29b	3969	papillary thyroid carcinoma (PTC)	up-regulated	microarray	Differentially expressed miRNA in PTC tumors	unknown	unknown	2005	16365291	Unspecified
+hsa-miR-29b	12236	primary biliary cirrhosis (PBC)	down-regulated	microarray	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	unknown	2008	18631158	Unspecified
+hsa-miR-29b	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	1236			
+hsa-miR-29b	5419	schizophrenia	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed miRNA from the prefrontal cortex of subjects with schizophrenia compared to psychiatrically healthy subjects.	unknown	unknown	2007	17326821	Unspecified
+hsa-miR-29b	13223	uterine leiomyoma (ULM)	down-regulated	"Northern blot, qRT-PCR etc"	One of the top five down-regulated miRNAs in Uterine Leiomyomas (ULMs).	unknown	unknown	2007	17243163	Unspecified
+hsa-miR-29b	13223	uterine leiomyoma (ULM)	down-regulated	microarray	Twenty most differentially expressed microRNA species in leiomyoma versus myometrium microarray.	unknown	unknown	2008	17765232	Unspecified
+hsa-miR-29b-1	10652	Alzheimer's disease	down-regulated	"Northern blot, qRT-PCR etc"	"that miR-29a, -29b-1, and -9 can regulate BACE1 expression in vitro. The miR-29a/b-1 cluster was significantly (and AD-dementia-specific) decreased in AD patients displaying abnormally high BACE1 protein."	BACE1	unknown	2008	18434550	Causal
+hsa-miR-29b-2	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	MicroRNA Signature Associated with Prognostic Factors (ZAP-70 Expression and IgVH Mutations) and Disease Progression in Patients with CLL.	unknown	unknown	2005	16251535	Unspecified
+hsa-miR-29b-2	3459	breast cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-29b-2	1985	colorectal cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-29b-2	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-29b-2	4905	pancreatic cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-29b-2	10286	prostate cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-29c	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	MicroRNA Signature Associated with Prognostic Factors (ZAP-70 Expression and IgVH Mutations) and Disease Progression in Patients with CLL.	unknown	unknown	2005	16251535	Unspecified
+hsa-miR-29c	3905	lung cancer	down-regulated	"Northern blot, qRT-PCR etc"	" Expression of miR-29s is inversely correlated to DNA methyltransferase(DNMT)3A and -3B in lung cancer tissues, and that miR-29s directly target both DNMT3A and -3B.The enforced expression of miR-29s in lung cancer cell lines restores normal patterns of DNA methylation, induces reexpression of methylation-silenced tumor suppressor genes."	"DNMT3A, DNMT3B"	unknown	2007	17890317	Causal
+hsa-miR-29c	9261	nasopharyngeal carcinoma (NPC)	down-regulated	"Northern blot, qRT-PCR etc"	"In NPC tumors, the lower mir-29c levels correlated with higher levels of multiple mRNAs whose 3  UTRs can bind mir-29c at target sequences conserved across many vertebrates. In cultured cells, introduction of mir-29c down-regulated these genes at the level of mRNA and inhibited expression of luciferase encoded by vectors having the 3  UTRs of these genes. Moreover, for each of several genes tested, mutating the mir-29c target sites in the 3  UTR abrogated mir-29c induced inhibition of luciferase expression. Most of the mir-29ctargeted genes identified encode extracellular matrix proteins, including multiple collagens and laminin 1, that are associated with tumor cell invasiveness and metastatic potential, prominent characteristics of NPC. The 3  UTRs of all of these 10 candidate target genes (Collagen 1A1, 1A2, 3A1, 4A1, 4A2, 15A1, FUSIP1iso1, laminin  1, SPARC, and TDG) elicited significantly decreased luciferase activities in mir-29c transfected cells."	"COL1A1, COL1A2, COL3A1, COL4A1, COL4A2, COL15A1, FUSIP1iso1, LAMININ gamma1, SPARC, TDG"	unknown	2008	18390668	Causal
+hsa-miR-29c	9351	type 2 diabetes	up-regulated	"Northern blot, qRT-PCR etc"	"Adenovirus-mediated overexpression of miR-29a, miR-29b and miR-29c in rat adipocytes largely repressed insulin-stimulated glucose uptake, revealing a crucial role of miR-29 in type 2 diabetes."	unknown	unknown	2007	17652184	Causal
+hsa-miR-29c	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-29c	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Confirmation of the Aberrant miRNA Expression in Hypertrophic Hearts by Northern Blot Analysis and/or qRT-PCR.	unknown	unknown	2007	17525252	Unspecified
+hsa-miR-29c	14691	Duchenne muscular dystrophy (DMD)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-29c	3191	nemaline myopathy (NM)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-29c	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-29c	3498	pancreatic ductal adenocarcinoma (PDAC)	down-regulated	microarray	differentially expressed between normal and PDAC or cell line samples.	unknown	unknown	2007	17237814	Unspecified
+hsa-miR-29c	3969	papillary thyroid carcinoma (PTC)	up-regulated	microarray	Differentially expressed miRNA in PTC tumors	unknown	unknown	2005	16365291	Unspecified
+hsa-miR-29c	5419	schizophrenia	down-regulated	microarray	Differentially expressed miRNA from the prefrontal cortex of subjects with schizophrenia compared to psychiatrically healthy subjects.	unknown	unknown	2007	17326821	Unspecified
+hsa-miR-29c	13223	uterine leiomyoma (ULM)	down-regulated	microarray	Twenty most differentially expressed microRNA species in leiomyoma versus myometrium microarray.	unknown	unknown	2008	17765232	Unspecified
+hsa-miR-301	8524	follicular lymphoma (FL)	up-regulated	microarray	"Nine miRNAs (hsa-miR-9, hsa-miR-301, hsa-miR-213, hsa-miR-9*, hsa-miR-330, hsa-miR-106a, hsa-miR-338, hsa-miR-155, hsa-miR-210) were significantly up- and three miRNAs (hsa-miR-320, hsa-miR-149, hsa-miR-139) down-regulated in the lymphoma samples. Expression of hsa-miR-9 was most strongly increased (12-fold) and of hsa-miR-320 most strongly decreased (3-fold)."	unknown	unknown	2008	18537969	Unspecified
+hsa-miR-301	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	One of the 22 significantly up- and down-regulated miRNAs obtained using significance analysis of microarrays with false discovery rate of 5%. Majority of the predicted targets of these 22 differentially regulated miRNAs reside in pathways reported to be dysregulated during carcinogenesis.	unknown	unknown	2008	18319255	Unspecified
+hsa-miR-301	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Aberrantly expressed miRNA precursors in pancreatic adenocarcinoma.PAM testing was conducted on 10 tumor samples and 15 adjacent benign samples. PAM has correctly classified 100% of the tested tumor samples and 11 of 15 of the tested benign samples. The 20 top ranked differentially expressed miRNAs in pancreatic adenocarcinoma as selected by PAM.	unknown	unknown	2006	17149698	Unspecified
+hsa-miR-302	3305	teratocarcinoma	up-regulated	"Northern blot, qRT-PCR etc"	"The miR-302 cluster was potently expressed in undifferentiated NTera2D1 and P19 cells, but hardly in differentiated cells, such that miR-124a showed an opposite expression pattern to the miR-302 cluster.it is suggested that the miR-302 cluster and miR-124a may be useful molecular indicators in the assessment of degree of undifferentiation and/or differentiation in the course of neuronal differentiation."	unknown	unknown	2007	17716626	Unspecified
+hsa-miR-302a	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-302a	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-302b	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-302b	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-302b*	9119	acute myeloid leukemia (AML)	down-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-302c	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	DNA copy number status of 17 genomic loci containing miRNAs differentially expressed between IOSE cells and EOC cell lines.	unknown	unknown	2008	18458333	Unspecified
+hsa-miR-302c	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-302c*	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-302c*	10286	prostate cancer	up-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	1274			
+hsa-miR-302d	9119	acute myeloid leukemia (AML)	down-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-302d	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-302d	5556	testicular germ cell tumor	up-regulated	microarray	Differentially expressed miRNA in the various histological subtypes of  germ cell tumour (GCT) (TE = teratoma; SE = seminoma; EC = embryonal carcinoma).	unknown	unknown	2007	17893849	Unspecified
+hsa-miR-30a	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	survival-related and metastasis-related miRNA.	unknown	unknown	2008	18176954	Unspecified
+hsa-miR-30a	13223	uterine leiomyoma (ULM)	up-regulated	"Northern blot, qRT-PCR etc"	One of the top five up-regulated miRNAs in Uterine Leiomyomas (ULMs).	unknown	unknown	2007	17243163	Unspecified
+hsa-miR-30a-3p	9119	acute myeloid leukemia (AML)	down-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-30a-3p	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-30a-3p	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	unknown	2006	16609010	Unspecified
+hsa-miR-30a-3p	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed between neoplastic conditions (CRC cell lines and tumor samples) and non-tumoral colon tissues.	unknown	unknown	2006	16854228	Unspecified
+hsa-miR-30a-3p	10223	dermatomyositis (DM)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-30a-3p	14691	Duchenne muscular dystrophy (DMD)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-30a-3p	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-30a-3p	423	miyoshi myopathy (MM)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-30a-3p	3191	nemaline myopathy (NM)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-30a-3p	10222	polymyositis (PM)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-30a-5p	7012	anaplastic thyroid carcinoma (ATC)	down-regulated	"Northern blot, qRT-PCR etc"	"A significant decrease in miR-30d, miR-125b, miR-26a and miR-30a-5p was detected in ATC in comparison to normalthyroid tissue."	unknown	unknown	2007	17563749	Unspecified
+hsa-miR-30a-5p	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change correlative with the increase in heart/body weight(7-14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-30a-5p	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	unknown	2006	16609010	Unspecified
+hsa-miR-30a-5p	14691	Duchenne muscular dystrophy (DMD)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-30a-5p	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-30a-5p	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-30a-5p	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	1296			
+hsa-miR-30a-5p	5419	schizophrenia	down-regulated	microarray	Differentially expressed miRNA from the prefrontal cortex of subjects with schizophrenia compared to psychiatrically healthy subjects.	unknown	unknown	2007	17326821	Unspecified
+hsa-miR-30b	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change correlative with the increase in heart/body weight(7-14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-30b	14691	Duchenne muscular dystrophy (DMD)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-30b	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-30b	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-30b	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-30b	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	1303			
+hsa-miR-30b	5419	schizophrenia	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed miRNA from the prefrontal cortex of subjects with schizophrenia compared to psychiatrically healthy subjects.	unknown	unknown	2007	17326821	Unspecified
+hsa-miR-30c	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change correlative with the increase in heart/body weight(7-14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-30c	2786	Cerebellar neurodegeneration	down-regulated	"Northern blot, qRT-PCR etc"	Essential for the survival of Purkinje cells and its absence leads to a slow degeneration of these cells.	unknown	unknown	2007	17606634	Unspecified
+hsa-miR-30c	1985	colorectal cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-30c	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	unknown	2006	16609010	Unspecified
+hsa-miR-30c	14691	Duchenne muscular dystrophy (DMD)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-30c	423	miyoshi myopathy (MM)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-30c	4905	pancreatic cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-30c	10286	prostate cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-30c	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	1313			
+hsa-miR-30c	10286	prostate cancer	up-regulated	"Northern blot, qRT-PCR etc"	One of the upregulated microRNAs in tumors with perineural invasion (FDR 10%).	unknown	unknown	2008	18459106	Unspecified
+hsa-miR-30c	9088	psoriasis	down-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	unknown	2007	17622355	Unspecified
+hsa-miR-30c-1	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	survival-related and metastasis-related miRNA.	unknown	unknown	2008	18176954	Unspecified
+hsa-miR-30d	9119	acute myeloid leukemia (AML)	up-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-30d	7012	anaplastic thyroid carcinoma (ATC)	down-regulated	"Northern blot, qRT-PCR etc"	"A significant decrease in miR-30d, miR-125b, miR-26a and miR-30a-5p was detected in ATC in comparison to normalthyroid tissue."	unknown	unknown	2007	17563749	Unspecified
+hsa-miR-30d	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change correlative with the increase in heart/body weight(7-14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-30d	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	"miR-30d together with miR-181a and let-7a,play important role in normal mouse and human hematopoiesis,particularly during B- and T-lymphocyte lineage differentiation and in B-cell lymphomas."	unknown	unknown	2007	17989717	Unspecified
+hsa-miR-30d	14691	Duchenne muscular dystrophy (DMD)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-30d	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-30d	12236	primary biliary cirrhosis (PBC)	down-regulated	microarray	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	unknown	2008	18631158	Unspecified
+hsa-miR-30d	5419	schizophrenia	down-regulated	microarray	Differentially expressed miRNA from the prefrontal cortex of subjects with schizophrenia compared to psychiatrically healthy subjects.	unknown	unknown	2007	17326821	Unspecified
+hsa-miR-30e	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	survival-related and metastasis-related miRNA.	unknown	unknown	2008	18176954	Unspecified
+hsa-miR-30e	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-30e	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Confirmation of the Aberrant miRNA Expression in Hypertrophic Hearts by Northern Blot Analysis and/or qRT-PCR.	unknown	unknown	2007	17525252	Unspecified
+hsa-miR-30e	5419	schizophrenia	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed miRNA from the prefrontal cortex of subjects with schizophrenia compared to psychiatrically healthy subjects.	unknown	unknown	2007	17326821	Unspecified
+hsa-miR-30e*	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-30e-5p	14691	Duchenne muscular dystrophy (DMD)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-30e-5p	5520	head and neck squamous cell carcinoma (HNSCC)	down-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-30e-5p	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-30e-5p	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-30e-5p	9088	psoriasis	up-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	unknown	2007	17622355	Unspecified
+hsa-miR-31	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change correlative with the increase in heart/body weight(7-14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-31	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed between neoplastic conditions (CRC cell lines and tumor samples) and non-tumoral colon tissues.	unknown	unknown	2006	16854228	Unspecified
+hsa-miR-31	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Expression levels of analyzed miRNAs significantly differed among tumors and adjacent non-tumor tissues: miR-21 (p = 0.0001) and miR-31 (p = 0.0006) were upregulated, and miR-143 (p = 0.011) and miR-145 (p = 0.004) were downregulated in tumors."	unknown	unknown	2007	18196926	Unspecified
+hsa-miR-31	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-31	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	"Distinct up-regulations of miR-222, miR-221, and miR-31, and down-regulations of miR-223, miR-126, and miR-122a were identified. Further investigations suggested the highly deregulated miR-223 and miR-222 could unequivocally distinguish HCC from adjacent nontumoral liver, irrespective of viral associations (P<=.0002)."	unknown	unknown	2008	18555017	Unspecified
+hsa-miR-31	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-31	8894	Oral Squamous Cell Carcinoma (OSCC)	up-regulated	microarray	miRNAs frequently up-regulated in OSCC cell lines(>1.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-31	3498	pancreatic ductal adenocarcinoma (PDAC)	up-regulated	microarray	differentially expressed between normal and PDAC or cell line samples.	unknown	unknown	2007	17237814	Unspecified
+hsa-miR-31	9088	psoriasis	up-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	unknown	2007	17622355	Unspecified
+hsa-miR-32	934	PFV-1 infection	down-regulated	"Northern blot, qRT-PCR etc"	A cellular microRNA effectively restricts the accumulation of the retrovirus primate foamy virus type 1 (PFV-1) in human cells. 	unknown	PFV-1	2005	15845854	Causal
+hsa-miR-32	1985	colorectal cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	PFV-1	2006	16461460	Unspecified
+hsa-miR-32	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	PFV-1	2006	16530703	Unspecified
+hsa-miR-32	4905	pancreatic cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	PFV-1	2006	16461460	Unspecified
+hsa-miR-32	10286	prostate cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	PFV-1	2006	16461460	Unspecified
+hsa-miR-32	13223	uterine leiomyoma (ULM)	down-regulated	"Northern blot, qRT-PCR etc"	One of the top five down-regulated miRNAs in Uterine Leiomyomas (ULMs).	unknown	PFV-1	2007	17243163	Unspecified
+hsa-miR-320	10923	homozygous sickle cell disease (HbSS)	down-regulated	"Northern blot, qRT-PCR etc"	"miR-320 played an important role for the down-regulation of its target gene, CD71 during reticulocyte terminal differentiation. Further investigation revealed that poor expression of miR-320 in HbSS cells was associated with their defective downregulation CD71 during terminal differentiation."	CD71	unknown	2008	18523662	Causal
+hsa-miR-320	10652	Alzheimer's disease	up-regulated	microarray	Significantly changed miRNAs in cortex of sporadic AD cases.	unknown	unknown	2008	18434550	Unspecified
+hsa-miR-320	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	unknown	2006	16609010	Unspecified
+hsa-miR-320	353	diffuse large B-cell lymphoma (DLBCL)	down-regulated	microarray	"Four hsa-miR-As (miR-210, hsa-miR-155, hsa-miR-106a, hsa-miR-17-5p) were expressed at a significantly higher level in DLBCL than in normal tissue. In contrast, the remaining 11 miRNAs (hsa-miR-150, hsa-miR-145, hsa-miR-328, hsa-miR-139, hsa-miR-99a, hsa-miR-10a, hsa-miR-95, hsa-miR-149, hsa-miR-320, hsa-miR-151,let-7e) were expressed at a significantly lower level in DLBCL."	unknown	unknown	2008	18537969	Unspecified
+hsa-miR-320	8524	follicular lymphoma (FL)	down-regulated	microarray	"Nine miRNAs (hsa-miR-9, hsa-miR-301, hsa-miR-213, hsa-miR-9*, hsa-miR-330, hsa-miR-106a, hsa-miR-338, hsa-miR-155, hsa-miR-210) were significantly up- and three miRNAs (hsa-miR-320, hsa-miR-149, hsa-miR-139) down-regulated in the lymphoma samples. Expression of hsa-miR-9 was most strongly increased (12-fold) and of hsa-miR-320 most strongly decreased (3-fold)."	unknown	unknown	2008	18537969	Unspecified
+hsa-miR-320	10286	prostate cancer	up-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	1355			
+hsa-miR-320-2	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	unknown	2006	16924677	Unspecified
+hsa-miR-320a	1208	autism spectrum disorder (ASD)	down-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	unknown	2008	18563458	Unspecified
+hsa-miR-323	3073	glioblastoma multiforme (GBM)	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed microRNA in glioblastoma multiforme tumors relative to non-neoplastic brain tissue.	unknown	unknown	2008	18577219	Unspecified
+hsa-miR-323	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-323	13223	uterine leiomyoma (ULM)	up-regulated	"Northern blot, qRT-PCR etc"	Real-time reverse transcriptase polymerase chain reaction (RT-PCR) validation of microarray. Realtime					
+"semiquantitative RT-PCR of five different microRNA species (miR-21, miR-34a, miR-125b, miR-139, and miR-323) across ten subjects. miR-21, miR-34a, miR-125b, and miR-323 were overexpressed in leiomyoma in the ten pairs tested and miR-139 was underexpressed, consistent with the microarray results."	unknown	unknown	2008	17765232	Unspecified	0	1360			
+hsa-miR-324-3p	12236	primary biliary cirrhosis (PBC)	down-regulated	microarray	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	unknown	2008	18631158	Unspecified
+hsa-miR-324-5p	9119	acute myeloid leukemia (AML)	up-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-324-5p	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	One of the 22 significantly up- and down-regulated miRNAs obtained using significance analysis of microarrays with false discovery rate of 5%. Majority of the predicted targets of these 22 differentially regulated miRNAs reside in pathways reported to be dysregulated during carcinogenesis.	unknown	unknown	2008	18319255	Unspecified
+hsa-miR-324-5p	1909	malignant melanoma	up-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-325	9119	acute myeloid leukemia (AML)	down-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-325	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-326	9119	acute myeloid leukemia (AML)	up-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-326	12236	primary biliary cirrhosis (PBC)	down-regulated	microarray	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	unknown	2008	18631158	Unspecified
+hsa-miR-326	9088	psoriasis	down-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	unknown	2007	17622355	Unspecified
+hsa-miR-328	9119	acute myeloid leukemia (AML)	up-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-328	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed between neoplastic conditions (CRC cell lines and tumor samples) and non-tumoral colon tissues.	unknown	unknown	2006	16854228	Unspecified
+hsa-miR-328	353	diffuse large B-cell lymphoma (DLBCL)	down-regulated	microarray	"Four hsa-miR-As (miR-210, hsa-miR-155, hsa-miR-106a, hsa-miR-17-5p) were expressed at a significantly higher level in DLBCL than in normal tissue. In contrast, the remaining 11 miRNAs (hsa-miR-150, hsa-miR-145, hsa-miR-328, hsa-miR-139, hsa-miR-99a, hsa-miR-10a, hsa-miR-95, hsa-miR-149, hsa-miR-320, hsa-miR-151,let-7e) were expressed at a significantly lower level in DLBCL."	unknown	unknown	2008	18537969	Unspecified
+hsa-miR-328	3073	glioblastoma multiforme (GBM)	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed microRNA in glioblastoma multiforme tumors relative to non-neoplastic brain tissue.	unknown	unknown	2008	18577219	Unspecified
+hsa-miR-328	12236	primary biliary cirrhosis (PBC)	down-regulated	microarray	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	unknown	2008	18631158	Unspecified
+hsa-miR-328-1	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	unknown	2006	16924677	Unspecified
+hsa-miR-33	1040	B-cell chronic lymphocytic leukemia	up-regulated	microarray	Differentially expressed in CLL cells versus CD27 cells.	unknown	unknown	2004	15284443	Unspecified
+hsa-miR-33	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-330	8524	follicular lymphoma (FL)	up-regulated	microarray	"Nine miRNAs (hsa-miR-9, hsa-miR-301, hsa-miR-213, hsa-miR-9*, hsa-miR-330, hsa-miR-106a, hsa-miR-338, hsa-miR-155, hsa-miR-210) were significantly up- and three miRNAs (hsa-miR-320, hsa-miR-149, hsa-miR-139) down-regulated in the lymphoma samples. Expression of hsa-miR-9 was most strongly increased (12-fold) and of hsa-miR-320 most strongly decreased (3-fold).A classification tree was computed using four miRNAs (miR-330, miR-17-5p, miR-106a and miR-210) to correctly identify 98% of all 111 cases that were analysed in this study."	unknown	unknown	2008	18537969	Unspecified
+hsa-miR-330	12858	Huntington's disease (HD)	up-regulated	"Northern blot, qRT-PCR etc"	mir-29a and mir-330 are significantly higher in HD samples.	unknown	unknown	2007	18082412	Unspecified
+hsa-miR-330	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-331	9119	acute myeloid leukemia (AML)	up-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-331	14691	Duchenne muscular dystrophy (DMD)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-331	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	DNA copy number status of 17 genomic loci containing miRNAs differentially expressed between IOSE cells and EOC cell lines.	unknown	unknown	2008	18458333	Unspecified
+hsa-miR-331	5520	head and neck squamous cell carcinoma (HNSCC)	down-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-331	1909	malignant melanoma	up-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-331	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-335	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	miR-335 regulates a set of genes whose collective expression in a large cohort of human tumours is associated with risk of distal metastasis.	SOX4	unknown	2008	18185580	Causal
+hsa-miR-335	9952	acute lymphoblastic leukemia (ALL)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-335	9119	acute myeloid leukemia (AML)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	unknown	2007	18056805	Unspecified
+hsa-miR-335	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-335	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-335	11727	facioscapulohumeral muscular dystrophy (FSHD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-335	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-335	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-335	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-335	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-335	13223	uterine leiomyoma (ULM)	up-regulated	microarray	Twenty most differentially expressed microRNA species in leiomyoma versus myometrium microarray.	unknown	unknown	2008	17765232	Unspecified
+hsa-miR-337	4001	epithelial ovarian cancer (EOC)	down-regulated	"Northern blot, qRT-PCR etc"	"All eight miRNAs located in chromosome 14 cluster at Dlk1-Gtl2 Domain(mir-337, mir-432, mir-495,mir-368, mir-376a, mir-376b, mir-377, and mir-419) were expressed in all four IOSE, but in no EOC cell line, which were silenced by epigenetic alterations in EOC. Down-regulation of miRNAs located at Dlk1-Gtl2 domain is associated with higher tumor proliferation and shorter patient survival, suggesting that miRNAs in this cluster function as tumor suppressor genes. "	unknown	unknown	2008	18458333	Causal
+hsa-miR-337	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-338	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	survival-related and metastasis-related miRNA.	unknown	unknown	2008	18176954	Unspecified
+hsa-miR-338	8524	follicular lymphoma (FL)	up-regulated	microarray	"Nine miRNAs (hsa-miR-9, hsa-miR-301, hsa-miR-213, hsa-miR-9*, hsa-miR-330, hsa-miR-106a, hsa-miR-338, hsa-miR-155, hsa-miR-210) were significantly up- and three miRNAs (hsa-miR-320, hsa-miR-149, hsa-miR-139) down-regulated in the lymphoma samples. Expression of hsa-miR-9 was most strongly increased (12-fold) and of hsa-miR-320 most strongly decreased (3-fold)."	unknown	unknown	2008	18537969	Unspecified
+hsa-miR-338	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-339	13315	chronic pancreatitis	up-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-339	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	unknown	2006	16609010	Unspecified
+hsa-miR-340	9119	acute myeloid leukemia (AML)	up-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-340	8894	Oral Squamous Cell Carcinoma (OSCC)	up-regulated	microarray	miRNAs frequently up-regulated in OSCC cell lines(>1.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-341	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Confirmation of the Aberrant miRNA Expression in Hypertrophic Hearts by Northern Blot Analysis and/or qRT-PCR.	unknown	unknown	2007	17525252	Unspecified
+hsa-miR-342	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	"We report that expression of hsa-miR-342, a microRNA encoded in an intron of the gene EVL, is commonly suppressed in human colorectal cancer. The expression of hsa-miR-342 is coordinated with that of EVL and our results indicate that the mechanism of silencing is CpG island methylation upstream of EVL. We found methylation at the EVL/hsa-miR-342 locus in 86% of colorectal adenocarcinomas and in 67% of adenomas, indicating that it is an early event in colorectal carcinogenesis. Furthermore, reconstitution of hsa-miR-342 in the colorectal cancer cell line HT-29 induced apoptosis, suggesting that this microRNA could function as a proapoptotic tumor suppressor. In aggregate, these results support a novel mechanism for silencing intronic microRNAs in cancer by epigenetic alterations of cognate host genes."	unknown	unknown	2008	18264139	Causal
+hsa-miR-342	9119	acute promyelocytic leukemia (APL)	up-regulated	microarray	"Upregulation of miR-15a,miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223,miR-342 and miR-107, whereas miR-181b was downregulated in in acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment."	unknown	unknown	2007	17260024	Unspecified
+hsa-miR-342	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-345	4905	pancreatic cancer	down-regulated	"Northern blot, qRT-PCR etc"	Aberrantly expressed miRNA precursors in pancreatic adenocarcinoma.PAM testing was conducted on 10 tumor samples and 15 adjacent benign samples. PAM has correctly classified 100% of the tested tumor samples and 11 of 15 of the tested benign samples. The 20 top ranked differentially expressed miRNAs in pancreatic adenocarcinoma as selected by PAM.	unknown	unknown	2006	17149698	Unspecified
+hsa-miR-345	3969	papillary thyroid carcinoma (PTC)	up-regulated	microarray	Differentially expressed miRNA in PTC tumors	unknown	unknown	2005	16365291	Unspecified
+hsa-miR-345	10286	prostate cancer	up-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	1413			
+hsa-miR-346	3962	follicular thyroid carcinoma (FTC)	up-regulated	"Northern blot, qRT-PCR etc"	"Two specific miRNAs, miR-197 and miR-346, are significantly overexpressed in FTC. In vitro overexpression of either miRNA induces proliferation, whereas inhibition leads to growth arrest."	EFEMP2	unknown	2006	16822819	Causal
+hsa-miR-346	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-346	12236	primary biliary cirrhosis (PBC)	down-regulated	"Northern blot, qRT-PCR etc"	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	unknown	2008	18631158	Unspecified
+hsa-miR-347	178	vascular disease	down-regulated	"Northern blot, qRT-PCR etc"	Aberrant Expression of miRNA in Injured Arteries Is Confirmed by qRT-PCR or Northern Blot Analysis.	unknown	unknown	2007	17478730	Unspecified
+hsa-miR-34a	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	metastasis-related miRNA	unknown	E2F3	2008	18176954	Unspecified
+hsa-miR-34a	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	"miR-34a functions as a potent suppressor of cell proliferation through modulation of the E2F signaling pathway.  Abrogation of miR-34a function could contribute to aberrant cell proliferation, leading to colon cancer development."	E2F	E2F3	2007	17875987	Causal
+hsa-miR-34a	769	neuroblastoma (NB)	down-regulated	"Northern blot, qRT-PCR etc"	"Reintroduction of this miRNA into three different NB cell lines causes a dramatic reduction in cell proliferation through the induction of a caspase-dependent apoptotic pathway. miR-34a directly targets the messenger ribonucleic acid (mRNA) encoding E2F3 and significantly reduces the levels of E2F3 protein, a potent transcriptional inducer of cell-cycle progression."	E2F3	E2F3	2007	17297439	Causal
+hsa-miR-34a	769	neuroblastoma (NB)	down-regulated	"Northern blot, qRT-PCR etc"	"miR-34a caused the most significant suppression of cell growth through increased apoptosis and decreased DNA synthesis in neuroblastoma cell lines with MYCN amplification. Quantitative RT-PCR showed that neuroblastoma tumors with 1p36 loss expressed lower level of miR-34a than those with normal copies of 1p36. Furthermore, we demonstrated that MYCN is a direct target of miR-34a. Finally, using a series of mRNA expression profiling experiments, we identified other potential direct targets of miR-34a, and pathway analysis demonstrated that miR-34a suppresses cell-cycle genes and induces several neural-related genes. This study demonstrates one important regulatory role of miR-34a in cell growth and MYCN suppression in neuroblastoma."	MYCN	E2F3	2008	18504438	Causal
+hsa-miR-34a	769	neuroblastoma (NB)	down-regulated	"Northern blot, qRT-PCR etc"	"The miR-34a (1p36) and miR-34c (11q23) mimics showed dramatic growth inhibition in cell lines with 1p36 hemizygous deletion. In contrast, there was no growth inhibition by these mimics in cell lines without 1p36 deletions. Quantitative reverse transcription-PCR showed a perfect correlation of absent miR-34a expression in cell lines with a 1p36 aberration and phenotypic effect after mimetic add-back. Expression of miR-34a was also decreased in primary tumors (n = 54) with 1p36 deletion (P = 0.009), but no mutations were discovered in resequencing of the miR-34a locus in 30 neuroblastoma cell lines. BCL2 and MYCN were identified as miR-34a targets and likely mediators of the tumor suppressor phenotypic effect. These data support miR-34a as a tumor suppressor gene in human neuroblastoma. "	"BCL2, MYCN"	E2F3	2008	18505919	Causal
+hsa-miR-34a	3908	non-small cell lung cancer (NSCLC)	down-regulated	"Northern blot, qRT-PCR etc"	BCL2 is regulated directly by miR-34.The expression of two miR-34s is dramatically reduced in 6 of 14 (43%) non-small cell lung cancers (NSCLCs) and that the restoration of miR-34 expression inhibits growth of NSCLC cells.	BCL2	E2F3	2007	17656095	Causal
+hsa-miR-34a	4905	pancreatic cancer	down-regulated	"Northern blot, qRT-PCR etc"	"One important role of miR-34a is the modulation and fine-tuning of the gene expression program initiated by p53 for miR-34a-responsive genes are highly enriched for those that regulate cell-cycle progression, apoptosis, DNA repair, and angiogenesis."	"BIRC3,DcR3,BCL2"	E2F3	2007	17540599	Causal
+hsa-miR-34a	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	E2F3	2007	17942673	Unspecified
+hsa-miR-34a	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	E2F3	2007	17942673	Unspecified
+hsa-miR-34a	11727	facioscapulohumeral muscular dystrophy (FSHD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	E2F3	2007	17942673	Unspecified
+hsa-miR-34a	3429	Inclusion body myositis (IBM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	E2F3	2007	17942673	Unspecified
+hsa-miR-34a	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	E2F3	2007	17942673	Unspecified
+hsa-miR-34a	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	E2F3	2007	17942673	Unspecified
+hsa-miR-34a	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	E2F3	2007	17942673	Unspecified
+hsa-miR-34a	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	E2F3	2008	18381414	Unspecified
+hsa-miR-34a	3969	papillary thyroid carcinoma (PTC)	up-regulated	microarray	Differentially expressed miRNA in PTC tumors	unknown	E2F3	2005	16365291	Unspecified
+hsa-miR-34a	10222	polymyositis (PM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	E2F3	2007	17942673	Unspecified
+hsa-miR-34a	13223	uterine leiomyoma (ULM)	up-regulated	"Northern blot, qRT-PCR etc"	Real-time reverse transcriptase polymerase chain reaction (RT-PCR) validation of microarray. Realtime					
+"semiquantitative RT-PCR of five different microRNA species (miR-21, miR-34a, miR-125b, miR-139, and miR-323) across ten subjects. miR-21, miR-34a, miR-125b, and miR-323 were overexpressed in leiomyoma in the ten pairs tested and miR-139 was underexpressed, consistent with the microarray results."	unknown	E2F3	2008	17765232	Unspecified	0	1435			
+hsa-miR-34b	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Down-regulation of miR-34b/c is associated with hypermethylation of the neighboring CpG island; and that DAC treatment rapidly restores miR-34b/c expression. Methylation of the miR-34b/c CpG island was frequently observed in CRC cell lines (nine of nine, 100%) and in primary CRC tumors (101 of 111, 90%), but not in normal colonic mucosa. Transfection of precursor miR-34b or miR-34c into CRC cells induced dramatic changes in the gene expression profile, and there was significant overlap between the genes down-regulated by miR-34b/c and those down-regulated by DAC. We also found that the miR-34b/c CpG island is a bidirectional promoter which drives expression of both miR-34b/c and B-cell translocation gene 4 (BTG4). Our results suggest that miR-34b/c and BTG4 are novel tumor suppressors in CRC and that the miR-34b/c CpG island, which bidirectionally regulates miR-34b/c and BTG4, is a frequent target of epigenetic silencing in CRC."	unknown	unknown	2008	18519671	Causal
+hsa-miR-34b	3908	non-small cell lung cancer (NSCLC)	down-regulated	"Northern blot, qRT-PCR etc"	BCL2 is regulated directly by miR-34.The expression of two miR-34s is dramatically reduced in 6 of 14 (43%) non-small cell lung cancers (NSCLCs) and that the restoration of miR-34 expression inhibits growth of NSCLC cells.	BCL2	unknown	2007	17656095	Causal
+hsa-miR-34b	2144	ovarian cancer (OC)	down-regulated	"Northern blot, qRT-PCR etc"	miR-34b and miR-34c are direct targets of p53. miR-34b and miR-34c cooperate in suppressing proliferation and soft-agar colony formation of neoplastic epithelial ovarian cells.	unknown	unknown	2007	17823410	Causal
+hsa-miR-34b	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-34b	9261	nasopharyngeal carcinoma (NPC)	down-regulated	microarray	miRNAs differentially expressed between normal and NPC tumor tissues.	unknown	unknown	2008	18390668	Unspecified
+hsa-miR-34b	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	"Northern blot, qRT-PCR etc"	"Four of miRNAs (i.e., miR-34b, miR-137, miR-193a, and miR-203) located around CpG islands.The expression of those four genes was restored by treatment with 5-aza-2'-deoxycytidine in OSCC cells lacking their expression. In addition, expression levels of the four miRNAs were inversely correlated with their DNA methylation status in the OSCC lines. In primary tumors of OSCC with paired"					
+"normal oral mucosa, down-regulation of miRNA expression through tumor-specific hypermethylation was more frequently"										
+observed for miR-137 and miR-193a than for miR-34b and miR-203.	unknown	unknown	2008	18381414	Unspecified	0	1441			
+hsa-miR-34c	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Down-regulation of miR-34b/c is associated with hypermethylation of the neighboring CpG island; and that DAC treatment rapidly restores miR-34b/c expression. Methylation of the miR-34b/c CpG island was frequently observed in CRC cell lines (nine of nine, 100%) and in primary CRC tumors (101 of 111, 90%), but not in normal colonic mucosa. Transfection of precursor miR-34b or miR-34c into CRC cells induced dramatic changes in the gene expression profile, and there was significant overlap between the genes down-regulated by miR-34b/c and those down-regulated by DAC. We also found that the miR-34b/c CpG island is a bidirectional promoter which drives expression of both miR-34b/c and B-cell translocation gene 4 (BTG4). Our results suggest that miR-34b/c and BTG4 are novel tumor suppressors in CRC and that the miR-34b/c CpG island, which bidirectionally regulates miR-34b/c and BTG4, is a frequent target of epigenetic silencing in CRC."	unknown	unknown	2008	18519671	Causal
+hsa-miR-34c	3908	non-small cell lung cancer (NSCLC)	down-regulated	"Northern blot, qRT-PCR etc"	BCL2 is regulated directly by miR-34.The expression of two miR-34s is dramatically reduced in 6 of 14 (43%) non-small cell lung cancers (NSCLCs) and that the restoration of miR-34 expression inhibits growth of NSCLC cells.	BCL2	unknown	2007	17656095	Causal
+hsa-miR-34c	2144	ovarian cancer (OC)	down-regulated	"Northern blot, qRT-PCR etc"	miR-34b and miR-34c are direct targets of p53. miR-34b and miR-34c cooperate in suppressing proliferation and soft-agar colony formation of neoplastic epithelial ovarian cells.	unknown	unknown	2007	17823410	Causal
+hsa-miR-34c	9119	acute myeloid leukemia (AML)	down-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-34c	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-34c	9261	nasopharyngeal carcinoma (NPC)	down-regulated	microarray	miRNAs differentially expressed between normal and NPC tumor tissues.	unknown	unknown	2008	18390668	Unspecified
+hsa-miR-34c	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-34c	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-351	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change correlative with the increase in heart/body weight(7-14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-352	178	vascular disease	up-regulated	"Northern blot, qRT-PCR etc"	Aberrant Expression of miRNA in Injured Arteries Is Confirmed by qRT-PCR or Northern Blot Analysis.	unknown	unknown	2007	17478730	Unspecified
+hsa-miR-361	14691	Duchenne muscular dystrophy (DMD)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-361	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-361	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-361	12236	primary biliary cirrhosis (PBC)	down-regulated	microarray	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	unknown	2008	18631158	Unspecified
+hsa-miR-362	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-362	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-362	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-362	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-362	10222	polymyositis (PM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-363	10652	Alzheimer's disease	down-regulated	microarray	Significantly changed miRNAs in cortex of sporadic AD cases.	unknown	unknown	2008	18434550	Unspecified
+hsa-miR-365	9088	psoriasis	down-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	unknown	2007	17622355	Unspecified
+hsa-miR-365	178	vascular disease	down-regulated	"Northern blot, qRT-PCR etc"	Aberrant Expression of miRNA in Injured Arteries Is Confirmed by qRT-PCR or Northern Blot Analysis.	unknown	unknown	2007	17478730	Unspecified
+hsa-miR-367	9119	acute myeloid leukemia (AML)	down-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-367	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-367	5556	testicular germ cell tumor	up-regulated	microarray	Differentially expressed miRNA in the various histological subtypes of  germ cell tumour (GCT) (TE = teratoma; SE = seminoma; EC = embryonal carcinoma).	unknown	unknown	2007	17893849	Unspecified
+hsa-miR-368	4001	epithelial ovarian cancer (EOC)	down-regulated	"Northern blot, qRT-PCR etc"	"All eight miRNAs located in chromosome 14 cluster at Dlk1-Gtl2 Domain(mir-337, mir-432, mir-495,mir-368, mir-376a, mir-376b, mir-377, and mir-419) were expressed in all four IOSE, but in no EOC cell line, which were silenced by epigenetic alterations in EOC. Down-regulation of miRNAs located at Dlk1-Gtl2 domain is associated with higher tumor proliferation and shorter patient survival, suggesting that miRNAs in this cluster function as tumor suppressor genes. "	unknown	unknown	2008	18458333	Causal
+hsa-miR-368	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-368	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-368	11727	facioscapulohumeral muscular dystrophy (FSHD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-368	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-368	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-368	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-368	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-369-5p	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-369-5p	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-369-5p	11727	facioscapulohumeral muscular dystrophy (FSHD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-369-5p	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-370	4947	cholangiocarcinoma	down-regulated	"Northern blot, qRT-PCR etc"	"The oncogene mitogen-activated protein kinase kinase kinase 8 (MAP3K8) was identified as a target of miR-370.Overexpression of IL-6 reduced miR-370 expression and reinstated MAP3K8 expression in vitro as well as in tumor cell xenografts in vivo. Thus, IL-6 may contribute to tumor growth by modulation of expression of selected miRNAs, such as miR-370."	MAP3K8	unknown	2008	17621267	Causal
+hsa-miR-370	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-370	10286	prostate cancer	up-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	1481			
+hsa-miR-371	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-371	5556	testicular germ cell tumor	up-regulated	microarray	Differentially expressed miRNA in the various histological subtypes of  germ cell tumour (GCT) (TE = teratoma; SE = seminoma; EC = embryonal carcinoma).	unknown	unknown	2007	17893849	Unspecified
+hsa-miR-372	3908	non-small cell lung cancer (NSCLC)	up-regulated	"Northern blot, qRT-PCR etc"	"A five-microRNA signature (let-7a, miR-221, miR-137, miR-372, and miR-182*) that is associated with survival and cancer relapse in NSCLC patients. This microRNA signature was validated by the testing set and an independent cohort. Patients with high-risk scores in their microRNA signatures had poor overall and disease-free survivals compared to the low-risk-score patients. This microRNA signature is an independent predictor of the cancer relapse and survival of NSCLC patients.promoted invasiveness of lung cancer cell lines."	unknown	LATS2	2008	18167339	Causal
+hsa-miR-372	5556	testicular germ cell tumor	up-regulated	"Northern blot, qRT-PCR etc"	"miR-372 and miR-373 are capable of promoting human cell transformation in collaboration with oncogenic Ras, by inhibiting the expression of the protein kinase LATS2 and sustaining the activity of CDK3."	LATS2	LATS2	2006	16564011	Causal
+hsa-miR-372	9119	acute myeloid leukemia (AML)	down-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	LATS2	2008	18478077	Unspecified
+hsa-miR-372	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	LATS2	2006	16609010	Unspecified
+hsa-miR-372	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	LATS2	2008	18381414	Unspecified
+hsa-miR-372	5556	testicular germ cell tumor	up-regulated	microarray	Differentially expressed miRNA in the various histological subtypes of  germ cell tumour (GCT) (TE = teratoma; SE = seminoma; EC = embryonal carcinoma).	unknown	LATS2	2007	17893849	Unspecified
+hsa-miR-373	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"miR-373 and miR-520c stimulated cancer cell migration and invasion in vitro and in vivo. Mechanistically, the migration phenotype of miR-373 and miR-520c can be explained by suppression of CD44. We found significant upregulation of miR-373 in clinical breast cancer metastasis samples that correlated inversely with CD44 expression."	CD44	LATS2	2008	18193036	Causal
+hsa-miR-373	5556	testicular germ cell tumor	up-regulated	"Northern blot, qRT-PCR etc"	"miR-372 and miR-373 are capable of promoting human cell transformation in collaboration with oncogenic Ras, by inhibiting the expression of the protein kinase LATS2 and sustaining the activity of CDK3."	LATS2	LATS2	2006	16564011	Causal
+hsa-miR-373	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	LATS2	2007	17222355	Unspecified
+hsa-miR-373	5556	testicular germ cell tumor	up-regulated	microarray	Differentially expressed miRNA in the various histological subtypes of  germ cell tumour (GCT) (TE = teratoma; SE = seminoma; EC = embryonal carcinoma).	unknown	LATS2	2007	17893849	Unspecified
+hsa-miR-373*	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-373*	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-373*	10286	prostate cancer	up-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	1496			
+hsa-miR-374	9119	acute myeloid leukemia (AML)	up-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-374	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	Differentially expressed between tumors and normals.	unknown	unknown	2007	17875710	Unspecified
+hsa-miR-374	5520	head and neck squamous cell carcinoma (HNSCC)	down-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-374	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	One of the 22 significantly up- and down-regulated miRNAs obtained using significance analysis of microarrays with false discovery rate of 5%. Majority of the predicted targets of these 22 differentially regulated miRNAs reside in pathways reported to be dysregulated during carcinogenesis.	unknown	unknown	2008	18319255	Unspecified
+hsa-miR-374	1909	malignant melanoma	up-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-374	8894	Oral Squamous Cell Carcinoma (OSCC)	up-regulated	microarray	miRNAs frequently up-regulated in OSCC cell lines(>1.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-375	4905	pancreatic cancer	down-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	"Adipor2,C1qbp,Jak2,Mtpn,Usp1"	2007	17473300	Unspecified
+hsa-miR-375	3498	pancreatic ductal adenocarcinoma (PDAC)	down-regulated	microarray	"differentially expressed between normal and PDAC or cell line samples. several miRNAs(hsa-miR-141, -148a, -200a, -200b, -200c, -216, -217 and -375) with expression patterns distinctive for pancreas, suggesting a possible role of these miRNAs in pancreas differentiation."					
+	unknown	"Adipor2,C1qbp,Jak2,Mtpn,Usp1"	2007	17237814	Unspecified	0	1504			
+hsa-miR-376a	4001	epithelial ovarian cancer (EOC)	down-regulated	"Northern blot, qRT-PCR etc"	"All eight miRNAs located in chromosome 14 cluster at Dlk1-Gtl2 Domain(mir-337, mir-432, mir-495,mir-368, mir-376a, mir-376b, mir-377, and mir-419) were expressed in all four IOSE, but in no EOC cell line, which were silenced by epigenetic alterations in EOC. Down-regulation of miRNAs located at Dlk1-Gtl2 domain is associated with higher tumor proliferation and shorter patient survival, suggesting that miRNAs in this cluster function as tumor suppressor genes. "	unknown	unknown	2008	18458333	Causal
+hsa-miR-376a	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-376a	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-376a	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-376a	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-376a	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Aberrantly expressed miRNA precursors in pancreatic adenocarcinoma.PAM testing was conducted on 10 tumor samples and 15 adjacent benign samples. PAM has correctly classified 100% of the tested tumor samples and 11 of 15 of the tested benign samples. The 20 top ranked differentially expressed miRNAs in pancreatic adenocarcinoma as selected by PAM.	unknown	unknown	2006	17149698	Unspecified
+hsa-miR-376b	4001	epithelial ovarian cancer (EOC)	down-regulated	"Northern blot, qRT-PCR etc"	"All eight miRNAs located in chromosome 14 cluster at Dlk1-Gtl2 Domain(mir-337, mir-432, mir-495,mir-368, mir-376a, mir-376b, mir-377, and mir-419) were expressed in all four IOSE, but in no EOC cell line, which were silenced by epigenetic alterations in EOC. Down-regulation of miRNAs located at Dlk1-Gtl2 domain is associated with higher tumor proliferation and shorter patient survival, suggesting that miRNAs in this cluster function as tumor suppressor genes. "	unknown	unknown	2008	18458333	Causal
+hsa-miR-376b	13223	uterine leiomyoma (ULM)	up-regulated	microarray	Twenty most differentially expressed microRNA species in leiomyoma versus myometrium microarray.	unknown	unknown	2008	17765232	Unspecified
+hsa-miR-377	4001	epithelial ovarian cancer (EOC)	down-regulated	"Northern blot, qRT-PCR etc"	"All eight miRNAs located in chromosome 14 cluster at Dlk1-Gtl2 Domain(mir-337, mir-432, mir-495,mir-368, mir-376a, mir-376b, mir-377, and mir-419) were expressed in all four IOSE, but in no EOC cell line, which were silenced by epigenetic alterations in EOC. Down-regulation of miRNAs located at Dlk1-Gtl2 domain is associated with higher tumor proliferation and shorter patient survival, suggesting that miRNAs in this cluster function as tumor suppressor genes. "	unknown	unknown	2008	18458333	Causal
+hsa-miR-377	13223	uterine leiomyoma (ULM)	up-regulated	microarray	Twenty most differentially expressed microRNA species in leiomyoma versus myometrium microarray.	unknown	unknown	2008	17765232	Unspecified
+hsa-miR-378	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-379	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-379	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-379	11727	facioscapulohumeral muscular dystrophy (FSHD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-379	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-379	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-379	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-379	10222	polymyositis (PM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-155	10763	hypertension	normal	"Northern blot, qRT-PCR etc"	"We further experimentally investigated one of these target sites for hsa-miR-155, within the 3' UTR of the human AGTR1 gene that contains SNP rs5186. Using reporter silencing assays, we show that hsa-miR-155 down-regulates the expression of only the 1166A, and not the 1166C, allele of rs5186. Remarkably, the 1166C allele has been associated with hypertension in many studies. Thus, the 1166C allele may be functionally associated with hypertension by abrogating regulation by hsa-miR-155, thereby elevating AGTR1 levels. Since hsa-miR-155 is on chromosome 21, we hypothesize that the observed lower blood pressure in trisomy 21 is partially caused by the overexpression of hsa-miR-155 leading to allele-specific underexpression of AGTR1. Indeed, we have shown in fibroblasts from monozygotic twins discordant for trisomy 21 that levels of AGTR1 protein are lower in trisomy 21."	AGTR1	AGTR1	2008	17668390	Causal
+hsa-let-7a	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	"caspase-3, the executioner caspase, was confirmed to be the target of let-7a as ectopic expression of let-7a decreased the luciferase activity of a reporter construct containing the 3' untranslated region of caspase-3 and at the same time repressed the enzyme expression in human squamous carcinoma A431 cells and hepatocellular carcinoma HepG2 cells. Moreover, let-7a was over-expressed while caspase-3 was down-regulated in A10A cells, a doxorubicin-resistant A431 subline. Enforced let-7a expression increased the resistance in A431 cells and HepG2 cells to apoptosis induced by therapeutic drugs such as interferon-gamma, doxorubicin and paclitaxel. On the other hand, down-regulation of let-7a by the anti-let-7a inhibitor increased the doxorubicin-induced apoptosis in A431 parent cells, A10A cells and HepG2 cells while the increase was suppressed by caspase-3 inhibitor. Both anti-let-7a inhibitor and caspase-3 inhibitor however failed to affect the drug-induced apoptosis in human breast cancer MCF7 cells, the cells that do not express caspase-3. Therefore, let-7a by targeting caspase-3 may play a functional role in modulating drug-induced cell death in human cancer cells."					
+	caspase-3	NF2	2008	18758960	Causal	1	1941			
+hsa-let-7a	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Transfection of melanoma cells with let-7a pre-miR(TM) molecules resulted in the downregulation of integrin beta(3) mRNA and protein expression. In addition, we cloned the 3'-UTR of the integrin beta(3) mRNA containing the let-7a target sequence into a reporter plasmid and revealed that let-7a negatively regulates reporter gene expression. The repressed expression of integrin beta(3) accompanies with reduced invasive potential of melanoma cells transfected with synthetic let-7a molecules observed in Boyden chamber assays. On the other hand, the induction of integrin beta(3) expression was achieved in melanocytes by transfection with let-7a anti-miRs, resulting in invasive behavior of transfected melanocytes. In summary, we determined miRNA let-7a to be an important regulator of integrin beta(3) expression and showed that the loss of let-7a expression is involved in development and progression of malignant melanoma."	integrin beta(3)	NF2	2008	18679415	Causal
+hsa-let-7a	1749	squamous carcinoma	down-regulated	"Northern blot, qRT-PCR etc"	"caspase-3, the executioner caspase, was confirmed to be the target of let-7a as ectopic expression of let-7a decreased the luciferase activity of a reporter construct containing the 3' untranslated region of caspase-3 and at the same time repressed the enzyme expression in human squamous carcinoma A431 cells and hepatocellular carcinoma HepG2 cells. Moreover, let-7a was over-expressed while caspase-3 was down-regulated in A10A cells, a doxorubicin-resistant A431 subline. Enforced let-7a expression increased the resistance in A431 cells and HepG2 cells to apoptosis induced by therapeutic drugs such as interferon-gamma, doxorubicin and paclitaxel. On the other hand, down-regulation of let-7a by the anti-let-7a inhibitor increased the doxorubicin-induced apoptosis in A431 parent cells, A10A cells and HepG2 cells while the increase was suppressed by caspase-3 inhibitor. Both anti-let-7a inhibitor and caspase-3 inhibitor however failed to affect the drug-induced apoptosis in human breast cancer MCF7 cells, the cells that do not express caspase-3. Therefore, let-7a by targeting caspase-3 may play a functional role in modulating drug-induced cell death in human cancer cells."					
+	caspase-3	NF2	2008	18758960	Causal	1	1943			
+hsa-let-7c	8584	Burkitt lymphoma	down-regulated	"Northern blot, qRT-PCR etc"	" Our results demonstrated a modulation of specific miRNAs. In particular, down-regulation of hsa-let-7c was observed in BL cases, compared to normal controls."	unknown	unknown	2008	18802929	Causal
+hsa-let-7e	768	retinoblastoma	up-regulated	microarray	"A cluster of microRNAs was identified as highly expressed in retinoblastoma, including hsa-miR-494, hsa-let-7e, hsa-miR-513-1, hsa-miR-513-2, hsa-miR-518c*, hsa-miR-129-1, hsa-miR-129-2, hsa-miR-198, hsa-miR-492, hsa-miR-498, hsa-miR-320, hsa-miR-503, and hsa-miR-373*. CONCLUSION: These miRNAs are the first to be reported for human retinoblastoma and may play significant roles in regulating tumor genesis."	unknown	SMC1L1	2008	18818933	Unspecified
+hsa-let-7f	3459	breast cancer	up-regulated	microarray	"Nine miRNAs of hsa-miR-21, hsa-miR-365, hsa-miR-181b, hsa-let-7f, hsa-miR-155, hsa-miR-29b, hsa-miR-181d, hsa-miR-98, and hsa-miR-29c were observed to be up-regulated greater than twofold in BC compared with normal adjacent tumor tissues (NATs), whereas seven miRNAs of hsa-miR-497, hsa-miR-31, hsa-miR-355, hsa-miR-320, rno-mir-140, hsa-miR-127 and hsa-miR-30a-3p were observed to be down-regulated greater than twofold."	unknown	unknown	2008	18812439	Unspecified
+hsa-miR-1	3905	lung cancer	down-regulated	"Northern blot, qRT-PCR etc"	"we report that microRNA-1 (miR-1), abundant in the cardiac and smooth muscles, is expressed in the lung and is down regulated in human primary lung cancer tissues and cell lines. In situ hybridization demonstrated localization of miR-1 in bronchial epithelial cells. The tumor suppressor C/EBPa, frequently suppressed in lung cancer reactivated miR-1 expression in the lung cancer cells. Repressed miR-1 was also activated in lung cancer cells upon treatment with a histone deacetylase inhibitor. Expression of miR-1 in nonexpressing A549 and H1299 cells reversed their tumorigenic properties such as growth, replication potential, motility/migration, clonogenic survival and tumor formation in nude mice. Exogenous miR-1 significantly reduced expression of oncogenic targets such as MET, a receptor tyrosine kinase, and Pim-1, a ser/thr kinase, frequently upregulated in lung cancer. Similarly, the level of two additional targets, FoxP1, a transcription factor with oncogeneic property, and HDAC4 that represses differentiation-promoting genes, was reduced in miR-1 expressing cells. Conversely, depletion of miR-1 facilitated N417 cell growth with concomitant elevation of these targets. Further, ectopic miR-1 induced apoptosis in A549 cells in response to the potent anticancer drug doxorubicin (DOXR). Enhanced activation of caspases 3 and 7, cleavage of their substrate PARP-1 and depletion of antiapoptotic Mcl-1 contributed to the sensitivity of miR-1 expressing cells to DOXR. Thus, miR-1 has potential therapeutic application against lung cancers."					
+	"C/EBPa, MET, FoxP1, HDAC4, "	"GJA1,Hand2,HDAC4,TMSB4X"	2008	18818206	Causal	1	1947			
+hsa-miR-1	10584	retinitis pigmentosa (RP)	up-regulated	"Northern blot, qRT-PCR etc"	"expression of miR-96, -182 and -183 decreased by 14.1-53.2%, while expression of miR-1, -133 and -142 was up-regulated by 186.1-538.5%. Significantly, the detected pan-retinal miR signature was mirrored by similar miR expression profiles in FACS-isolated rod photoreceptors from these mice. "	unknown	"GJA1,Hand2,HDAC4,TMSB4X"	2008	18834879	Unspecified
+hsa-miR-106b	9538	multiple myeloma (MM)	up-regulated	"Northern blot, qRT-PCR etc"	"We have confirmed that the proapoptotic BIM is a target of the miR-17-92 cluster in MM cells. Therefore, miR-17-92, along with miR-21, blocks apoptosis and promotes cell survival. On the other hand, miR-106b-25, miR-181a, and miR-32 but not miR-17-92 cluster (specifically miR-19s and miR-92), target PCAF, a p53 positive regulator. We speculate, consistent with the low frequency of p53 mutations in MM, that down-regulation of PCAF by the miR-106b-25 cluster, miR-181s, and miR-32, keeps p53 at low level or partially inactivated by controlling its stability through Hdm2  and working as a histone acetyltransferase."	PCAF	unknown	2008	18728182	Causal
+hsa-miR-122	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	"miR-122, a hepato-specific microRNA (miRNA), is frequently down-regulated in human hepatocellular carcinoma (HCC). In an effort to identify novel miR-122 targets, we performed an in silico analysis and detected a putative binding site in the 3'-untranslated region (3'-UTR) of Bcl-w, an anti-apoptotic Bcl-2 family member. In the HCC-derived cell lines, Hep3B and HepG2, we confirmed that miR-122 modulates Bcl-w expression by directly targeting binding site within the 3'-UTR. The cellular mRNA and protein levels of Bcl-w were repressed by elevated levels of miR-122, which subsequently led to reduction of cell viability and activation of caspase-3. Thus, Bcl-w is a direct target of miR-122 that functions as an endogenous apoptosis regulator in these HCC-derived cell lines."	Bcl-w	CAT-1	2008	18692484	Causal
+hsa-miR-125b	3858	medulloblastoma	down-regulated	"Northern blot, qRT-PCR etc"	" Using a miRNA high-throughput profile screening, we identify here a downregulated miRNA signature in human MBs with high Hh signalling. Specifically, we identify miR-125b and miR-326 as suppressors of the pathway activator Smoothened together with miR-324-5p, which also targets the downstream transcription factor Gli1. Downregulation of these miRNAs allows high levels of Hh-dependent gene expression leading to tumour cell proliferation. Interestingly, the downregulation of miR-324-5p is genetically determined by MB-associated deletion of chromosome 17p. These findings identify a novel regulatory circuitry of the Hh signalling and suggest that misregulation of specific miRNAs, leading to its aberrant activation, sustain cancer development."					
+	Gli1	Lin28	2008	18756266	Causal	1	1951			
+hsa-miR-126	9119	acute myeloid leukemia (AML)	up-regulated	"Northern blot, qRT-PCR etc"	"Our gain- and loss-of-function experiments showed that miR-126/126* inhibited apoptosis and increased the viability of AML cells and enhanced the colony-forming ability of mouse normal bone marrow progenitor cells alone and particularly, in cooperation with AML1-ETO, likely through targeting Polo-like kinase 2 (PLK2), a tumor suppressor. A significantly negative effect on luciferase activity was observed in the presence of miR-126 on the 3  UTR of PLK2. These results indicate that PLK2  is a bona fide target of miR-126."	PLK2	unknown	2008	18832181	Causal
+hsa-miR-126	9256	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Using micro(RNA) arrays, we found a ubiquitous loss of miR-126 expression in colon cancer lines when compared to normal human colon epithelia. Reconstitution of miR-126 in colon cancer cells resulted in a significant growth reduction as evidenced in clonogenic assays. A search for miR-126 gene targets revealed p85beta, a regulatory subunit involved in stabilizing and propagating the phosphatidylinositol 3-kinase (PI3K) signal. Additionally, using reporter constructs, we show that the p85beta-3' untranslated region is directly targeted by miR-126. Furthermore, this miR-126 mediated reduction of p85beta was accompanied by a substantial reduction in phosphorylated AKT levels in the cancer cells, suggesting an impairment in PI3K signaling. Finally, in a panel of matched normal colon and primary colon tumors, each of the tumors demonstrated miR-126 down-regulation together with an increase in the p85beta protein level. Taken together, we propose that miR-126 regulates PI3K signaling partly by targeting p85beta, and that the loss of miR-126 may provide a selective growth advantage during colon carcinogenesis."					
+	p85beta	unknown	2008	18663744	Causal	1	1953			
+hsa-miR-126*	9119	acute myeloid leukemia (AML)	up-regulated	"Northern blot, qRT-PCR etc"	"Expression signatures of a minimum of two (i.e., miR-126/126*), three (i.e., miR-224, miR-368, and miR-382), and seven (miR-17�C5p and miR-20a, plus the aforementioned five) miRNAs could accurately discriminate CBF, t(15;17), and MLL-rearrangement AMLs, respectively, from each other. We further showed that the elevated expression of miR-126/126* in CBF AMLs was associated with promoter demethylation but not with amplification or mutation of the genomic locus. Our gain- and loss-of-function experiments showed that miR-126/126* inhibited apoptosis and increased the viability of AML cells"	unknown	unknown	2008	18832181	Causal
+hsa-miR-127	3459	breast cancer	down-regulated	microarray	"Nine miRNAs of hsa-miR-21, hsa-miR-365, hsa-miR-181b, hsa-let-7f, hsa-miR-155, hsa-miR-29b, hsa-miR-181d, hsa-miR-98, and hsa-miR-29c were observed to be up-regulated greater than twofold in BC compared with normal adjacent tumor tissues (NATs), whereas seven miRNAs of hsa-miR-497, hsa-miR-31, hsa-miR-355, hsa-miR-320, rno-mir-140, hsa-miR-127 and hsa-miR-30a-3p were observed to be down-regulated greater than twofold."	unknown	"BCL6,Rtl1/Peg11"	2008	18812439	Unspecified
+hsa-miR-128	2627	glioma	down-regulated	"Northern blot, qRT-PCR etc"	"Here we show that brain-enriched miR-128 is down-regulated in glioma tissues and cell lines when compared to normal brain tissues. Overexpression of miR-128 in glioma cells inhibited cell proliferation. A bioinformatics search revealed a conserved target site within the 3'untranslated region (UTR) of E2F3a, a transcription factor that regulates cell cycle progression. The protein levels of E2F3a in gliomas and normal brain tissues were negatively correlated to the expression levels of miR-128 in these tissues. Overexpression of miR-128 suppressed a luciferase-reporter containing the E2F3a-3'UTR and reduced the level of E2F3a protein in T98G cells. Moreover, knocking down of E2F3a had similar effect as overexpression of miR-128, and overexpression of E2F3a can partly rescue the proliferation inhibition caused by miR-128. Taken together, our study demonstrates that miR-128 can inhibit proliferation of glioma cells through one of its targets, E2F3a."					
+	E2F3a	unknown	2008	18810376	Causal	1	1956			
+hsa-miR-128a	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Supervised analysis in the initial subset and subsequent analysis in additional tumors significantly linked four miRNAs (miR-7, miR-128a, miR-210, and miR-516-3p) to ER(+)/LNN breast cancer aggressiveness (n=147) and one miRNA (miR-210) to metastatic capability in ER(-)/LNN breast cancer ( n=114) and in the clinically important triple-negative subgroup (n=69) (all P<0.05). Bioinformatic analysis coupled miR-210 to hypoxia/VEGF signaling, miR-7 and miR-516-3p to cell cycle progression and chromosomal instability, and miR-128a to cytokine signaling. In conclusion, our work connects four miRNAs to breast cancer progression and to several distinct biological processes involved therein."					
+	unknown	unknown	2008	18755890	Causal	1	1957			
+hsa-miR-129-1	768	retinoblastoma	up-regulated	microarray	"A cluster of microRNAs was identified as highly expressed in retinoblastoma, including hsa-miR-494, hsa-let-7e, hsa-miR-513-1, hsa-miR-513-2, hsa-miR-518c*, hsa-miR-129-1, hsa-miR-129-2, hsa-miR-198, hsa-miR-492, hsa-miR-498, hsa-miR-320, hsa-miR-503, and hsa-miR-373*. CONCLUSION: These miRNAs are the first to be reported for human retinoblastoma and may play significant roles in regulating tumor genesis."	unknown	unknown	2008	18818933	Unspecified
+hsa-miR-129-2	768	retinoblastoma	up-regulated	microarray	"A cluster of microRNAs was identified as highly expressed in retinoblastoma, including hsa-miR-494, hsa-let-7e, hsa-miR-513-1, hsa-miR-513-2, hsa-miR-518c*, hsa-miR-129-1, hsa-miR-129-2, hsa-miR-198, hsa-miR-492, hsa-miR-498, hsa-miR-320, hsa-miR-503, and hsa-miR-373*. CONCLUSION: These miRNAs are the first to be reported for human retinoblastoma and may play significant roles in regulating tumor genesis."	unknown	unknown	2008	18818933	Unspecified
+hsa-miR-133	10584	retinitis pigmentosa (RP)	up-regulated	"Northern blot, qRT-PCR etc"	"expression of miR-96, -182 and -183 decreased by 14.1-53.2%, while expression of miR-1, -133 and -142 was up-regulated by 186.1-538.5%. Significantly, the detected pan-retinal miR signature was mirrored by similar miR expression profiles in FACS-isolated rod photoreceptors from these mice. "	unknown	"ERG,PTBP2,SRF"	2008	18834879	Unspecified
+hsa-miR-142	10584	retinitis pigmentosa (RP)	up-regulated	"Northern blot, qRT-PCR etc"	"expression of miR-96, -182 and -183 decreased by 14.1-53.2%, while expression of miR-1, -133 and -142 was up-regulated by 186.1-538.5%. Significantly, the detected pan-retinal miR signature was mirrored by similar miR expression profiles in FACS-isolated rod photoreceptors from these mice. "	unknown	unknown	2008	18834879	Unspecified
+hsa-miR-143	9970	Obesity	up-regulated	"Northern blot, qRT-PCR etc"	"We showed that the expression of miR-143 in the mesenteric fat was up-regulated in mice fed a high-fat diet. Increased miR-143 expression was associated with an elevated body weight and mesenteric fat weight. Furthermore, miR-143 levels were closely correlated with expression levels of adipocyte differentiation markers such as PPARgamma and aP2 as well as plasma levels of leptin, one of the important adipocytokines involved in insulin resistance. These findings provide the first evidence for the up-regulated expression of miR-143 in the mesentric fat of high-fat diet-induced obese mice, which might contribute to the regulated expression of adipocyte genes involved in the pathophysiology of obesity."					
+	unknown	unknown	2008	18809385	Unspecified	0	1962			
+hsa-miR-145	9256	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	miR-145 showing the lowest expression in cancer relative to normal tissue. Functional studies showed that miR-145 potently suppressed growth of					
+"three different colon carcinoma cell lines. Our data indicate that altered expression levels of miRNA-145 in colon cancer has a functional effect on transformed cells, and that miR-145 may act as a potent suppressor of tumor growth through an increased rate of cell death."	unknown	FLJ21308	2008	18676867	Causal	1	1963			
+hsa-miR-146a	10652	Alzheimer's disease	up-regulated	"Northern blot, qRT-PCR etc"	" Here we provide evidence in AD brains of a specific up-regulation of an NF-kB-sensitive miRNA-146a highly complementary to the 3' un-translated region (3'UTR) of complement factor H (CFH), an important repressor of the brain's inflammatory response. Up-regulation of miRNA-146a coupled to down-regulation of CFH was observed in AD brain and in IL-1ss, Ass42 and/or oxidatively-stressed human neural (HN) cells in primary culture. Transfection of HN cells using an NF-kB-containing pre-miRNA-146a promoter-luciferase reporter construct in stressed HN cells showed significant up-regulation of luciferase activity that paralleled decreases in CFH gene expression. Treatment of stressed HN cells with the NF-kB inhibitors pyrollidine dithiocarbamate (PDTC) or the resveratrol analog CAY10512 abrogated this response. Incubation of an antisense oligonucleotide to miRNA-146a (anti-miRNA-146a; AM146a) was found to restore CFH expression levels. These data indicate that NF-kB-sensitive miRNA-146a-mediated modulation of CFH gene expression may in part regulate an inflammatory response in AD brain and in stressed HN cell models of AD, and illustrates the potential for anti-miRNAs as an effective therapeutic strategy against pathogenic inflammatory signaling."	CFH	unknown	2008	18801740	Causal
+hsa-miR-146a	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"A G to C polymorphism (rs2910164) is located within the sequence of miR-146a precursor, which leads to a change from a G:U pair to a C:U mismatch in its stem region. The predicted miR-146a target genes include BRCA1 and BRCA2, which are key breast and ovarian cancer genes. we studied associations between this polymorphism and age of diagnosis in 42 patients with familial breast cancer and 82 patients with familial ovarian cancer. Breast cancer patients who had at least one miR-146a variant allele were diagnosed at an earlier age than with no variant alleles (Median age: 45 vs 56, p=0.029) and ovarian cancer patients who had at least one miR-146a variant allele were diagnosed younger than women without any variant allele (Median age: 45 vs 50, p=0.014). in a target in vitro assay we observed that miR-146a could bind to the 3'UTRs of BRCA1 and BRCA2 mRNAs and potentially modulate their mRNA expression. Intriguingly, the binding capacity between the 3'UTR of BRCA1 and miR-146a were statistically significantly stronger in variant C-allele than those in common G-allele (p=0.046). Taken together, our data suggest that breast/ovarian cancer patients with variant C-allele miR-146a may have high levels of mature miR-146 and that these variants predispose them to an earlier age of onset of familial breast and ovarian cancer."					
+ 	"BRCA1, BRCA2"	unknown	2008	18660546	Causal	1	1965			
+hsa-miR-146a	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	"A G>C polymorphism (rs2910164) is located in the stem region opposite to the mature miR-146a sequence, which results in a change from G:U pair to C:U mismatch in the stem structure of miR-146a precursor. Here, we elucidated the biological significance of this polymorphism, based on cancer association study and cell model system. The cancer association study included 479 hepatocellular carcinoma (HCC) and 504 control subjects. We found that the genotype distribution of this polymorphism in HCC cases was significantly different from that in control subjects (P = 0.026). The results revealed that male individuals with GG genotype were two-fold more susceptible to HCC (OR = 2.016, 95% CI = 1.056-3.848, P = 0.034) compared to those with CC genotype. We next examined the influence of this polymorphism on the production of mature miR-146a and found that G-allelic miR-146a precursor displayed increased production of mature miR-146a compared with C-allelic one. Further investigations disclosed that miR-146a could obviously promote cell proliferation and colony formation in NIH/3T3, an immortalized but non-transformed cell line. These data suggest that the G>C polymorphism in miR-146a precursor may result in important phenotypic traits that have biomedical implications."	unknown	unknown	2008	18711148	Causal
+hsa-miR-146a	2144	ovarian cancer (OC)	up-regulated	"Northern blot, qRT-PCR etc"	"A G to C polymorphism (rs2910164) is located within the sequence of miR-146a precursor, which leads to a change from a G:U pair to a C:U mismatch in its stem region. The predicted miR-146a target genes include BRCA1 and BRCA2, which are key breast and ovarian cancer genes. we studied associations between this polymorphism and age of diagnosis in 42 patients with familial breast cancer and 82 patients with familial ovarian cancer. Breast cancer patients who had at least one miR-146a variant allele were diagnosed at an earlier age than with no variant alleles (Median age: 45 vs 56, p=0.029) and ovarian cancer patients who had at least one miR-146a variant allele were diagnosed younger than women without any variant allele (Median age: 45 vs 50, p=0.014). in a target in vitro assay we observed that miR-146a could bind to the 3'UTRs of BRCA1 and BRCA2 mRNAs and potentially modulate their mRNA expression. Intriguingly, the binding capacity between the 3'UTR of BRCA1 and miR-146a were statistically significantly stronger in variant C-allele than those in common G-allele (p=0.046). Taken together, our data suggest that breast/ovarian cancer patients with variant C-allele miR-146a may have high levels of mature miR-146 and that these variants predispose them to an earlier age of onset of familial breast and ovarian cancer."					
+ 	"BRCA1, BRCA2"	unknown	2008	18660546	Causal	1	1967			
+hsa-miR-155	3459	breast cancer	up-regulated	microarray	"Nine miRNAs of hsa-miR-21, hsa-miR-365, hsa-miR-181b, hsa-let-7f, hsa-miR-155, hsa-miR-29b, hsa-miR-181d, hsa-miR-98, and hsa-miR-29c were observed to be up-regulated greater than twofold in BC compared with normal adjacent tumor tissues (NATs), whereas seven miRNAs of hsa-miR-497, hsa-miR-31, hsa-miR-355, hsa-miR-320, rno-mir-140, hsa-miR-127 and hsa-miR-30a-3p were observed to be down-regulated greater than twofold."	unknown	AGTR1	2008	18812439	Unspecified
+hsa-miR-17-5p	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	"Two known oncomiRs--miRNAs with known roles in cancer--the miR-17-92 polycistron and miR-21, exhibited increased expression in 100% of primary human and woodchuck hepatocellular carcinomas surveyed. To determine the importance of these miRNAs in tumorigenesis, an in vitro antisense oligonucleotide knockdown model was evaluated for its ability to reverse the malignant phenotype. Both in human and woodchuck HCC cell lines, separate treatments with antisense oligonucleotides specific for either the miR-17-92 polycistron (all six members) or miR-21 caused a 50% reduction in both hepatocyte proliferation and anchorage-independent growth. The combination of assays presented here supports a role for these miRNAs in the maintenance of the malignant transformation of hepatocytes."	unknown	"AIB1,E2F1"	2008	18688024	Causal
+hsa-miR-17-5p	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	" Herein, levels of the miR-17-5p/miR-20a miRNA cluster were inversely correlated to cyclin D1 abundance in human breast tumors and cell lines. MiR-17/20 suppressed breast cancer cell proliferation and tumor colony formation by negatively regulating cyclin D1 translation via a conserved 3' untranslated region miRNA-binding site, thereby inhibiting serum-induced S phase entry. The cell cycle effect of miR-17/20 was abrogated by cyclin D1 siRNA and in cyclin D1-deficient breast cancer cells. Mammary epithelial cell-targeted cyclin D1 expression induced miR-17-5p and miR-20a expression in vivo, and cyclin D1 bound the miR-17/20 cluster promoter regulatory region. In summary, these studies identify a novel cyclin D1/miR-17/20 regulatory feedback loop through which cyclin D1 induces miR-17-5p/miR-20a. In turn, miR-17/20 limits the proliferative function of cyclin D1, thus linking expression of a specific miRNA cluster to the regulation of oncogenesis."	CCND1	"AIB1,E2F1"	2008	18695042	Causal
+hsa-miR-181a	2627	glioma	down-regulated	"Northern blot, qRT-PCR etc"	"We reported that the down-regulated hsa-miR-181a and hsa-miR-181b of hsa-miR-181 family were also involved in oncogenesis of glioma. Our studies showed that hsa-miR-181a and hsa-miR-181b functioned as tumor suppressors which triggered growth inhibition, induced apoptosis and inhibited invasion in glioma cells. Furthermore, the tumor-suppressive effect of hsa-miR-181b in glioma cells was more apparent than the effect of hsa-miR-181a. These findings suggest aberrantly down-regulated hsa-miR-181a and hsa-miR-181b may be critical factors that contribute to malignant appearance in human gliomas."					
+	unknown	unknown	2008	18710654	Causal	1	1971			
+hsa-miR-181a	9538	multiple myeloma (MM)	up-regulated	"Northern blot, qRT-PCR etc"	"Xenograft studies using human MM cell lines treated with miR-19a and b, and miR-181a and b antagonists resulted in significant suppression of tumor growth in nude mice."	PCAF	unknown	2008	18728182	Causal
+hsa-miR-181b	3459	breast cancer	up-regulated	microarray	"Nine miRNAs of hsa-miR-21, hsa-miR-365, hsa-miR-181b, hsa-let-7f, hsa-miR-155, hsa-miR-29b, hsa-miR-181d, hsa-miR-98, and hsa-miR-29c were observed to be up-regulated greater than twofold in BC compared with normal adjacent tumor tissues (NATs), whereas seven miRNAs of hsa-miR-497, hsa-miR-31, hsa-miR-355, hsa-miR-320, rno-mir-140, hsa-miR-127 and hsa-miR-30a-3p were observed to be down-regulated greater than twofold."	unknown	unknown	2008	18812439	Unspecified
+hsa-miR-181b	2627	glioma	down-regulated	"Northern blot, qRT-PCR etc"	"We reported that the down-regulated hsa-miR-181a and hsa-miR-181b of hsa-miR-181 family were also involved in oncogenesis of glioma. Our studies showed that hsa-miR-181a and hsa-miR-181b functioned as tumor suppressors which triggered growth inhibition, induced apoptosis and inhibited invasion in glioma cells. Furthermore, the tumor-suppressive effect of hsa-miR-181b in glioma cells was more apparent than the effect of hsa-miR-181a. These findings suggest aberrantly down-regulated hsa-miR-181a and hsa-miR-181b may be critical factors that contribute to malignant appearance in human gliomas."					
+	unknown	unknown	2008	18710654	Causal	1	1974			
+hsa-miR-181b	9538	multiple myeloma (MM)	up-regulated	"Northern blot, qRT-PCR etc"	"Xenograft studies using human MM cell lines treated with miR-19a and b, and miR-181a and b antagonists resulted in significant suppression of tumor growth in nude mice."	PCAF	unknown	2008	18728182	Causal
+hsa-miR-181d	3459	breast cancer	up-regulated	microarray	"Nine miRNAs of hsa-miR-21, hsa-miR-365, hsa-miR-181b, hsa-let-7f, hsa-miR-155, hsa-miR-29b, hsa-miR-181d, hsa-miR-98, and hsa-miR-29c were observed to be up-regulated greater than twofold in BC compared with normal adjacent tumor tissues (NATs), whereas seven miRNAs of hsa-miR-497, hsa-miR-31, hsa-miR-355, hsa-miR-320, rno-mir-140, hsa-miR-127 and hsa-miR-30a-3p were observed to be down-regulated greater than twofold."	unknown	unknown	2008	18812439	Unspecified
+hsa-miR-182	10584	retinitis pigmentosa (RP)	down-regulated	"Northern blot, qRT-PCR etc"	"expression of miR-96, -182 and -183 decreased by 14.1-53.2%, while expression of miR-1, -133 and -142 was up-regulated by 186.1-538.5%. Significantly, the detected pan-retinal miR signature was mirrored by similar miR expression profiles in FACS-isolated rod photoreceptors from these mice. "	unknown	unknown	2008	18834879	Unspecified
+hsa-miR-183	10584	retinitis pigmentosa (RP)	down-regulated	"Northern blot, qRT-PCR etc"	"expression of miR-96, -182 and -183 decreased by 14.1-53.2%, while expression of miR-1, -133 and -142 was up-regulated by 186.1-538.5%. Significantly, the detected pan-retinal miR signature was mirrored by similar miR expression profiles in FACS-isolated rod photoreceptors from these mice. "	unknown	unknown	2008	18834879	Unspecified
+hsa-miR-18a	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	"Two known oncomiRs--miRNAs with known roles in cancer--the miR-17-92 polycistron and miR-21, exhibited increased expression in 100% of primary human and woodchuck hepatocellular carcinomas surveyed. To determine the importance of these miRNAs in tumorigenesis, an in vitro antisense oligonucleotide knockdown model was evaluated for its ability to reverse the malignant phenotype. Both in human and woodchuck HCC cell lines, separate treatments with antisense oligonucleotides specific for either the miR-17-92 polycistron (all six members) or miR-21 caused a 50% reduction in both hepatocyte proliferation and anchorage-independent growth. The combination of assays presented here supports a role for these miRNAs in the maintenance of the malignant transformation of hepatocytes."	unknown	unknown	2008	18688024	Causal
+hsa-miR-196a	1107	esophageal cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Analysis of paired normal/tumor tissues from additional 10 patients revealed an increase in miR-196a in the cancers (P=0.003), accompanied by a decrease in ANXA1 mRNA (P=0.004). Increasing miR-196a levels in cells by miR-196a mimics resulted in decreased ANXA1 mRNA and protein. In addition, miR-196a mimics inhibited luciferase expression in luciferase plasmid reporter that included predicted miR-196a recognition sequence from ANXA1 3'-untranslated region confirming that miR-196a directly targets ANXA1. miR-196a promoted cell proliferation, anchorage-independent growth and suppressed apoptosis, suggesting its oncogenic potential. This study demonstrated a novel mechanism of post-transcriptional regulation of ANXA1 expression and identified miR-196a as a marker of esophageal cancer."	ANXA1	unknown	2008	18663355	Causal
+hsa-miR-196a	3498	pancreatic ductal adenocarcinoma (PDAC)	up-regulated	"Northern blot, qRT-PCR etc"	"The combination of miR-196a and miR-217 biomarkers further improved the ability to distinguish between healthy tissue, PDAC, and chronic pancreatitis in the training set (P = 8.2 x 10(-10)), as well as segregate PDAC FNA samples from other FNA samples (P = 1.1 x 10(-5)). Furthermore, we showed that miR-196a production is likely specific to PDAC cells and that its incidence paralleled the progression of PDAC. To the best of our knowledge, this study is the first to evaluate the diagnostic potential of miRNAs in a clinical setting and has shown that miRNA analysis of pancreatic FNA biopsy samples can aid in the pathologic evaluation of suspicious cases and may provide a new strategy for improving the diagnosis of pancreatic diseases."					
+	unknown	unknown	2008	18719196	Unspecified	0	1981			
+hsa-miR-198	768	retinoblastoma	up-regulated	microarray	"A cluster of microRNAs was identified as highly expressed in retinoblastoma, including hsa-miR-494, hsa-let-7e, hsa-miR-513-1, hsa-miR-513-2, hsa-miR-518c*, hsa-miR-129-1, hsa-miR-129-2, hsa-miR-198, hsa-miR-492, hsa-miR-498, hsa-miR-320, hsa-miR-503, and hsa-miR-373*. CONCLUSION: These miRNAs are the first to be reported for human retinoblastoma and may play significant roles in regulating tumor genesis."	unknown	unknown	2008	18818933	Unspecified
+hsa-miR-19a	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	"Two known oncomiRs--miRNAs with known roles in cancer--the miR-17-92 polycistron and miR-21, exhibited increased expression in 100% of primary human and woodchuck hepatocellular carcinomas surveyed. To determine the importance of these miRNAs in tumorigenesis, an in vitro antisense oligonucleotide knockdown model was evaluated for its ability to reverse the malignant phenotype. Both in human and woodchuck HCC cell lines, separate treatments with antisense oligonucleotides specific for either the miR-17-92 polycistron (all six members) or miR-21 caused a 50% reduction in both hepatocyte proliferation and anchorage-independent growth. The combination of assays presented here supports a role for these miRNAs in the maintenance of the malignant transformation of hepatocytes."	unknown	PTEN	2008	18688024	Causal
+hsa-miR-19a	9538	multiple myeloma (MM)	up-regulated	"Northern blot, qRT-PCR etc"	"Our findings indicate that miR-19a and b are up-regulated >100-fold in patient samples,  >2,000 times in the cell lines , and are both almost absent in normal PCs and MGUS. These data suggest that both miRNAs contribute to the development of MM. miR-19a and miR-19b Target SOCS-1, a Negative Regulator of IL-6R/STAT-3 Pathway. Moreover, miR-19a and miR-19b mimics inhibited the expression of a reporter vector containing SOCS-1 3 UTR, while mutation of the predicted miRNA-binding site abrogated this effect. These studies suggest a role of miR-19s in the IL-6 antiapoptotic signal in the pathogenesis and malignant growth of MM. U266 cells were transfected with miR-19s ASOs and BIM expression was evaluated using immunoblot. We found a significant increase of BIM protein levels at 48 h after treatment with anti-miR-19s compared to scrambled oligonucleotides.BIM as a direct target of miR-17-92 and suggest a possible mechanism through which over-expression of miR-17 92 contributes to the antiapoptotic signals in MM."	"SOCS-1, BIM"	PTEN	2008	18728182	Causal
+hsa-miR-19b	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	"Two known oncomiRs--miRNAs with known roles in cancer--the miR-17-92 polycistron and miR-21, exhibited increased expression in 100% of primary human and woodchuck hepatocellular carcinomas surveyed. To determine the importance of these miRNAs in tumorigenesis, an in vitro antisense oligonucleotide knockdown model was evaluated for its ability to reverse the malignant phenotype. Both in human and woodchuck HCC cell lines, separate treatments with antisense oligonucleotides specific for either the miR-17-92 polycistron (all six members) or miR-21 caused a 50% reduction in both hepatocyte proliferation and anchorage-independent growth. The combination of assays presented here supports a role for these miRNAs in the maintenance of the malignant transformation of hepatocytes."	unknown	unknown	2008	18688024	Causal
+hsa-miR-19b	9538	multiple myeloma (MM)	up-regulated	"Northern blot, qRT-PCR etc"	"Our findings indicate that miR-19a and b are up-regulated >100-fold in patient samples,  >2,000 times in the cell lines , and are both almost absent in normal PCs and MGUS. These data suggest that both miRNAs contribute to the development of MM. miR-19a and miR-19b Target SOCS-1, a Negative Regulator of IL-6R/STAT-3 Pathway. Moreover, miR-19a and miR-19b mimics inhibited the expression of a reporter vector containing SOCS-1 3 UTR, while mutation of the predicted miRNA-binding site abrogated this effect. These studies suggest a role of miR-19s in the IL-6 antiapoptotic signal in the pathogenesis and malignant growth of MM. miR-17 92 Cluster Target."	"SOCS-1, BIM"	unknown	2008	18728182	Causal
+hsa-miR-205	4007	bladder cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Cell lines characterized as invasive showed a miR-21:miR-205 ratio at least 10-fold higher than the quantitative ratio obtained from non-invasive cell lines. The same expression ratio was determined in 53 bladder tumors. From these results, we recorded a sensitivity and specificity of 100% and 78%, respectively, using a cutoff of 1.79 to predict an invasive lesion. The area under the receiver operator characteristic curve was 0.89. Using in vitro invasion assays, we have demonstrated a role for miR-21 in establishing the invasive phenotype of bladder carcinoma cells. "	unknown	unknown	2008	18799331	Unspecified
+hsa-miR-205	3908	non-small cell lung cancer (NSCLC)	up-regulated	"Northern blot, qRT-PCR etc"	" We detected overexpression of mature miR-21 in 25 (52.0%) of the 48 NSCLC paired specimens and overexpression of miR-205 in 31 (64.6%). Overexpression was assessed after comparison of miRNA expression in NSCLC tissues and in their corresponding noncancerous tissues with respect to U6 expression. During the follow-up period, 29 of 48 (60.4%) patients relapsed, and 23 of 48 died (47.9%). Mature miR-21 was upregulated in 16 of 29 (55.2%) patients who relapsed and 15 of 23 (65.2%) patients who died. Mature miR-205 was overexpressed in 19 of 29 patients who relapsed (65.5%) and 15 of 23 patients who died (65.2%). Mature miR-21 overexpression correlated with overall survival (OS) of the patients (P = 0.027), whereas overexpression of mature miR-205 did not. "	unknown	unknown	2008	18719201	Unspecified
+hsa-miR-20a	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	" Herein, levels of the miR-17-5p/miR-20a miRNA cluster were inversely correlated to cyclin D1 abundance in human breast tumors and cell lines. MiR-17/20 suppressed breast cancer cell proliferation and tumor colony formation by negatively regulating cyclin D1 translation via a conserved 3' untranslated region miRNA-binding site, thereby inhibiting serum-induced S phase entry. The cell cycle effect of miR-17/20 was abrogated by cyclin D1 siRNA and in cyclin D1-deficient breast cancer cells. Mammary epithelial cell-targeted cyclin D1 expression induced miR-17-5p and miR-20a expression in vivo, and cyclin D1 bound the miR-17/20 cluster promoter regulatory region. In summary, these studies identify a novel cyclin D1/miR-17/20 regulatory feedback loop through which cyclin D1 induces miR-17-5p/miR-20a. In turn, miR-17/20 limits the proliferative function of cyclin D1, thus linking expression of a specific miRNA cluster to the regulation of oncogenesis."	CCND1	TGFBR2	2008	18695042	Causal
+hsa-miR-20a	9256	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	"in vitro inhibition of two miRNAs highly expressed in tumor tissue, miR-20a and miR-92, did not affect cell viability. This was unexpected, considering that these miRNAs are part of the miR-17-92 cluster reported to be oncogenic in other cancer types. Although our data indicated that the viability"					
+"of colon cancer cell lines were unaffected by inhibition of miR-20a and miR-92, other cancer hall marks such as motility, invasion, and angiogenesis might have been influenced."	unknown	TGFBR2	2008	18676867	Unspecified	0	1990			
+hsa-miR-20a	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	"Two known oncomiRs--miRNAs with known roles in cancer--the miR-17-92 polycistron and miR-21, exhibited increased expression in 100% of primary human and woodchuck hepatocellular carcinomas surveyed. To determine the importance of these miRNAs in tumorigenesis, an in vitro antisense oligonucleotide knockdown model was evaluated for its ability to reverse the malignant phenotype. Both in human and woodchuck HCC cell lines, separate treatments with antisense oligonucleotides specific for either the miR-17-92 polycistron (all six members) or miR-21 caused a 50% reduction in both hepatocyte proliferation and anchorage-independent growth. The combination of assays presented here supports a role for these miRNAs in the maintenance of the malignant transformation of hepatocytes."	unknown	TGFBR2	2008	18688024	Causal
+hsa-miR-21	4007	bladder cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Cell lines characterized as invasive showed a miR-21:miR-205 ratio at least 10-fold higher than the quantitative ratio obtained from non-invasive cell lines. The same expression ratio was determined in 53 bladder tumors. From these results, we recorded a sensitivity and specificity of 100% and 78%, respectively, using a cutoff of 1.79 to predict an invasive lesion. The area under the receiver operator characteristic curve was 0.89. Using in vitro invasion assays, we have demonstrated a role for miR-21 in establishing the invasive phenotype of bladder carcinoma cells. "	unknown	"PTEN,TPM1"	2008	18799331	Unspecified
+hsa-miR-21	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"hsa-mir-21 (miR-21), was quantitatively analyzed by TaqMan real-time PCR in 113 BC tumors. Interestingly, among the 113 BC cases, high level expression of miR-21 was significantly correlated with advanced clinical stage (P=0.006, Fisher's exact text), lymph node metastasis (P=0.007, Fisher's exact text), and shortened survival of the patients (hazard ratio [HR]=5.476, P<0.001). Multivariate Cox regression analysis revealed this prognostic impact (HR=4.133, P=0.001) to be independent of disease stage (HR=2.226, P=0.013) and histological grade (HR=3.681, P=0.033). This study could identify the differentiated miRNAs expression profile in BC and reveal that miR-21 overexpression was correlated with specific breast cancer biopathologic features, such as advanced tumor stage, lymph node metastasis, and poor survival of the patients, indicating that miR-21 may serve as a molecular prognostic marker for BC and disease progression."					
+	unknown	"PTEN,TPM1"	2008	18812439	Unspecified	1	1993			
+hsa-miR-21	3068	glioblastoma	up-regulated	"Northern blot, qRT-PCR etc"	"In this study, we show for the first time that miR-21 targets multiple important components of the p53, transforming growth factor-beta (TGF-beta), and mitochondrial apoptosis tumor-suppressive pathways. Down-regulation of miR-21 in glioblastoma cells leads to derepression of these pathways, causing repression of growth, increased apoptosis, and cell cycle arrest. These phenotypes are dependent on two of the miR-21 targets validated in this study, HNRPK and TAp63. These findings establish miR-21 as an important oncogene that targets a network of p53, TGF-beta, and mitochondrial apoptosis tumor suppressor genes in glioblastoma cells."					
+	"TGF-beta, HNRPK, TAp63"	"PTEN,TPM1"	2008	18829576	Causal	1	1994			
+hsa-miR-21	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	"Two known oncomiRs--miRNAs with known roles in cancer--the miR-17-92 polycistron and miR-21, exhibited increased expression in 100% of primary human and woodchuck hepatocellular carcinomas surveyed. To determine the importance of these miRNAs in tumorigenesis, an in vitro antisense oligonucleotide knockdown model was evaluated for its ability to reverse the malignant phenotype. Both in human and woodchuck HCC cell lines, separate treatments with antisense oligonucleotides specific for either the miR-17-92 polycistron (all six members) or miR-21 caused a 50% reduction in both hepatocyte proliferation and anchorage-independent growth. The combination of assays presented here supports a role for these miRNAs in the maintenance of the malignant transformation of hepatocytes."	unknown	"PTEN,TPM1"	2008	18688024	Causal
+hsa-miR-21	3908	non-small cell lung cancer (NSCLC)	up-regulated	"Northern blot, qRT-PCR etc"	" We detected overexpression of mature miR-21 in 25 (52.0%) of the 48 NSCLC paired specimens and overexpression of miR-205 in 31 (64.6%). Overexpression was assessed after comparison of miRNA expression in NSCLC tissues and in their corresponding noncancerous tissues with respect to U6 expression. During the follow-up period, 29 of 48 (60.4%) patients relapsed, and 23 of 48 died (47.9%). Mature miR-21 was upregulated in 16 of 29 (55.2%) patients who relapsed and 15 of 23 (65.2%) patients who died. Mature miR-205 was overexpressed in 19 of 29 patients who relapsed (65.5%) and 15 of 23 patients who died (65.2%). Mature miR-21 overexpression correlated with overall survival (OS) of the patients (P = 0.027), whereas overexpression of mature miR-205 did not. "	unknown	"PTEN,TPM1"	2008	18719201	Unspecified
+hsa-miR-210	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Supervised analysis in the initial subset and subsequent analysis in additional tumors significantly linked four miRNAs (miR-7, miR-128a, miR-210, and miR-516-3p) to ER(+)/LNN breast cancer aggressiveness (n=147) and one miRNA (miR-210) to metastatic capability in ER(-)/LNN breast cancer ( n=114) and in the clinically important triple-negative subgroup (n=69) (all P<0.05). Bioinformatic analysis coupled miR-210 to hypoxia/VEGF signaling, miR-7 and miR-516-3p to cell cycle progression and chromosomal instability, and miR-128a to cytokine signaling. In conclusion, our work connects four miRNAs to breast cancer progression and to several distinct biological processes involved therein."					
+	unknown	unknown	2008	18755890	Causal	1	1997			
+hsa-miR-217	3498	pancreatic ductal adenocarcinoma (PDAC)	up-regulated	"Northern blot, qRT-PCR etc"	"The combination of miR-196a and miR-217 biomarkers further improved the ability to distinguish between healthy tissue, PDAC, and chronic pancreatitis in the training set (P = 8.2 x 10(-10)), as well as segregate PDAC FNA samples from other FNA samples (P = 1.1 x 10(-5)). Furthermore, we showed that miR-196a production is likely specific to PDAC cells and that its incidence paralleled the progression of PDAC. To the best of our knowledge, this study is the first to evaluate the diagnostic potential of miRNAs in a clinical setting and has shown that miRNA analysis of pancreatic FNA biopsy samples can aid in the pathologic evaluation of suspicious cases and may provide a new strategy for improving the diagnosis of pancreatic diseases."					
+	unknown	unknown	2008	18719196	Unspecified	0	1998			
+hsa-miR-221	3073	glioblastoma multiforme (GBM)	up-regulated	"Northern blot, qRT-PCR etc"	"We observed selective up-regulation of miRNA-221 and down-regulation of a miRNA-221 messenger RNA target encoding the survivin-1 homolog BIRC1, a neuronal inhibitor of apoptosis protein (NIAP) and marker for neurodegeneration. The expression of BIRC5 (survivin-1) and caspase-3 were found to be significantly up-regulated, particularly in stage IV GBM. These studies suggest that the abundance and speciation of the BIRC family of neural cell fate regulators are differentially regulated in glioma and GBM, and may contribute to progressive changes in apoptotic signaling and altered neural cell cycling functions."	BIRC1	KIT	2008	18759060	Causal
+hsa-miR-25	9538	multiple myeloma (MM)	up-regulated	"Northern blot, qRT-PCR etc"	"We have confirmed that the proapoptotic BIM is a target of the miR-17-92 cluster in MM cells. Therefore, miR-17-92, along with miR-21, blocks apoptosis and promotes cell survival. On the other hand, miR-106b-25, miR-181a, and miR-32 but not miR-17-92 cluster (specifically miR-19s and miR-92), target PCAF, a p53 positive regulator. We speculate, consistent with the low frequency of p53 mutations in MM, that down-regulation of PCAF by the miR-106b-25 cluster, miR-181s, and miR-32, keeps p53 at low level or partially inactivated by controlling its stability through Hdm2  and working as a histone acetyltransferase."	PCAF	unknown	2008	18728182	Causal
+hsa-miR-26a	8584	Burkitt lymphoma	down-regulated	"Northern blot, qRT-PCR etc"	"The MYC oncogene, which is commonly mutated/amplified in tumors, represents an important regulator of cell growth owing to its ability to induce both proliferation and apoptosis. Recent evidence links MYC to altered miRNA expression, thereby suggesting that MYC-regulated miRNAs might contribute to tumorigenesis. To further analyze the impact of MYC-regulated miRNAs we investigated a murine lymphoma model harboring the MYC transgene in a Tet-off system. Among the miRNAs repressed by MYC we identified the potential tumor suppressor miR-26a, which possessed the ability to attenuate proliferation in MYC-dependent cells. Interestingly, miR-26a was also found to be deregulated in primary human Burkitt lymphoma samples, thereby likely being of clinical relevance.we could show that ectopic expression of miR-26a influenced cell cycle progression by targeting the bona fide oncogene EZH2, a Polycomb protein and global regulator of gene expression yet unknown to be regulated by miRNAs. Thus, in addition to directly targeting protein-coding genes, MYC modulates genes important to oncogenesis via deregulation of miRNAs."	EZH2	PLAG1	2008	18713946	Causal
+hsa-miR-28	3945	Glomerulosclerosis	down-regulated	"Northern blot, qRT-PCR etc"	down-regulated in Dicer Mutant Podocytes.	unknown	unknown	2008	18776119	Unspecified
+hsa-miR-29b	3459	breast cancer	up-regulated	microarray	"Nine miRNAs of hsa-miR-21, hsa-miR-365, hsa-miR-181b, hsa-let-7f, hsa-miR-155, hsa-miR-29b, hsa-miR-181d, hsa-miR-98, and hsa-miR-29c were observed to be up-regulated greater than twofold in BC compared with normal adjacent tumor tissues (NATs), whereas seven miRNAs of hsa-miR-497, hsa-miR-31, hsa-miR-355, hsa-miR-320, rno-mir-140, hsa-miR-127 and hsa-miR-30a-3p were observed to be down-regulated greater than twofold."	unknown	unknown	2008	18812439	Unspecified
+hsa-miR-29c	3459	breast cancer	up-regulated	microarray	"Nine miRNAs of hsa-miR-21, hsa-miR-365, hsa-miR-181b, hsa-let-7f, hsa-miR-155, hsa-miR-29b, hsa-miR-181d, hsa-miR-98, and hsa-miR-29c were observed to be up-regulated greater than twofold in BC compared with normal adjacent tumor tissues (NATs), whereas seven miRNAs of hsa-miR-497, hsa-miR-31, hsa-miR-355, hsa-miR-320, rno-mir-140, hsa-miR-127 and hsa-miR-30a-3p were observed to be down-regulated greater than twofold."	unknown	unknown	2008	18812439	Unspecified
+hsa-miR-30a-3p	3459	breast cancer	down-regulated	microarray	"Nine miRNAs of hsa-miR-21, hsa-miR-365, hsa-miR-181b, hsa-let-7f, hsa-miR-155, hsa-miR-29b, hsa-miR-181d, hsa-miR-98, and hsa-miR-29c were observed to be up-regulated greater than twofold in BC compared with normal adjacent tumor tissues (NATs), whereas seven miRNAs of hsa-miR-497, hsa-miR-31, hsa-miR-355, hsa-miR-320, rno-mir-140, hsa-miR-127 and hsa-miR-30a-3p were observed to be down-regulated greater than twofold."	unknown	unknown	2008	18812439	Unspecified
+hsa-miR-30b	3945	Glomerulosclerosis	down-regulated	"Northern blot, qRT-PCR etc"	"Among 15 upregulated target genes of the mir-30 miRNA, four genes known to be expressed and/or functional in podocytes were identified, including receptor for advanced glycation end product, vimentin, heat-shock protein 20, and immediate early response 3. Receptor for advanced glycation end product and immediate early response 3 are known to mediate podocyte apoptosis, whereas vimentin and heat-shock protein-20 are involved in cytoskeletal structure. Taken together, these results provide a knowledge base for ongoing investigations to validate functional roles for the mir-30 miRNA family in podocyte homeostasis and podocytopathies. In conclusion, our results demonstrate that miRNA are important genomic regulators of molecular podocyte homeostasis. Disruption of miRNA-controlled gene networks results in progressive proteinuria and glomerulosclerosis."	unknown	unknown	2008	18776119	Unspecified
+hsa-miR-30c-1	3945	Glomerulosclerosis	down-regulated	"Northern blot, qRT-PCR etc"	"Among 15 upregulated target genes of the mir-30 miRNA, four genes known to be expressed and/or functional in podocytes were identified, including receptor for advanced glycation end product, vimentin, heat-shock protein 20, and immediate early response 3. Receptor for advanced glycation end product and immediate early response 3 are known to mediate podocyte apoptosis, whereas vimentin and heat-shock protein-20 are involved in cytoskeletal structure. Taken together, these results provide a knowledge base for ongoing investigations to validate functional roles for the mir-30 miRNA family in podocyte homeostasis and podocytopathies. In conclusion, our results demonstrate that miRNA are important genomic regulators of molecular podocyte homeostasis. Disruption of miRNA-controlled gene networks results in progressive proteinuria and glomerulosclerosis."	unknown	unknown	2008	18776119	Unspecified
+hsa-miR-30c-2	3945	Glomerulosclerosis	down-regulated	"Northern blot, qRT-PCR etc"	"Among 15 upregulated target genes of the mir-30 miRNA, four genes known to be expressed and/or functional in podocytes were identified, including receptor for advanced glycation end product, vimentin, heat-shock protein 20, and immediate early response 3. Receptor for advanced glycation end product and immediate early response 3 are known to mediate podocyte apoptosis, whereas vimentin and heat-shock protein-20 are involved in cytoskeletal structure. Taken together, these results provide a knowledge base for ongoing investigations to validate functional roles for the mir-30 miRNA family in podocyte homeostasis and podocytopathies. In conclusion, our results demonstrate that miRNA are important genomic regulators of molecular podocyte homeostasis. Disruption of miRNA-controlled gene networks results in progressive proteinuria and glomerulosclerosis."	unknown	unknown	2008	18776119	Unspecified
+hsa-miR-30d	3945	Glomerulosclerosis	down-regulated	"Northern blot, qRT-PCR etc"	"Among 15 upregulated target genes of the mir-30 miRNA, four genes known to be expressed and/or functional in podocytes were identified, including receptor for advanced glycation end product, vimentin, heat-shock protein 20, and immediate early response 3. Receptor for advanced glycation end product and immediate early response 3 are known to mediate podocyte apoptosis, whereas vimentin and heat-shock protein-20 are involved in cytoskeletal structure. Taken together, these results provide a knowledge base for ongoing investigations to validate functional roles for the mir-30 miRNA family in podocyte homeostasis and podocytopathies. In conclusion, our results demonstrate that miRNA are important genomic regulators of molecular podocyte homeostasis. Disruption of miRNA-controlled gene networks results in progressive proteinuria and glomerulosclerosis."	unknown	unknown	2008	18776119	Unspecified
+hsa-miR-31	3459	breast cancer	down-regulated	microarray	"Nine miRNAs of hsa-miR-21, hsa-miR-365, hsa-miR-181b, hsa-let-7f, hsa-miR-155, hsa-miR-29b, hsa-miR-181d, hsa-miR-98, and hsa-miR-29c were observed to be up-regulated greater than twofold in BC compared with normal adjacent tumor tissues (NATs), whereas seven miRNAs of hsa-miR-497, hsa-miR-31, hsa-miR-355, hsa-miR-320, rno-mir-140, hsa-miR-127 and hsa-miR-30a-3p were observed to be down-regulated greater than twofold."	unknown	unknown	2008	18812439	Unspecified
+hsa-miR-32	9538	multiple myeloma (MM)	up-regulated	"Northern blot, qRT-PCR etc"	"We have confirmed that the proapoptotic BIM is a target of the miR-17-92 cluster in MM cells. Therefore, miR-17-92, along with miR-21, blocks apoptosis and promotes cell survival. On the other hand, miR-106b-25, miR-181a, and miR-32 but not miR-17-92 cluster (specifically miR-19s and miR-92), target PCAF, a p53 positive regulator. We speculate, consistent with the low frequency of p53 mutations in MM, that down-regulation of PCAF by the miR-106b-25 cluster, miR-181s, and miR-32, keeps p53 at low level or partially inactivated by controlling its stability through Hdm2  and working as a histone acetyltransferase."	PCAF	PFV-1	2008	18728182	Causal
+hsa-miR-320	3459	breast cancer	down-regulated	microarray	"Nine miRNAs of hsa-miR-21, hsa-miR-365, hsa-miR-181b, hsa-let-7f, hsa-miR-155, hsa-miR-29b, hsa-miR-181d, hsa-miR-98, and hsa-miR-29c were observed to be up-regulated greater than twofold in BC compared with normal adjacent tumor tissues (NATs), whereas seven miRNAs of hsa-miR-497, hsa-miR-31, hsa-miR-355, hsa-miR-320, rno-mir-140, hsa-miR-127 and hsa-miR-30a-3p were observed to be down-regulated greater than twofold."	unknown	unknown	2008	18812439	Unspecified
+hsa-miR-320	9256	colorectal cancer	up-regulated	microarray	Our microarray data showing that miR-320 is more abundantly expressed in cancer relative to normal tissue. It may therefore be speculated that miR-320 expression is involved in maintaining the undifferentiated and proliferative tumor phenotype.	unknown	unknown	2008	18676867	Unspecified
+hsa-miR-320	768	retinoblastoma	up-regulated	microarray	"A cluster of microRNAs was identified as highly expressed in retinoblastoma, including hsa-miR-494, hsa-let-7e, hsa-miR-513-1, hsa-miR-513-2, hsa-miR-518c*, hsa-miR-129-1, hsa-miR-129-2, hsa-miR-198, hsa-miR-492, hsa-miR-498, hsa-miR-320, hsa-miR-503, and hsa-miR-373*. CONCLUSION: These miRNAs are the first to be reported for human retinoblastoma and may play significant roles in regulating tumor genesis."	unknown	unknown	2008	18818933	Unspecified
+hsa-miR-324-5p	3858	medulloblastoma	down-regulated	"Northern blot, qRT-PCR etc"	" Using a miRNA high-throughput profile screening, we identify here a downregulated miRNA signature in human MBs with high Hh signalling. Specifically, we identify miR-125b and miR-326 as suppressors of the pathway activator Smoothened together with miR-324-5p, which also targets the downstream transcription factor Gli1. Downregulation of these miRNAs allows high levels of Hh-dependent gene expression leading to tumour cell proliferation. Interestingly, the downregulation of miR-324-5p is genetically determined by MB-associated deletion of chromosome 17p. These findings identify a novel regulatory circuitry of the Hh signalling and suggest that misregulation of specific miRNAs, leading to its aberrant activation, sustain cancer development."					
+	Gli1	unknown	2008	18756266	Causal	1	2015			
+hsa-miR-326	3858	medulloblastoma	down-regulated	"Northern blot, qRT-PCR etc"	" Using a miRNA high-throughput profile screening, we identify here a downregulated miRNA signature in human MBs with high Hh signalling. Specifically, we identify miR-125b and miR-326 as suppressors of the pathway activator Smoothened together with miR-324-5p, which also targets the downstream transcription factor Gli1. Downregulation of these miRNAs allows high levels of Hh-dependent gene expression leading to tumour cell proliferation. Interestingly, the downregulation of miR-324-5p is genetically determined by MB-associated deletion of chromosome 17p. These findings identify a novel regulatory circuitry of the Hh signalling and suggest that misregulation of specific miRNAs, leading to its aberrant activation, sustain cancer development."					
+	Gli1	unknown	2008	18756266	Causal	1	2016			
+hsa-miR-335	9538	multiple myeloma (MM)	up-regulated	"Northern blot, qRT-PCR etc"	"We identified transcripts specific to six miRNA host genes (CCPG1, GULP1, EVL, TACSTD1, MEST, and TNIK) whose average changes in expression varied at least 2-fold from the mean of the examined dataset. We evaluated the expression levels of the corresponding intronic miRNAs and identified a significant correlation between the expression levels of MEST, EVL, and GULP1 and those of the corresponding miRNAs miR-335, miR-342-3p, and miR-561, respectively. Genome-wide profiling of the 20 HMCLs indicated that the increased expression of the three host genes and their corresponding intronic miRNAs was not correlated with local copy number variations. Notably, miRNAs and their host genes were overexpressed in a fraction of primary tumors with respect to normal plasma cells. The predicted putative miRNA targets and the transcriptional profiles associated with the primary tumors suggest that MEST/miR-335 and EVL/miR-342-3p may play a role in plasma cell homing and/or interactions with the bone marrow microenvironment. Our data support the idea that intronic miRNAs and their host genes are regulated dependently, and may contribute to the understanding of their biological roles in cancer."	unknown	unknown	2008	18700954	Unspecified
+hsa-miR-342	9538	multiple myeloma (MM)	up-regulated	"Northern blot, qRT-PCR etc"	"We identified transcripts specific to six miRNA host genes (CCPG1, GULP1, EVL, TACSTD1, MEST, and TNIK) whose average changes in expression varied at least 2-fold from the mean of the examined dataset. We evaluated the expression levels of the corresponding intronic miRNAs and identified a significant correlation between the expression levels of MEST, EVL, and GULP1 and those of the corresponding miRNAs miR-335, miR-342-3p, and miR-561, respectively. Genome-wide profiling of the 20 HMCLs indicated that the increased expression of the three host genes and their corresponding intronic miRNAs was not correlated with local copy number variations. Notably, miRNAs and their host genes were overexpressed in a fraction of primary tumors with respect to normal plasma cells. The predicted putative miRNA targets and the transcriptional profiles associated with the primary tumors suggest that MEST/miR-335 and EVL/miR-342-3p may play a role in plasma cell homing and/or interactions with the bone marrow microenvironment. Our data support the idea that intronic miRNAs and their host genes are regulated dependently, and may contribute to the understanding of their biological roles in cancer."	unknown	unknown	2008	18700954	Unspecified
+hsa-miR-34a	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	"Here, we show for the first time that microRNA-34a is significantly downregulated in CLL patients with TP53 deletions compared with CLL patients without such deletions. In these cases, we were not able to reveal BCL2 as a target of microRNA-34a. Still, BCL2 being only one of the microRNA-34a targets, a"					
+"potential function of a regulatory circuit involving the important tumor suppressor TP53 and microRNA-34a in the pathogenesis of CLL cannot be excluded, and needs to be further investigated."	unknown	E2F3	2008	18818704	Unspecified	0	2019			
+hsa-miR-34a	3945	Glomerulosclerosis	down-regulated	"Northern blot, qRT-PCR etc"	down-regulated in Dicer Mutant Podocytes.	unknown	E2F3	2008	18776119	Unspecified
+hsa-miR-34a	10286	prostate cancer	down-regulated	"Northern blot, qRT-PCR etc"	"MiR-34a expression was markedly reduced in p53-null PC3 cells and p53-mutated DU145 cells compared with LNCaP cells expressing wild-type p53. In PC3 cell, ectopic expression of miR-34a decreased the SIRT1 mRNA and protein levels as well as protein levels of known direct target genes. Reporter assays revealed that miR-34a-induced SIRT1 inhibition occurred at the transcriptional but not post-transcriptional level despite the presence of a potential miR-34a binding site within its 3'-UTR. Ectopic miR-34a expression resulted in cell cycle arrest and growth inhibition and attenuated chemoresistance to anticancer drug camptothecin by inducing apoptosis, suggesting a potential role of miR-34a for the treatment of p53-defective prostate cancer."	SIRT1	E2F3	2008	18834855	Causal
+hsa-miR-34b	8584	Burkitt lymphoma	down-regulated	"Northern blot, qRT-PCR etc"	"Our results demonstrated a modulation of specific miRNAs. In particular, down-regulation of hsa-let-7c was observed in BL cases, compared to normal controls. More interestingly, hsa-mir-34b was found to be down-regulated only in BL cases that were negative for MYC translocation, suggesting that this event might be responsible for c-Myc deregulation in such cases. This hypothesis was further confirmed by our in vitro experiments, which demonstrated that increasing doses of synthetic hsa-mir-34b were able to modulate c-Myc expression. These results indicate for the first time that hsa-mir-34b may influence c-Myc expression in Burkitt lymphoma as the more common aberrant control exercised by the immunoglobulin enhancer locus."	c-myc	unknown	2008	18802929	Causal
+hsa-miR-355	3459	breast cancer	down-regulated	microarray	"Nine miRNAs of hsa-miR-21, hsa-miR-365, hsa-miR-181b, hsa-let-7f, hsa-miR-155, hsa-miR-29b, hsa-miR-181d, hsa-miR-98, and hsa-miR-29c were observed to be up-regulated greater than twofold in BC compared with normal adjacent tumor tissues (NATs), whereas seven miRNAs of hsa-miR-497, hsa-miR-31, hsa-miR-355, hsa-miR-320, rno-mir-140, hsa-miR-127 and hsa-miR-30a-3p were observed to be down-regulated greater than twofold."	unknown	unknown	2008	18812439	Unspecified
+hsa-miR-365	3459	breast cancer		microarray	"Nine miRNAs of hsa-miR-21, hsa-miR-365, hsa-miR-181b, hsa-let-7f, hsa-miR-155, hsa-miR-29b, hsa-miR-181d, hsa-miR-98, and hsa-miR-29c were observed to be up-regulated greater than twofold in BC compared with normal adjacent tumor tissues (NATs), whereas seven miRNAs of hsa-miR-497, hsa-miR-31, hsa-miR-355, hsa-miR-320, rno-mir-140, hsa-miR-127 and hsa-miR-30a-3p were observed to be down-regulated greater than twofold."	unknown	unknown	2008	18812439	Unspecified
+hsa-miR-373*	768	retinoblastoma	up-regulated	microarray	"A cluster of microRNAs was identified as highly expressed in retinoblastoma, including hsa-miR-494, hsa-let-7e, hsa-miR-513-1, hsa-miR-513-2, hsa-miR-518c*, hsa-miR-129-1, hsa-miR-129-2, hsa-miR-198, hsa-miR-492, hsa-miR-498, hsa-miR-320, hsa-miR-503, and hsa-miR-373*. CONCLUSION: These miRNAs are the first to be reported for human retinoblastoma and may play significant roles in regulating tumor genesis."	unknown	unknown	2008	18818933	Unspecified
+hsa-miR-492	768	retinoblastoma	up-regulated	microarray	"A cluster of microRNAs was identified as highly expressed in retinoblastoma, including hsa-miR-494, hsa-let-7e, hsa-miR-513-1, hsa-miR-513-2, hsa-miR-518c*, hsa-miR-129-1, hsa-miR-129-2, hsa-miR-198, hsa-miR-492, hsa-miR-498, hsa-miR-320, hsa-miR-503, and hsa-miR-373*. CONCLUSION: These miRNAs are the first to be reported for human retinoblastoma and may play significant roles in regulating tumor genesis."	unknown	unknown	2008	18818933	Unspecified
+hsa-miR-494	768	retinoblastoma	up-regulated	microarray	"A cluster of microRNAs was identified as highly expressed in retinoblastoma, including hsa-miR-494, hsa-let-7e, hsa-miR-513-1, hsa-miR-513-2, hsa-miR-518c*, hsa-miR-129-1, hsa-miR-129-2, hsa-miR-198, hsa-miR-492, hsa-miR-498, hsa-miR-320, hsa-miR-503, and hsa-miR-373*. CONCLUSION: These miRNAs are the first to be reported for human retinoblastoma and may play significant roles in regulating tumor genesis."	unknown	unknown	2008	18818933	Unspecified
+hsa-miR-497	3459	breast cancer	down-regulated	microarray	"Nine miRNAs of hsa-miR-21, hsa-miR-365, hsa-miR-181b, hsa-let-7f, hsa-miR-155, hsa-miR-29b, hsa-miR-181d, hsa-miR-98, and hsa-miR-29c were observed to be up-regulated greater than twofold in BC compared with normal adjacent tumor tissues (NATs), whereas seven miRNAs of hsa-miR-497, hsa-miR-31, hsa-miR-355, hsa-miR-320, rno-mir-140, hsa-miR-127 and hsa-miR-30a-3p were observed to be down-regulated greater than twofold."	unknown	unknown	2008	18812439	Unspecified
+hsa-miR-498	768	retinoblastoma	up-regulated	microarray	"A cluster of microRNAs was identified as highly expressed in retinoblastoma, including hsa-miR-494, hsa-let-7e, hsa-miR-513-1, hsa-miR-513-2, hsa-miR-518c*, hsa-miR-129-1, hsa-miR-129-2, hsa-miR-198, hsa-miR-492, hsa-miR-498, hsa-miR-320, hsa-miR-503, and hsa-miR-373*. CONCLUSION: These miRNAs are the first to be reported for human retinoblastoma and may play significant roles in regulating tumor genesis."	unknown	unknown	2008	18818933	Unspecified
+hsa-miR-503	768	retinoblastoma	up-regulated	microarray	"A cluster of microRNAs was identified as highly expressed in retinoblastoma, including hsa-miR-494, hsa-let-7e, hsa-miR-513-1, hsa-miR-513-2, hsa-miR-518c*, hsa-miR-129-1, hsa-miR-129-2, hsa-miR-198, hsa-miR-492, hsa-miR-498, hsa-miR-320, hsa-miR-503, and hsa-miR-373*. CONCLUSION: These miRNAs are the first to be reported for human retinoblastoma and may play significant roles in regulating tumor genesis."	unknown	unknown	2008	18818933	Unspecified
+hsa-miR-513-1	768	retinoblastoma	up-regulated	microarray	"A cluster of microRNAs was identified as highly expressed in retinoblastoma, including hsa-miR-494, hsa-let-7e, hsa-miR-513-1, hsa-miR-513-2, hsa-miR-518c*, hsa-miR-129-1, hsa-miR-129-2, hsa-miR-198, hsa-miR-492, hsa-miR-498, hsa-miR-320, hsa-miR-503, and hsa-miR-373*. CONCLUSION: These miRNAs are the first to be reported for human retinoblastoma and may play significant roles in regulating tumor genesis."	unknown	unknown	2008	18818933	Unspecified
+hsa-miR-513-2	768	retinoblastoma	up-regulated	microarray	"A cluster of microRNAs was identified as highly expressed in retinoblastoma, including hsa-miR-494, hsa-let-7e, hsa-miR-513-1, hsa-miR-513-2, hsa-miR-518c*, hsa-miR-129-1, hsa-miR-129-2, hsa-miR-198, hsa-miR-492, hsa-miR-498, hsa-miR-320, hsa-miR-503, and hsa-miR-373*. CONCLUSION: These miRNAs are the first to be reported for human retinoblastoma and may play significant roles in regulating tumor genesis."	unknown	unknown	2008	18818933	Unspecified
+hsa-miR-516-3p	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Supervised analysis in the initial subset and subsequent analysis in additional tumors significantly linked four miRNAs (miR-7, miR-128a, miR-210, and miR-516-3p) to ER(+)/LNN breast cancer aggressiveness (n=147) and one miRNA (miR-210) to metastatic capability in ER(-)/LNN breast cancer ( n=114) and in the clinically important triple-negative subgroup (n=69) (all P<0.05). Bioinformatic analysis coupled miR-210 to hypoxia/VEGF signaling, miR-7 and miR-516-3p to cell cycle progression and chromosomal instability, and miR-128a to cytokine signaling. In conclusion, our work connects four miRNAs to breast cancer progression and to several distinct biological processes involved therein."					
+	unknown	unknown	2008	18755890	Causal	1	2033			
+hsa-miR-518c*	768	retinoblastoma	up-regulated	microarray	"A cluster of microRNAs was identified as highly expressed in retinoblastoma, including hsa-miR-494, hsa-let-7e, hsa-miR-513-1, hsa-miR-513-2, hsa-miR-518c*, hsa-miR-129-1, hsa-miR-129-2, hsa-miR-198, hsa-miR-492, hsa-miR-498, hsa-miR-320, hsa-miR-503, and hsa-miR-373*. CONCLUSION: These miRNAs are the first to be reported for human retinoblastoma and may play significant roles in regulating tumor genesis."	unknown	unknown	2008	18818933	Unspecified
+hsa-miR-521	10286	prostate cancer	up-regulated	"Northern blot, qRT-PCR etc"	"To determine the role of miR-521 in radiation response we transiently overexpressed miR-521 using miR-521 mimic. The miR-521 mimic significantly sensitized prostate cancer cells to radiation treatment. Conversely, ectopic inhibition of miR-521 resulted in radiation resistance of prostate cancer cells. To determine the mechanism by which miR-521 modulates radiation sensitivity we measured the expression levels of one of its predicted target protein, Cockayne syndrome protein A (CSA). CSA is a DNA repair protein, and its levels correlated inversely with the levels of miR-521. Radiation treatment downregulated the levels of miR-521 and upregulated CSA protein. Similarly, ectopic inhibition of miR-521 resulted in increased CSA protein levels. Therefore by altering the levels of CSA protein, miR-521 sensitized prostate cancer cells to radiation treatment. CONCLUSION: miR-521 modulates the expression levels of DNA repair protein, CSA and plays an important role, in the radio-sensitivity of prostate cancer cell lines. Thus miR-521 can be a potential target for enhancing the effect of radiation treatment on prostate cancer cells."	CSA	unknown	2008	18668526	Causal
+hsa-miR-561	9538	multiple myeloma (MM)	up-regulated	"Northern blot, qRT-PCR etc"	"We identified transcripts specific to six miRNA host genes (CCPG1, GULP1, EVL, TACSTD1, MEST, and TNIK) whose average changes in expression varied at least 2-fold from the mean of the examined dataset. We evaluated the expression levels of the corresponding intronic miRNAs and identified a significant correlation between the expression levels of MEST, EVL, and GULP1 and those of the corresponding miRNAs miR-335, miR-342-3p, and miR-561, respectively. Genome-wide profiling of the 20 HMCLs indicated that the increased expression of the three host genes and their corresponding intronic miRNAs was not correlated with local copy number variations. Notably, miRNAs and their host genes were overexpressed in a fraction of primary tumors with respect to normal plasma cells. The predicted putative miRNA targets and the transcriptional profiles associated with the primary tumors suggest that MEST/miR-335 and EVL/miR-342-3p may play a role in plasma cell homing and/or interactions with the bone marrow microenvironment. Our data support the idea that intronic miRNAs and their host genes are regulated dependently, and may contribute to the understanding of their biological roles in cancer."	unknown	unknown	2008	18700954	Unspecified
+hsa-miR-615-3p	5082	HBV-related cirrhosis	up-regulated	"Northern blot, qRT-PCR etc"	hsa-miR-615-3p was significantly up-regulated in					
+hypersplenism. Dynamic changes in miRNA expression occurred during the										
+pathogenesis of portal hypertension-induced hypersplenism in HBV-related cirrhosis.										
+The miRNAs then are novel regulatory RNAs in hypersplenism in patients with										
+HBV-related cirrhosis.	unknown	unknown	2008	18791127	Unspecified	0	2037			
+hsa-miR-659	10216	frontotemporal dementia	normal	"Northern blot, qRT-PCR etc"	"Here we expand the role of GRN in FTLD-U and demonstrate that a common genetic variant (rs5848), located in the 3'untranslated region (UTR) of GRN in a binding-site for miR-659, is a major susceptibility factor for FTLD-U. In a series of pathologically confirmed FTLD-U patients without GRN mutations, we show that carriers homozygous for the T-allele of rs5848 have a 3.2-fold increased risk to develop FTLD-U compared to homozygous C-allele carriers (95% CI: 1.50-6.73). We further demonstrate that miR-659 can regulate GRN expression in vitro, with miR-659 binding more efficiently to the high risk T-allele of rs5848 resulting in augmented translational inhibition of GRN. A significant reduction in GRN protein was observed in homozygous T-allele carriers in vivo, through biochemical and immunohistochemical methods, mimicking the effect of heterozygous loss-of-function GRN mutations."	GRN	unknown	2008	18723524	Causal
+hsa-miR-7	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Supervised analysis in the initial subset and subsequent analysis in additional tumors significantly linked four miRNAs (miR-7, miR-128a, miR-210, and miR-516-3p) to ER(+)/LNN breast cancer aggressiveness (n=147) and one miRNA (miR-210) to metastatic capability in ER(-)/LNN breast cancer ( n=114) and in the clinically important triple-negative subgroup (n=69) (all P<0.05). Bioinformatic analysis coupled miR-210 to hypoxia/VEGF signaling, miR-7 and miR-516-3p to cell cycle progression and chromosomal instability, and miR-128a to cytokine signaling. In conclusion, our work connects four miRNAs to breast cancer progression and to several distinct biological processes involved therein."					
+	unknown	unknown	2008	18755890	Causal	1	2039			
+hsa-miR-92	9256	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	"in vitro inhibition of two miRNAs highly expressed in tumor tissue, miR-20a and miR-92, did not affect cell viability. This was unexpected, considering that these miRNAs are part of the miR-17-92 cluster reported to be oncogenic in other cancer types. Although our data indicated that the viability"					
+"of colon cancer cell lines were unaffected by inhibition of miR-20a and miR-92, other cancer hall marks such as motility, invasion, and angiogenesis might have been influenced."	unknown	unknown	2008	18676867	Unspecified	0	2040			
+hsa-miR-92a	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	"Two known oncomiRs--miRNAs with known roles in cancer--the miR-17-92 polycistron and miR-21, exhibited increased expression in 100% of primary human and woodchuck hepatocellular carcinomas surveyed. To determine the importance of these miRNAs in tumorigenesis, an in vitro antisense oligonucleotide knockdown model was evaluated for its ability to reverse the malignant phenotype. Both in human and woodchuck HCC cell lines, separate treatments with antisense oligonucleotides specific for either the miR-17-92 polycistron (all six members) or miR-21 caused a 50% reduction in both hepatocyte proliferation and anchorage-independent growth. The combination of assays presented here supports a role for these miRNAs in the maintenance of the malignant transformation of hepatocytes."	unknown	unknown	2008	18688024	Causal
+hsa-miR-93	9538	multiple myeloma (MM)	up-regulated	"Northern blot, qRT-PCR etc"	"We have confirmed that the proapoptotic BIM is a target of the miR-17-92 cluster in MM cells. Therefore, miR-17-92, along with miR-21, blocks apoptosis and promotes cell survival. On the other hand, miR-106b-25, miR-181a, and miR-32 but not miR-17-92 cluster (specifically miR-19s and miR-92), target PCAF, a p53 positive regulator. We speculate, consistent with the low frequency of p53 mutations in MM, that down-regulation of PCAF by the miR-106b-25 cluster, miR-181s, and miR-32, keeps p53 at low level or partially inactivated by controlling its stability through Hdm2  and working as a histone acetyltransferase."	PCAF	unknown	2008	18728182	Causal
+hsa-miR-96	10584	retinitis pigmentosa (RP)	down-regulated	"Northern blot, qRT-PCR etc"	"expression of miR-96, -182 and -183 decreased by 14.1-53.2%, while expression of miR-1, -133 and -142 was up-regulated by 186.1-538.5%. Significantly, the detected pan-retinal miR signature was mirrored by similar miR expression profiles in FACS-isolated rod photoreceptors from these mice. "	unknown	unknown	2008	18834879	Unspecified
+hsa-miR-98	3459	breast cancer	up-regulated	microarray	"Nine miRNAs of hsa-miR-21, hsa-miR-365, hsa-miR-181b, hsa-let-7f, hsa-miR-155, hsa-miR-29b, hsa-miR-181d, hsa-miR-98, and hsa-miR-29c were observed to be up-regulated greater than twofold in BC compared with normal adjacent tumor tissues (NATs), whereas seven miRNAs of hsa-miR-497, hsa-miR-31, hsa-miR-355, hsa-miR-320, rno-mir-140, hsa-miR-127 and hsa-miR-30a-3p were observed to be down-regulated greater than twofold."	unknown	unknown	2008	18812439	Unspecified
+hsa-miR-196b	9952	acute lymphoblastic leukemia (ALL)	up-regulated	microarray	"Most remarkably, miR-708 was 250-up to 6500-fold higher expressed in 57 TEL-AML1, BCR-ABL, E2A-PBX1, hyperdiploid and B-other cases than in 20 MLL-rearranged and 15 T-ALL cases (0.0001< P<0.01), whereas the expression of miR-196b was 500-fold higher in MLL-rearranged and 800-fold higher in 5 of 15 T-ALL cases as compared with the expression level in the remaining precursor B-ALL cases (P<0.001). The expression did not correlate with the maturation status of leukemia cells based on immunoglobulin and T-cell receptor rearrangements, immunophenotype or MLL-fusion partner. In conclusion, we identified new miRNA genes and showed that miRNA expression profiles are ALL subtype-specific rather than linked to the differentiation stadium associated with these subtypes."	unknown	unknown	2008	18923441	Unspecified
+hsa-miR-708	9952	acute lymphoblastic leukemia (ALL)	up-regulated	microarray	"Most remarkably, miR-708 was 250-up to 6500-fold higher expressed in 57 TEL-AML1, BCR-ABL, E2A-PBX1, hyperdiploid and B-other cases than in 20 MLL-rearranged and 15 T-ALL cases (0.0001< P<0.01), whereas the expression of miR-196b was 500-fold higher in MLL-rearranged and 800-fold higher in 5 of 15 T-ALL cases as compared with the expression level in the remaining precursor B-ALL cases (P<0.001). The expression did not correlate with the maturation status of leukemia cells based on immunoglobulin and T-cell receptor rearrangements, immunophenotype or MLL-fusion partner. In conclusion, we identified new miRNA genes and showed that miRNA expression profiles are ALL subtype-specific rather than linked to the differentiation stadium associated with these subtypes."	unknown	unknown	2008	18923441	Unspecified
+hsa-miR-210	9119	Acute Promyelocytic Leukemia (APL)	down-regulated	"Northern blot, qRT-PCR etc"	the miR-210 and the miR-23a/24-2 are directly repressed by the PMLRARA oncogene in APL cells and are regulated by RARA/RXRA heterodimers in non APL					
+cells.The miRNAs repressed by PML-RARA are also implicated in the control of crucial pathways linked to leukemogenesis.	unknown	unknown	2008	18941112	Causal	1	2047			
+hsa-miR-23a 	9119	Acute Promyelocytic Leukemia (APL)	down-regulated	"Northern blot, qRT-PCR etc"	the miR-210 and the miR-23a/24-2 are directly repressed by the PMLRARA oncogene in APL cells and are regulated by RARA/RXRA heterodimers in non APL					
+cells.The miRNAs repressed by PML-RARA are also implicated in the control of crucial pathways linked to leukemogenesis.	unknown	"CXCL12,FLJ13158"	2008	18941112	Causal	1	2048			
+hsa-miR-17	353	B-cell lymphoma	up-regulated	"Northern blot, qRT-PCR etc"	"To identify essential target(s) of miR-17-92 in lymphomagenesis, we first transfected miR-17-92 into two genetically distinct B-cell lymphoma cell lines: Raji cells, which overexpress c-Myc, and SUDHL4 cells, which overexpress Bcl2. Raji cells transfected with miR-17-19b-1 exhibited downregulated expression Bim and a slight upregulation in Bcl2 expression. On the other hand, SUDHL4 cell transfectants showed aggressive cell growth reflecting facilitated cell cycle progression at the G1-S transition and decreased expression of CDKN1A mRNA and p21 protein (CDKN1A/p21) that was independent of p53 expression. Conversely, transfection of antisense oligonucleotides against miR-17 and miR-20a into Jeko-1 cells led to upregulation of CDKN1A/p21, resulting in decreased cell growth with G1-S arrest. Thus, CDKN1A/p21 appears to be an essential target of miR-17-92 during B-cell lymphomagenesis, which suggests the miR-17-92 polycistron has distinct targets in different B-cell lymphoma subtypes."	"CDKN1A, p21"	unknown	2008	18941111	Causal
+hsa-miR-20a	353	B-cell lymphoma	up-regulated	"Northern blot, qRT-PCR etc"	"To identify essential target(s) of miR-17-92 in lymphomagenesis, we first transfected miR-17-92 into two genetically distinct B-cell lymphoma cell lines: Raji cells, which overexpress c-Myc, and SUDHL4 cells, which overexpress Bcl2. Raji cells transfected with miR-17-19b-1 exhibited downregulated expression Bim and a slight upregulation in Bcl2 expression. On the other hand, SUDHL4 cell transfectants showed aggressive cell growth reflecting facilitated cell cycle progression at the G1-S transition and decreased expression of CDKN1A mRNA and p21 protein (CDKN1A/p21) that was independent of p53 expression. Conversely, transfection of antisense oligonucleotides against miR-17 and miR-20a into Jeko-1 cells led to upregulation of CDKN1A/p21, resulting in decreased cell growth with G1-S arrest. Thus, CDKN1A/p21 appears to be an essential target of miR-17-92 during B-cell lymphomagenesis, which suggests the miR-17-92 polycistron has distinct targets in different B-cell lymphoma subtypes."	"CDKN1A, p21"	TGFBR2	2008	18941111	Causal
+hsa-miR-155	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Transforming growth factor beta (TGF-beta) signaling facilitates metastasis in advanced malignancy. While a number of protein-encoding genes are known to be involved in this process, information on the role of microRNAs (miRNAs) in TGF-beta-induced cell migration and invasion is still limited. By hybridizing a 515-miRNA oligonucleotide-based microarray library, a total of 28 miRNAs were found to be significantly deregulated in TGF-beta-treated normal murine mammary gland (NMuMG) epithelial cells but not Smad4 knockdown NMuMG cells. Among upregulated miRNAs, miR-155 was the most significantly elevated miRNA. TGF-beta induces miR-155 expression and promoter activity through Smad4. The knockdown of miR-155 suppressed TGF-beta-induced epithelial-mesenchymal transition (EMT) and tight junction dissolution, as well as cell migration and invasion. Further, the ectopic expression of miR-155 reduced RhoA protein and disrupted tight junction formation. Reintroducing RhoA cDNA without the 3' untranslated region largely reversed the phenotype induced by miR-155 and TGF-beta. In addition, elevated levels of miR-155 were frequently detected in invasive breast cancer tissues. These data suggest that miR-155 may play an important role in TGF-beta-induced EMT and cell migration and invasion by targeting RhoA and indicate that it is a potential therapeutic target for breast cancer intervention."					
+	RhoA	AGTR1	2008	18794355	Causal	1	2053			
+hsa-miR-204	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Prostate-derived Ets factor (PDEF) is an ETS transcription factor expressed in normal tissues with high epithelial cell content and noninvasive breast cancer cells. A putative tumor suppressor PDEF protein expression is often lost during progression to a more invasive phenotype. Interestingly, PDEF mRNA has been found to be retained or even overexpressed in the absence of protein; however, the mechanisms for this remain to be elucidated. This study identifies two microRNAs (miRNA) that directly act on and repress PDEF mRNA translation, leading to the loss of PDEF protein expression and the gain of phenotypes associated with invasive cells. In addition, we show that these miRNAs are elevated in human breast tumor samples. Together, these data describe a mechanism of regulation that explains, for the first time, the lack of correlation between PDEF mRNA and protein levels, providing insight into the underexplored role of posttranscriptional regulation and how this contributes to dysregulated protein expression in cancer. These observations have critical implications for therapeutically targeting miRNAs that contribute to cancer progression."	PDEF	unknown	2008	18922924	Causal
+hsa-miR-21	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"MicroRNA-21 (miR-21) is considered an onco-microRNA given its abilities to suppress the actions of several tumor suppressor genes and to promote tumor cell growth, invasion and metastasis. Recently, transforming growth factor-beta (TGF-beta) is found to up-regulate the expression of miR-21, and elevated miR-21 expression is seen frequently in breast cancer. The study results showed that the expression of miR-21 was detected in all tumor samples with substantial variation. High miR-21 expression was associated with features of aggressive disease, including high tumor grade, negative hormone receptor status, and ductal carcinoma. High miR-21 was also positively correlated with TGF-beta1. No associations were found between patient survival and miR-21 expression among all patients, but high miR-21 was associated with poor disease-free survival in early stage patients (HR=2.08, 95% CI:1.08-4.00) despite no value for prognosis. The study supports the notion that miR-21 is an onco-microRNA for breast cancer. Elevated miR-21 expression may facilitate tumor progression, and TGF-beta may up-regulate its expression."	unknown	"PTEN,TPM1"	2008	18932017	Causal
+hsa-miR-221	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"The expression of miR-221 and miR-222 was also significantly (2-fold) elevated in HER2/neu-positive primary human breast cancer tissues that are known to be resistant to endocrine therapy compared with HER2/neu-negative tissue samples. Ectopic expression of miR-221/222 rendered the parental MCF-7 cells resistant to tamoxifen. The protein level of the cell cycle inhibitor p27(Kip1), a known target of miR-221/222, was reduced by 50% in OHT(R) cells and by 28-50% in miR-221/222-overexpressing MCF-7 cells. Furthermore, overexpression of p27(Kip1) in the resistant OHT(R) cells caused enhanced cell death when exposed to tamoxifen. This is the first study demonstrating a relationship between miR-221/222 expression and HER2/neu overexpression in primary breast tumors that are generally resistant to tamoxifen therapy. This finding also provides the rationale for the application of altered expression of specific miRNAs as a predictive tamoxifen-resistant breast cancer marker."	p27(Kip1)	KIT	2008	18708351	Unspecified
+hsa-miR-221	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"A search for regulators of estrogen receptor alpha (ERalpha) expression has yielded a set of microRNAs (miRNAs) for which expression is specifically elevated in ERalpha-negative breast cancer. Here we show distinct expression of a panel of miRNAs between ERalpha-positive and ERalpha-negative breast cancer cell lines and primary tumors. Of the elevated miRNAs in ERalpha-negative cells, miR-221 and miR-222 directly interact with the 3'-untranslated region of ERalpha. Ectopic expression of miR-221 and miR-222 in MCF-7 and T47D cells resulted in a decrease in expression of ERalpha protein but not mRNA, whereas knockdown of miR-221 and miR-222 partially restored ERalpha in ERalpha protein-negative/mRNA-positive cells. Notably, miR-221- and/or miR-222-transfected MCF-7 and T47D cells became resistant to tamoxifen compared with vector-treated cells. Furthermore, knockdown of miR-221 and/or miR-222 sensitized MDA-MB-468 cells to tamoxifen-induced cell growth arrest and apoptosis. These findings indicate that miR-221 and miR-222 play a significant role in the regulation of ERalpha expression at the protein level and could be potential targets for restoring ERalpha expression and responding to antiestrogen therapy in a subset of breast cancers."	ER-alpha	KIT	2008	18790736	Causal
+hsa-miR-222	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"The expression of miR-221 and miR-222 was also significantly (2-fold) elevated in HER2/neu-positive primary human breast cancer tissues that are known to be resistant to endocrine therapy compared with HER2/neu-negative tissue samples. Ectopic expression of miR-221/222 rendered the parental MCF-7 cells resistant to tamoxifen. The protein level of the cell cycle inhibitor p27(Kip1), a known target of miR-221/222, was reduced by 50% in OHT(R) cells and by 28-50% in miR-221/222-overexpressing MCF-7 cells. Furthermore, overexpression of p27(Kip1) in the resistant OHT(R) cells caused enhanced cell death when exposed to tamoxifen. This is the first study demonstrating a relationship between miR-221/222 expression and HER2/neu overexpression in primary breast tumors that are generally resistant to tamoxifen therapy. This finding also provides the rationale for the application of altered expression of specific miRNAs as a predictive tamoxifen-resistant breast cancer marker."	p27(Kip1)	KIT	2008	18708351	Unspecified
+hsa-miR-222	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"A search for regulators of estrogen receptor alpha (ERalpha) expression has yielded a set of microRNAs (miRNAs) for which expression is specifically elevated in ERalpha-negative breast cancer. Here we show distinct expression of a panel of miRNAs between ERalpha-positive and ERalpha-negative breast cancer cell lines and primary tumors. Of the elevated miRNAs in ERalpha-negative cells, miR-221 and miR-222 directly interact with the 3'-untranslated region of ERalpha. Ectopic expression of miR-221 and miR-222 in MCF-7 and T47D cells resulted in a decrease in expression of ERalpha protein but not mRNA, whereas knockdown of miR-221 and miR-222 partially restored ERalpha in ERalpha protein-negative/mRNA-positive cells. Notably, miR-221- and/or miR-222-transfected MCF-7 and T47D cells became resistant to tamoxifen compared with vector-treated cells. Furthermore, knockdown of miR-221 and/or miR-222 sensitized MDA-MB-468 cells to tamoxifen-induced cell growth arrest and apoptosis. These findings indicate that miR-221 and miR-222 play a significant role in the regulation of ERalpha expression at the protein level and could be potential targets for restoring ERalpha expression and responding to antiestrogen therapy in a subset of breast cancers."	ER-alpha	KIT	2008	18790736	Causal
+hsa-miR-510	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Prostate-derived Ets factor (PDEF) is an ETS transcription factor expressed in normal tissues with high epithelial cell content and noninvasive breast cancer cells. A putative tumor suppressor PDEF protein expression is often lost during progression to a more invasive phenotype. Interestingly, PDEF mRNA has been found to be retained or even overexpressed in the absence of protein; however, the mechanisms for this remain to be elucidated. This study identifies two microRNAs (miRNA) that directly act on and repress PDEF mRNA translation, leading to the loss of PDEF protein expression and the gain of phenotypes associated with invasive cells. In addition, we show that these miRNAs are elevated in human breast tumor samples. Together, these data describe a mechanism of regulation that explains, for the first time, the lack of correlation between PDEF mRNA and protein levels, providing insight into the underexplored role of posttranscriptional regulation and how this contributes to dysregulated protein expression in cancer. These observations have critical implications for therapeutically targeting miRNAs that contribute to cancer progression."	PDEF	unknown	2008	18922924	Causal
+hsa-miR-7	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"We show that miR-7 inhibits p21-activated kinase 1 (Pak1) expression, a widely up-regulated signaling kinase in multiple human cancers, by targeting the 3'-untranslated region (UTR) of Pak1 mRNA. We noticed an inverse correlation between the levels of endogenous miR-7 and Pak1 expression in human cancer cells. We discovered that endogenous miR-7 expression is positively regulated by a homeodomain transcription factor, HoxD10, the loss of which leads to an increased invasiveness. HoxD10 directly interacts with the miR-7 chromatin. Accordingly, the levels of Pak1 protein are progressively up-regulated whereas those of miR-7 and its upstream activator HoxD10 are progressively down-regulated in a cellular model of breast cancer progression from low to highly invasive phenotypes. Furthermore, HoxD10 expression in highly invasive breast cancer cells resulted in an increased miR-7 expression but reduced Pak1 3'-UTR-luciferase activity and reduced Pak1 protein. Finally, we show that miR-7 introduction inhibits the motility, invasiveness, anchorage-independent growth, and tumorigenic potential of highly invasive breast cancer cells. Collectively, these findings establish for the first time that Pak1 is a target of miR-7 and that HoxD10 plays a regulatory role in modifying the expression of miR-7."	Pak1	unknown	2008	18922890	Causal
+hsa-miR-425	3068	glioblastoma	down-regulated	"Northern blot, qRT-PCR etc"	"We examined the microRNA profiles of Glioblastoma stem (CD133+) and non-stem (CD133-) cell populations and found up-regulation of several miRs in the CD133- cells, including miR-451, miR-486, and miR-425, some of which may be involved in regulation of brain differentiation."	unknown	unknown	2008	18765229	Unspecified
+hsa-miR-451	3068	glioblastoma	down-regulated	"Northern blot, qRT-PCR etc"	"We examined the microRNA profiles of Glioblastoma stem (CD133+) and non-stem (CD133-) cell populations and found up-regulation of several miRs in the CD133- cells, including miR-451, miR-486, and miR-425, some of which may be involved in regulation of brain differentiation. Transfection of GBM cells with the above miRs inhibited neurosphere formation and transfection with the mature miR-451 dispersed neurospheres, and inhibited GBM cell growth. Furthermore, transfection of miR-451 combined with Imatinib mesylate treatment had a cooperative effect in dispersal of GBM neurospheres. In addition, we identified a target site for SMAD in the promoter region of miR-451 and showed that SMAD3 and 4 activate such a promoter-luciferase construct. Transfection of SMAD in GBM cells inhibited their growth, suggesting that SMAD may drive GBM stem cells to differentiate to CD133- cells through up-regulation of miR-451 and reduces their tumorigenicity."	unknown	unknown	2008	18765229	Causal
+hsa-miR-486	3068	glioblastoma	down-regulated	"Northern blot, qRT-PCR etc"	"We examined the microRNA profiles of Glioblastoma stem (CD133+) and non-stem (CD133-) cell populations and found up-regulation of several miRs in the CD133- cells, including miR-451, miR-486, and miR-425, some of which may be involved in regulation of brain differentiation."	unknown	unknown	2008	18765229	Unspecified
+hsa-miR-296	2627	glioma	up-regulated	"Northern blot, qRT-PCR etc"	"Here, we demonstrate that a small regulatory microRNA, miR-296, has a major role in this process. Glioma cells and angiogenic growth factors elevate the level of miR-296 in primary human brain microvascular endothelial cells in culture. The miR-296 level is also elevated in primary tumor endothelial cells isolated from human brain tumors compared to normal brain endothelial cells. Growth factor-induced miR-296 contributes significantly to angiogenesis by directly targeting the hepatocyte growth factor-regulated tyrosine kinase substrate (HGS) mRNA, leading to decreased levels of HGS and thereby reducing HGS-mediated degradation of the growth factor receptors VEGFR2 and PDGFRbeta. Furthermore, inhibition of miR-296 with antagomirs reduces angiogenesis in tumor xenografts in vivo."	HGS	unknown	2008	18977327	Causal
+hsa-miR-30a	2976	glomerular disease	down-regulated	"Northern blot, qRT-PCR etc"	"To define their role in glomerular function, miRNA biogenesis was disrupted in mouse podocytes using a conditional Dicer allele. Mutant mice developed proteinuria by 3 wk after birth and progressed rapidly to end-stage kidney disease. Podocyte pathology included effacement, vacuolization, and hypertrophy with crescent formation. Despite normal expression of WT1, podocytes underwent dedifferentiation, exemplified by cytoskeletal disruption with early transcriptional downregulation of synaptopodin. These abnormalities differed from Cd2ap(-/-) mice, indicating they were not a general consequence of glomerular disease. Glomerular labeling of ezrin, moesin, and gelsolin was altered at 3 wk, but expression of nestin and alpha-actinin was unchanged. Abnormal cell proliferation or apoptosis was not responsible for the glomerular injury. Mutant podocytes were incapable of synthesizing mature miRNA, as revealed by their loss of miR-30a. In contrast, expression of glomerular endothelial and mesangial cell miRNAs (miR-126 and miR-145, respectively) was unchanged. These findings demonstrate a critical role for miRNA in glomerular function and suggest a pathway that may participate in the pathogenesis of kidney diseases of podocyte origin. The unique architecture of podocytes may make them especially susceptible to cytoskeletal alterations initiated by aberrant miRNA dynamics."	unknown	unknown	2008	18776121	Causal
+hsa-miR-127	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	"We showed that the development of hepatocellular carcinoma (HCC) is characterized by prominent early changes in expression of miRNA genes, specifically by inhibition of expression of microRNAs miR-34a, miR-127, miR-200b, and miR-16a involved in the regulation of apoptosis, cell proliferation, cell-to-cell connection, and epithelial-mesenchymal transition. The mechanistic link between these alterations in miRNAs expression and the development of HCC was confirmed by the corresponding changes in the levels of E2F3, NOTCH1, BCL6, ZFHX1B, and BCL2 proteins targeted by these miRNAs. The significance of miRNAs expression dysregulation in respect to hepatocarcinogenesis was confirmed by the persistence of these miRNAs alterations in the livers of methyl-deficient rats re-fed a methyl-adequate diet. Altogether, the early occurrence of alterations in miRNAs expression and their persistence during the entire process of hepatocarcinogenesis indicate that the dysregulation of microRNAs expression may be an important contributing factor in the development of HCC"	BCL6	"BCL6,Rtl1/Peg11"	2008	18942116	Causal
+hsa-miR-16a	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	"We showed that the development of hepatocellular carcinoma (HCC) is characterized by prominent early changes in expression of miRNA genes, specifically by inhibition of expression of microRNAs miR-34a, miR-127, miR-200b, and miR-16a involved in the regulation of apoptosis, cell proliferation, cell-to-cell connection, and epithelial-mesenchymal transition. The mechanistic link between these alterations in miRNAs expression and the development of HCC was confirmed by the corresponding changes in the levels of E2F3, NOTCH1, BCL6, ZFHX1B, and BCL2 proteins targeted by these miRNAs. The significance of miRNAs expression dysregulation in respect to hepatocarcinogenesis was confirmed by the persistence of these miRNAs alterations in the livers of methyl-deficient rats re-fed a methyl-adequate diet. Altogether, the early occurrence of alterations in miRNAs expression and their persistence during the entire process of hepatocarcinogenesis indicate that the dysregulation of microRNAs expression may be an important contributing factor in the development of HCC"	BCL2	unknown	2008	18942116	Causal
+hsa-miR-200b	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	"We next measured the levels of let-7 in available patient tumors with or without the variant allele, using reverse transcription-PCR. On average, we found that the levels of let-7a, b, d, and g were lower in patients with the variant allele compared with patients without the variant allele. We showed that the development of hepatocellular carcinoma (HCC) is characterized by prominent early changes in expression of miRNA genes, specifically by inhibition of expression of microRNAs miR-34a, miR-127, miR-200b, and miR-16a involved in the regulation of apoptosis, cell proliferation, cell-to-cell connection, and epithelial-mesenchymal transition. The mechanistic link between these alterations in miRNAs expression and the development of HCC was confirmed by the corresponding changes in the levels of E2F3, NOTCH1, BCL6, ZFHX1B, and BCL2 proteins targeted by these miRNAs. The significance of miRNAs expression dysregulation in respect to hepatocarcinogenesis was confirmed by the persistence of these miRNAs alterations in the livers of methyl-deficient rats re-fed a methyl-adequate diet. Altogether, the early occurrence of alterations in miRNAs expression and their persistence during the entire process of hepatocarcinogenesis indicate that the dysregulation of microRNAs expression may be an important contributing factor in the development of HCC"	ZFHX1B	unknown	2008	18942116	Causal
+hsa-miR-34a	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	"We showed that the development of hepatocellular carcinoma (HCC) is characterized by prominent early changes in expression of miRNA genes, specifically by inhibition of expression of microRNAs miR-34a, miR-127, miR-200b, and miR-16a involved in the regulation of apoptosis, cell proliferation, cell-to-cell connection, and epithelial-mesenchymal transition. The mechanistic link between these alterations in miRNAs expression and the development of HCC was confirmed by the corresponding changes in the levels of E2F3, NOTCH1, BCL6, ZFHX1B, and BCL2 proteins targeted by these miRNAs. The significance of miRNAs expression dysregulation in respect to hepatocarcinogenesis was confirmed by the persistence of these miRNAs alterations in the livers of methyl-deficient rats re-fed a methyl-adequate diet. Altogether, the early occurrence of alterations in miRNAs expression and their persistence during the entire process of hepatocarcinogenesis indicate that the dysregulation of microRNAs expression may be an important contributing factor in the development of HCC"	"E2F3, NOTCH1"	E2F3	2008	18942116	Causal
+hsa-miR-183	3905	lung cancer	down-regulated	"Northern blot, qRT-PCR etc"	"We identified miR-183 as a potential metastasis-inhibitor. Expression level of miR-183 was reversely correlated with the metastatic potential of lung cancer cells. Furthermore, over-expression of miR-183 inhibited migration and invasion of lung cancer cells. Mechanistically, we identified VIL2-coding-protein Ezrin as a bona fide target of miR-183. We also found that miR-183 could regulate the expression of other genes involved in migration and invasion. Taken together, our findings demonstrated a new role and regulatory mechanism of miR-183 in controlling cancer metastasis."	Ezrin	unknown	2008	18840437	Causal
+hsa-let-7a	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	NF2	2008	18998140	Unspecified
+hsa-let-7e	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	SMC1L1	2008	18998140	Unspecified
+hsa-miR-124a	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-130b	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-133a	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-134	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-142-5p	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-150	10952	lupus nephritis	down-regulated	microarray	30 miRNAs down-regulated detected in LN compared to NC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-15b	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-184	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-185	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-195	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-197	10952	lupus nephritis	up-regulated	microarray	36 miRNAs up-regulated detected in LN compared toNC group.	unknown	unknown	2008	18998140	Unspecified
+hsa-miR-17-3p	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-17-5p	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Altered expression of miR-17-5p, miR-106a, and EGFL7 was associated with pathological tumor features of poor prognosis. Downregulation of miR-106a predicted shortened DFS (P=0.03) and OS (P=0.04). miR-17-5p correlated with DFS only at early stages (P=0.07). Inverse correlations were found between miR-17-5p and miR-106a levels and their target expression, E2F1 (P=0.04 and P=0.03, respectively).  Inverse correlation between miR-17-5p and miR-106a and E2F1 levels supports E2F1 as a target mRNA for the two miRNAs."	E2F1	"AIB1,E2F1"	2008	18521848	Unspecified
+hsa-miR-17-5p	7012	anaplastic thyroid carcinoma (ATC)	up-regulated	"Northern blot, qRT-PCR etc"	"MiRNAs in a miR-17-92 cluster were overexpressed in ARO cells. We confirmed the overexpression of those miRNAs by Northern blot analysis in ARO and FRO cells. In 3 of 6 clinical ATC samples, miR-17-3p and miR-17-5p were robustly overexpressed in cancer lesions compared to adjacent normal tissue. To investigate the functional role of these miRNAs in ATC cells, ARO and FRO cells were transfected with miRNA inhibitors, antisense oligonucleotides containing locked nucleic acids. Suppression of miR-17-3p caused complete growth arrest, presumably due to caspase activation resulting in apoptosis. MiR-17-5p or miR-19a inhibitor also induced strong growth reduction, but only miR-17-5p inhibitor led to cellular senescence. On the other hand, miR-18a inhibitor only moderately attenuated the cell growth. Thus, we have clarified functional differences among the members of the cluster in ATC cells. In conclusion, these findings suggest that the miR-17-92 cluster plays an important role in certain types of ATCs and could be a novel target for ATC treatment."	unknown	"AIB1,E2F1"	2008	18429962	Causal
+hsa-miR-17-5p	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	Mir-17-5p Regulates breast cancer Cell Proliferation by Inhibiting Translation of AIB1 mRNA.	AIB1	"AIB1,E2F1"	2006	16940181	Causal
+hsa-miR-17-5p	8552	chronic myeloid leukemia (CML)	down-regulated	"Northern blot, qRT-PCR etc"	Cotransfection of the miR-17-5p and miR-20a antisense oligonucleotides					
+"(antagomir-17-5p and antagomiR-20a),increases normalized luciferase activity.Luciferase activity is enhanced in K562 cells with RNAi-reduced c-myc expression and can be further increased by antagomir-17-5p or antagomir-20a."	unknown	"AIB1,E2F1"	2007	17284533	Causal	1	1527			
+hsa-miR-17-5p	3905	lung cancer	up-regulated	"Northern blot, qRT-PCR etc"	Inhibition of miR-17-5p and miR-20a with antisense oligonucleotides (ONs) can induce apoptosis selectively in lung cancer cells overexpressing miR-17-92.	unknown	"AIB1,E2F1"	2007	17384677	Causal
+hsa-miR-17-5p	353	MYC-rearranged lymphoma	up-regulated	"Northern blot, qRT-PCR etc"	Myc can upregulate the miR-17 cluster by binding directly upstream of the miR-17 locus.Deregulation of the miR-17 polycistron can be assumed to contribute to aggressive cancer development by repressing tumor suppressor genes.T��RII is the direct downstream target of the miR-17 polycistron.	T��RII	"AIB1,E2F1"	2007	17608773	Causal
+hsa-miR-17-5p	4007	bladder cancer	up-regulated	microarray	"Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b,miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P<0.05) compared to normal bladder"					
+mucosa.	unknown	"AIB1,E2F1"	2007	17826655	Unspecified	0	1530			
+hsa-miR-17-5p	3459	breast cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	"AIB1,E2F1"	2006	16461460	Unspecified
+hsa-miR-17-5p	1985	colorectal cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	"AIB1,E2F1"	2006	16461460	Unspecified
+hsa-miR-17-5p	353	diffuse large B-cell lymphoma (DLBCL)	up-regulated	microarray	"Four hsa-miR-As (miR-210, hsa-miR-155, hsa-miR-106a, hsa-miR-17-5p) were expressed at a significantly higher level in DLBCL than in normal tissue. In contrast, the remaining 11 miRNAs (hsa-miR-150, hsa-miR-145, hsa-miR-328, hsa-miR-139, hsa-miR-99a, hsa-miR-10a, hsa-miR-95, hsa-miR-149, hsa-miR-320, hsa-miR-151,let-7e) were expressed at a significantly lower level in DLBCL. A classification tree was"					
+"computed using four miRNAs (miR-330, miR-17-5p, miR-106a and miR-210) to correctly identify 98% of all 111 cases that were analysed in this study.A classification tree was computed using four miRNAs (miR-330, miR-17-5p, miR-106a and miR-210) to correctly identify 98% of all 111 cases that were analysed in this study."	unknown	"AIB1,E2F1"	2008	18537969	Unspecified	0	1533			
+hsa-miR-17-5p	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	"AIB1,E2F1"	2006	16924677	Unspecified
+hsa-miR-17-5p	3905	lung cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	"AIB1,E2F1"	2006	16461460	Unspecified
+hsa-miR-17-5p	353	malignant lymphoma	up-regulated	"Northern blot, qRT-PCR etc"	"six mature miRNAs (miR-17-5p, miR-17-3p, miR-19a, miR-19b, miR-20 and miR-92-1) in the cell lines with a 13q31 gain/amplification displays overexpression significantly higher than in those without."	unknown	"AIB1,E2F1"	2005	16167061	Unspecified
+hsa-miR-17-5p	769	neuroblastoma (NB)	up-regulated	"Northern blot, qRT-PCR etc"	Positively correlated with MYCN-amplification in tumors in vivo.	unknown	"AIB1,E2F1"	2007	17943719	Unspecified
+hsa-miR-17-5p	4905	pancreatic cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	"AIB1,E2F1"	2006	16461460	Unspecified
+hsa-miR-17-5p	12236	primary biliary cirrhosis (PBC)	down-regulated	"Northern blot, qRT-PCR etc"	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	"AIB1,E2F1"	2008	18631158	Unspecified
+hsa-miR-17-5p	10286	prostate cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	"AIB1,E2F1"	2006	16461460	Unspecified
+hsa-miR-17-5p	9088	psoriasis	up-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	"AIB1,E2F1"	2007	17622355	Unspecified
+hsa-miR-17-92	8584	Burkitt lymphoma	up-regulated	"northern blot, qRT-PCR etc"	miR-17-92 promotes cell proliferation by shifting the E2F transcriptional balance away from the pro-apoptotic E2F1 and toward the proliferative E2F3 transcriptional network.	E2F1	unknown	2007	17135268	Causal
+hsa-miR-17-92	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Both Tsp1 and CTGF are predicted targets for repression by the miR-17-92 microRNA cluster, which was upregulated in colonocytes coexpressing K-Ras and c-Myc. Indeed, miR-17-92 knockdown with antisense 2'-O-methyl oligoribonucleotides partly restored Tsp1 and CTGF expression.In addition, transduction of Ras-only cells with a miR-17-92-encoding retrovirus reduced Tsp1 and CTGF levels. Notably, miR-17-92-transduced cells formed larger, better-perfused tumors."	"Tsp1, CTGF"	unknown	2006	16878133	Causal
+hsa-miR-17-92	353	diffuse large B-cell lymphoma (DLBCL)	up-regulated	"Northern blot, qRT-PCR etc"	The mir-17-92 polycistron is located in a region of DNA that is amplified in human B-cell lymphomas.Enforced expression of the mir-17-92 cluster acted with c-myc expression to accelerate tumour development in a mouse B-cell lymphoma model.	E2F1	unknown	2005	15944707	Causal
+hsa-miR-17-92	619	lymphoproliferative disease	up-regulated	"Northern blot, qRT-PCR etc"	Mice with higher expression of miR-17-92 in lymphocytes developed lymphoproliferative disease and autoimmunity and died prematurely. Lymphocytes from these mice showed more proliferation and less activation-induced cell death. The miR-17-92 miRNA suppressed expression of the tumor suppressor PTEN and the proapoptotic protein Bim.	"PTEN,proapoptotic protein Bim"	unknown	2008	18327259	Causal
+hsa-miR-18	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	The degree of tumor differentiation was inversely related to the expression levels of this miRNA.	"CTGF,RANKL"	unknown	2006	16331254	Unspecified
+hsa-miR-181a	9119	acute myeloid leukemia (AML)	up-regulated	"Northern blot, qRT-PCR etc"	"miR-181a correlated strongly with the AML morphological sub-type and with the expression of genes previously identified through sequence analysis as potential interaction targets,suggesting the"					
+direct regulation at transcript level.	unknown	unknown	2007	17330104	Unspecified	0	1547			
+hsa-miR-181a	9119	acute myeloid leukemia (AML)	up-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-181a	2786	Cerebellar neurodegeneration	down-regulated	"Northern blot, qRT-PCR etc"	Essential for the survival of Purkinje cells and its absence leads to a slow degeneration of these cells.	unknown	unknown	2007	17606634	Unspecified
+hsa-miR-181a	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	miR-181a is expressed in bone marrow progenitor cells and is upregulated in mature B lymphocytes.	unknown	unknown	2007	17989717	Unspecified
+hsa-miR-181a	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	unknown	2006	16609010	Unspecified
+hsa-miR-181a	3068	glioblastoma	down-regulated	"Northern blot, qRT-PCR etc"	"The strong down-regulation of miR-128 and miR-181 family might indicate some non-random correlation with the de-differentiated state of tumor cells, or even with their stem-like nature, in some way resembling early embryonic stages."	unknown	unknown	2005	16039986	Unspecified
+hsa-miR-181a	10923	homozygous sickle cell disease (HbSS)	down-regulated	microarray	"Several microRNAs (miR-320, let-7s, miR-181, miR-141) were over-represented in the HbAA erythrocytes, while other microRNAs (miR-29a, miR-144, miR-451, miR-140) were overrepresented in the HbSS erythrocytes."	unknown	unknown	2008	18523662	Unspecified
+hsa-miR-181a	1909	malignant melanoma	up-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-181a	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Aberrantly expressed miRNA precursors in pancreatic adenocarcinoma.PAM testing was conducted on 10 tumor samples and 15 adjacent benign samples. PAM has correctly classified 100% of the tested tumor samples and 11 of 15 of the tested benign samples. The 20 top ranked differentially expressed miRNAs in pancreatic adenocarcinoma as selected by PAM.	unknown	unknown	2006	17149698	Unspecified
+hsa-miR-181a	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-181a	3969	papillary thyroid carcinoma (PTC)	up-regulated	microarray	Differentially expressed miRNA in PTC tumors	unknown	unknown	2005	16365291	Unspecified
+hsa-miR-181a*	8894	Oral Squamous Cell Carcinoma (OSCC)	up-regulated	microarray	miRNAs frequently up-regulated in OSCC cell lines(>1.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-181a-1	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	unknown	2007	17616664	Unspecified
+hsa-miR-148a	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	1560			
+hsa-miR-148b	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	survival-related and metastasis-related miRNA.	unknown	unknown	2008	18176954	Unspecified
+hsa-miR-186	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	One of the 22 significantly up- and down-regulated miRNAs obtained using significance analysis of microarrays with false discovery rate of 5%. Majority of the predicted targets of these 22 differentially regulated miRNAs reside in pathways reported to be dysregulated during carcinogenesis.	unknown	unknown	2008	18319255	Unspecified
+hsa-miR-188	1040	B-cell chronic lymphocytic leukemia	up-regulated	microarray	Differentially expressed in CLL cells versus CD18 cells.	unknown	unknown	2004	15284443	Unspecified
+hsa-miR-189	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	SLITRK1	2008	18379589	Unspecified
+hsa-miR-22	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	1565			
+hsa-miR-22	9088	psoriasis	down-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	unknown	2007	17622355	Unspecified
+hsa-miR-220	1040	B-cell chronic lymphocytic leukemia	down-regulated	microarray	Differentially expressed in CLL cells versus CD25 cells.	unknown	unknown	2004	15284443	Unspecified
+hsa-miR-220	3068	glioblastoma	up-regulated	microarray	Significantly differentially expressed between glioblastoma cell line samples and the control samples.	unknown	unknown	2005	16039986	Unspecified
+hsa-miR-220	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-220	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-220	3969	papillary thyroid carcinoma (PTC)	up-regulated	microarray	Differentially expressed miRNA in PTC tumors	unknown	unknown	2005	16365291	Unspecified
+hsa-miR-221	1040	chronic lymphocytic leukemia (CLL)	up-regulated	"Northern blot, qRT-PCR etc"	MicroRNA Signature Associated with Prognostic Factors (ZAP-70 Expression and IgVH Mutations) and Disease Progression in Patients with CLL.	unknown	KIT	2005	16251535	Unspecified
+hsa-miR-221	3068	glioblastoma	up-regulated	"Northern blot, qRT-PCR etc"	"miRNAs repress the expression of the cell cycle regulator p27Kip1 in glioblastoma cells, and that miRNA 221/ 222, which has previously been shown to be upregulated in glioblastoma, is the specific miRNA responsible for this."	p27Kip1(CDKN1B)	KIT	2007	17721077	Causal
+hsa-miR-221	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	"miR-221 has an oncogenic function in hepatocarcinogenesis by targeting CDKN1B/p27 and CDKN1C/p57, hence promoting proliferation by controlling cell-cycle inhibitors. These findings establish a basis toward the development of therapeutic strategies aimed at blocking miR-221 in HCC."	"CDKN1B/p27, CDKN1C/p57"	KIT	2008	18521080	Causal
+hsa-miR-221	1909	malignant melanoma	up-regulated	"Northern blot, qRT-PCR etc"	"The authors have identified the promyelocytic leukemia zinc finger (PLZF) transcription factor as a repressor of miR-221 and miR-222 by direct binding to their putative regulatory region. Specifically, PLZF silencing in melanomas unblocks miR-221 and miR-222, which in turn controls the progression of the neoplasia through down-modulation of p27Kip1/CDKN1B and c-KIT receptor, leading to enhanced proliferation and differentiation blockade of the melanoma cells, respectively."	"p27Kip1(CDKN1B), c-KIT"	KIT	2008	18417445	Causal
+hsa-miR-221	3908	non-small cell lung cancer (NSCLC)	down-regulated	"Northern blot, qRT-PCR etc"	"A five-microRNA signature (let-7a, miR-221, miR-137, miR-372, and miR-182*) that is associated with survival and cancer relapse in NSCLC patients. This microRNA signature was validated by the testing set and an independent cohort. Patients with high-risk scores in their microRNA signatures had poor overall and disease-free survivals compared to the low-risk-score patients. This microRNA signature is an independent predictor of the cancer relapse and survival of NSCLC patients.promoted invasiveness of lung cancer cell lines."	unknown	KIT	2008	18167339	Causal
+hsa-miR-221	3908	non-small cell lung cancer (NSCLC)	up-regulated	"Northern blot, qRT-PCR etc"	"We demonstrate that these miR-221 and miR-222 impair TRAIL-dependent apoptosis by inhibiting the expression of key functional proteins. Indeed, transfection with anti-miR-221 and -222 rendered CALU-1-resistant cells sensitive to TRAIL. Conversely, H460-sensitive cells treated with -221 and -222 pre-miRs become resistant to TRAIL. miR-221 and -222 target the 3'-UTR of Kit and p27(kip1) mRNAs, but interfere with TRAIL signaling mainly through p27(kip1). In conclusion, we show that high expression levels of miR-221 and -222 are needed to maintain the TRAIL-resistant phenotype, thus making these miRs as promising therapeutic targets or diagnostic tool for TRAIL resistance in NSCLC."	"Kit, p27(kip1)"	KIT	2008	18246122	Causal
+hsa-miR-221	3969	papillary thyroid carcinoma (PTC)	up-regulated	"Northern blot, qRT-PCR etc"	"Up-regulation of several miRs (miR-221, -222, and -146) and regulation of KIT are involved in PTC pathogenesis, and that sequence changes in genes targeted by miRNAs can contribute to their regulation."	KIT	KIT	2005	16365291	Causal
+hsa-miR-221	10286	prostate cancer	down-regulated	"Northern blot, qRT-PCR etc"	"miR-221/222 can be regarded as a new family of oncogenes, directly targeting the tumor suppressor p27Kip1, and that their overexpression might be one of the factors contributing to the oncogenesis and progression of prostate carcinoma through p27Kip1 down-regulation."	p27Kip1(CDKN1B)	KIT	2007	17569667	Causal
+hsa-miR-221	9952	acute lymphoblastic leukemia (ALL)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	KIT	2007	18056805	Unspecified
+hsa-miR-221	9119	acute myeloid leukemia (AML)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	KIT	2007	18056805	Unspecified
+hsa-miR-221	9119	acute myeloid leukemia (AML)	up-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	KIT	2008	18478077	Unspecified
+hsa-miR-221	14691	Becker muscular dystrophy (BMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	KIT	2007	17942673	Unspecified
+hsa-miR-221	4007	bladder cancer	up-regulated	microarray	"Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b,miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P<0.05) compared to normal bladder"					
+mucosa.	unknown	KIT	2007	17826655	Unspecified	0	1584			
+hsa-miR-221	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change correlative with the increase in heart/body weight(7-14 days post-TAC).	unknown	KIT	2008	17234972	Unspecified
+hsa-miR-221	1985	colorectal cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	KIT	2006	16461460	Unspecified
+hsa-miR-221	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	KIT	2007	17942673	Unspecified
+hsa-miR-221	353	diffuse large B-cell lymphoma (DLBCL)	up-regulated	"Northern blot, qRT-PCR etc"	"Identified microRNAs(miR-155, miR-21 and miR-221) that were more highly expressed in ABC-type than GCB-type cell lines. These microRNAs were over-expressed in de novo DLBCL (n=35), transformed DLBCL"					
+(n=14) and follicular center lymphoma cases (n=27) compared to normal B cells.	unknown	KIT	2007	17487835	Unspecified	0	1588			
+hsa-miR-221	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	KIT	2007	17942673	Unspecified
+hsa-miR-221	11727	facioscapulohumeral muscular dystrophy (FSHD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	KIT	2007	17942673	Unspecified
+hsa-miR-221	5517	gastric cancer (stomach cancer)	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	KIT	2006	16461460	Unspecified
+hsa-miR-221	3068	glioblastoma	up-regulated	"Northern blot, qRT-PCR etc"	Significantly differentially expressed between glioblastoma cell line samples and the control samples.	unknown	KIT	2005	16039986	Unspecified
+hsa-miR-221	684	hepatocellular carcinoma (HCC)	up-regulated	"Northern blot, qRT-PCR etc"	"Three of the deregulated miRNAs (miR-221, let-7a-1, and miR-122a) were further assayed by Northern blot and quantitative realtime RT-PCR for validation purposes.Overall, Northern blot analysis revealed that miR-221 was up-regulated in 83% of HCCs when compared with matched cirrhotic tissue, let-7a-1 was down-regulated in 70% of HCCs, and miR-122a resulted down-regulated in 70%"					
+of HCCs.	unknown	KIT	2007	17616664	Unspecified	0	1593			
+hsa-miR-221	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	One of the 22 significantly up- and down-regulated miRNAs obtained using significance analysis of microarrays with false discovery rate of 5%. Majority of the predicted targets of these 22 differentially regulated miRNAs reside in pathways reported to be dysregulated during carcinogenesis.	unknown	KIT	2008	18319255	Unspecified
+hsa-miR-221	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	"Distinct up-regulations of miR-222, miR-221, and miR-31, and down-regulations of miR-223, miR-126, and miR-122a were identified. Further investigations suggested the highly deregulated miR-223 and miR-222 could unequivocally distinguish HCC from adjacent nontumoral liver, irrespective of viral associations (P<=.0002)."	unknown	KIT	2008	18555017	Unspecified
+hsa-miR-221	3429	Inclusion body myositis (IBM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	KIT	2007	17942673	Unspecified
+hsa-miR-221	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	KIT	2007	17942673	Unspecified
+hsa-miR-221	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	KIT	2007	17942673	Unspecified
+hsa-miR-221	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	KIT	2007	17942673	Unspecified
+hsa-miR-221	769	neuroblastoma (NB)	up-regulated	"Northern blot, qRT-PCR etc"	Positively correlated with MYCN-amplification in tumors in vivo.	unknown	KIT	2007	17943719	Unspecified
+hsa-miR-221	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	KIT	2008	18560586	Unspecified
+hsa-miR-221	4905	pancreatic cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	KIT	2006	16461460	Unspecified
+hsa-miR-221	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Aberrantly expressed miRNA precursors in pancreatic adenocarcinoma.PAM testing was conducted on 10 tumor samples and 15 adjacent benign samples. PAM has correctly classified 100% of the tested tumor samples and 11 of 15 of the tested benign samples. The 20 top ranked differentially expressed miRNAs in pancreatic adenocarcinoma as selected by PAM.	unknown	KIT	2006	17149698	Unspecified
+hsa-miR-221	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	KIT	2007	17473300	Unspecified
+hsa-miR-221	3498	pancreatic ductal adenocarcinoma (PDAC)	up-regulated	microarray	differentially expressed between normal and PDAC or cell line samples.	unknown	KIT	2007	17237814	Unspecified
+hsa-miR-221	3969	papillary thyroid carcinoma (PTC)	up-regulated	"Northern blot, qRT-PCR etc"	"Preliminary analysis of 6 miRNAs in 10 papillary thyroid carcinoma and 10 follicular adenoma identified significant overexpression of miR-146b, -221, and -222 in papillary thyroid carcinoma (P<0.02), but not miR-146a, -155, or -187 (P>0.08). particularly miR-146b, might potentially be adjunct markers for diagnosing papillary thyroid carcinoma in both FNA and surgical pathology specimens."	unknown	KIT	2008	18587330	Unspecified
+hsa-miR-221	10222	polymyositis (PM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	KIT	2007	17942673	Unspecified
+hsa-miR-221	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	KIT	2007	17616669	Unspecified	0	1608			
+hsa-miR-222	3068	glioblastoma	up-regulated	"Northern blot, qRT-PCR etc"	"miRNAs repress the expression of the cell cycle regulator p27Kip1 in glioblastoma cells, and that miRNA 221/ 222, which has previously been shown to be upregulated in glioblastoma, is the specific miRNA responsible for this."	p27Kip1(CDKN1B)	KIT	2007	17721077	Causal
+hsa-miR-222	1909	malignant melanoma	up-regulated	"Northern blot, qRT-PCR etc"	"The authors have identified the promyelocytic leukemia zinc finger (PLZF) transcription factor as a repressor of miR-221 and miR-222 by direct binding to their putative regulatory region. Specifically, PLZF silencing in melanomas unblocks miR-221 and miR-222, which in turn controls the progression of the neoplasia through down-modulation of p27Kip1/CDKN1B and c-KIT receptor, leading to enhanced proliferation and differentiation blockade of the melanoma cells, respectively."	"p27Kip1(CDKN1B), c-KIT"	KIT	2008	18417445	Causal
+hsa-miR-222	3908	non-small cell lung cancer (NSCLC)	up-regulated	"Northern blot, qRT-PCR etc"	"We demonstrate that these miR-221 and miR-222 impair TRAIL-dependent apoptosis by inhibiting the expression of key functional proteins. Indeed, transfection with anti-miR-221 and -222 rendered CALU-1-resistant cells sensitive to TRAIL. Conversely, H460-sensitive cells treated with -221 and -222 pre-miRs become resistant to TRAIL. miR-221 and -222 target the 3'-UTR of Kit and p27(kip1) mRNAs, but interfere with TRAIL signaling mainly through p27(kip1). In conclusion, we show that high expression levels of miR-221 and -222 are needed to maintain the TRAIL-resistant phenotype, thus making these miRs as promising therapeutic targets or diagnostic tool for TRAIL resistance in NSCLC."	"Kit, p27(kip1)"	KIT	2008	18246122	Causal
+hsa-miR-222	3969	papillary thyroid carcinoma (PTC)	up-regulated	"Northern blot, qRT-PCR etc"	"Up-regulation of several miRs (miR-221, -222, and -146) and regulation of KIT are involved in PTC pathogenesis, and that sequence changes in genes targeted by miRNAs can contribute to their regulation."	KIT	KIT	2005	16365291	Causal
+hsa-miR-222	10286	prostate cancer	down-regulated	"Northern blot, qRT-PCR etc"	"miR-221/222 can be regarded as a new family of oncogenes, directly targeting the tumor suppressor p27Kip1, and that their overexpression might be one of the factors contributing to the oncogenesis and progression of prostate carcinoma through p27Kip1 down-regulation."	p27Kip1(CDKN1B)	KIT	2007	17569667	Causal
+hsa-miR-222	9952	acute lymphoblastic leukemia (ALL)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	KIT	2007	18056805	Unspecified
+hsa-miR-222	9119	acute myeloid leukemia (AML)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	KIT	2007	18056805	Unspecified
+hsa-miR-222	9119	acute myeloid leukemia (AML)	up-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	KIT	2008	18478077	Unspecified
+hsa-miR-222	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change correlative with the increase in heart/body weight(7-14 days post-TAC).	unknown	KIT	2008	17234972	Unspecified
+hsa-miR-148b	2841	asthma	normal	"Northern blot, qRT-PCR etc"	" +3142C/G influences miRNA targeting of HLA-G and is associated with risk of asthma.Interestingly,"					
+"the three miRNA genes are located at regions that have been linked to asthma or IgE: 7p15(miR-148a), 12q13(miR-148b), and 17q21(miR-152), raising the possibility that variation in the miRNA genes themselves might contribute to asthma risk, perhaps by interacting with HLA-G."	HLA-G	unknown	2007	17847008	Causal	1	1618			
+hsa-miR-148b	1208	autism spectrum disorder (ASD)	up-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	unknown	2008	18563458	Unspecified
+hsa-miR-148b	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-148b	5520	head and neck squamous cell carcinoma (HNSCC)	down-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-148b	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-148b	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-148b	4905	pancreatic cancer	down-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-148b	3498	pancreatic ductal adenocarcinoma (PDAC)	down-regulated	microarray	differentially expressed between normal and PDAC or cell line samples.	unknown	unknown	2007	17237814	Unspecified
+hsa-miR-149	3459	breast cancer	up-regulated	microarray	Differentially expressed between breast carcinoma and normal breast tissue.	unknown	unknown	2005	16103053	Unspecified
+hsa-miR-149	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change correlative with the increase in heart/body weight(7-14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-149	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Confirmation of the Aberrant miRNA Expression in Hypertrophic Hearts by Northern Blot Analysis and/or qRT-PCR.	unknown	unknown	2007	17525252	Unspecified
+hsa-miR-149	353	diffuse large B-cell lymphoma (DLBCL)	down-regulated	microarray	"Four hsa-miR-As (miR-210, hsa-miR-155, hsa-miR-106a, hsa-miR-17-5p) were expressed at a significantly higher level in DLBCL than in normal tissue. In contrast, the remaining 11 miRNAs (hsa-miR-150, hsa-miR-145, hsa-miR-328, hsa-miR-139, hsa-miR-99a, hsa-miR-10a, hsa-miR-95, hsa-miR-149, hsa-miR-320, hsa-miR-151,let-7e) were expressed at a significantly lower level in DLBCL."	unknown	unknown	2008	18537969	Unspecified
+hsa-miR-149	8524	follicular lymphoma (FL)	down-regulated	microarray	"Nine miRNAs (hsa-miR-9, hsa-miR-301, hsa-miR-213, hsa-miR-9*, hsa-miR-330, hsa-miR-106a, hsa-miR-338, hsa-miR-155, hsa-miR-210) were significantly up- and three miRNAs (hsa-miR-320, hsa-miR-149, hsa-miR-139) down-regulated in the lymphoma samples. Expression of hsa-miR-9 was most strongly increased (12-fold) and of hsa-miR-320 most strongly decreased (3-fold)."	unknown	unknown	2008	18537969	Unspecified
+hsa-miR-149	3073	glioblastoma multiforme (GBM)	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed microRNA in glioblastoma multiforme tumors relative to non-neoplastic brain tissue.	unknown	unknown	2008	18577219	Unspecified
+hsa-miR-149	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-149	3829	pituitary adenoma	up-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	unknown	2007	17111382	Unspecified
+hsa-miR-15	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	"miR-15 and miR-16 are located at chromosome 13q14, a region deleted in more than half of B cell chronic lymphocytic leukemia (CLL)s (B-CLL). Detailed deletion and expression analysis shows that miR-15 and miR-16 are located within a 30-kb region of loss in CLL, and that both genes are deleted or down-regulated in the majority (68%) of CLL cases."	unknown	"BCL2,DMTF1"	2002	12434020	Causal
+hsa-miR-150	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change correlative with the increase in heart/body weight(7-14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-150	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Confirmation of the Aberrant miRNA Expression in Hypertrophic Hearts by Northern Blot Analysis and/or qRT-PCR.	unknown	unknown	2007	17525252	Unspecified
+hsa-miR-150	1040	chronic lymphocytic leukemia (CLL)	down-regulated	"Northern blot, qRT-PCR etc"	miR-150 and miR-92 are significantly deregulated in patients with CLL.	unknown	unknown	2007	17327404	Unspecified
+hsa-miR-150	353	diffuse large B-cell lymphoma (DLBCL)	down-regulated	microarray	"Four hsa-miR-As (miR-210, hsa-miR-155, hsa-miR-106a, hsa-miR-17-5p) were expressed at a significantly higher level in DLBCL than in normal tissue. In contrast, the remaining 11 miRNAs (hsa-miR-150, hsa-miR-145, hsa-miR-328, hsa-miR-139, hsa-miR-99a, hsa-miR-10a, hsa-miR-95, hsa-miR-149, hsa-miR-320, hsa-miR-151,let-7e) were expressed at a significantly lower level in DLBCL."	unknown	unknown	2008	18537969	Unspecified
+hsa-miR-150	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	DNA copy number status of 17 genomic loci containing miRNAs differentially expressed between IOSE cells and EOC cell lines.	unknown	unknown	2008	18458333	Unspecified
+hsa-miR-150	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	unknown	2007	17616664	Unspecified
+hsa-miR-150	3905	lung cancer	up-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-150	3498	pancreatic ductal adenocarcinoma (PDAC)	up-regulated	microarray	differentially expressed between normal and PDAC or cell line samples.	unknown	unknown	2007	17237814	Unspecified
+hsa-miR-150	-1	polycythemia vera (PV)	down-regulated	"Northern blot, qRT-PCR etc"	significantly differs between PV and controls.	unknown	unknown	2007	17976518	Unspecified
+hsa-miR-150	12236	primary biliary cirrhosis (PBC)	down-regulated	microarray	Twenty-three miRNAs in the array were found to be lowly expressed and 2 showed high levels of expression in the peripheral blood of PBC patients. 	unknown	unknown	2008	18631158	Unspecified
+hsa-miR-150	13223	uterine leiomyoma (ULM)	down-regulated	microarray	Twenty most differentially expressed microRNA species in leiomyoma versus myometrium microarray.	unknown	unknown	2008	17765232	Unspecified
+hsa-miR-151	9119	acute myeloid leukemia (AML)	down-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-151	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-151	353	diffuse large B-cell lymphoma (DLBCL)	down-regulated	microarray	"Four hsa-miR-As (miR-210, hsa-miR-155, hsa-miR-106a, hsa-miR-17-5p) were expressed at a significantly higher level in DLBCL than in normal tissue. In contrast, the remaining 11 miRNAs (hsa-miR-150, hsa-miR-145, hsa-miR-328, hsa-miR-139, hsa-miR-99a, hsa-miR-10a, hsa-miR-95, hsa-miR-149, hsa-miR-320, hsa-miR-151,let-7e) were expressed at a significantly lower level in DLBCL."	unknown	unknown	2008	18537969	Unspecified
+hsa-miR-154	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-154	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-154	10222	polymyositis (PM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-154*	3073	glioblastoma multiforme (GBM)	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed microRNA in glioblastoma multiforme tumors relative to non-neoplastic brain tissue.	unknown	unknown	2008	18577219	Unspecified
+hsa-miR-155	1040	chronic lymphocytic leukemia (CLL)	up-regulated	"Northern blot, qRT-PCR etc"	MicroRNA Signature Associated with Prognostic Factors (ZAP-70 Expression and IgVH Mutations) and Disease Progression in Patients with CLL.	unknown	AGTR1	2005	16251535	Unspecified
+hsa-miR-155	353	diffuse large B-cell lymphoma (DLBCL)	up-regulated	"Northern blot, qRT-PCR etc"	"Whether microRNAs have diagnostic utility by comparing levels of tumour-associated miR-155, miR-210 and miR-21 in serum from diffuse large B-cell lymphoma (DLBCL) patients (n=60) with healthy controls (n=43). Levels were higher in patient than control sera (P=0.009, 0.02 and 0.04 respectively). Moreover, high miR-21 expression was associated with relapse-free survival (P=0.05)."	unknown	AGTR1	2008	18318758	Unspecified
+hsa-miR-155	3905	lung cancer	up-regulated	"Northern blot, qRT-PCR etc"	"miRNAs (miR-155, miR-17-3p, miR-106a, miR-93, let-7a-2, miR-145, let-7b, and miR-21) were related to the adenocarcinoma patient��s survival. Patients with high expression of either hsamir-155, miR-17-3p, miR-106a, miR-93, or miR-21 and low expression of either let-7a-2, let-7b, or miR-145 were found to have a significantly worse prognosis."	unknown	AGTR1	2006	16530703	Unspecified
+hsa-miR-155	9952	acute lymphoblastic leukemia (ALL)	up-regulated	"Northern blot, qRT-PCR etc"	"Transgenic mice with overexpression of miR155 develop a lymphoproliferative disease resembling the human diseases, thus strongly suggesting that miR-155 is directly implicated in the initiation and or progression of these diseases."	unknown	AGTR1	2006	16641092	Causal
+hsa-miR-155	353	diffuse large B-cell lymphoma (DLBCL)	up-regulated	"Northern blot, qRT-PCR etc"	"miR-155 can bind to the 3'-untranslated region(UTR) of hAT(1)R mRNAs and translationally repress the expression of this protein in vivo. Importantly, the translational repression mediated by miR-155 can be regulated by physiological stimuli."	hAT1R	AGTR1	2006	16675453	Causal
+hsa-miR-155	2356	myeloproliferative disorder	up-regulated	"Northern blot, qRT-PCR etc"	"miR-155 expression is greatly increased in mouse bone marrow cells after LPS injection and is suffi cient to drive GM expansion when constitutively expressed in mouse HSCs in vivo. However, sustained expression of miR-155 also leads to several features characteristic of pathological myeloid proliferations, correlating with its overexpression in samples from human acute myeloid leukemia"					
+"(AML) patients. Finally, miR-155 directly repressed a broad range of target mRNAs implicated in myeloid hyperplasia and/or hematopoiesis."	unknown	AGTR1	2008	18299402	Causal	1	1675			
+hsa-miR-222	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	KIT	2007	17942673	Unspecified
+hsa-miR-222	11727	facioscapulohumeral muscular dystrophy (FSHD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	KIT	2007	17942673	Unspecified
+hsa-miR-222	3068	glioblastoma	up-regulated	microarray	Significantly differentially expressed between glioblastoma cell line samples and the control samples.	unknown	KIT	2005	16039986	Unspecified
+hsa-miR-222	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	One of the 22 significantly up- and down-regulated miRNAs obtained using significance analysis of microarrays with false discovery rate of 5%. Majority of the predicted targets of these 22 differentially regulated miRNAs reside in pathways reported to be dysregulated during carcinogenesis.	unknown	KIT	2008	18319255	Unspecified
+hsa-miR-222	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	"Distinct up-regulations of miR-222, miR-221, and miR-31, and down-regulations of miR-223, miR-126, and miR-122a were identified. Further investigations suggested the highly deregulated miR-223 and miR-222 could unequivocally distinguish HCC from adjacent nontumoral liver, irrespective of viral associations (P<=.0002)."	unknown	KIT	2008	18555017	Unspecified
+hsa-miR-1	3363	coronary artery disease	up-regulated	"Northern blot, qRT-PCR etc"	"miR-1 overexpression slowed conduction and depolarized the cytoplasmic membrane by post-transcriptionally repressing KCNJ2 and GJA1 and this likely accounts at least in part for its arrhythmogenic potential. Thus, miR-1 may have important pathophysiological functions in the heart, and is a potential antiarrhythmic target."	"GAJ1,KCNJ2"	"GJA1,Hand2,HDAC4,TMSB4X"	2007	17401374	Causal
+hsa-miR-1	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	"The CGI spanning exon 1 and intron 1 of miR-1-1 was methylated in HCC cell lines and in primary human HCCs but not in matching liver tissues. The miR-1-1 gene was hypomethylated and activated in DNMT1-/- HCT 116 cells but not in DNMT3B null cells, indicating a key role for DNMT1 in its methylation. miR-1 expression was also markedly reduced in primary human hepatocellular carcinomas compared with matching normal liver tissues. Ectopic expression of miR-1 in HCC cells inhibited cell growth and reduced replication potential and clonogenic survival. The expression of FoxP1 and MET harboring three and two miR-1 cognate sites, respectively, in their respective 3'-untranslated regions, was markedly reduced by ectopic miR-1. Up-regulation of several miR-1 targets including FoxP1, MET, and HDAC4 in primary human HCCs and down-regulation of their expression in 5-AzaC-treated HCC cells suggest their role in hepatocarcinogenesis. The inhibition of cell cycle progression and induction of apoptosis after re-expression of miR-1 are some of the mechanisms by which DNA hypomethylating agents suppress hepatocarcinoma cell growth."	"FoxP1, MET, HDAC4"	"GJA1,Hand2,HDAC4,TMSB4X"	2008	18593903	Causal
+hsa-miR-1	2786	Cerebellar neurodegeneration	down-regulated	"Northern blot, qRT-PCR etc"	Essential for the survival of Purkinje cells and its absence leads to a slow degeneration of these cells.	unknown	"GJA1,Hand2,HDAC4,TMSB4X"	2007	17606634	Unspecified
+hsa-miR-1	10584	retinitis pigmentosa (RP)	down-regulated	"Northern blot, qRT-PCR etc"	"Expression of miR-1 and miR-133 decreased by more than 2.5-fold (P<0.001), whereas expression of miR-96 and miR-183 increased by more than 3-fold (P<0.001) in Pro347Ser retinas, as validated by qPCR."	unknown	"GJA1,Hand2,HDAC4,TMSB4X"	2007	18034880	Unspecified
+hsa-miR-100	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	Differentially expressed between tumors and normals.	unknown	unknown	2007	17875710	Unspecified
+hsa-miR-100	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	DNA copy number status of 17 genomic loci containing miRNAs differentially expressed between IOSE cells and EOC cell lines.	unknown	unknown	2008	18458333	Unspecified
+hsa-miR-100	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-100	3908	non-small cell lung cancer (NSCLC)	up-regulated	microarray	differentially expressed miRNA in TRAIL-resistant NSCLC cells.	unknown	unknown	2008	18246122	Unspecified
+hsa-miR-100	2144	ovarian cancer (OC)	down-regulated	microarray	"Frequent deregulation of miR-199a*, miR-214, miR-200a, and miR-100 in human ovarian cancer."	unknown	unknown	2008	18199536	Unspecified
+hsa-miR-100	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-100	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Aberrantly expressed miRNA precursors in pancreatic adenocarcinoma.PAM testing was conducted on 10 tumor samples and 15 adjacent benign samples. PAM has correctly classified 100% of the tested tumor samples and 11 of 15 of the tested benign samples. The 20 top ranked differentially expressed miRNAs in pancreatic adenocarcinoma as selected by PAM.	unknown	unknown	2006	17149698	Unspecified
+hsa-miR-100	10286	prostate cancer	up-regulated	"Northern blot, qRT-PCR etc"	miRNA precursors with significantly different expression.	unknown	unknown	2005	16192569	Unspecified
+hsa-miR-100	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	1693			
+hsa-miR-100	10286	prostate cancer	up-regulated	"Northern blot, qRT-PCR etc"	One of the upregulated microRNAs in tumors with perineural invasion (FDR 10%).	unknown	unknown	2008	18459106	Unspecified
+hsa-miR-100	9088	psoriasis	down-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	unknown	2007	17622355	Unspecified
+hsa-miR-100	5745	serous ovarian cancer	down-regulated	microarray	Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients.	unknown	unknown	2008	18451233	Unspecified
+hsa-miR-100-1	13315	chronic pancreatitis	up-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-100-1	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-100-1	3829	pituitary adenoma	down-regulated	microarray	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	unknown	2007	17111382	Unspecified
+hsa-miR-100-2	13315	chronic pancreatitis	up-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-100-2	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-100-2	3829	pituitary adenoma	down-regulated	microarray	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	unknown	2007	17111382	Unspecified
+hsa-miR-101	10652	Alzheimer's disease	down-regulated	microarray	Significantly changed miRNAs in cortex of sporadic AD cases.	unknown	"Enx-1,MYCN"	2008	18434550	Unspecified
+hsa-miR-101	1040	B-cell chronic lymphocytic leukemia	up-regulated	microarray	Differentially expressed in CLL cells versus CD5 cells.	unknown	"Enx-1,MYCN"	2004	15284443	Unspecified
+hsa-miR-101	14691	Duchenne muscular dystrophy (DMD)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	"Enx-1,MYCN"	2007	17942673	Unspecified
+hsa-miR-101	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	Differentially expressed between tumors and normals.	MYCN	"Enx-1,MYCN"	2007	17875710	Unspecified
+hsa-miR-101	3073	glioblastoma multiforme (GBM)	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed microRNA in glioblastoma multiforme tumors relative to non-neoplastic brain tissue.	unknown	"Enx-1,MYCN"	2008	18577219	Unspecified
+hsa-miR-101	5520	head and neck squamous cell carcinoma (HNSCC)	down-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	"Enx-1,MYCN"	2007	17222355	Unspecified
+hsa-miR-101-1	3459	breast cancer	down-regulated	microarray	Differentially expressed between breast carcinoma and normal breast tissue.	unknown	unknown	2005	16103053	Unspecified
+hsa-miR-101-1	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-101a	2786	Cerebellar neurodegeneration	down-regulated	"Northern blot, qRT-PCR etc"	Essential for the survival of Purkinje cells and its absence leads to a slow degeneration of these cells.	unknown	unknown	2007	17606634	Unspecified
+hsa-miR-101b-2	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	unknown	2006	16924677	Unspecified
+hsa-miR-102	3969	papillary thyroid carcinoma (PTC)	up-regulated	microarray	Differentially expressed miRNA in PTC tumors	unknown	unknown	2005	16365291	Unspecified
+hsa-miR-103	1107	esophageal cancer	up-regulated	"Northern blot, qRT-PCR etc"	"miR-103/107 showed a strong correlation between low expression levels and a high overall and disease-free survival periods for esophageal cancer patients by univariate analysis, as well as by multivariate analysis."	unknown	unknown	2008	18172293	Unspecified
+hsa-miR-103	9119	acute myeloid leukemia (AML)	down-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-103	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-103	2786	Cerebellar neurodegeneration	down-regulated	"Northern blot, qRT-PCR etc"	Essential for the survival of Purkinje cells and its absence leads to a slow degeneration of these cells.	unknown	unknown	2007	17606634	Unspecified
+hsa-miR-103	4001	epithelial ovarian cancer (EOC)	up-regulated	microarray	DNA copy number status of 17 genomic loci containing miRNAs differentially expressed between IOSE cells and EOC cell lines.	unknown	unknown	2008	18458333	Unspecified
+hsa-miR-103	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	"the expression of miR-103 and miR-107, associated with lack of expression of miR-155, discriminates tumors from normal."	unknown	unknown	2006	16966691	Unspecified
+hsa-miR-103	3829	pituitary adenoma	up-regulated	microarray	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	unknown	2007	17111382	Unspecified
+hsa-miR-103	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	unknown	2007	17616669	Unspecified	0	1721			
+hsa-miR-103-1	4007	bladder cancer	up-regulated	microarray	"Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b,miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P<0.05) compared to normal bladder"					
+mucosa.	unknown	FBXW1B	2007	17826655	Unspecified	0	1722			
+hsa-miR-103-2	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	unknown	2006	16924677	Unspecified
+hsa-miR-103-2	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-103-2	3829	pituitary adenoma	up-regulated	microarray	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	unknown	2007	17111382	Unspecified
+hsa-miR-104	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-105	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	Differentially expressed between tumors and normals.	unknown	unknown	2007	17875710	Unspecified
+hsa-miR-105	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-106a	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Altered expression of miR-17-5p, miR-106a, and EGFL7 was associated with pathological tumor features of poor prognosis. Downregulation of miR-106a predicted shortened DFS (P=0.03) and OS (P=0.04). miR-17-5p correlated with DFS only at early stages (P=0.07). Inverse correlations were found between miR-17-5p and miR-106a levels and their target expression, E2F1 (P=0.04 and P=0.03, respectively).  Inverse correlation between miR-17-5p and miR-106a and E2F1 levels supports E2F1 as a target mRNA for the two miRNAs."	E2F1	RB1	2008	18521848	Unspecified
+hsa-miR-106a	3905	lung cancer	up-regulated	microarray	"miRNAs (miR-155, miR-17-3p, miR-106a, miR-93, let-7a-2, miR-145, let-7b, and miR-21) were related to the adenocarcinoma patient��s survival. Patients with high expression of either hsamir-155, miR-17-3p, miR-106a, miR-93, or miR-21 and low expression of either let-7a-2, let-7b, or miR-145 were found to have a significantly worse prognosis."	unknown	RB1	2006	16530703	Unspecified
+hsa-miR-106a	715	T-cell leukemia	up-regulated	"Northern blot, qRT-PCR etc"	"The authors conclude that, in addition to miR-106a, miR-20b, miR-19b-2, and miR-92-2 overexpression in tumors, their capacity to induce anchorage independence growth strongly supports an oncogenic"					
+"potential for those miRNAs. they also conclude that Mylip and Rbp1-like are true targets of the miR-106-363 cluster(miR-106a, miR-18b, miR-20b, miR-19b-2, miR-92-2, and miR-363). More specifically, Rbp1-like seemed only targeted by miR-106a/miR-20b, whereas Mylip could be targeted by the four miRNAs(miR-106a, miR-20b, miR-19b-2, and miR-92-2) with miR-106a/miR-20b being more efficient."	"Mylip, Rbp1-like"	RB1	2006	17575136	Causal	1	1731			
+hsa-miR-106a	1208	autism spectrum disorder (ASD)	down-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	RB1	2008	18563458	Unspecified
+hsa-miR-106a	1985	colorectal cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	RB1	2006	16461460	Unspecified
+hsa-miR-106a	353	diffuse large B-cell lymphoma (DLBCL)	up-regulated	microarray	"Four hsa-miR-As (miR-210, hsa-miR-155, hsa-miR-106a, hsa-miR-17-5p) were expressed at a significantly higher level in DLBCL than in normal tissue. In contrast, the remaining 11 miRNAs (hsa-miR-150, hsa-miR-145, hsa-miR-328, hsa-miR-139, hsa-miR-99a, hsa-miR-10a, hsa-miR-95, hsa-miR-149, hsa-miR-320, hsa-miR-151,let-7e) were expressed at a significantly lower level in DLBCL."	unknown	RB1	2008	18537969	Unspecified
+hsa-miR-106a	8524	follicular lymphoma (FL)	up-regulated	microarray	"Nine miRNAs (hsa-miR-9, hsa-miR-301, hsa-miR-213, hsa-miR-9*, hsa-miR-330, hsa-miR-106a, hsa-miR-338, hsa-miR-155, hsa-miR-210) were significantly up- and three miRNAs (hsa-miR-320, hsa-miR-149, hsa-miR-139) down-regulated in the lymphoma samples. Expression of hsa-miR-9 was most strongly increased (12-fold) and of hsa-miR-320 most strongly decreased (3-fold).A classification tree was"					
+"computed using four miRNAs (miR-330, miR-17-5p, miR-106a and miR-210) to correctly identify 98% of all 111 cases that were analysed in this study."	unknown	RB1	2008	18537969	Unspecified	0	1735			
+hsa-miR-106a	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	RB1	2008	18379589	Unspecified
+hsa-miR-106a	769	neuroblastoma (NB)	up-regulated	"Northern blot, qRT-PCR etc"	Positively correlated with MYCN-amplification in tumors in vivo.	unknown	RB1	2007	17943719	Unspecified
+hsa-miR-106a	4905	pancreatic cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	RB1	2006	16461460	Unspecified
+hsa-miR-106a	10286	prostate cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	RB1	2006	16461460	Unspecified
+hsa-miR-106a	9088	psoriasis	up-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	RB1	2007	17622355	Unspecified
+hsa-miR-106a-1	684	hepatocellular carcinoma (HCC)	up-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	unknown	2006	16924677	Unspecified
+hsa-miR-124a	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed between neoplastic conditions (CRC cell lines and tumor samples) and non-tumoral colon tissues.	unknown	unknown	2006	16854228	Unspecified
+hsa-miR-124a	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	Differentially expressed between tumors and normals.	unknown	unknown	2007	17875710	Unspecified
+hsa-miR-124a	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-124a	3305	teratocarcinoma	down-regulated	"Northern blot, qRT-PCR etc"	"The miR-302 cluster was potently expressed in undifferentiated NTera2D1 and P19 cells, but hardly in differentiated cells, such that miR-124a showed an opposite expression pattern to the miR-302 cluster.it is suggested that the miR-302 cluster and miR-124a may be useful molecular indicators in the assessment of degree of undifferentiation and/or differentiation in the course of neuronal differentiation."	unknown	unknown	2007	17716626	Unspecified
+hsa-miR-124a-1	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-124a-2	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	survival-related and metastasis-related miRNA.	unknown	unknown	2008	18176954	Unspecified
+hsa-miR-124a-2	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	unknown	2007	17616664	Unspecified
+hsa-miR-124a-3	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Aberrant hypermethylation leads to miRNA gene inactivation in human breast cancer. Aberrant hypermethylation was shown for mir-9-1, mir-124a-3, mir-148, mir-152, and mir-663 in 34-86% of cases in a series of 71 primary human breast cancer specimens.miRNA gene hypermethylation correlated strongly with methylation of known tumour suppressor genes (p = 0.003)."	unknown	unknown	2007	17948228	Unspecified
+hsa-miR-124a-3	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Aberrant hypermethylation was shown for miR-9-1, miR-124a-3, miR-148, miR-152, and miR-663 in 34-86% of cases in a series of 71 primary human breast cancer specimens. miRNA gene hypermethylation correlated strongly with methylation of known tumour suppressor genes (p = 0.003). "	unknown	unknown	2007	18314617	Unspecified
+hsa-miR-124a-3	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-125a	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"After retroviral delivery and overexpression of these miRNAs in an ERBB2-amplified and -overexpressing human breast cancer cell line, SKBR3. Overexpression of miR-125a or miR-125b reduced ERBB2 and ERBB3 at both the transcript and protein level in these cells, leading to reduced ERK1/2 and AKT signaling. Functionally, miR-125a or miR-125b-overexpressing SKBR3 cells displayed diminished plating and anchorage-dependent growth in addition to markedly reduced cell migration and invasion capacities."	"ERBB2, ERBB3"	"ERBB2,ERBB3,Lin28"	2006	17110380	Causal
+hsa-miR-125a	9952	acute lymphoblastic leukemia (ALL)	down-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	"ERBB2,ERBB3,Lin28"	2007	18056805	Unspecified
+hsa-miR-125a	9119	acute myeloid leukemia (AML)	up-regulated	microarray	"Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL."	unknown	"ERBB2,ERBB3,Lin28"	2007	18056805	Unspecified
+hsa-miR-125a	3459	breast cancer	down-regulated	microarray	Differentially expressed between breast carcinoma and normal breast tissue.	unknown	"ERBB2,ERBB3,Lin28"	2005	16103053	Unspecified
+hsa-miR-125a	13315	chronic pancreatitis	up-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	"ERBB2,ERBB3,Lin28"	2007	17473300	Unspecified
+hsa-miR-125a	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	"ERBB2,ERBB3,Lin28"	2006	16609010	Unspecified
+hsa-miR-125a	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	Differentially expressed between tumors and normals.	unknown	"ERBB2,ERBB3,Lin28"	2007	17875710	Unspecified
+hsa-miR-125a	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	Significantly differentially expressed between hepatocellular carcinoma and adjacent non-tumor tissue.	unknown	"ERBB2,ERBB3,Lin28"	2006	16331254	Unspecified
+hsa-miR-125a	3905	lung cancer	down-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	"ERBB2,ERBB3,Lin28"	2006	16530703	Unspecified
+hsa-miR-125a	769	neuroblastoma (NB)	down-regulated	"Northern blot, qRT-PCR etc"	"Three neuronal miRNAs (9,125a,and 125b) act in an additive manner by repressing a common target, the truncated isoform of the neurotrophin receptor tropomyosin-related kinase C, to control human neuroblastoma cell proliferation."	unknown	"ERBB2,ERBB3,Lin28"	2007	17483472	Unspecified
+hsa-miR-125a	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	"ERBB2,ERBB3,Lin28"	2007	17473300	Unspecified
+hsa-miR-125a	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	"ERBB2,ERBB3,Lin28"	2007	17616669	Unspecified	0	1763			
+hsa-miR-125a	5745	serous ovarian cancer	down-regulated	microarray	Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients.	unknown	"ERBB2,ERBB3,Lin28"	2008	18451233	Unspecified
+hsa-miR-125a	178	vascular disease	down-regulated	"Northern blot, qRT-PCR etc"	Aberrant Expression of miRNA in Injured Arteries Is Confirmed by qRT-PCR or Northern Blot Analysis.	unknown	"ERBB2,ERBB3,Lin28"	2007	17478730	Unspecified
+hsa-miR-125b	7012	anaplastic thyroid carcinoma (ATC)	down-regulated	"Northern blot, qRT-PCR etc"	miR-125b plays a role in slowing the cell proliferation.	HMGA(HMGA1 and HMGA2)	Lin28	2007	17563749	Causal
+hsa-miR-125b	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"miR-125b, which is down-modulated in breast cancer, is located at chromosome 11q23-24, one of the regions most frequently deleted in breast,ovarian, and lung tumors. The recognition of a bona fide"					
+tumor suppressor gene located at 11q23-24 involved in the pathogenesis of human breast cancer is still lacking. The miR-125b gene establishes itself as an important candidate for this role.	unknown	Lin28	2005	16103053	Causal	1	1767			
+hsa-miR-125b	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"After retroviral delivery and overexpression of these miRNAs in an ERBB2-amplified and -overexpressing human breast cancer cell line, SKBR3. Overexpression of miR-125a or miR-125b reduced ERBB2 and ERBB3 at both the transcript and protein level in these cells, leading to reduced ERK1/2 and AKT signaling. Functionally, miR-125a or miR-125b-overexpressing SKBR3 cells displayed diminished plating and anchorage-dependent growth in addition to markedly reduced cell migration and invasion capacities."	"ERBB2, ERBB3"	Lin28	2006	17110380	Causal
+hsa-miR-125b	10286	prostate cancer	down-regulated	"Northern blot, qRT-PCR etc"	"let-7c, miR-145 and miR-125b target mRNAs whose proteins have been shown to be increased in prostate cancer."	EIF4EBP1	Lin28	2007	17891175	Causal
+hsa-miR-125b	10286	prostate cancer	up-regulated	"Northern blot, qRT-PCR etc"	"Differential expression of miR-125b in androgen-dependent and independent prostate cancer (CaP) cells, as well as in benign and malignant prostate tissues. Furthermore, androgen signaling was able to up-regulate the expression of miR-125b. In addition, transfection of synthetic miR-125b stimulated androgen-independent growth of CaP cells and down-regulated the expression of Bak1."	Bak1	Lin28	2007	18056640	Causal
+hsa-miR-125b	10652	Alzheimer's disease	up-regulated	"Northern blot, qRT-PCR etc"	"Significant change in micro-RNA abundance in the hippocampal region of fetal, adult and Alzheimer's disease brain."	unknown	Lin28	2007	17314675	Unspecified
+hsa-miR-125b	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change correlative with the increase in heart/body weight(7-14 days post-TAC).	unknown	Lin28	2008	17234972	Unspecified
+hsa-miR-125b	2786	Cerebellar neurodegeneration	down-regulated	"Northern blot, qRT-PCR etc"	Essential for the survival of Purkinje cells and its absence leads to a slow degeneration of these cells.	unknown	Lin28	2007	17606634	Unspecified
+hsa-miR-125b	6000	heart failure	up-regulated	"Northern blot, qRT-PCR etc"	"Northern blot analysis of the hypertrophy-regulated miRNAs in idiopathic end-stage failing human hearts showed increased expression of miR-24, miR-125b, miR-195, miR-199a, and miR-216."	unknown	Lin28	2006	17108080	Unspecified
+hsa-miR-125b	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	Lin28	2008	18379589	Unspecified
+hsa-miR-125b	769	neuroblastoma (NB)	down-regulated	"Northern blot, qRT-PCR etc"	"Three neuronal miRNAs (9,125a,and 125b) act in an additive manner by repressing a common target, the truncated isoform of the neurotrophin receptor tropomyosin-related kinase C, to control human neuroblastoma cell proliferation."	unknown	Lin28	2007	17483472	Unspecified
+hsa-miR-125b	3908	non-small cell lung cancer (NSCLC)	up-regulated	microarray	differentially expressed miRNA in TRAIL-resistant NSCLC cells.	unknown	Lin28	2008	18246122	Unspecified
+hsa-miR-125b	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	Lin28	2007	17616669	Unspecified	0	1778			
+hsa-miR-125b	10286	prostate cancer	up-regulated	"Northern blot, qRT-PCR etc"	One of the upregulated microRNAs in tumors with perineural invasion (FDR 10%).	unknown	Lin28	2008	18459106	Unspecified
+hsa-miR-125b	9088	psoriasis	down-regulated	"Northern blot, qRT-PCR etc"	The level of miR-125b  significantly (p<0.001 for both) decreased both in					
+psoriasis and atopic eczema.	unknown	Lin28	2007	17622355	Unspecified	0	1780			
+hsa-miR-125b	5745	serous ovarian cancer	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients.	unknown	Lin28	2008	18451233	Unspecified
+hsa-miR-125b	13223	uterine leiomyoma (ULM)	up-regulated	"Northern blot, qRT-PCR etc"	Real-time reverse transcriptase polymerase chain reaction (RT-PCR) validation of microarray. Realtime					
+"semiquantitative RT-PCR of five different microRNA species (miR-21, miR-34a, miR-125b, miR-139, and miR-323) across ten subjects. miR-21, miR-34a, miR-125b, and miR-323 were overexpressed in leiomyoma in the ten pairs tested and miR-139 was underexpressed, consistent with the microarray results."	unknown	Lin28	2008	17765232	Unspecified	0	1782			
+hsa-miR-125b	178	vascular disease	down-regulated	"Northern blot, qRT-PCR etc"	Aberrant Expression of miRNA in Injured Arteries Is Confirmed by qRT-PCR or Northern Blot Analysis.	unknown	Lin28	2007	17478730	Unspecified
+hsa-miR-125b-1	13315	chronic pancreatitis	up-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-125b-1	4001	epithelial ovarian cancer (EOC)	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed between tumors and normals.	unknown	unknown	2007	17875710	Unspecified
+hsa-miR-125b-1	3068	glioblastoma	down-regulated	microarray	Significantly differentially expressed between glioblastoma cell line samples and the control samples.	unknown	unknown	2005	16039986	Unspecified
+hsa-miR-125b-1	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	unknown	2006	16924677	Unspecified
+hsa-miR-125b-1	4905	pancreatic cancer	up-regulated	"Northern blot, qRT-PCR etc"	Aberrantly expressed miRNA precursors in pancreatic adenocarcinoma.PAM testing was conducted on 10 tumor samples and 15 adjacent benign samples. PAM has correctly classified 100% of the tested tumor samples and 11 of 15 of the tested benign samples. The 20 top ranked differentially expressed miRNAs in pancreatic adenocarcinoma as selected by PAM.	unknown	unknown	2006	17149698	Unspecified
+hsa-miR-125b-1	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-125b-2	13315	chronic pancreatitis	up-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-125b-2	14250	Down syndrome (DS)	up-regulated	"Northern blot, qRT-PCR etc"	"Bioinformatic analyses demonstrate that human chromosome 21(Hsa21) harbors five miRNA genes; miR-99a, let-7c, miR-125b-2, miR-155, and miR-802. MiRNA expression profiling, miRNA RT-PCR, and miRNA in situ hybridization experiments demonstrate that these miRNAs are overexpressed in fetal brain and heart specimens from individuals with DS when compared with age- and sex-matched controls."	unknown	unknown	2008	18387358	Unspecified
+hsa-miR-125b-2	3068	glioblastoma	down-regulated	microarray	Significantly differentially expressed between glioblastoma cell line samples and the control samples.	unknown	unknown	2005	16039986	Unspecified
+hsa-miR-125b-2	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	unknown	2006	16924677	Unspecified
+hsa-miR-125b-2	3905	lung cancer	down-regulated	"Northern blot, qRT-PCR etc"	"let-7c,miR-99a, and miR-125b-2 were also mapped in a region with Homozygous Deletion at 21q11-q23."	unknown	unknown	2007	17674361	Unspecified
+hsa-miR-126	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	survival-related and metastasis-related miRNA.	unknown	unknown	2008	18176954	Unspecified
+hsa-miR-126	9119	acute promyelocytic leukemia (APL)	down-regulated	"Northern blot, qRT-PCR etc"	"miR-126 is not expressed in myeloid lineage leukemic cell lines, which express high levels of Hoxa9.miR-126 and Hoxa9 are inversely expressed in some primary myeloid leukemias. miR-126 inhibits endogenous HOXA9 protein in MLL-ENL cells. Knock-down of endogenous miR-126 increases HOXA9 protein."	HOXA9	unknown	2008	18474618	Causal
+hsa-miR-126	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	miR-126 suppresses overall tumour growth and proliferation. miR-126 restoration reduces overall tumour growth and proliferation.	unknown	unknown	2008	18185580	Causal
+hsa-miR-126	3908	non-small cell lung cancer (NSCLC)	down-regulated	"Northern blot, qRT-PCR etc"	"Increased expression of Crk has been described in lung cancer and associated with increased tumor invasiveness. Crk is a predicted putative target gene for miR-126. Over-expression of miR126 in a lung cancer cell line resulted in a decrease in Crk protein without any alteration in the associated mRNA. These lung cancer cells exhibit a decrease in adhesion, migration, and invasion. Decreased cancer cell invasion was also evident following targeted knockdown of Crk. MiR-126 alters lung cancer cell phenotype by inhibiting adhesion, migration, and invasion and the effects on invasion may be partially mediated through Crk regulation."	CRK	unknown	2008	18602365	Causal
+hsa-miR-126	13315	chronic pancreatitis	up-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-126	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	Differentially expressed between tumors and normals.	unknown	unknown	2007	17875710	Unspecified
+hsa-miR-145	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"A noticeable decrease of miR-145 expression was observed in hyperplastic, probable preneoplastic,ducts present in some of the cases examined. Loss of miR-145 expression is an early event during breast cancer progression,"	unknown	FLJ21308	2007	18089790	Unspecified
+hsa-miR-145	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	"miR-143 and miR-145, consistently display reduced steady-state levels of the mature miRNA at the adenomatous and cancer stages of colorectal neoplasia."	unknown	FLJ21308	2003	14573789	Unspecified
+hsa-miR-145	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed between neoplastic conditions (CRC cell lines and tumor samples) and non-tumoral colon tissues.	unknown	FLJ21308	2006	16854228	Unspecified
+hsa-miR-145	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Expression levels of analyzed miRNAs significantly differed among tumors and adjacent non-tumor tissues: miR-21 (p = 0.0001) and miR-31 (p = 0.0006) were upregulated, and miR-143 (p = 0.011) and miR-145 (p = 0.006) were downregulated in tumors."	unknown	FLJ21308	2007	18196926	Unspecified
+hsa-miR-145	353	diffuse large B-cell lymphoma (DLBCL)	down-regulated	microarray	"Four hsa-miR-As (miR-210, hsa-miR-155, hsa-miR-106a, hsa-miR-17-5p) were expressed at a significantly higher level in DLBCL than in normal tissue. In contrast, the remaining 11 miRNAs (hsa-miR-150, hsa-miR-145, hsa-miR-328, hsa-miR-139, hsa-miR-99a, hsa-miR-10a, hsa-miR-95, hsa-miR-149, hsa-miR-320, hsa-miR-151,let-7e) were expressed at a significantly lower level in DLBCL."	unknown	FLJ21308	2008	18537969	Unspecified
+hsa-miR-145	4001	epithelial ovarian cancer (EOC)	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed between tumors and normals.	unknown	FLJ21308	2007	17875710	Unspecified
+hsa-miR-145	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	DNA copy number status of 17 genomic loci containing miRNAs differentially expressed between IOSE cells and EOC cell lines.	unknown	FLJ21308	2008	18458333	Unspecified
+hsa-miR-145	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	FLJ21308	2007	17616664	Unspecified
+hsa-miR-145	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	One of the 22 significantly up- and down-regulated miRNAs obtained using significance analysis of microarrays with false discovery rate of 5%. Majority of the predicted targets of these 22 differentially regulated miRNAs reside in pathways reported to be dysregulated during carcinogenesis.	unknown	FLJ21308	2008	18319255	Unspecified
+hsa-miR-145	3498	pancreatic ductal adenocarcinoma (PDAC)	up-regulated	microarray	differentially expressed between normal and PDAC or cell line samples.	unknown	FLJ21308	2007	17237814	Unspecified
+hsa-miR-145	10286	prostate cancer	down-regulated	microarray	Differential expression in the prostate carcinoma samples compared with the benign prostatic					
+hyperplasia samples.	unknown	FLJ21308	2007	17616669	Unspecified	0	1811			
+hsa-miR-145	10286	prostate cancer	up-regulated	microarray	One of the upregulated microRNAs in tumors with perineural invasion (FDR 10%).	unknown	FLJ21308	2008	18459106	Unspecified
+hsa-miR-145	5745	serous ovarian cancer	down-regulated	microarray	Differentially expressed miRNAs with>2-fold change in tumor versus normal ovarian tissues in at least 12 of 20 ovarian cancer patients.	unknown	FLJ21308	2008	18451233	Unspecified
+hsa-miR-145	5556	testicular germ cell tumor	up-regulated	microarray	Differentially expressed miRNA in the various histological subtypes of  germ cell tumour (GCT) (TE = teratoma; SE = seminoma; EC = embryonal carcinoma).	unknown	FLJ21308	2007	17893849	Unspecified
+hsa-miR-145	178	vascular disease	down-regulated	"Northern blot, qRT-PCR etc"	Aberrant Expression of miRNA in Injured Arteries Is Confirmed by qRT-PCR or Northern Blot Analysis.	unknown	FLJ21308	2007	17478730	Unspecified
+hsa-miR-146a	1040	chronic lymphocytic leukemia (CLL)	up-regulated	"Northern blot, qRT-PCR etc"	MicroRNA Signature Associated with Prognostic Factors (ZAP-70 Expression and IgVH Mutations) and Disease Progression in Patients with CLL.	unknown	unknown	2005	16251535	Unspecified
+hsa-miR-146a	3459	breast cancer	up-regulated	"Northern blot, qRT-PCR etc"	"NF-kB can induce the expression of miR-146a, which can then down-regulate IRAK1 and TRAF6 and thus acts as a component in a negative feedback loop that controls TLR signaling."	"IRAK1, TRAF6"	unknown	2006	16885212	Causal
+hsa-miR-146a	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"we demonstrate that microRNA-146a and microRNA-146b (miR-146a/b) when expressed in the highly metastatic human breast cancer cell line MDA-MB-231 function to negatively regulate NF-kappaB activity. Functionally, miR-146a/b-expressing MDA-MB-231 cells showed markedly impaired invasion and migration capacity relative to control cells. These findings implicate miR-146a/b as a negative regulator of constitutive NF-kappaB activity in a breast cancer setting and suggest that modulating miR-146a/b levels has therapeutic potential to suppress breast cancer metastases."	NF-kappaB	unknown	2008	18504431	Causal
+hsa-miR-146a	3969	papillary thyroid carcinoma (PTC)	up-regulated	"Northern blot, qRT-PCR etc"	"Up-regulation of several miRs (miR-221, -222, and -146) and regulation of KIT are involved in PTC pathogenesis, and that sequence changes in genes targeted by miRNAs can contribute to their regulation."	KIT	unknown	2005	16365291	Causal
+hsa-miR-146a	3969	papillary thyroid carcinoma (PTC)	down-regulated	"Northern blot, qRT-PCR etc"	"We show that a common G/C polymorphism (rs2910164) within the pre-miR-146a sequence reduced the amount of pre- and mature miR-146a from the C allele 1.9- and 1.8-fold, respectively, compared with the G allele.our data suggest that a common polymorphism in pre-miR-146a affects the miR expression, contributes to the genetic predisposition to PTC, and plays a role in the tumorigenesis through somatic mutation. Preliminary evidence suggests that these effects are mediated through target genes whose expression is affected by the SNP status."	unknown	unknown	2008	18474871	Causal
+hsa-miR-146a	10286	prostate cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Transfection of mir-146a suppressed >82% of the expression of the targeted protein-coding gene, ROCK1 in androgen-independent PC3 cells, consequently markedly reducing cell proliferation, invasion, and metastasis to human bone marrow endothelial cell monolayers."	ROCK1	unknown	2008	18174313	Causal
+hsa-miR-146a	3459	breast cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-146a	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Confirmation of the Aberrant miRNA Expression in Hypertrophic Hearts by Northern Blot Analysis and/or qRT-PCR.	unknown	unknown	2007	17525252	Unspecified
+hsa-miR-146a	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	unknown	2007	17616664	Unspecified
+hsa-miR-146a	3905	lung cancer	up-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-146a	8894	Oral Squamous Cell Carcinoma (OSCC)	up-regulated	microarray	miRNAs frequently up-regulated in OSCC cell lines(>1.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-146a	4905	pancreatic cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-146a	4905	pancreatic cancer	up-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-146a	3498	pancreatic ductal adenocarcinoma (PDAC)	up-regulated	microarray	differentially expressed between normal and PDAC or cell line samples.	unknown	unknown	2007	17237814	Unspecified
+hsa-miR-146a	10286	prostate cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-146a	9088	psoriasis	up-regulated	"Northern blot, qRT-PCR etc"	miR-146a was significantly over-expressed in psoriatic lesional skin (p<0.001) but not in atopic eczema lesions when compared with healthy skin.	unknown	unknown	2007	17622355	Unspecified
+hsa-miR-146a	178	vascular disease	up-regulated	"Northern blot, qRT-PCR etc"	Aberrant Expression of miRNA in Injured Arteries Is Confirmed by qRT-PCR or Northern Blot Analysis.	unknown	unknown	2007	17478730	Unspecified
+hsa-miR-146b	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"we demonstrate that microRNA-146a and microRNA-146b (miR-146a/b) when expressed in the highly metastatic human breast cancer cell line MDA-MB-231 function to negatively regulate NF-kappaB activity. Functionally, miR-146a/b-expressing MDA-MB-231 cells showed markedly impaired invasion and migration capacity relative to control cells. These findings implicate miR-146a/b as a negative regulator of constitutive NF-kappaB activity in a breast cancer setting and suggest that modulating miR-146a/b levels has therapeutic potential to suppress breast cancer metastases."	NF-kappaB	unknown	2008	18504431	Causal
+hsa-miR-146b	1208	autism spectrum disorder (ASD)	down-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	unknown	2008	18563458	Unspecified
+hsa-miR-146b	14691	Becker muscular dystrophy (BMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-146b	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-146b	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-146b	11727	facioscapulohumeral muscular dystrophy (FSHD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-146b	3429	Inclusion body myositis (IBM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-146b	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-146b	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-146b	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-146b	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-146b	3969	papillary thyroid carcinoma (PTC)	up-regulated	"Northern blot, qRT-PCR etc"	"Preliminary analysis of 6 miRNAs in 10 papillary thyroid carcinoma and 10 follicular adenoma identified significant overexpression of miR-146b, -221, and -222 in papillary thyroid carcinoma (P<0.02), but not miR-146a, -155, or -187 (P>0.08). particularly miR-146b, might potentially be adjunct markers for diagnosing papillary thyroid carcinoma in both FNA and surgical pathology specimens."	unknown	unknown	2008	18587330	Unspecified
+hsa-miR-146b	10222	polymyositis (PM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-146b	9088	psoriasis	up-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	unknown	2007	17622355	Unspecified
+hsa-miR-147	9119	acute myeloid leukemia (AML)	down-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-147	4001	epithelial ovarian cancer (EOC)	down-regulated	microarray	Differentially expressed between tumors and normals.	unknown	unknown	2007	17875710	Unspecified
+hsa-miR-148a	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	survival-related and metastasis-related miRNA.	unknown	unknown	2008	18176954	Unspecified
+hsa-miR-148a	2841	asthma	normal	"Northern blot, qRT-PCR etc"	" +3142C/G influences miRNA targeting of HLA-G and is associated with risk of asthma.Interestingly,"					
+"the three miRNA genes are located at regions that have been linked to asthma or IgE: 7p15(miR-148a), 12q13(miR-148b), and 17q21(miR-152), raising the possibility that variation in the miRNA genes themselves might contribute to asthma risk, perhaps by interacting with HLA-G."	HLA-G	unknown	2007	17847008	Causal	1	1850			
+hsa-miR-148a	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Aberrant hypermethylation leads to miRNA gene inactivation in human breast cancer. Aberrant hypermethylation was shown for mir-9-1, mir-124a-3, mir-148, mir-152, and mir-663 in 34-86% of cases in a series of 71 primary human breast cancer specimens.miRNA gene hypermethylation correlated strongly with methylation of known tumour suppressor genes (p = 0.003)."	unknown	unknown	2007	17948228	Unspecified
+hsa-miR-148a	3459	breast cancer	down-regulated	"Northern blot, qRT-PCR etc"	"Aberrant hypermethylation was shown for miR-9-1, miR-124a-3, miR-148, miR-152, and miR-663 in 34-86% of cases in a series of 71 primary human breast cancer specimens. miRNA gene hypermethylation correlated strongly with methylation of known tumour suppressor genes (p = 0.003). "	unknown	unknown	2007	18314617	Unspecified
+hsa-miR-148a	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-148a	14691	Duchenne muscular dystrophy (DMD)	up-regulated	"Northern blot, qRT-PCR etc"	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-148a	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-148a	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-148a	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-148a	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-148a	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	microarray	miRNAs frequently down-regulated in OSCC cell lines(<0.5-fold expression).	unknown	unknown	2008	18381414	Unspecified
+hsa-miR-148a	4905	pancreatic cancer	down-regulated	microarray	Differentially Expressed MicroRNA in pancreatic cancer compared to Normal Pancreas.	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-1	3978	cardiomyopathy	down-regulated	"Northern blot, qRT-PCR etc"	" Hand2, a transcription factor that promotes ventricular cardiomyocyte expansion, is a target of miR-1. This work suggests that miR-1 genes titrate the effects of critical cardiac regulatory proteins to control the balance between differentiation and proliferation during cardiogenesis."					
+	Hand2	"GJA1,Hand2,HDAC4,TMSB4X"	2005	15951802	Causal	1	1861			
+hsa-miR-181a-1	10286	prostate cancer	up-regulated	microarray	One of the upregulated microRNAs in tumors with perineural invasion (FDR 10%).	unknown	unknown	2008	18459106	Unspecified
+hsa-miR-189	11119	tourette's syndrome	normal	"Northern blot, qRT-PCR etc"	"We studied Slit and Trk-like 1 (SLITRK1) as a candidate gene on chromosome 13q31.1 because of its proximity to a de novo chromosomal inversion in a child with TS. Among 174 unrelated probands, we identified a frameshift mutation and two independent occurrences of the identical variant in the binding site for microRNA hsa-miR-189. These variants were absent from 3600 control chromosomes. SLITRK1 mRNA and hsa-miR-189 showed an overlapping expression pattern in brain regions previously implicated in TS. Wild-type SLITRK1, but not the frameshift mutant, enhanced dendritic growth in primary neuronal cultures. Collectively, these findings support the association of rare SLITRK1 sequence variants with TS."	SLITRK1	SLITRK1	2008	16224024	Causal
+hsa-miR-18a	7012	anaplastic thyroid carcinoma (ATC)	up-regulated	"Northern blot, qRT-PCR etc"	"MiRNAs in a miR-17-92 cluster were overexpressed in ARO cells. We confirmed the overexpression of those miRNAs by Northern blot analysis in ARO and FRO cells. In 3 of 6 clinical ATC samples, miR-17-3p and miR-17-5p were robustly overexpressed in cancer lesions compared to adjacent normal tissue. To investigate the functional role of these miRNAs in ATC cells, ARO and FRO cells were transfected with miRNA inhibitors, antisense oligonucleotides containing locked nucleic acids. Suppression of miR-17-3p caused complete growth arrest, presumably due to caspase activation resulting in apoptosis. MiR-17-5p or miR-19a inhibitor also induced strong growth reduction, but only miR-17-5p inhibitor led to cellular senescence. On the other hand, miR-18a inhibitor only moderately attenuated the cell growth. Thus, we have clarified functional differences among the members of the cluster in ATC cells. In conclusion, these findings suggest that the miR-17-92 cluster plays an important role in certain types of ATCs and could be a novel target for ATC treatment."	unknown	unknown	2008	18429962	Causal
+hsa-miR-18a	3905	lung cancer	up-regulated	"Northern blot, qRT-PCR etc"	"frequent and marked overexpression, with occasional gene amplification, of clustered miRNAs (miR-17-92) within intron 3 of the C13orf 25 gene at 13q31.3 in lung cancers, especially examples with small-cell lung cancer histology.The authors further showed the stimulatory activity of this miRNA cluster in lung cancer cell growth."	unknown	unknown	2005	16266980	Causal
+hsa-miR-18a	3498	pancreatic ductal adenocarcinoma (PDAC)	up-regulated	microarray	differentially expressed between normal and PDAC or cell line samples.	unknown	unknown	2007	17237814	Unspecified
+hsa-miR-18b	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	miR-18b and miR-21 regulate cardiomyocyte hypertrophy.	unknown	unknown	2007	17498736	Unspecified
+hsa-miR-190	1040	B-cell chronic lymphocytic leukemia	up-regulated	microarray	Differentially expressed in CLL cells versus CD19 cells.	unknown	unknown	2004	15284443	Unspecified
+hsa-miR-190	1909	malignant melanoma	down-regulated	"Northern blot, qRT-PCR etc"	"Differentially expressed microRNAs in primary malignant melanomas compared with benign nevi, analyzed by TaqMan realtime PCR."	unknown	unknown	2008	18379589	Unspecified
+hsa-miR-190	2144	ovarian cancer (OC)	up-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-191	3459	breast cancer	up-regulated	microarray	Differentially expressed between breast carcinoma and normal breast tissue.	unknown	unknown	2005	16103053	Unspecified
+hsa-miR-191	1985	colorectal cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-191	1985	colorectal cancer	down-regulated	"Northern blot, qRT-PCR etc"	The expression levels of miRNA is affected by wtp53. Down-regulation of wt-p53 via siRNA abolishes the effect of wt-p53 in regulating miRNAs in HCT-116 (wt-p53) cells.	unknown	unknown	2006	16609010	Unspecified
+hsa-miR-191	1985	colorectal cancer	up-regulated	"Northern blot, qRT-PCR etc"	"miR-15b (p = 0.0278), miR-181b (p = 0.0002), miR-191(p = 0.0264) and miR-200c (p = 0.0017) were significantly over-expressed in tumors compared to normal colorectal samples."	unknown	unknown	2006	18079988	Unspecified
+hsa-miR-191	5517	gastric cancer (stomach cancer)	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-191	3068	glioblastoma	up-regulated	microarray	Significantly differentially expressed between glioblastoma cell line samples and the control samples.	unknown	unknown	2005	16039986	Unspecified
+hsa-miR-191	5520	head and neck squamous cell carcinoma (HNSCC)	up-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-191	3905	lung cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-191	3905	lung cancer	up-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	unknown	2006	16530703	Unspecified
+hsa-miR-191	4905	pancreatic cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-191	10286	prostate cancer	up-regulated	microarray	commonly up-regulated microRNA in 3 or more types of solid cancers	unknown	unknown	2006	16461460	Unspecified
+hsa-miR-191	10286	prostate cancer	up-regulated	microarray	One of the upregulated microRNAs in tumors with perineural invasion (FDR 10%).	unknown	unknown	2008	18459106	Unspecified
+hsa-miR-192	1040	B-cell chronic lymphocytic leukemia	down-regulated	microarray	Differentially expressed in CLL cells versus CD20 cells.	unknown	SIP1	2004	15284443	Unspecified
+hsa-miR-192	3905	lung cancer	up-regulated	microarray	One of the forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues.	unknown	SIP1	2006	16530703	Unspecified
+hsa-miR-192	9261	nasopharyngeal carcinoma (NPC)	up-regulated	microarray	miRNAs differentially expressed between normal and NPC tumor tissues.	unknown	SIP1	2008	18390668	Unspecified
+hsa-miR-192-1	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	unknown	2006	16924677	Unspecified
+hsa-miR-192-2	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	Differentially Regulated miR in HCCs.	unknown	unknown	2006	16924677	Unspecified
+hsa-miR-192-2	3829	pituitary adenoma	down-regulated	microarray	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	unknown	2007	17111382	Unspecified
+hsa-miR-192-3	3829	pituitary adenoma	up-regulated	microarray	Differentially expressed between normal pituitary and pituitary adenomas.One of the 24 miRNAs able to correctly predict the nature of each sample (adenoma or normal pituitary).	unknown	unknown	2007	17111382	Unspecified
+hsa-miR-193a	8894	Oral Squamous Cell Carcinoma (OSCC)	down-regulated	"Northern blot, qRT-PCR etc"	the ectopic transfection of miR-137 or miR-193a into OSCC lines lacking their expressions significantly					
+"reduced cell growth, with down-regulation of the translation of cyclin-dependent kinase 6 or E2F transcription factor"										
+"6, respectively. Taken together, our results clearly show that miR-137 and miR-193a are tumor suppressor miRNAs epigenetically"										
+silenced during oral carcinogenesis.	E2F6	unknown	2008	18381414	Causal	1	1890			
+hsa-miR-193b	1208	autism spectrum disorder (ASD)	down-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	unknown	2008	18563458	Unspecified
+hsa-miR-193b	14691	Duchenne muscular dystrophy (DMD)	down-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-193b	1909	uveal melanoma	up-regulated	microarray	"The top six miRNA discriminators ( let-7b, miR-199a,miR-199a*, miR-143, miR-193b, and miR-652) accurately distinguished class 1 (low metastatic risk) from class 2 (high metastatic risk) with 100% sensitivity and specificity."	unknown	unknown	2008	18477892	Unspecified
+hsa-miR-194	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	survival-related and metastasis-related miRNA.	unknown	unknown	2008	18176954	Unspecified
+hsa-miR-194	11984	cardiac hypertrophy	down-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-194	13315	chronic pancreatitis	up-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-195	1040	chronic lymphocytic leukemia (CLL)	up-regulated	"Northern blot, qRT-PCR etc"	MicroRNA Signature Associated with Prognostic Factors (ZAP-70 Expression and IgVH Mutations) and Disease Progression in Patients with CLL.	unknown	unknown	2005	16251535	Unspecified
+hsa-miR-195	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	"Cardiac overexpression of miR-195, which was up-regulated during cardiac hypertrophy,"					
+resulted in pathological cardiac growth and heart failure in transgenic mice.	unknown	unknown	2006	17108080	Causal	1	1898			
+hsa-miR-195	9119	acute myeloid leukemia (AML)	up-regulated	microarray	One of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.	unknown	unknown	2008	18478077	Unspecified
+hsa-miR-195	11984	cardiac hypertrophy	up-regulated	"Northern blot, qRT-PCR etc"	Change during the latter stage of hypertrophy (14 days post-TAC).	unknown	unknown	2008	17234972	Unspecified
+hsa-miR-195	13315	chronic pancreatitis	up-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-195	5520	head and neck squamous cell carcinoma (HNSCC)	down-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-195	6000	heart failure	up-regulated	"Northern blot, qRT-PCR etc"	"Northern blot analysis of the hypertrophy-regulated miRNAs in idiopathic end-stage failing human hearts showed increased expression of miR-24, miR-125b, miR-195, miR-199a, and miR-214."	unknown	unknown	2006	17108080	Unspecified
+hsa-miR-195	684	hepatocellular carcinoma (HCC)	down-regulated	"Northern blot, qRT-PCR etc"	Significantly differentially expressed between hepatocellular carcinoma and adjacent non-tumor tissue.	unknown	unknown	2006	16331254	Unspecified
+hsa-miR-195	684	hepatocellular carcinoma (HCC)	down-regulated	microarray	"One of the miRNAs differentially expressed between human HCC and LC.To validate their ability to correctly distinguish HCC or cirrhosis tissue types, the 35 deregulated miRNAs were assayed using the algorithms SVM and PAM. PAM correctly classified 86% of the samples and SVM classified 91%."	unknown	unknown	2007	17616664	Unspecified
+hsa-miR-195	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-195	10286	prostate cancer	up-regulated	microarray	One of the upregulated microRNAs in tumors with perineural invasion (FDR 10%).	unknown	unknown	2008	18459106	Unspecified
+hsa-miR-195	5419	schizophrenia	down-regulated	"Northern blot, qRT-PCR etc"	Differentially expressed miRNA from the prefrontal cortex of subjects with schizophrenia compared to psychiatrically healthy subjects.	unknown	unknown	2007	17326821	Unspecified
+hsa-miR-196a	3459	breast cancer	up-regulated	microarray	Differentially expressed between breast carcinoma and normal breast tissue.	unknown	unknown	2005	16103053	Unspecified
+hsa-miR-196a	3498	pancreatic ductal adenocarcinoma (PDAC)	up-regulated	"Northern blot, qRT-PCR etc"	differentially expressed between normal and PDAC or cell line samples. The mode of expression of miR-196a and -196b is especially interesting. These miRNAs are completely absent in normal and chronic pancreatitis tissues but significantly upregulated in PDAC.					
+	unknown	unknown	2007	17237814	Unspecified	0	1910			
+hsa-miR-196a-2	1040	B-cell chronic lymphocytic leukemia	up-regulated	microarray	Differentially expressed in CLL cells versus CD21 cells.	unknown	unknown	2004	15284443	Unspecified
+hsa-miR-196a-2	3459	breast cancer	up-regulated	microarray	Differentially expressed between breast carcinoma and normal breast tissue.	unknown	unknown	2005	16103053	Unspecified
+hsa-miR-196b	2893	cervical cancer	down-regulated	microarray	"let-7b, let-7c, miR-23b, miR-196b, and miR-143 showed significantly reduced abundance in cervical cancer cell lines. miR-21 displayed higher abundance in the cancer group."	unknown	unknown	2007	17616659	Unspecified
+hsa-miR-196b	3498	pancreatic ductal adenocarcinoma (PDAC)	up-regulated	microarray	differentially expressed between normal and PDAC or cell line samples. The mode of expression of miR-196a and -196b is especially interesting. These miRNAs are completely absent in normal and chronic pancreatitis tissues but significantly upregulated in PDAC.					
+	unknown	unknown	2007	17237814	Unspecified	0	1914			
+hsa-miR-196b	13223	uterine leiomyoma (ULM)	up-regulated	microarray	Twenty most differentially expressed microRNA species in leiomyoma versus myometrium microarray.	unknown	unknown	2008	17765232	Unspecified
+hsa-miR-197	3962	follicular thyroid carcinoma (FTC)	up-regulated	"Northern blot, qRT-PCR etc"	"Two specific miRNAs, miR-197 and miR-346, are significantly overexpressed in FTC. In vitro overexpression of either miRNA induces proliferation, whereas inhibition leads to growth arrest."	"ACVR1,TSPAN3"	unknown	2006	16822819	Causal
+hsa-miR-197	10652	Alzheimer's disease	up-regulated	microarray	Significantly changed miRNAs in cortex of sporadic AD cases.	unknown	unknown	2008	18434550	Unspecified
+hsa-miR-197	13315	chronic pancreatitis	up-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-197	14691	Duchenne muscular dystrophy (DMD)	down-regulated	"Northern blot, qRT-PCR etc"	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-197	3068	glioblastoma	down-regulated	microarray	Significantly differentially expressed between glioblastoma cell line samples and the control samples.	unknown	unknown	2005	16039986	Unspecified
+hsa-miR-197	5520	head and neck squamous cell carcinoma (HNSCC)	down-regulated	microarray	Differentially expressed following hypoxia in SCC cells.	unknown	unknown	2007	17222355	Unspecified
+hsa-miR-381	1208	autism spectrum disorder (ASD)	down-regulated	microarray	one of wenty-eight miRNAs was expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.	unknown	unknown	2008	18563458	Unspecified
+hsa-miR-381	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-381	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-381	3429	Inclusion body myositis (IBM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-381	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-381	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-381	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-381	2144	ovarian cancer (OC)	down-regulated	microarray	Differentially expressed miRNA in ovarian cancer tissues and cell lines.	unknown	unknown	2008	18560586	Unspecified
+hsa-miR-381	9088	psoriasis	down-regulated	microarray	Showing more than 1.7-fold change between psoriasis and healthy skin.	unknown	unknown	2007	17622355	Unspecified
+hsa-miR-382	10223	dermatomyositis (DM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-382	14691	Duchenne muscular dystrophy (DMD)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-382	11724	limb-girdle muscular dystrophies types 2A (LGMD2A)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-382	423	miyoshi myopathy (MM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-382	3191	nemaline myopathy (NM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-382	10222	polymyositis (PM)	up-regulated	microarray	Commonly dysregulated miRNA in five or more types of muscular disorders.	unknown	unknown	2007	17942673	Unspecified
+hsa-miR-383	13315	chronic pancreatitis	up-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	unknown	2007	17473300	Unspecified
+hsa-miR-409-3p	13315	chronic pancreatitis	up-regulated	microarray	Differentially Expressed MicroRNA in Chronic Pancreatitis compared to Normal Pancreas	unknown	unknown	2007	17473300	Unspecified